Randomized Phase II Cancer Clinical T

Biostatistics

In cancer research, a traditional phase II trial is designed as a single-

arm trial that compares the experimental therapy to a historical

control. This simple trial design has led to several adverse issues,

including increased false positivity of phase II trial results and

Randomized

negative phase III trials. To rectify these problems, oncologists

and biostatisticians have begun to use a randomized phase II trial

that compares an experimental therapy with a prospective control

Phase II Cancer

therapy.

Randomized Phase II Cancer Clinical Trials explains how to

Clinical Trials

properly select and accurately use diverse statistical methods for

designing and analyzing phase II trials. The author first reviews

the statistical methods for single-arm phase II trials since some

methodologies for randomized phase II trials stem from single-arm

phase II trials and many phase II cancer clinical trials still use single-

arm designs. The book then presents methods for randomized

phase II trials and describes statistical methods for both single-arm

and randomized phase II trials. Although the text focuses on phase

II cancer clinical trials, the statistical methods covered can also be

used (with minor modifications) in phase II trials for other diseases

and in phase III cancer clinical trials.

Suitable for cancer clinicians and biostatisticians, this book shows

rials

how randomized phase II trials with a prospective control resolve

the shortcomings of traditional single-arm phase II trials. It provides

readers with numerous statistical design and analysis methods for

randomized phase II trials in oncology.

Sin-Ho Jung

Jung

K13295

K13295_Cover.indd 1

3/25/13 10:44 AM





CRC Press

Taylor & Francis Group

6000 Broken Sound Parkway NW, Suite 300

Boca Raton, FL 33487-2742

© 2013 by Taylor & Francis Group, LLC

CRC Press is an imprint of Taylor & Francis Group, an Informa business

No claim to original U.S. Government works

Version Date: 20130315

International Standard Book Number-13: 978-1-4398-7186-7 (eBook - PDF)

This book contains information obtained from authentic and highly regarded sources. Reasonable

efforts have been made to publish reliable data and information, but the author and publisher cannot

assume responsibility for the validity of all materials or the consequences of their use. The authors and publishers have attempted to trace the copyright holders of all material reproduced in this publication

and apologize to copyright holders if permission to publish in this form has not been obtained. If any

copyright material has not been acknowledged please write and let us know so we may rectify in any

future reprint.

Except as permitted under U.S. Copyright Law, no part of this book may be reprinted, reproduced,

transmitted, or utilized in any form by any electronic, mechanical, or other means, now known or

hereafter invented, including photocopying, microfilming, and recording, or in any information stor-

age or retrieval system, without written permission from the publishers.

For permission to photocopy or use material electronically from this work, please access www.copy-

right.com (http://www.copyright.com/) or contact the Copyright Clearance Center, Inc. (CCC), 222

Rosewood Drive, Danvers, MA 01923, 978-750-8400. CCC is a not-for-profit organization that pro-

vides licenses and registration for a variety of users. For organizations that have been granted a pho-

tocopy license by the CCC, a separate system of payment has been arranged.

Trademark Notice: Product or corporate names may be trademarks or registered trademarks, and are

used only for identification and explanation without intent to infringe.

Visit the Taylor & Francis Web site at

http://www.taylorandfrancis.com

and the CRC Press Web site at

http://www.crcpress.com





Contents

Preface

xiii

1 Introduction

1

2 Single-Arm Phase II Trial Designs

5

2.1

Single-Stage Designs . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 5

2.1.1

Design of Single-Stage Phase II Trial . . . . . . . . . . . . . . . . . . 6

2.2

Two-Stage Designs . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 11

2.2.1

Gehan’s Design . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 11

2.2.2

Simon’s Optimal Design . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 11

2.2.3

Admissible Designs . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 12

2.2.3.1

A Class of Admissible Designs . . . . . . . . . . . . . . . 14

2.2.3.2

Search for Admissible Designs . . . . . . . . . . . . . . . . 15

2.3

Two-Stage Designs with Both Upper and Lower

Stopping Values . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 18

References . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 23

3 Inference on the Binomial Probability in Single-Arm

Multistage Clinical Trials

25

3.1

Point Estimation . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 26

3.1.1

Two-Stage Designs . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 28

3.1.2

Numerical Studies . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 29

3.2

Confidence Intervals . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 35

3.3

P-Values . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 36

3.3.1

P-Values under Two-Stage Designs . . . . . . . . . . . . . . . . . . . 38

3.4

When Realized Sample Size Is Different from

That Specified in Design . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 43

References . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 48

4 Single-Arm Phase II Clinical Trials with

Time-to-Event Endpoints

51

4.1

A Test Based on Median Survival Time. . . . . . . . . . . . . . . . . . . . . . .51

4.1.1

Statistical Testing . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 52

4.1.2

Sample Size Calculation . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 53

4.1.2.1

Under Uniform Accrual and Exponential

Survival Models . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 54

4.1.2.2

When Accrual Rate Is Given . . . . . . . . . . . . . . . . . 56

vii

viii

Contents

4.2

Maximum Likelihood Method for Exponential Distribution . . . 56

4.2.1

Statistical Testing . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 57

4.2.2

Sample Size Calculation . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 57

4.2.2.1

Under a Uniform Accrual Model . . . . . . . . . . . . . 58

4.2.2.2

When Accrual Rate Is Known. . . . . . . . . . . . . . . .58

4.3

One-Sample Log-Rank Test . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 59

4.3.1

Statistical Testing . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 60

4.3.2

Sample Size Calculation . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 60

4.3.2.1

Under Proportional Hazards

Model Assumption . . . . . . . . . . . . . . . . . . . . . . . . . . 61

4.3.2.2

Under Uniform Accrual and Exponential

Survival Models. . . . . . . . . . . . . . . . . . . . . . . . . . . . . .62

4.3.2.3

When Accrual Rate Is Given . . . . . . . . . . . . . . . . . 62

4.4

Two-Stage Trials Using One-Sample Log-Rank Test . . . . . . . . . . 63

4.4.1

Two-Stage One-Sample Log-Rank Test . . . . . . . . . . . . . . . 64

4.4.2

Sample Size Calculation . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 65

4.4.2.1

Under Uniform Accrual and Exponential

Survival Models . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 67

4.5

Binomial Testing on t-Year Survival Probability . . . . . . . . . . . . . . 69

References . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 69

5 Single-Arm Phase II Trials with Heterogeneous

Patient Populations: Binary and Survival Outcomes

71

5.1

Binary Outcome Case . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 72

5.1.1

Single-Stage Designs . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 73

5.1.1.1

Unstratified Testing . . . . . . . . . . . . . . . . . . . . . . . . . . 73

5.1.1.2

Stratified Testing . . . . . . . . . . . . . . . . . . . . . . . . . . . . 74

5.1.2

Two-Stage Designs . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 78

5.1.2.1

Unstratified Testing . . . . . . . . . . . . . . . . . . . . . . . . . . 79

5.1.2.2

Stratified Testing . . . . . . . . . . . . . . . . . . . . . . . . . . . . 79

5.1.3

Some Extensions . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 83

5.1.3.1

Conditional P-Value . . . . . . . . . . . . . . . . . . . . . . . . . 83

5.1.3.2

When There Are More than Two

Subpopulations . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 84

5.2

Survival Outcome Case: Stratified One-Sample

Log-Rank Test . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 86

5.2.1

Statistical Testing . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 86

5.2.2

Sample Size Calculation . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 87

5.2.2.1

Under Uniform Accrual and Exponential

Survival Models . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 88

5.2.2.2

When Accrual Rate Is Given . . . . . . . . . . . . . . . . . 88

References . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 89

Contents

ix

6 Randomized Phase II Trials for Selection:

No Prospective Control Arms

91

6.1

With a Historical Control . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 93

6.1.1

When Both Arms Have Identical Two-Stage Designs. . .93

6.1.1.1

One-Sided Test . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 93

6.1.1.2

Two-Sided Test . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 97

6.1.2

When Two Arms Have Different Two-Stage Designs . . . 98

6.1.2.1

One-Sided Test . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 99

6.1.2.2

Two-Sided Test. . . . . . . . . . . . . . . . . . . . . . . . . . . . . .100

6.2

When No Historical Control Exists . . . . . . . . . . . . . . . . . . . . . . . . . . . 101

6.3

Extension to More than Two Arms. . . . . . . . . . . . . . . . . . . . . . . . . . .102

6.3.1

When a Historical Control Exists. . . . . . . . . . . . . . . . . . . . .102

6.3.2

When No Historical Control Exists . . . . . . . . . . . . . . . . . . . 103

References. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .103

7 Randomized Phase II Cancer Clinical Trials with

a Prospective Control on Binary Endpoints (I):

Two-Sample Binomial Test

105

7.1

Two-Sample Binomial Test . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 106

7.1.1

Single-Stage Design . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 106

7.1.2

Two-Stage Designs with Interim Futility Test . . . . . . . . 107

7.1.2.1

Optimal Design . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 117

7.1.2.2

Minimax Design . . . . . . . . . . . . . . . . . . . . . . . . . . . . 118

7.1.3

Extensions . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 119

7.1.3.1

Unbalanced Randomized Trials . . . . . . . . . . . . . 119

7.1.3.2

Strict Type I and II Error Control . . . . . . . . . . 121

7.1.3.3

Randomized Trials with One Control

and K Experimental Arms . . . . . . . . . . . . . . . . . . 122

7.2

Two-Stage Designs with Both Upper and

Lower Stopping Values . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 126

7.2.1

Strict Control of Type I Error Rate and Power . . . . . . 138

7.3

Discussions . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 138

References. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .140

8 Randomized Phase II Cancer Clinical Trials

with a Prospective Control on Binary Endpoints (II):

Fisher’s Exact Test

141

8.1

Single-Stage Design . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 142

8.1.1

Algorithm for Single-Stage Design . . . . . . . . . . . . . . . . . . . 143

8.2

Two-Stage Design . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 144

8.2.1

Two-Stage Designs with a Futility Interim

Test Only . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 144

8.2.1.1

Choice of a 1 and a . . . . . . . . . . . . . . . . . . . . . . . . . . 154

8.2.1.2

Choice of n 1 and n 2 . . . . . . . . . . . . . . . . . . . . . . . . . 155

x

Contents

8.2.2

Two-Stage Designs with Both Superiority

and Futility Interim Tests . . . . . . . . . . . . . . . . . . . . . . . . . . . . 157

8.2.2.1

Choice of a 1, b 1, and a . . . . . . . . . . . . . . . . . . . . . . 157

8.2.2.2

Choice of n 1 and n 2 . . . . . . . . . . . . . . . . . . . . . . . . . 158

8.3

Extensions . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 159

8.3.1

Unbalanced Two-Stage Randomized Trials . . . . . . . . . . . 159

8.3.2

Conditional P-Value . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 170

8.4

Discussions . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 171

References. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .173

9 Randomized Phase II Trials with Heterogeneous

Patient Populations: Stratified Fisher’s Exact Test

175

9.1

Single-Stage Stratified Fisher’s Exact Test . . . . . . . . . . . . . . . . . . . 175

9.1.1

Statistical Testing . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 176

9.1.2

Power and Sample Size Calculation . . . . . . . . . . . . . . . . . . 177

9.1.3

Numerical Studies . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 180

9.1.4

Discussions . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 184

9.2

Two-Stage Designs with an Interim Futility Test . . . . . . . . . . . . 185

9.2.1

How to Choose (a 1 , a) . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 187

9.2.2

Two-Stage Designs for Stratified Fisher’s

Exact Test . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 188

9.2.3

Conditional P-Value . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 189

References. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .190

10 Randomized Phase II Clinical Trials Based

on Survival Endpoints: Two-Sample Log-Rank Test

191

10.1

Two-Sample Log-Rank Test . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 191

10.1.1

Test Statistic . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 191

10.1.2

Sample Size Calculation. . . . . . . . . . . . . . . . . . . . . . . . . . .192

10.1.2.1

Under Exponential Survival and

Uniform Censoring Distributions . . . . . . . . 193

10.1.2.2

When Accrual Rate Is Specified

Instead of Accrual Period . . . . . . . . . . . . . . . 194

10.2

Two-Stage Log-Rank Test . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 195

10.2.1

Statistical Testing . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 195

10.2.2

Sample Size Calculation. . . . . . . . . . . . . . . . . . . . . . . . . . .197

10.2.2.1

Under Uniform Accrual and Exponential

Survival Models . . . . . . . . . . . . . . . . . . . . . . . . . 201

10.3

Stratified Two-Sample Log-Rank Test for

Single-Stage Designs . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 202

10.3.1

Test Statistic . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 202

10.3.2

Sample Size Calculation. . . . . . . . . . . . . . . . . . . . . . . . . . .203

References . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 205

Contents

xi

11 Some Flexible Phase II Clinical Trial Designs

207

11.1

Comparing Survival Distributions under

General Hypothesis Testing . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 207

11.1.1

Generalized Log-Rank Test . . . . . . . . . . . . . . . . . . . . . . . 208

11.1.2

Sample Size Calculation. . . . . . . . . . . . . . . . . . . . . . . . . . .209

11.1.2.1

Under Uniform Accrual and Exponential

Survival Models . . . . . . . . . . . . . . . . . . . . . . . . . 210

11.1.2.2

When Accrual Rate Is Specified Instead

of Accrual Period . . . . . . . . . . . . . . . . . . . . . . . 211

11.1.3

Sample Size Calculation under a General

Accrual Pattern . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 212

11.2

Randomized Phase II Trials for Comparing

Maintenance Therapies. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .216

11.2.1

Two-Sample Log-Rank Test . . . . . . . . . . . . . . . . . . . . . . . 216

11.2.2

Sample Size Calculation. . . . . . . . . . . . . . . . . . . . . . . . . . .217

References . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 219





Preface

A clinical trial is an important research tool in the evaluation of the efficacy

and safety of cancer therapies. Cancer therapies include anticancer drugs, gene

therapy, surgical procedure, radiation therapy, and combinations of these.

An experimental therapy is evaluated through three phases of cancer clinical

trials. A phase I trial has the objective of selecting the appropriate dose level

of an experimental therapy (mostly an anticancer drug) to be used for further

investigation. Once a dose level is chosen, the experimental therapy is tested

through a small phase II trial requiring 50 to 100 patients. An experimental

therapy that is shown to have a promising activity in phase II is evaluated

by a large-scale phase III trial compared to a current standard therapy. Since

evaluation of an experimental therapy through these clinical trials is limited

to a specific type of disease, a single experimental therapy may go through

multiple phase II and III trials for different disease types, especially when it

is shown to be very efficacious from earlier trials.

If a new cancer therapy is shown to be inefficacious from a phase II trial, it

is very likely that no phase III trials will be conducted for further evaluation.

In this sense, phase II trials are called screening trials. Among the three phases

of cancer trials, phase II trials usually comprise the largest volume of cancer

research activity for individual cancer centers and cooperative cancer trial

groups. In order to expedite the conduct of phase II trials, a traditional phase

II trial has been designed as a single-arm trial to treat all the patients using

the experimental therapy to be compared with a historical control. This simple

phase II trial design has resulted in many issues, including increased false

positivity of phase II trial results and many negative phase III trials. Pointing

out these issues, many oncologists and biostatisticians began to propose to

use a randomized phase II trial to compare an experimental therapy with a

prospective control therapy.

It is critical to use accurate statistical methods for designing and analyzing

phase II trials. Because of the small sample sizes, exact statistical methods

have been used for phase II clinical trials. This book is intended to provide

diverse statistical design and analysis methods for randomized phase II trials

in oncology. Since a large part of methodologies for randomized phase II trials

stems from those of single-arm phase II trials and many phase II cancer clinical

trials still use single-arm designs, we also review the statistical methods for

single-arm phase II trials in Chapters 1 to 5. This book will be useful for

cancer clinicians as well as biostatisticians.

xiii





Chapter 1

Introduction

Cancer clinical trials investigate the efficacy and toxicity of experimental

cancer therapies. Through a phase I trial, we determine an appropriate dose

level for treating humans based on the information collected from preclinical

animal studies. In a phase I trial, the most popular primary clinical outcome

is toxicity. Usually, for an anticancer chemotherapy, both the efficacy and tox-

icity increase as the dose level increases. We choose a dose with a tolerable

toxicity level for further investigation of the therapy.

Once a dose level is determined from a phase I trial, we assess the drug’s

anticancer activity through phase II clinical trials. Phase II clinical trials have

the objective of screening out inefficacious experimental therapies before they

proceed to further investigation through large-scale phase III trials. In order

to expedite this process, a conventional phase II trial is designed as a single-

arm trial to treat patients with the experimental therapy only. In this case,

the efficacy of the experimental therapy is compared with that of a historical

control. The most popular primary endpoint of phase II cancer clinical trials

is tumor response, which is measured by the change in tumor size before

and during treatment. For a solid tumor, if the index tumor shrinks to half

or less compared to the baseline, we call it a partial response. If the tumor

disappears during treatment, then we call it a complete response. Overall

response is defined as a partial or complete response.

If an experimental therapy is shown to have anticancer activity through a

phase II trial, we proceed to a phase III trial to compare its efficacy with

that of a standard therapy using a confirmatory endpoint such as overall sur-

vival. Unlike conventional single-arm phase II trials, a phase III trial random-

izes the patients between an experimental therapy and a standard therapy, a

control. The ultimate goal of cancer therapies is to extend the lifetime of can-

cer patients. In this sense, we usually choose overall survival time, defined

as the time period between registration and death from any cause, as our

primary efficacy endpoint. While a single-arm phase II trial requires around

50 patients, a phase III trial usually requires hundreds, or possibly thousands,

of patients for proper evaluation of an experimental therapy.

Phase II trials generally require a shorter study period than phase III trials.

Consequently, phase II trials have small sample sizes, so that exact statistical

1

2

Randomized Phase II Cancer Clinical Trials

methods are preferable to asymptotic methods for their design and analysis.

Various exact methods have been published for phase II trials with binary

outcomes (e.g., tumor response). For survival outcomes (e.g., progression-free

survival or time to recurrence), however, we have to use an asymptotic method

due to lack of exact methods. Furthermore, phase II trials use a surrogate

outcome (such as tumor response, or progression-free survival) rather than a

confirmatory endpoint, such as overall survival, which requires a longer follow-

up time. As another effort to lower the sample size of phase II trials, we may

compromise-type I error rate and power, such as a one-sided alpha of 5% to

20% and a power of 80% to 90%, compared to two-sided alpha of 5% and a

power of 90% or higher in phase III trials.

Usually, the historical control data for a single-arm phase II trial come from

a previous study, frequently a previous phase II trial. The patient populations

for different phase II trials are often quite heterogeneous, so that the distri-

butions of patient characteristics for a new single-arm phase II trial are quite

different from those of the prior trial which provides the historical control.

Furthermore, as in most phase II trials, a historical control study may have a

small sample size, so that the estimated response rate will have a large vari-

ance. In designing a new single-arm phase II trial, however, we often treat

the estimated response rate from a previous trial as the true parameter value.

Even if all the conditions are comparable between a new single-arm trial and

a previous study giving the historical control data for the new study, regard-

ing the response rate for the historical control as a parameter can drastically

increase the type I error rate in testing. The methods of response assess-

ment may be different between a historical control study and the current

trial.

Because of these and other reasons, the traditional single-arm phase II

trial designs lead to a high failure rate of phase III trials, see, for example,

Djulbegovic et al. (2008). Wrong trial designs and selection of endpoints of

phase II trials lead to failure of phase III clinical trials as well. For exam-

ple, endpoints utilized for cytotoxic compounds may not be appropriate in

the development of newer targeted, cytostatic therapeutic agents. Random-

ized phase II trials with a prospective control resolve these shortcomings of

traditional single-arm phase II trials.

In this book, we review design and analysis methods of single-arm phase

II trials (Chapters 2–5) and investigate methods for randomized phase II

trials (Chapters 6–10). In Chapter 11, we discuss some statistical methods

that can be used for both single-arm and randomized phase II cancer clinical

trials. Although we discuss the statistical methods for phase II cancer clin-

ical trials, they can be used for phase II trials for other diseases with some

minor modification. Some methods can be used for phase III cancer clinical

trials.

Introduction

3

References

Djulbegovic, B., Kumar, A., Soares, H.P., Hozo, I., Bepler, G., Clarke, M.,

Bennett, C.L. (2008). New cancer treatment successes identified in

phase 3 randomized controlled trials conducted by the National Cancer

Institute–Sponsored Cooperative Oncology Groups, 1955 to 2006.

Archives of Internal Medicine, 168 (6), 632–642.





Chapter 2

Single-Arm Phase II Trial Designs

Traditionally, phase II cancer clinical trials have single-arm designs using over-

all response as the primary endpoint. In a traditional single-arm phase II trial,

patients are treated by only an experimental therapy. At the end of such a

trial, the efficacy of the experimental therapy is evaluated compared to that

of a preselected historical control, which is usually chosen among the current

standard therapies for the study population. In this chapter, we review some

optimal designs for single-arm phase II clinical trials.

2.1

Single-Stage Designs

For ethical reasons, most phase II clinical trials are conducted through two

stages. If the accrual rate is very fast, however, we may use a single-stage

design.

Suppose that we want to investigate an experimental therapy for a patient

population. Let p denote the response rate of the experimental therapy, and

p 0 denote the response rate of a selected historical control therapy to which

the experimental therapy will be compared.

In order to test the hypotheses H 0 : p ≤ p 0 vs. H 1 : p > p 0, we treat n patients with the experimental therapy. Let X denote the number of responders among n patients. We reject the experimental therapy if X ≤ a for a

rejection value a. Assuming the patient responses are independent and iden-

tically distributed, X is a binomial random variable with n independent trials

and probability of success p, denoted as B(n, p). For a response rate p, the

probability of rejecting the therapy (or failing to reject H 0) is P (X ≤ a| p) =





B(a| n, p), where B(x| n, p) =

x

b(i| n, p) and b(x| n, p) = n px ( 1 − p)n− x

i =0

x

are the cumulative distribution function and the probability mass function

of B(n, p).

5

6

Randomized Phase II Cancer Clinical Trials

For a specified type I error rate α∗, the rejection value a is chosen as the

smallest integer a satisfying

α ≡ 1 − B(a| n, p 0 ) ≤ α∗ .

Suppose that we consider the experimental therapy to have promising anti-

cancer activity if its response rate is p 1 (> p 0 ) or higher. Then, for H 1 : p = p 1, the one-stage design specified by (n, a) has a power of

1 − β = 1 − B(a| n, p 1 ).

The design of a single-stage phase II trial with a type I error rate not exceeding

α∗ and a power of at least 1 − β∗ proceeds as follows.

2.1.1

Design of Single-Stage Phase II Trial

1. Specify design parameters (α∗ , 1 − β∗ , p 0 , p 1 ).

2. For n(> 0 ),

a. Find the smallest integer a satisfying

B(a| n, p 0 ) ≥ 1 − α∗ .

b. Calculate the the power

1 − β = 1 − B(a| n, p 1 ).

3. If 1 − β ≥ 1 − β∗, select n and a as the number of patients required and the critical value, respectively, and stop the procedure. Otherwise,

repeat the above step 2 with n + 1.

The design identified by this procedure is an optimal single-stage design in

the sense that it requires the smallest number of patients among the designs

satisfying (α∗ , 1 − β∗ ) restriction. Tables 2.1–2.4 list the optimal single-stage designs under various design settings of (α∗ , 1 − β∗ , p 0 , p 1 ).

Example 2.1

Suppose that we want to evaluate an experimental chemotherapy in patients

with relapsed or refractory classical Hodgkin’s lymphoma (HL). For this pa-

tient population, it is known that a standard chemotherapy has p 0 = 65%

response rate. We will be highly interested in the experimental chemotherapy

if its response rate is p 1 = 80% or higher. Given (α∗ , 1 − β∗ ) = ( 0 . 1 , 0 . 9 ), the optimal single-stage design is given as (n, a) = ( 61 , 44 ) from Table 2.4. This design has an exact type I error rate of α = 0 . 095 and a power of 1− β = 0 . 912.

Single-Arm Phase II Trial Designs

7

)

EN

33.6

17.6

12.0

24.7

15.0

30.4

19.0

35.4

20.6

39.5

22.6

41.7

23.6

43.5

24.8

44.9

24.5

45.1

24.7

43.7

23.5

42.0

22.3

39.3

20.5

35.4

18.2

30.3

14.8

24.6

11.0

18.0

33.7

. 8 , 0

β

. 05

−1 0.800 0.801 0.812 0.800 0.805 0.801 0.811 0.800 0.800 0.802 0.803 0.802 0.803 0.801 0.800 0.805 0.801 0.804 0.804 0.802 0.804 0.805 0.805 0.800 0.802 0.804 0.804 0.807 0.804 0.809 0.800 0.812 0.800

( 0= Design

)∗

α

β

0.045

0.044

0.043

0.042

0.033

0.048

0.049

0.043

0.034

0.043

0.046

0.047

0.050

0.046

0.048

0.044

0.038

0.047

0.042

0.046

0.049

0.045

0.043

0.049

0.045

0.049

0.046

0.048

0.047

0.045

0.049

0.044

0.047

− , 1 Optimal

∗

/n

/ 56 / 29

/ 43 / 29 / 55

/ 72 / 43 / 71 / 41 / 81 / 46 / 77 / 44 / 84 / 46 / 77 / 43 / 83 / 43 / 76 / 43 / 67 / 43 / 67 / 33 / 59 / 27 / 48 / 22 / 34 / 65

(α

,a

/ 17

/ 34

1

, 5 , 3 , 2 , 7 , 5 , 12 , 8 , 19 , 12 , 23 , 14 , 30 , 18 , 33 , 20 , 40 , 23 , 41 , 24 , 48 , 26 , 48 , 28 , 46 , 30 , 49 , 25 , 46

, 40

, 30 , 59

/n

, 22

, 19

/ 9

/ 9

for

/ 23 / 10 0 / 18 / 10 / 19 1 / 22 / 13 / 20 / 17 / 27 / 15 / 27 / 14 / 26 / 16 / 26 / 15 / 28 / 15 / 26 / 15 / 27 / 11 / 18 / 14 / 19 / 6 / 13 / 3 / 14 / 13

a 1

1

0

2

1

3

5

3

5

5

9

5

4

2

10

5

11

7

12

7

15

8

15

9

17

7

12

10

14

10

12

11

designs

EN

39.8

19.8

13.8

28.8

19.5

34.5

20.1

40.4

22.3

52.0

25.1

49.6

25.7

57.0

26.3

60.1

34.4

53.9

31.2

66.1

27.7

45.8

26.1

43.8

20.8

41.9

25.4

34.4

23.2

27.5

16.3

17.7

41.6

o-stage

β−

tw

1

0.802

0.801

0.801

0.803

0.802

0.804

0.803

0.802

0.801

0.803

0.800

0.803

0.804

0.801

0.801

0.802

0.802

0.800

0.806

0.801

0.801

0.800

0.801

0.802

0.808

0.801

0.807

0.801

0.801

0.802

0.805

0.802

0.811

Design

α

optimal

0.045

0.044

0.043

0.042

0.033

0.048

0.049

0.043

0.034

0.043

0.046

0.047

0.050

0.046

0.048

0.044

0.038

0.047

0.042

0.046

0.049

0.045

0.043

0.049

0.045

0.049

0.046

0.048

0.047

0.045

0.049

0.044

0.047

and

Minimax

/n

/ 48

/ 53 / 33 / 60 / 36 / 65 / 39 / 66 / 39 / 70 / 39 / 70 / 39 / 68 / 37 / 67 / 36 / 62 / 35 / 55 / 30 / 49 / 26 / 39 / 20

/ 57

,a

/ 52 / 27 / 16 / 40 / 25

/ 28

/ 29

1

, 5 , 3 , 2 , 7 , 5 , 11 , 7 , 15 , 10 , 20 , 13 , 25 , 16 , 29 , 18 , 34 , 20 , 38 , 22 , 40 , 23 , 43 , 24 , 43 , 25 , 41 , 23 , 39 , 21 , 33 , 17

, 52

/n

, 26

/ 30 / 13 / 12 / 22 / 15

/ 15

/ 51

/ 46

/ 55

/ 59 / 34 / 42 / 30 / 66 / 23 / 35 / 24 / 30

/ 31 / 25 / 23 / 23 / 22 / 16 / 9 / 39

1

0

0

2

1

/ 23 2 / 31 / 18

/ 17

/ 19

/ 21

/ 13

7

minimax

a 1

3

6

4

16

4

16

6

22

8

28

17

19

16

39

12

20

15

18

8

20

19

16

19

17

14

35

and

β−1 0.812 0.818 0.803 0.818 0.807 0.819 0.818 0.806 0.805 0.803 0.817 0.815 0.832 0.802 0.831 0.802 0.803 0.804 0.818 0.802 0.807 0.820 0.806 0.812 0.832 0.803 0.827 0.809 0.858 0.841 0.895 0.812 0.828

designs,

Design

α

0.045

0.044

0.043

0.042

0.033

0.048

0.049

0.043

0.034

0.043

0.046

0.047

0.050

0.046

0.048

0.044

0.038

0.047

0.042

0.046

0.049

0.045

0.043

0.049

0.045

0.049

0.046

0.048

0.047

0.045

0.049

0.044

0.047

/n

/ 52 / 27 / 16 / 40 / 25 / 48 / 28 / 56 / 35 / 62 / 36 / 67 / 39 / 68 / 41 / 71 / 42 / 70 / 42 / 69 / 37 / 70 / 37 / 62 / 36 / 55 / 31 / 49 / 28 / 45 / 23 / 30 / 59

Single-stage

Single-Stage

a

5

3

2

7

5

11

7

16

11

21

13

26

16

30

19

35

22

38

24

41

23

45

25

43

26

41

24

39

23

38

20

27

54

2.1

p 1

0.15

0.20

0.25

0.25

0.30

0.30

0.35

0.35

0.40

0.40

0.45

0.45

0.50

0.50

0.55

0.55

0.60

0.60

0.65

0.65

0.70

0.70

0.75

0.75

0.80

0.80

0.85

0.85

0.90

0.90

0.95

0.95

0.95

ableT

p 0

0.05

0.10

0.15

0.20

0.25

0.30

0.35

0.40

0.45

0.50

0.55

0.60

0.65

0.70

0.75

0.80

0.85

8

Randomized Phase II Cancer Clinical Trials

). 85

EN

41.1

22.0

14.1

29.7

18.3

36.9

22.3

42.2

25.2

46.6

27.0

49.7

28.5

51.8

29.2

52.1

29.3

52.9

28.9

51.6

28.0

49.7

26.5

46.0

24.2

41.7

20.7

35.9

17.6

28.7

13.2

20.0

38.7

, 0 . 05

β

( 0

−

0.855

0.851

0.850

0.853

0.851

0.851

0.851

0.853

0.854

0.852

0.850

0.853

0.850

0.851

0.851

0.850

0.851

0.853

0.852

0.851

0.855

0.854

0.850

0.851

0.854

0.851

0.851

0.851

0.854

0.857

0.857

0.856

0.852

=

1

)∗ Design

β

α

−

0.037

0.029

0.026

0.041

0.047

0.039

0.049

0.049

0.043

0.049

0.042

0.049

0.044

0.050

0.050

0.049

0.048

0.046

0.043

0.046

0.048

0.050

0.045

0.044

0.045

0.049

0.042

0.049

0.047

0.045

0.049

0.045

0.047

, 1∗ (α Optimal /n

/ 66 / 46 / 80 / 51 / 81 / 50 / 86 / 48 / 98 / 49 / 93 / 50 / 100 / 49 / 92 / 52 / 93 / 51 / 81 / 41 / 77 / 37 / 71 / 32 / 53 / 23 / 41 / 74

,a

/ 70 / 41 / 26 / 50 / 35

for

1

, 6 , 4 , 3 , 8 , 6 , 14 , 10 , 21 , 14 , 26 , 17 , 32 , 19 , 41 , 22 , 44 , 25 , 52 , 27 , 53 , 31 , 58 , 33 , 55 , 29 , 56 , 28 , 55 , 26 , 44 , 20 , 36 , 67

/n

/ 25 / 17 / 80 / 20 / 11 / 28 / 16 / 27 / 17 / 30 / 18 / 29 / 21 / 34 / 17 / 33 / 19 / 35 / 19 / 34 / 17 / 31 / 14 / 26 / 16 / 29 / 12 / 23 / 11 / 18 / 10 / 12 / 23

a 1

1

1

2

1

5

3

6

4

8

5

9

7

13

6

14

8

9

9

8

8

8

8

17

18

18

16

10

20

17

14

10

20

designs

EN

52.3

27.5

17.1

34.0

20.4

42.3

23.4

45.6

26.0

50.0

32.5

55.1

37.6

71.7

42.1

61.0

34.0

77.2

37.8

74.3

31.1

54.6

38.2

47.8

34.3

45.4

21.7

39.3

19.3

44.2

13.2

24.6

54.0

o-stage

β

tw

−1 0.850 0.850 0.854 0.853 0.851 0.852 0.850 0.850 0.850 0.851 0.851 0.850 0.851 0.850 0.852 0.851 0.851 0.851 0.851 0.850 0.851 0.852 0.852 0.851 0.852 0.850 0.851 0.850 0.852 0.851 0.856 0.861 0.853

Design

optimal

α

0.037

0.029

0.026

0.041

0.047

0.039

0.049

0.049

0.043

0.049

0.042

0.049

0.044

0.050

0.050

0.049

0.048

0.046

0.043

0.046

0.048

0.050

0.045

0.044

0.045

0.049

0.042

0.049

0.047

0.045

0.049

0.045

0.047

and

Minimax

/n

/ 54

/ 65 / 37 / 70 / 42 / 76 / 42 / 79 / 44 / 81 / 45 / 81 / 45 / 79 / 44 / 77 / 41 / 73 / 38 / 65 / 34 / 57 / 28 / 47 / 22 / 35 / 65

,a

/ 63 / 35 / 23 / 47 / 27

/ 33

1

, 6 , 4 , 3 , 8 , 5 , 12 , 8 , 18 , 11 , 23 , 15 , 29 , 17 , 34 , 20 , 39 , 23 , 43 , 25 , 46 , 27 , 49 , 27 , 50 , 27 , 48 , 26 , 45 , 23 , 39 , 19 , 31 , 59

/n

/ 38 / 17 / 12 / 24 / 18

/ 19

/ 35 / 37 / 71 / 42 / 56 / 27 / 77 / 37 / 74 / 22 / 38 / 38 / 34 / 34 / 32 / 15 / 22

/ 44

/ 23 / 53

minimax

/ 39

/ 31 / 17 / 36 / 25

/ 13

/ 11

a 1

1

0

0

2

2

7

3

6

3

9

6

10

14

30

19

25

11

41

20

43

11

21

25

21

24

21

10

15

9

37

9

20

48

and

β−1 0.853 0.857 0.863 0.865 0.864 0.851 0.868 0.866 0.871 0.870 0.854 0.861 0.854 0.867 0.870 0.874 0.856 0.855 0.853 0.854 0.861 0.863 0.857 0.858 0.859 0.860 0.856 0.862 0.858 0.878 0.895 0.888 0.876

designs,

Design

α

0.037

0.029

0.026

0.041

0.047

0.039

0.049

0.049

0.043

0.049

0.042

0.049

0.044

0.050

0.050

0.049

0.048

0.046

0.043

0.046

0.048

0.050

0.045

0.044

0.045

0.049

0.042

0.049

0.047

0.045

0.049

0.045

0.047

Single-stage

/n

/ 63 / 35 / 23 / 47 / 27 / 57 / 33 / 65 / 40 / 73 / 42 / 76 / 44 / 81 / 46 / 85 / 45 / 82 / 46 / 80 / 44 / 77 / 42 / 74 / 39 / 65 / 35 / 57 / 28 / 50 / 23 / 37 / 68

Single-Stage

a

6

4

3

8

5

13

8

18

12

24

15

29

18

35

21

41

23

44

26

47

27

49

28

51

28

48

27

45

23

42

20

33

62

2.2

p 1

0.15

0.20

0.25

0.25

0.30

0.30

0.35

0.35

0.40

0.40

0.45

0.45

0.50

0.50

0.55

0.55

0.60

0.60

0.65

0.65

0.70

0.70

0.75

0.75

0.80

0.80

0.85

0.85

0.90

0.90

0.95

0.95

0.95

ableT

p 0

0.05

0.10

0.15

0.20

0.25

0.30

0.35

0.40

0.45

0.50

0.55

0.60

0.65

0.70

0.75

0.80

0.85

Single-Arm Phase II Trial Designs

9

). 9

EN

50.2

26.7

16.8

36.8

22.5

45.1

26.9

51.4

30.4

56.2

32.5

60.8

34.7

62.7

35.6

64.0

36.0

64.0

34.9

62.3

34.0

59.8

32.1

55.6

29.5

50.3

25.2

43.4

21.2

34.3

14.7

24.4

47.0

, 0 . 05

β

( 0

−

0.901

0.902

0.902

0.902

0.902

0.901

0.905

0.901

0.904

0.900

0.900

0.901

0.903

0.900

0.901

0.900

0.902

0.900

0.901

0.901

0.901

0.900

0.901

0.901

0.901

0.902

0.902

0.904

0.905

0.900

0.901

0.903

0.905

=

1

)∗ Design

β

α

−

0.038

0.040

0.034

0.044

0.042

0.049

0.049

0.045

0.037

0.047

0.046

0.045

0.049

0.047

0.045

0.049

0.049

0.044

0.045

0.048

0.049

0.048

0.043

0.047

0.045

0.049

0.043

0.048

0.044

0.045

0.046

0.044

0.050

, 1∗ (α Optimal /n

/ 66

/ 82 / 44 / 83 / 54 / 99 / 57 / 110 / 63 / 105 / 59 / 104 / 66 / 116 / 61 / 105 / 61 / 110 / 54 / 95 / 53 / 93 / 44 / 79 / 36 / 63

/ 42 / 83

,a

/ 84 / 41 / 30

/ 35

/ 28

for

1

, 7 , 4 , 3 , 10 , 6 , 17 , 10 , 22 , 15 , 31 , 19 , 40 , 24 , 44 , 26 , 49 , 32 , 60 , 33 , 60 , 36 , 68 , 35 , 64 , 37 , 67 , 33 , 61 , 29 , 52

, 37 , 75

/n

, 24

/ 37 / 21 / 90 / 21 / 18 / 30 / 19 / 37 / 19 / 37 / 22 / 40 / 24 / 43 / 20 / 45 / 25 / 40 / 23 / 42 / 24 / 38 / 18 / 34 / 19 / 31 / 15 / 25 / 15 / 23 / 9 / 19 / 30

a 1

2

1

2

2

5

3

8

4

7

10

6

8

7

13

16

19

11

19

11

22

13

22

10

21

12

21

10

18

11

18

16

26

designs

EN

58.6

32.9

20.4

40.0

26.2

51.8

29.9

58.4

31.2

72.1

37.1

78.5

36.6

67.4

45.9

78.9

38.1

93.1

40.6

75.0

36.1

81.7

36.3

73.2

35.9

61.8

37.2

48.5

22.7

36.0

22.2

35.3

49.2

o-stage

β

tw

−1 0.901 0.900 0.901 0.901 0.902 0.900 0.901 0.900 0.900 0.900 0.900 0.901 0.902 0.900 0.900 0.900 0.901 0.902 0.900 0.900 0.900 0.901 0.902 0.900 0.900 0.900 0.902 0.902 0.901 0.902 0.902 0.900 0.901

Design

optimal

α

0.038

0.040

0.034

0.044

0.042

0.049

0.049

0.045

0.037

0.047

0.046

0.045

0.049

0.047

0.045

0.049

0.049

0.044

0.045

0.048

0.049

0.048

0.043

0.047

0.045

0.049

0.043

0.048

0.044

0.045

0.046

0.044

0.050

and

Minimax

/n

/ 64

/ 77 / 45 / 83 / 49 / 88 / 53 / 94 / 53 / 94 / 54 / 95 / 54 / 93 / 53 / 89 / 49 / 84 / 45 / 75 / 40 / 68 / 32 / 54 / 26 / 40 / 75

,a

/ 77 / 38 / 25 / 55 / 33

/ 38

1

, 7 , 4 , 3 , 9 , 6 , 14 , 9 , 21 , 13 , 27 , 17 , 33 , 21 , 40 , 24 , 45 , 27 , 50 , 30 , 54 , 32 , 56 , 32 , 57 , 32 , 55 , 30 , 53 , 26 , 45 , 22 , 35 , 68

/n

/ 46 / 29 / 15 / 31 / 22

/ 23

/ 57

/ 77

/ 46 / 37 / 62 / 29 / 93 / 31 / 57 / 27 / 81 / 33 / 72 / 26 / 52 / 37 / 44 / 18 / 25 / 22 / 35 / 40

minimax

/ 42

/ 42 / 24

/ 26

/ 24

a 1

2

1

0

3

2

6

3

8

5

13

6

27

7

16

12

24

12

49

14

28

14

50

20

48

15

34

28

33

13

19

19

31

35

and

β−1 0.907 0.901 0.904 0.911 0.906 0.903 0.904 0.905 0.901 0.900 0.905 0.908 0.916 0.908 0.900 0.900 0.917 0.902 0.904 0.901 0.914 0.909 0.902 0.904 0.901 0.900 0.911 0.915 0.929 0.906 0.945 0.933 0.914

designs,

Design

α

0.038

0.040

0.034

0.044

0.042

0.049

0.049

0.045

0.037

0.047

0.046

0.045

0.049

0.047

0.045

0.049

0.049

0.044

0.045

0.048

0.049

0.048

0.043

0.047

0.045

0.049

0.043

0.048

0.044

0.045

0.046

0.044

0.050

Single-stage

/n

/ 77 / 38 / 25 / 55 / 33 / 64 / 38 / 77 / 47 / 83 / 49 / 93 / 53 / 96 / 53 / 94 / 56 / 98 / 54 / 93 / 53 / 92 / 50 / 85 / 45 / 75 / 42 / 69 / 37 / 55 / 29 / 44 / 76

Single-Stage

a

7

4

3

9

6

14

9

21

14

27

17

35

21

41

24

45

28

52

30

54

32

58

33

58

32

55

32

54

30

46

25

39

69

2.3

p 1

0.15

0.20

0.25

0.25

0.30

0.30

0.35

0.35

0.40

0.40

0.45

0.45

0.50

0.50

0.55

0.55

0.60

0.60

0.65

0.65

0.70

0.70

0.75

0.75

0.80

0.80

0.85

0.85

0.90

0.90

0.95

0.95

0.95

ableT

p 0

0.05

0.10

0.15

0.20

0.25

0.30

0.35

0.40

0.45

0.50

0.55

0.60

0.65

0.70

0.75

0.80

0.85

10

Randomized Phase II Cancer Clinical Trials

). 9 , 0 EN 43.6 23.5 14.5 31.2 19.8 37.7 23.4 43.6 26.0 48.1 28.4 51.4 29.9 53.2 30.8 54.5 30.2 54.2 30.2 53.0 29.0 50.1 27.0 47.1 25.4 41.8 21.7 36.2 17.8 29.0 12.8 21.2 39.5

. 1 ( 0

β

= )

−

0.902

0.902

0.903

0.901

0.901

0.901

0.904

0.902

0.903

0.901

0.901

0.901

0.905

0.902

0.905

0.900

0.900

0.901

0.900

0.900

0.902

0.900

0.901

0.904

0.904

0.900

0.904

0.901

0.910

0.904

0.904

0.907

0.901

∗

1

β− Design α

, 1

0.079

0.074

0.075

0.100

0.098

0.091

0.096

0.088

0.089

0.099

0.086

0.091

0.094

0.096

0.099

0.098

0.097

0.091

0.078

0.097

0.100

0.096

0.095

0.095

0.090

0.095

0.082

0.091

0.090

0.096

0.091

0.093

0.097

∗ (α Optimal /n

/ 81

/ 88

/ 78

/ 84 / 45 / 75 / 41 / 71

/ 63 / 34 / 59

/ 48

/ 59

for

/ 55

/ 63 / 37 / 72 / 44 / 82 / 46

/ 47

/ 46

/ 45

/ 38

,a

/ 66 / 37 / 24 / 50 / 35

/ 33

/ 28

/ 20 / 37

1

, 5 , 3 , 2 , 7 , 5 , 11 , 7 , 16 , 10 , 22 , 14 , 29 , 17 , 33 , 20 , 40 , 22 , 40 , 24 , 47 , 26 , 46 , 26 , 47 , 26 , 45 , 25 , 45

, 39

, 53

/n

, 22

, 17 , 32

/ 28 / 12 / 90 / 21 / 12 / 23 / 19 / 27 / 17 / 29 / 14 / 30 / 22 / 34 / 20 / 38 / 18 / 32 / 20 / 35 / 21 / 34 / 18 / 34 / 11 / 30 / 15 / 20 / 9 / 16 / 7 / 9 / 29

a 1

1

0

2

1

3

3

5

3

7

3

9

7

6

5

7

12

7

16

7

14

9

18

11

19

10

21

6

20

10

14

12

25

designs

EN

51.3

26.4

16.4

33.7

20.4

41.7

24.2

45.5

28.3

52.1

31.5

56.0

35.0

59.3

36.9

57.2

33.8

68.0

30.8

58.0

31.0

60.1

32.9

54.4

28.5

42.6

22.0

36.8

20.0

33.1

12.0

20.8

47.3

o-stage

tw

β−1 0.901 0.901 0.903 0.900 0.903 0.900 0.905 0.900 0.902 0.900 0.901 0.902 0.900 0.900 0.903 0.900 0.901 0.902 0.900 0.900 0.902 0.901 0.902 0.900 0.900 0.901 0.904 0.903 0.902 0.900 0.904 0.905 0.906

Design

optimal

α

0.079

0.074

0.075

0.100

0.098

0.091

0.096

0.088

0.089

0.099

0.086

0.091

0.094

0.096

0.099

0.098

0.097

0.091

0.078

0.097

0.100

0.096

0.095

0.095

0.090

0.095

0.082

0.091

0.090

0.096

0.091

0.093

0.097

and

Minimax

/n

/ 53

/ 58 / 36 / 64 / 39 / 69 / 39 / 72 / 42 / 73 / 41 / 74 / 41 / 72 / 39 / 70 / 38 / 64 / 35 / 60 / 31 / 52 / 25 / 40

/ 58

,a

/ 60 / 32 / 20 / 40 / 25

/ 32

/ 19 / 31

1

, 5 , 3 , 2 , 6 , 4 , 11 , 7 , 15 , 10 , 20 , 13 , 25 , 15 , 30 , 18 , 34 , 20 , 38 , 22 , 41 , 23 , 43 , 24 , 43 , 24 , 43 , 23 , 40 , 20 , 33 , 16 , 27 , 52

minimax

/n

/ 39 / 18 / 13 / 27 / 16 / 34 / 17 / 33 / 19 / 39 / 23 / 50 / 28 / 43 / 36 / 45 / 28 / 67 / 21 / 40 / 23 / 58 / 32 / 43 / 27 / 33 / 13 / 22 / 16 / 27 / 8 / 7 / 45

a 1

1

0

0

2

1

5

2

6

3

9

5

6

5

16

7

14

15

18

11

34

9

19

11

35

20

25

18

22

8

15

11

20

40

and

β−1 0.903 0.907 0.909 0.904 0.910 0.909 0.918 0.905 0.910 0.905 0.905 0.904 0.900 0.903 0.922 0.909 0.903 0.902 0.901 0.904 0.906 0.909 0.914 0.901 0.911 0.912 0.904 0.909 0.902 0.900 0.925 0.926 0.921

designs,

Design

α

0.079

0.074

0.075

0.100

0.098

0.091

0.096

0.088

0.089

0.099

0.086

0.091

0.094

0.096

0.099

0.098

0.097

0.091

0.078

0.097

0.100

0.096

0.095

0.095

0.090

0.095

0.082

0.091

0.090

0.096

0.091

0.093

0.097

Single-stage

/n

/ 60 / 32 / 20 / 40 / 25 / 53 / 32 / 61 / 36 / 64 / 39 / 71 / 39 / 72 / 44 / 75 / 41 / 75 / 44 / 72 / 39 / 71 / 39 / 64 / 36 / 61 / 32 / 53 / 25 / 40 / 20 / 32 / 60

Single-Stage

a

5

3

2

6

4

11

7

16

10

20

13

26

15

30

19

35

20

39

24

41

23

44

25

43

25

44

24

41

20

33

17

28

54

2.4

p 1

0.15

0.20

0.25

0.25

0.30

0.30

0.35

0.35

0.40

0.40

0.45

0.45

0.50

0.50

0.55

0.55

0.60

0.60

0.65

0.65

0.70

0.70

0.75

0.75

0.80

0.80

0.85

0.85

0.90

0.90

0.95

0.95

0.95

ableT

p 0

0.05

0.10

0.15

0.20

0.25

0.30

0.35

0.40

0.45

0.50

0.55

0.60

0.65

0.70

0.75

0.80

0.85

Single-Arm Phase II Trial Designs

11

2.2

Two-Stage Designs

For ethical reasons, most clinical trials are required to have sequential designs.

Yet, for practical reasons, they are usually conducted as multistage experi-

ments instead of being fully sequential. Two-stage designs are commonly used

for phase II cancer clinical trials because of simplicity and diminishing returns

beyond two stages. In this section, we discuss various two-stage phase II trial

design methods.

2.2.1

Gehan’s Design

Gehan (1961) proposes a two-stage phase II trial design method. Let p denote

the true response rate of the experimental therapy of a phase II trial. At

the first stage, n 1 patients are treated with an experimental therapy to test

hypotheses H 0 : p ≤ p 0 vs. H 1 : p > p 0 for a specified value p 0. Let X 1 denote the number of responders among the n 1 patients. Given α, such as 0.05 or 0.1,

n 1 is chosen as the largest integer satisfying that the probability of observing

no responders among n 1 treated patients is no larger than α when p = p 0, that is, P (X > 0| p 0 ) ≤ α. For example, with p 0 = 0 . 2, we have n 1 = 14 if α = 0 . 05 and n 1 = 11 if α = 0 . 1.

If no responders are observed among the n 1 patients, then the study is

stopped after the first stage, concluding H 0. Otherwise, the study proceeds

to the second stage to treat an additional n 2 patients. The stage 2 sample

size n 2 is chosen so that the asymptotic standard error for the estimated

√

response rate from n = (n 1 + n 2 ) patients, SE =

p( 1 − p)/n, is smaller than

a prespecified value. Noting that SE depends on the unknown true response

rate p, Gehan proposed using the upper 75% confidence limit of p from stage 1

as an estimate of p in calculating SE. This estimate of p would provide a

conservative estimation of SE when the existing cancer drugs had low response

rates in the early years of cancer treatment. Using p = 0 . 5 will result in a

most conservative estimation of SE and n 2.

2.2.2

Simon’s Optimal Design

We consider a two-stage trial that is conducted as follows. During stage 1, n 1

patients are enrolled and treated. If the number of responders X 1 is less than or

equal to a 1, the trial is terminated for lack of efficacy, and it is concluded that

the treatment does not warrant further investigation. Otherwise, the study

is continued to stage 2, during which an additional n 2 patients are enrolled

and treated. Let X 2 denote the number of responders from stage 2. If the

cumulative number of responders after stage 2, X = X 1 + X 2, does not exceed

a, it is concluded that the treatment lacks sufficient efficacy. Otherwise, it is

concluded that the treatment has sufficient activity, and the treatment will

be considered for further investigation in subsequent trials.

12

Randomized Phase II Cancer Clinical Trials

A two-stage design is defined by the number of patients to be accrued during

stages 1 and 2, n 1 and n 2, and the rejection values a 1 and a ( a 1 < a), so we denote any two-stage design by (a 1 /n 1 , a/n), where n = n 1 + n 2 called the maximum sample size. The values of (a 1 /n 1 , a/n) are determined based on some prespecified design parameters ( p 0 , p 1 , α∗ , 1 − β∗ ) as in the single-stage design cases described in the previous section.

Noting that, for k = 1 , 2, Xk are independent B(nk, p) random variables, the probability of rejecting the treatment (or equivalently failing to reject

H 0 : p ≤ p 0) for a two-stage design is expressed as

R( p) = P(X 1 ≤ a 1 or X ≤ a| p)

min (n 1 ,a)



= B(a 1| n 1 , p) +

b(x 1| n 1 , p)B(a − x 1| n 2 , p)

x 1= a 1+1

when the true response rate is p. Note that the probability of early termination

after stage 1 is given as PET ( p) ≡ B(a 1| n 1 , p). The constraints on type I error probability and power are expressed as R( p 0 ) ≥ 1 − α∗ and R( p 1 ) ≤ β∗. Given (p 0 , p 1 , α∗ , 1 − β∗ ), there are many two-stage designs (a 1 /n 1 , a/n) satisfying the constraints.

Simon (1989) proposes two criteria to select a good two-stage design among

these designs. The minimax design minimizes the maximum sample size, n,

among the designs satisfying the (α∗ , 1 − β∗ )-constraint. On the other hand, the so-called optimal design minimizes the expected sample size EN under the

null hypothesis determined by

EN = PET ( p 0 ) × n 1 + {1 − PET ( p 0 )} × n.

Tables 2.1–2.4 present Simon’s minimax and optimal two-stage designs under

various design settings of ( p 0 , p 1 , α∗ , 1 − β∗ ). Note that under each design setting the maximum sample size for the two-stage minimax design is slightly

smaller than or equal to the sample size of the single-stage design. Further-

more, if the maximum sample size for the two-stage minimax design equals

the sample size of the single-stage design, then the rejection value of the sec-

ond stage for the two-stage design is the same as the rejection value of the

corresponding single-stage design.

2.2.3

Admissible Designs

Simon’s minimax and optimal designs have both been widely used, and other

designs have largely been ignored in the past for such two-stage phase II cancer

clinical trials. However, Simon’s designs may result in highly divergent sample

size requirements, as shown in the example below. For example, the minimax

design may have an excessively large EN as compared to the optimal design,

or the optimal design may have an excessively large maximum sample size n

as compared to the minimax design. This results from the discrete nature of

the binomial distribution.

Single-Arm Phase II Trial Designs

13

Example 2.2

For the design parameters ( p 0 , p 1 , α∗ , 1 − β∗ ) = ( 0 . 1 , 0 . 3 , 0 . 05 , 0 . 85 ), the minimax design is given by (a 1 /n 1 , a/n) = ( 2 / 18 , 5 / 27 ) and the optimal design by ( 1 / 11 , 6 / 35 ) from Table 2.2. The maximum sample size n for the minimax design is eight less than that for the optimal design. However, under H 0 the

expected sample size EN = 18 . 3 for the optimal design is only slightly smaller

than EN = 20 . 4 for the minimax design.

Simon’s designs are to some extent mathematical niceties. Also, as indi-

cated above, the minimax and optimal designs can be quite different. Often,

practical compromises are possible without changing the statistical operating

characteristics appreciably. To avoid these discrepancies in the maximum sam-

ple size and the expected sample size under the null hypothesis between the

minimax and the optimal designs, Jung, Carey, and Kim (2001) proposed a

heuristic graphical method to search for compromise designs, neither minimax

nor optimal, but with more desirable and practically appealing features.

Example 2.3 (Example 2.2 revisited)

For the same design parameters ( p 0 , p 1 , α∗ , 1 − β∗ ) = ( 0 . 1 , 0 . 3 , 0 . 05 , 0 . 85 ), the design given by (a 1 /n 1 , a/n) = ( 1 / 13 , 5 / 28 ) requires only one more patient in the maximum sample size n than the minimax design, but its expected

sample size EN under H 0 is very comparable to that of the optimal design

(18.7 vs. 18.3). Jung, Carey, and Kim (2001) recommend this design as a good

compromise between the minimax design and the optimal design.

For a given maximum sample size n, the designs satisfying the (α∗ , 1 − β∗ )-

constraint can be determined by an exhaustive enumeration. This can be

achieved readily by changing n 1 (= 1 , . . . , n − 1), a 1, and a (0 ≤ a 1 ≤ a ∧ n 1; a 1 ≤ a ≤ a 1 + n − n 1). From these designs, the one that minimizes EN is determined. This design dominates (in terms of n and EN) all other designs

for the given n. So, our search procedure for a good design will go through

only these dominating designs within a range of n values. We will call them

candidate designs. If n is too small, there may exist no designs satisfying the

(α∗ , 1− β∗ )-constraint, and as a result no candidate design either. This process is repeated by increasing n by 1 each time until an arbitrary upper limit, say

N , is reached. Typically, N may represent the number of available subjects

that can be accrued in a reasonable time period.

A program is developed to plot EN of the candidate designs against n given

the design parameters ( p 0 , p 1 , α∗ , 1 − β∗) and N . The plot starts with Simon’s minimax design and ends with n = N . From the plot, the design minimizing

EN within the range can be easily identified and is marked as “optimal.”

When N is large enough, this local optimal design is Simon’s optimal design.

This program, available from the author upon request, is written in Java and

is thus platform-independent.

14

Randomized Phase II Cancer Clinical Trials

Two-Stage Phase II Designs

P 0 26

ze under 24

ple Si

am S 22

edct

MiniMax

peEx 20

Admissible

Optimal

27

28

29

30

31

32

33

34

35

36

37

Maximal Sample Size

Figure 2.1

Two-stage designs for ( p 0 , p 1 , α∗ , 1 − β∗ ) = ( 0 . 1 , 0 . 3 , 0 . 05 , 0 . 85 ) with N = 37.

Figure 2.1 shows the plot of EN against n for ( p 0 , p 1 , α∗ , 1 − β∗ ) =

( 0 . 1 , 0 . 3 , 0 . 05 , 0 . 85 ) and N = 37 discussed in Example 2.2. Simon’s minimax design is given by (a 1 /n 1 , a/n) = ( 2 / 18 , 5 / 27 ) and optimal design by ( 1 / 11 , 6 / 35 ), which is also Simon’s optimal design. The program provides the specification of a design ( a 1 /n 1 , a/n) along with EN, PET ( p 0 ), PET ( p 1 ), and the exact type I error rate and power when the circle representing the candidate design, actually (n, EN ), is clicked with a pointer. Table 2.5 summarizes

the operating characteristics of various designs.

2.2.3.1

A Class of Admissible Designs

In this section, we will use formal statistical criteria to define a class of ad-

missible designs according to which compromise designs between the mini-

max and the optimal designs as proposed by Jung, Carey, and Kim (2001)

can be justified. In order to identify appropriate designs, we need to specify

(p 0 , p 1 , α∗ , 1 − β∗ ) and N.

Given ( p 0 , p 1 , α∗ , 1 − β∗ ) and N , let D denote the space of all candidate designs with n ≤ N satisfying the (α∗ , 1 − β∗ ) constraint. We consider two outcomes, ω 1 = n and ω 2 = EN, from each design d ∈ D. We use notations n(d) and EN (d), in place of n and EN, to relate each design to its outcomes.

Define a loss function

L(ω, d) = n(d)I (ω = ω 1 ) + EN (d)I (ω = ω 2 )

Single-Arm Phase II Trial Designs

15

in × D, where = { ω 1 , ω 2} and I (· ) is an indicator function. This loss function is justified on the ethical grounds that it is desirable to minimize

both the maximum number and the expected number of patients under the

null hypothesis in two-stage phase II cancer clinical trials.

Let Q be a probability distribution defined over as Q(ω = ω 1 ) = q and Q(ω = ω 2 ) = 1 − q for q ∈ [0 , 1]. For any design d ∈ D, the expected loss, or risk, is defined as



ρ(Q, d) =

L(ω, d)d Q(ω) = q × n(d) + ( 1 − q) × EN (d).



By considering only the designs with n ≤ N with N prespecified, ρ(Q, d) is finite for every d ∈ D. For a probability distribution Q, the Bayes risk is

defined as

ρ∗ (Q) = inf ρ(Q, d).

d∈ D

Any design d∗ ∈ D whose risk equals the Bayes risk is called a Bayes design

against the distribution Q under the specified loss function. Note that the

minimax design is a Bayes design against Q with q = 1 and Simon’s optimal

design is a Bayes design against Q with q = 0. Since Q is uniquely defined by

a constant q ∈ [0 , 1], we may use q and Q interchangeably.

A design d∗ is admissible if it is a Bayes design against a distribution Q.

Equivalently, a design d ∈ D is inadmissible if it is not a Bayes design for any

choice of q ∈ [0 , 1], that is, there exists dq ∈ D such that, for some q ∈ [0 , 1], ρ(q, d) > ρ(q, dq).

For d 1 , d 2 ∈ D, it is said that d 1 dominates d 2 if n(d 1 ) ≤ n(d 2 ) and EN (d 1 ) < EN (d 2 ), or n(d 1 ) < n(d 2 ) and EN (d 1 ) ≤ EN (d 2 ). In this case, d 2 cannot be an admissible design.

This approach can be easily modified to handle any number of stages and

different loss functions. Unlike Bayesian multistage designs or designs based

on predictive probabilities which have to assign a prior probability to the

probability of success, this method assumes that the probability of success is

fixed. Instead, we combine some existing optimality criteria, that is, assign

prior probabilities to the criteria, and identify admissible designs under the

criteria defined by various combinations of the existing criteria.

2.2.3.2

Search for Admissible Designs

Suppose that we want to find a Bayes design against the distribution with a

specified q in [0 , 1] according to the derivation given in the previous section.

There are two ways to identify admissible designs.

The first approach is to consider a straight line q × n + ( 1 − q) × EN = ρ

determined by ρ on the (n, EN )-plane, that is, a line with slope − q/( 1− q) and

16

Randomized Phase II Cancer Clinical Trials

intercept ρ/( 1 − q). Starting from a small ρ, we move the straight line upward

until it touches a design. The first design touched by the line is a Bayes design

with Bayes risk ρ∗ , where ρ∗ /( 1 − q) is the intercept of the straight line when it touches the Bayes design.

Suppose that we choose q = 1 / 2 for Example 2.2. Then, from Figure 2.1,

design (a 1 /n 1 , a/n) = ( 1 / 13 , 5 / 28 ) is a unique Bayes design. Noting that n = 28 and EN = 18 . 7 for this design, we obtain Bayes risk ρ∗ = q ×

n(d) + ( 1 − q) × EN (d) = 23 . 3. Again, Table 2.5 shows the two-stage designs discussed above, that is, Simon’s minimax and optimal designs and a

compromise design by Jung, Carey, and Kim (2001) for the design parameters

(p 0 , p 1 , α∗ , 1 − β∗ ) = ( 0 . 1 , 0 . 3 , 0 . 05 , 0 . 85 ) in Example 2.3. It also summarizes their operating characteristics such as the expected sample size EN under the

null hypothesis, exact type I error probability and power, the probability of

early termination both under the null and alternative hypotheses, and the

distribution Q specified by q against which the design is admissible.

In designing a phase II study, q ∈ [0 , 1] may be chosen depending on the

relative importance of n and EN. For example, if the study is on a rare disease

so that the accrual is very low, then we may choose a larger q to favor the

minimax design. On the other hand, if the accrual is not a problem but we

want to stop the study as early as possible when the treatment is inactive,

then we may choose a small q to favor the optimal design. Whichever is the

case, given ( p 0 , p 1 , α∗ , 1 − β∗ ) and N , a design may be regarded as a good one if it is a Bayes design over a wide range of q in [0 , 1]. In Figure 2.1, the

compromise design (a 1 /n 1 , a/n) = ( 1 / 13 , 5 / 28 ), which is admissible, can be identified by any straight line with slope − q/( 1− q) between −1 . 72 and −0 . 06, that is, for q ∈ [0 . 057 , 0 . 632]. Similarly we can show that Simon’s minimax and optimal designs are Bayes designs for q ∈ [0 . 632 , 1] and q ∈ [0 , 0 . 057], respectively.

The second approach is to consider a convex hull formed by connecting

candidate designs between Simon’s minimax design and the optimal design.

According to DeGroot (1970, pp. 125–127), any designs on the convex hull

are admissible. This procedure is implemented in our Java program so that

other admissible designs besides Simon’s minimax and optimal designs can be

automatically identified.

Table 2.5

Two-stage admissible designs for ( p 0 , p 1 , α∗ , 1 − β∗ ) =

( 0 . 1 , 0 . 3 , 0 . 05 , 0 . 85 )

( r 1 /n 1 , r/n)

EN

α

1 − β

PET ( p 0 )

PET ( p 1 )

q

(2/18, 5/27)

20.4

0.0444

0.851

0.734

0.060

[0.632, 1]

(1/13, 5/28)

18.7

0.0498

0.858

0.621

0.063

[0.057, 0.632]

(1/11, 6/35)

18.3

0.0422

0.851

0.697

0.113

[0, 0.057]

Note: The first and the third designs are Simon’s minimal and optimal designs, respectively.

Single-Arm Phase II Trial Designs

17

Two-Stage Phase II Designs

MiniMax

P 0 20

ze under 19

ple Si

Admissible

am S 18

edctpe

Admissible

Ex 17

Optimal

25

26

27

28

29

30

31

32

Maximal Sample Size

Figure 2.2

Two-stage designs for ( p 0 , p 1 , α∗ , 1− β∗ ) = ( 0 . 05 , 0 . 25 , 0 . 05 , 0 . 9 ) with N = 32.

In Figure 2.1, the design given by (a 1 /n 1 , a/n) = ( 1 / 13 , 5 / 28 ) is the only admissible design except for the minimax and the optimal designs.

Figure 2.2 shows candidate two-stage designs for ( p 0 , p 1 , α∗ , 1 − β∗ ) =

( 0 . 05 , 0 . 25 , 0 . 05 , 0 . 9 ) with N = 32. Admissible designs are highlighted at n = 25 (minimax design), 26, 28, and 30 (Simon’s optimal design). The designs

with n = 26 and 28 are admissible for q ∈ [0 . 377 , 0 . 660] and q ∈ [0 . 187 , 0 . 377], respectively. Table 2.6 summarizes admissible two-stage designs identified in

Figure 2.2 along with their operating characteristics.

Table 2.6

Two-stage admissible designs for ( p 0 , p 1 , α, 1 − β∗ ) =

( 0 . 05 , 0 . 25 , 0 . 05 , 0 . 9 )

(r 1 /n 1 , r/n)

EN

α

1 − β

PET ( p 0 )

PET ( p 1 )

q

(0/15, 3/25)

20.4

0.0336

0.901

0.463

0.013

[0.660, 1]

(0/12, 3/26)

18.4

0.0365

0.905

0.540

0.032

[0.377, 0.660]

(0/10, 3/28)

17.2

0.0426

0.906

0.599

0.056

[0.187, 0.372]

(0/9, 3/30)

16.8

0.0489

0.902

0.630

0.075

[0, 0.187]

Note: The first and the last designs are Simon’s minimal and optimal designs, respectively.

18

Randomized Phase II Cancer Clinical Trials

2.3

Two-Stage Designs with Both Upper and Lower

Stopping Values

When the experimental therapy of a phase II trial seems to be efficacious at

an interim analysis, there usually is no ethical rule to continue the trial and

collect more data to be used to design a future phase III trial. So, most two-

stage phase II cancer clinical trials use a lower (or futility) stopping value only

as in the previous sections. Sometimes, however, one may want to consider

stopping early when the experimental therapy is efficacious too.

A two-stage phase II trial with design { (a 1 , b 1 )/n 1 , a/n} proceeds as follows.

Stage 1: Treat n 1 patients, and observe the number of responders X 1.

(a) IF X 1 ≤ a 1, reject the experimental therapy and stop the trial.

(b) IF X 1 ≥ b 1, accept the experimental therapy and stop the trial.

(c) IF a 1 < X 1 < b 1, continue to stage 2.

Stage 2: Treat n 2 patients, and observe the number of responders X 2.

(a) IF X 1 + X 2 ≤ a, reject the experimental therapy.

(b) IF X 1 > a, accept the experimental therapy.

For a two-stage design { (a 1 , b 1 )/n 1 , a/n}, the probability of rejecting the therapy is given as

b 1−1



R( p) = B(a 1| n 1 , p) +

b(x| n 1 , p)B(a − x| n 2 , p).

x= a 1+1

The constraint on type I error probability and power is expressed as R( p 0 ) ≥

1 − α∗ and R( p 1 ) ≤ β∗.

Given ( p 0 , p 1 ), there are many designs satisfying a type I error rate and

power constraint (α∗ , 1 − β∗ ). Among them, the minimax design minimizes the maximum number of patients n = n 1 + n 2. For a response probability p, the expected sample size is given as

EN ( p) = PET ( p) × n 1 + {1 − PET ( p)} × n,

where PET ( p) = B(a 1| n 1 , p) + 1 − B(b 1| n 1 , p) is the probability of early termination after stage 1. Then the optimal design minimizes the average of the

expected sample sizes for p = p 0 and p = p 1 which is given as

EN = {EN ( p 0 ) + EN ( p 1 )} / 2

among the designs satisfying (α∗ , 1 − β∗ ).

Tables 2.7–2.10 list minimax and optimal two-stage designs with both up-

per and lower stopping values under various design settings of (α∗ , 1 − β∗ , p 0 , p 1 ). Here, EN0 = EN ( p 0 ) and EN1 = EN ( p 1 ).

Single-Arm Phase II Trial Designs

19

EN

37.3

19.1

12.5

27.0

16.9

34.4

20.3

40.2

23.9

45.4

25.7

48.7

27.3

50.1

28.7

51.8

29.2

52.2

29.0

50.8

27.7

49.5

27.0

45.6

25.0

42.1

22.4

36.9

18.8

30.2

15.0

22.7

42.5

1

EN

38.2

20.0

13.2

29.1

18.3

37.2

21.5

43.1

27.1

48.3

27.9

55.0

30.0

54.7

31.8

57.9

32.3

57.7

32.0

56.3

30.3

54.8

31.0

50.8

27.5

45.4

25.9

39.9

21.7

34.5

16.4

26.3

50.4

0

EN

36.3

18.1

11.9

24.9

15.5

31.7

19.0

37.3

20.7

42.6

23.5

42.4

24.6

45.6

25.7

45.7

26.0

46.6

25.9

45.3

25.1

44.1

23.0

40.4

22.6

38.9

18.8

33.8

15.8

25.8

13.6

19.1

34.6

). 8

β

, 0

Design

−1 0.800 0.806 0.812 0.801 0.812 0.805 0.801 0.802 0.802 0.801 0.801 0.801 0.802 0.801 0.808 0.801 0.807 0.802 0.805 0.802 0.801 0.806 0.805 0.801 0.801 0.801 0.808 0.800 0.815 0.804 0.835 0.804 0.803

. 05 ( 0= α

)

Optimal

0.050

0.050

0.047

0.050

0.048

0.049

0.050

0.049

0.047

0.050

0.048

0.049

0.050

0.049

0.050

0.050

0.049

0.049

0.048

0.049

0.049

0.049

0.049

0.050

0.047

0.050

0.048

0.048

0.048

0.050

0.048

0.049

0.049

∗ β−

/n

/ 64

/ 79

/ 79 / 42 / 78 / 46 / 76 / 47 / 76 / 46 / 80 / 42 / 78 / 42 / 68 / 44 / 62 / 38 / 55 / 28 / 49 / 25 / 46 / 66

, 1

,a

/ 60 / 28 / 17 / 47 / 27 / 53 / 35

/ 37

/ 39

∗

1

, 30

, 34

, 37

, 41 , 26 , 47 , 26 , 50

, 47 , 32 , 46 , 29 , 44

, 41 , 22 , 41 , 60

n

, 6 , 3 , 2 , 8 , 5 , 12 , 9 , 18 , 11 , 27 , 14

, 17

, 21

, 24

, 28

, 23

(α

)/

25

11

9

18

11

13

30

32

30

20

36

20

31

20

32

20

35

20

31

14

30

18

34

14

26

12

21

12

15

27

)/ )/ )/ )/ )/ 24

14

18

)/ )/ )/ )/ )/ )/ )/ )/ )/ )/ )/ )/ )/ )/ )/ )/ )/ )/ )/ )/ )/ )/ )/ )/ )/ )/ )/ )/

,b 1

, 4 , 3 , 3 ( 0 , 5 , 4 , 8 , 5 , 11 , 7 , 13 , 9 , 15 , 11 , 19 , 12 , 19 , 13 , 21 , 14 , 24 , 15 , 23 , 12 , 24 , 15 , 28 , 13 , 23 , 12 , 20 , 12 , 15 , 27

(a 1

( 1 ( 0

( 2 ( 1 ( 4 ( 2 ( 7 ( 3 ( 9 ( 5

( 7

( 8

( 9

( 8 ( 19 ( 12 ( 24 ( 10 ( 19 ( 9 ( 17 ( 10 ( 13 ( 24

values

( 10

( 14

( 13

( 15 ( 10 ( 19 ( 11 ( 18

stopping

EN

40.4

19.0

13.6

33.9

19.2

36.8

21.7

44.4

24.9

51.6

26.7

52.3

31.0

58.8

29.7

55.8

34.7

54.2

33.5

66.1

29.5

56.0

28.8

47.1

25.7

45.3

26.1

38.4

23.4

32.0

16.8

23.3

46.9

erw

1

lo

EN

40.1

19.3

13.4

33.9

17.5

36.9

22.7

46.6

24.9

49.3

28.5

53.2

31.3

60.7

33.8

57.4

35.1

57.1

35.8

66.2

32.1

55.9

31.6

51.3

27.4

48.7

26.8

41.6

23.6

36.4

17.5

25.1

52.2

and

0

er

EN

40.7

18.6

13.8

33.9

20.8

36.6

20.7

42.3

24.9

53.8

24.9

51.3

30.7

56.9

25.6

54.2

34.3

51.3

31.2

66.0

26.9

56.0

26.0

43.0

24.0

41.8

25.4

35.2

23.1

27.5

16.2

21.4

41.6

upp

β

Design

oth

−

b

1

0.801

0.802

0.801

0.803

0.800

0.801

0.805

0.800

0.800

0.800

0.805

0.800

0.800

0.801

0.801

0.801

0.804

0.802

0.806

0.801

0.802

0.800

0.802

0.800

0.802

0.802

0.807

0.803

0.801

0.801

0.806

0.818

0.811

with

α

Minimax

0.046

0.049

0.043

0.048

0.049

0.049

0.048

0.049

0.049

0.050

0.049

0.049

0.049

0.050

0.050

0.050

0.050

0.050

0.050

0.049

0.050

0.050

0.050

0.050

0.049

0.050

0.048

0.049

0.046

0.050

0.049

0.050

0.050

/n

designs

/ 64

/ 66

/ 69 / 39 / 70 / 39 / 68 / 37 / 65 / 36 / 62 / 33 / 55 / 30 / 49 / 26 / 39 / 20 / 30 / 57

,a

/ 51 / 27 / 16 / 38 / 24 / 47 / 28 / 53 / 32 / 59 / 36

/ 36

/ 39

1

, 25

, 29

, 34 , 20 , 38 , 22 , 40 , 23 , 42 , 24 , 43 , 24 , 41 , 23 , 39 , 21 , 33 , 17 , 27 , 52

n

, 5 , 3 , 2 , 7 , 5 , 11 , 7 , 15 , 10 , 20 , 13

, 15

, 18

)/

32

12

12

33

13

18

39

38

43

27

55

19

41

34

41

30

66

20

48

24

35

17

31

25

30

23

23

16

19

39

)/ )/ )/ )/ )/ 29

15

17

)/ )/ )/ )/ )/ )/ )/ )/ )/ )/ )/ )/ )/ )/ )/ )/ )/ )/ )/ )/ )/ )/ )/ )/ )/ )/ )/ )/

o-stage

,b 1

, 5 , 3 , 3 , 7 , 4

, 7

, 22 , 41 , 16 , 34 , 20 , 28 , 15 , 27 , 22 , 27 , 21 , 23 , 16 , 19 , 39

( 1 ( 0 ( 0 ( 4 ( 0 , 9

, 7

, 9 , 20

, 29

, 24 , 20 , 26

( 4 ( 3 , 15 ( 2 , 16 ( 4

, 14

, 13

Tw

(a 1

( 9

( 7

( 13 ( 8 ( 22 ( 7 ( 16 ( 17 ( 19 ( 16 ( 39 ( 10 ( 26 ( 15 ( 22 ( 10 ( 20 ( 19 ( 22 ( 19 ( 18 ( 14 ( 16 ( 35

p 1

2.7

0.15

0.20

0.25

0.25

0.30

0.30

0.35

0.35

0.40

0.40

0.45

0.45

0.50

0.50

0.55

0.55

0.60

0.60

0.65

0.65

0.70

0.70

0.75

0.75

0.80

0.80

0.85

0.85

0.90

0.90

0.95

0.95

0.95

able

p 0

0.05

0.10

0.15

0.20

0.25

0.30

0.35

0.40

0.45

0.50

0.55

0.60

0.65

0.70

0.75

0.80

0.85

T

20

Randomized Phase II Cancer Clinical Trials

EN

44.9

23.3

15.2

32.7

20.6

39.9

23.4

47.2

27.4

52.1

30.1

56.1

31.2

58.2

32.9

59.7

33.8

59.6

33.5

58.9

32.4

56.7

30.6

52.9

28.5

47.9

25.3

42.3

21.7

34.7

16.2

26.0

48.3

1

EN

47.7

22.5

15.9

33.1

22.0

41.4

24.6

50.5

29.6

57.1

32.6

59.3

33.6

62.6

35.1

64.8

35.7

63.6

35.3

64.6

35.3

61.9

32.6

59.4

30.8

52.6

27.1

45.8

23.5

38.8

18.1

28.9

53.6

). 85

0

, 0

EN

42.2

24.1

14.6

32.3

19.3

38.4

22.1

43.9

25.3

47.1

27.6

52.8

28.8

53.9

30.7

54.6

31.8

55.6

31.6

53.1

29.5

51.5

28.5

46.4

26.2

43.1

23.5

38.7

20.0

30.6

14.3

23.1

42.9

. 05 ( 0

β−

=

Design

1

0.854

0.851

0.851

0.860

0.867

0.859

0.862

0.869

0.861

)

0.852

0.854

0.853

0.856

0.855

0.852

0.850

0.851

0.851

0.852

0.855

0.852

0.850

0.853

0.853

0.852

0.852

0.851

0.851

0.850

0.856

0.852

0.856

0.850

∗ β−

α

, 1

0.044

0.047

0.041

0.050

0.041

0.050

0.050

0.050

0.048

0.050

0.048

0.048

0.050

0.050

0.050

0.050

0.049

0.050

0.048

0.048

0.049

0.048

0.050

0.049

0.050

0.049

0.048

0.050

0.047

0.050

0.049

0.047

0.049

Optimal

∗ (α

/n

/ 89

/ 88

/ 58 / 99 / 53 / 89 / 54 / 93 / 48 / 85 / 53 / 83 / 35 / 66 / 34 / 50 / 30 / 38 / 78

,a

/ 78 / 35 / 27 / 47 / 33 / 62 / 41 / 78 / 41 / 86 / 49

/ 52

/ 48 / 102

1

, 34

, 38

, 30 , 53 , 30 , 52 , 33 , 59 , 32 , 58 , 38 , 61 , 27 , 52 , 28 , 42 , 26 , 34 , 71

n

, 7 , 4 , 3 , 8 , 6 , 14 , 10 , 21 , 12 , 28 , 17

, 21

, 22 , 49

42

38

23

43

26

38

22

39

22

33

21

33

19

31

16

22

12

18

35

values

)/

33

14

13

23

16

37

30

21

21

22

41

)/ )/ )/ )/ )/ 30 17

21

)/ )/ )/ )/ )/ )/ )/ )/ )/ )/ )/ )/ )/ )/ )/ )/ )/ )/ )/ )/ )/ )/ )/ )/ )/ )/ )/ )/

,b 1

, 5 , 3 , 3 , 6 , 5 , 9 , 6 , 13 , 9 , 13 , 10 , 19 , 11 , 20 , 13 , 23 , 14 , 26 , 17 , 26 , 16 , 28 , 17 , 26 , 17 , 27 , 17 , 27 , 15 , 21 , 12 , 18 , 34

(a 1

( 2 ( 0 ( 1 ( 2 ( 2 ( 5 ( 3 ( 9 ( 5 ( 8 ( 6 ( 14 ( 7 ( 14 ( 8 ( 18 ( 10 ( 21 ( 13 ( 20 ( 12 ( 23 ( 13 ( 21 ( 14 ( 23 ( 13 ( 23 ( 12 ( 17 ( 10 ( 15 ( 31

stopping

erw

EN

53.5

28.3

16.7

41.2

20.1

45.6

27.3

55.1

29.0

59.7

39.1

69.8

37.9

64.1

42.1

67.5

36.0

65.4

39.2

74.4

33.6

69.8

38.4

57.0

34.6

50.7

25.8

43.1

21.5

44.2

19.7

27.9

55.7

lo

1

and

EN

53.2

28.3

16.7

41.2

21.0

43.7

25.0

54.1

32.1

59.6

39.1

69.8

38.4

64.7

42.2

66.2

37.8

66.1

40.5

74.6

36.3

70.0

38.6

58.5

35.0

54.0

28.1

46.3

24.2

44.4

20.7

30.5

57.5

er

0

upp

EN

53.7

28.3

16.7

41.2

19.3

47.4

29.6

56.2

26.0

59.8

39.1

69.7

37.5

63.5

42.1

68.7

34.2

64.6

37.8

74.2

31.0

69.6

38.2

55.6

34.2

47.4

23.5

39.9

18.9

44.1

18.6

25.2

53.9

othb

β

Design

−1 0.850 0.850 0.852 0.852 0.851 0.850 0.850 0.850 0.851 0.850 0.851 0.852 0.851 0.850 0.852 0.850 0.851 0.850 0.851 0.851 0.854 0.850 0.852 0.850 0.852 0.854 0.851 0.853 0.852 0.851 0.895 0.856 0.853

with

α

0.050

0.050

0.046

0.049

0.047

0.050

0.049

0.050

0.049

0.050

0.047

0.050

0.050

0.050

0.050

0.050

0.048

0.049

0.050

0.050

0.049

0.050

0.050

0.049

0.049

0.050

0.050

0.050

0.049

0.047

0.050

0.048

0.050

Minimax

designs

/n

/ 69 / 41 / 75 / 42 / 78 / 44 / 80 / 45 / 80 / 45 / 79 / 44 / 75 / 41 / 71 / 38 / 65 / 34 / 57 / 28 / 47 / 23 / 35 / 65

,a

/ 60 / 31 / 21 / 44 / 27 / 53 / 32 / 61 / 37

1

, 23 , 15 , 29 , 17 , 34 , 20 , 39 , 23 , 43 , 25 , 46 , 27 , 48 , 27 , 49 , 27 , 48 , 26 , 45 , 23 , 39 , 20 , 31 , 59

n

, 6 , 4 , 3 , 8 , 5 , 12 , 8 , 17 , 11

52

28

16

41

14

37

20

48

56

39

69

37

57

42

57

30

50

37

74

22

69

38

38

34

41

21

34

14

44

18

24

53

o-stage

)/

)/ )/ )/ )/ )/ )/ )/ )/ 17 )/ )/ )/ )/ )/ )/ )/ )/ )/ )/ )/ )/ )/ )/ )/ )/ )/ )/ )/ )/ )/ )/ )/ )/ )/

,b 1

, 6 , 4 , 3 , 8 , 5

, 7

Tw

, 11

, 17 , 9 , 21 , 15 , 28 , 18 , 28 , 21 , 31 , 19 , 31 , 25 , 46 , 17 , 46 , 28 , 30 , 27 , 34 , 19 , 30 , 14 , 39 , 18 , 24 , 51

(a 1

( 3 ( 2 ( 1 ( 6 ( 1 ( 4 ( 1 ( 8 ( 3 ( 15 ( 13 ( 24 ( 14 ( 21 ( 19 ( 22 ( 13 ( 22 ( 20 ( 43 ( 11 ( 42 ( 25 ( 22 ( 24 ( 28 ( 15 ( 25 ( 10 ( 37 ( 15 ( 21 ( 48

2.8

p 1

0.15

0.20

0.25

0.25

0.30

0.30

0.35

0.35

0.40

0.40

0.45

0.45

0.50

0.50

0.55

0.55

0.60

0.60

0.65

0.65

0.70

0.70

0.75

0.75

0.80

0.80

0.85

0.85

0.90

0.90

0.95

0.95

0.95

able

p 0

0.05

0.10

0.15

0.20

0.25

0.30

0.35

0.40

0.45

0.50

0.55

0.60

0.65

0.70

0.75

0.80

0.85

T

Single-Arm Phase II Trial Designs

21

EN

52.4

28.2

17.2

38.2

23.3

47.7

27.7

54.6

32.5

60.8

35.2

65.2

37.3

67.9

38.8

69.9

39.2

70.0

39.1

68.7

37.8

65.9

36.1

61.6

33.0

55.4

29.5

48.4

24.3

39.7

19.8

28.4

56.3

1

EN

51.7

26.9

17.2

37.8

24.5

48.8

28.2

57.1

33.4

63.8

36.5

68.3

38.8

71.2

40.5

71.3

41.4

74.4

42.5

72.8

39.3

69.7

38.9

66.1

35.2

58.4

32.0

52.0

26.8

42.9

20.4

32.2

59.9

). 9

0

, 0

EN

53.1

29.4

17.2

38.7

22.2

46.6

27.3

52.1

31.6

57.8

33.8

62.2

35.8

64.6

37.0

68.4

37.0

65.6

35.7

64.7

36.4

62.1

33.3

57.1

30.7

52.3

27.0

44.7

21.7

36.5

19.3

24.6

52.7

. 05 ( 0

β−

=

Design

1

0.904

0.901

0.901

0.902

0.905

0.903

0.916

0.904

0.910

)

0.901

0.901

0.901

0.902

0.901

0.901

0.900

0.901

0.901

0.901

0.904

0.900

0.901

0.900

0.901

0.900

0.905

0.902

0.902

0.902

0.900

0.900

0.900

0.901

∗ β−

α

, 1

0.049

0.046

0.042

0.049

0.048

0.049

0.049

0.050

0.045

0.050

0.050

0.050

0.049

0.049

0.049

0.050

0.050

0.049

0.049

0.049

0.049

0.049

0.048

0.050

0.048

0.050

0.049

0.050

0.049

0.048

0.049

0.049

0.049

Optimal

∗ (α

/n

/ 99 / 63

/ 67

/ 62

/ 62

/ 59

/ 52

/ 55 / 86 / 57 / 82 / 42 / 61 / 32 / 44 / 99

,a

/ 78 / 46 / 26 / 60 / 41 / 86 / 42 / 89 / 54 / 100 / 61

/ 108

/ 110

/ 114

/ 109

/ 113

/ 106

1

, 37 , 25

, 30

, 31

, 34

, 36

, 34

, 39 , 63 , 43 , 64 , 34 , 51 , 28 , 39 , 90

n

, 7 , 5 , 3 , 10 , 7 , 19 , 10 , 24 , 16 , 32 , 21

, 46

, 53

, 60

, 63

, 71

, 72

49

29

30

26

25

22

27

22

41

21

35

16

27

18

18

43

values

)/

32

14

11

17

37

46

25

48

52

48

49

49

41

)/ )/ )/ 24

31

20

23

)/ )/ )/ )/ )/ )/ )/ )/ )/ )/ )/ )/ )/ )/ )/ )/ )/ )/ )/ )/ )/ )/ )/ )/ )/ )/ )/ )/ )/ )/

,b 1

, 5 , 3 , 3 , 6 , 5 , 9 , 7 , 13 , 9 , 18 , 11 , 22 , 14 , 24 , 16 , 28 , 16 , 29 , 17 , 32 , 16 , 34 , 21 , 31 , 18 , 33 , 18 , 30 , 15 , 25 , 17 , 18 , 41

(a 1

( 1 ( 0 ( 0 ( 2 ( 2 ( 5 ( 3 ( 8 ( 5 ( 13 ( 7 ( 16 ( 10 ( 18 ( 12 ( 22 ( 11 ( 23 ( 12 ( 26 ( 11 ( 29 ( 16 ( 26 ( 14 ( 28 ( 15 ( 26 ( 12 ( 21 ( 15 ( 15 ( 38

stopping

erw

EN

66.4

27.8

17.6

47.7

23.6

51.2

30.4

65.6

34.3

65.7

36.9

79.6

42.1

85.2

41.1

77.7

42.0

93.1

40.3

74.0

41.3

82.2

40.2

74.8

34.5

60.5

37.2

52.7

27.2

42.4

22.5

35.5

62.4

lo

1

and

EN

66.4

27.2

16.7

47.6

23.2

51.3

30.6

64.6

32.9

65.9

37.7

80.8

40.8

85.2

41.1

79.0

43.9

93.1

41.3

75.8

41.4

82.8

41.7

76.4

35.1

62.6

37.3

54.9

27.5

46.5

22.8

35.8

65.7

er

0

upp

EN

66.5

28.3

18.5

47.9

24.0

51.2

30.1

66.5

35.7

65.5

36.2

78.4

43.3

85.3

41.0

76.3

40.1

93.0

39.3

72.2

41.1

81.6

38.7

73.1

34.0

58.3

37.1

50.5

27.0

38.3

22.2

35.2

59.2

othb

β

Design

−1 0.901 0.901 0.903 0.901 0.900 0.901 0.901 0.900 0.901 0.900 0.901 0.901 0.900 0.900 0.901 0.900 0.902 0.902 0.901 0.900 0.900 0.901 0.902 0.900 0.902 0.900 0.902 0.900 0.901 0.901 0.902 0.901 0.903

with

α

0.049

0.050

0.045

0.049

0.047

0.050

0.049

0.048

0.050

0.050

0.048

0.050

0.050

0.049

0.049

0.050

0.050

0.050

0.049

0.050

0.049

0.050

0.050

0.050

0.050

0.050

0.050

0.050

0.049

0.049

0.049

0.050

0.049

Minimax

designs

/n

/ 76

/ 83

/ 88

/ 93 / 53 / 94 / 54 / 95 / 54 / 93 / 51 / 89 / 49 / 84 / 45 / 75 / 40 / 65 / 33 / 54 / 26 / 40 / 75

,a

/ 73 / 38 / 25 / 53 / 33 / 64 / 38

/ 44

/ 49

/ 50

1

, 21

, 27

, 33

, 40 , 24 , 45 , 27 , 50 , 30 , 54 , 31 , 56 , 32 , 57 , 32 , 55 , 30 , 51 , 27 , 45 , 22 , 35 , 68

n

, 7 , 4 , 3 , 9 , 6 , 14 , 9

, 13

, 17

, 20

66

24

13

47

16

38

26

62

25

57

28

77

34

84

30

53

36

93

32

59

34

81

37

72

24

46

37

41

26

34

22

35

57

o-stage

)/

)/ )/ )/ )/ )/ )/ )/ )/ )/ )/ )/ )/ )/ )/ )/ )/ )/ )/ )/ )/ )/ )/ )/ )/ )/ )/ )/ )/ )/ )/ )/ )/ )/

,b 1

, 7 , 4 , 3 , 9 , 5

, 9

Tw

, 12

, 19 , 10 , 22 , 13 , 34 , 17 , 38 , 17 , 31 , 22 , 51 , 21 , 39 , 24 , 55 , 28 , 54 , 20 , 38 , 30 , 36 , 23 , 32 , 21 , 33 , 55

(a 1

( 5 ( 1 ( 0 ( 6 ( 1 ( 5 ( 4 ( 13 ( 4 ( 15 ( 7 ( 27 ( 9 ( 33 ( 10 ( 20 ( 16 ( 49 ( 15 ( 30 ( 17 ( 50 ( 23 ( 48 ( 14 ( 30 ( 28 ( 29 ( 20 ( 27 ( 19 ( 31 ( 51

2.9

p 1

0.15

0.20

0.25

0.25

0.30

0.30

0.35

0.35

0.40

0.40

0.45

0.45

0.50

0.50

0.55

0.55

0.60

0.60

0.65

0.65

0.70

0.70

0.75

0.75

0.80

0.80

0.85

0.85

0.90

0.90

0.95

0.95

0.95

able

p 0

0.05

0.10

0.15

0.20

0.25

0.30

0.35

0.40

0.45

0.50

0.55

0.60

0.65

0.70

0.75

0.80

0.85

T

22

Randomized Phase II Cancer Clinical Trials

EN

43.0

22.7

14.0

30.7

19.3

38.1

22.8

43.6

26.0

48.2

28.6

51.7

29.4

54.0

30.9

54.8

30.7

54.8

30.9

54.0

29.4

51.7

28.6

48.2

26.0

43.6

22.8

38.1

19.3

30.7

14.0

22.7

43.0

1

41.3

21.2

13.0

29.3

17.9

38.3

22.3

42.8

25.7

47.5

29.0

52.6

29.6

54.4

30.5

54.7

30.7

55.0

31.3

53.6

29.3

50.8

28.2

48.9

26.3

44.4

23.4

37.9

20.8

32.0

15.0

24.3

44.7

)

EN

. 9

0

, 0 . 1

EN

44.7

24.3

15.0

32.0

20.8

37.9

23.4

44.4

26.3

48.9

28.2

50.8

29.3

53.6

31.3

55.0

30.7

54.7

30.5

54.4

29.6

52.6

29.0

47.5

25.7

42.8

22.3

38.3

17.9

29.3

13.0

21.2

41.3

( 0

β

= ) Design −

∗

1

0.901

0.900

0.900

0.900

0.902

0.900

0.904

0.902

0.903

0.900

0.903

0.902

0.900

0.902

0.904

0.902

0.901

0.902

0.900

0.913

0.912

β

0.900

0.903

0.907

0.901

0.906

0.903

0.904

0.900

0.906

0.901

0.905

0.901

− , 1

α

∗

Optimal

0.088

0.087

0.100

0.098

0.099

0.098

0.096

0.098

0.100

0.098

0.097

0.100

0.097

0.098

0.096

0.100

0.098

0.100

0.100

0.100

0.099

0.099

0.095

0.099

0.094

0.100

0.096

0.097

0.094

0.099

0.093

0.097

0.100

(α

/n

/ 83

/ 89

/ 79

/ 79

/ 89 / 47 / 83

/ 73 / 47 / 68 / 40 / 59

/ 50

/ 32 / 71

,a

/ 71 / 32 / 26 / 50

/ 68

/ 73

/ 47

/ 52

/ 49

/ 52

/ 46

/ 26

/ 30 / 59 / 40

/ 47

/ 46

/ 30

1

, 30

, 37

, 37

, 41

, 51 , 28 , 52 , 30 , 49 , 33 , 49 , 30 , 46

, 41 , 22 , 28 , 64

values

n

, 6 , 3 , 3 , 8 , 5 , 12 , 9 , 18 , 13 , 23 , 15

, 18

, 23

, 24

, 28

, 24

)/

29

16

10

23

9

15

34

33

33

20

34

18

38

22

38

18

34

20

33

17

33

19

34

15

27

9

23

10

16

29

)/ )/ )/ )/ )/ 27

19

17

)/ )/ )/ )/ )/ )/ )/ )/ )/ )/ )/ )/ )/ )/ )/ )/ )/ )/ )/ )/ )/ )/ )/ )/ )/ )/ )/ )/

,b 1

, 4 , 3 , 2 , 5 , 3

, 9

( 0 , 8 , 5 , 11 , 7 , 13 , 8 , 15 , 10 , 17 , 10 , 21 , 13 , 23 , 12 , 22 , 14 , 23 , 13 , 25 , 15 , 27 , 13 , 23 ( 6 , 21 , 10 , 16 , 28

(a 1

( 1 ( 0 ( 0 ( 2

( 4 ( 2 ( 7 ( 4 ( 8 ( 4 ( 10 ( 6 ( 12 ( 6 ( 15 ( 9 ( 17 ( 8 ( 17 ( 10 ( 18 ( 9 ( 20 ( 12 ( 23 ( 10 ( 19

( 18 ( 8 ( 13 ( 25

stopping

erwlo

EN

48.8

23.2

15.7

32.3

19.5

39.1

23.7

46.8

29.2

52.1

33.4

57.2

32.0

57.2

32.9

60.4

32.0

60.4

32.9

57.2

32.0

57.2

33.4

52.1

29.2

46.8

23.7

39.1

19.5

32.3

15.7

23.2

48.8

1

and

er

EN

47.6

21.3

15.2

31.0

18.7

36.4

22.4

48.3

28.3

51.8

32.8

58.0

31.3

56.6

31.4

63.7

32.0

57.1

34.3

57.8

32.7

56.4

34.0

52.3

30.1

45.3

25.1

41.8

20.3

33.6

16.2

25.1

49.9

upp

0

EN

49.9

25.1

16.2

33.6

20.3

41.8

25.1

45.3

30.1

52.3

34.0

56.4

32.7

57.8

34.3

57.1

32.0

63.7

31.4

56.6

31.3

58.0

32.8

51.8

28.3

48.3

22.4

36.4

18.7

31.0

15.2

21.3

47.6

othb

β

Design

−

0.902

0.901

0.903

0.901

0.903

0.900

0.905

0.901

0.903

0.902

0.900

0.901

0.901

0.901

0.902

0.900

0.900

0.900

0.902

0.901

0.903

0.900

0.902

0.900

0.901

0.900

0.901

0.901

0.901

0.900

0.926

0.910

0.903

with

1

α

0.097

0.090

0.074

0.100

0.099

0.099

0.099

0.100

0.099

0.100

0.098

0.100

0.097

0.099

0.098

0.100

0.100

0.100

0.098

0.099

0.099

0.099

0.100

0.098

0.097

0.099

0.095

0.100

0.097

0.099

0.097

0.099

0.098

designs

Minimax

/n

/ 64

/ 69

/ 72

/ 73

/ 73 / 41 / 72 / 39 / 69 / 38 / 64 / 35 / 58 / 31 / 52

/ 40 / 20 / 31 / 58

,a

/ 58 / 31 / 20 / 40 / 25 / 52 / 31 / 58 / 35

/ 38

/ 39

/ 41

/ 41

/ 25

1

, 20

, 25

, 30

, 34

, 38 , 22 , 41 , 23 , 43 , 24 , 43 , 24 , 42 , 23 , 40

, 33 , 17 , 27 , 52

n

, 5 , 3 , 2 , 6 , 4 , 11 , 7 , 15 , 10

, 13

, 15

, 18

, 20

, 20

o-stage

)/

46

18

13

22

11

19

33

42

32

52

26

38

26

45

22

45

26

38

26

52

32

42

27

33

19

28

11

22

13

18

46

)/ )/ )/ )/ )/ 28

27

)/ )/ )/ )/ )/ )/ )/ )/ )/ )/ )/ )/ )/ )/ )/ )/ )/ )/ )/ )/ )/ )/ )/ )/ )/ )/ )/ )/

Tw

,b 1

, 5 , 3 , 3 , 6 , 4 , 8 , 6 , 13 , 9 , 17 , 12 , 23 , 13 , 20 , 14 , 27 , 14 , 27 , 18 , 26 , 19 , 35 , 24 , 32 , 22 , 27 , 17 , 25 , 11 , 21 , 13 , 18 , 44

(a 1

( 2 ( 0 ( 0 ( 1 ( 0 ( 3 ( 2 ( 6 ( 5 ( 10 ( 8 ( 17 ( 7 ( 12 ( 8 ( 18 ( 8 ( 18 ( 12 ( 18 ( 13 ( 29 ( 20 ( 25 ( 18 ( 20 ( 13 ( 20 ( 7 ( 16 ( 10 ( 15 ( 41

2.10

p 1

0.15

0.20

0.25

0.25

0.30

0.30

0.35

0.35

0.40

0.40

0.45

0.45

0.50

0.50

0.55

0.55

0.60

0.60

0.65

0.65

0.70

0.70

0.75

0.75

0.80

0.80

0.85

0.85

0.90

0.90

0.95

0.95

0.95

able

p 0

0.05

0.10

0.15

0.20

0.25

0.30

0.35

0.40

0.45

0.50

0.55

0.60

0.65

0.70

0.75

0.80

0.85

T

Single-Arm Phase II Trial Designs

23

Chang et al. (1987) and Therneau et al. (1990) use the same optimality

criterion, but they search for optimal (a 1 , b 1 , b) with n or (n 1 , n 2 ) fixed, while we search for optimal designs for all possible (n 1 , n 2 ) values.

References

Chang, M.N., Therneau, T.M., Wieand, H.S., and Cha, S.S. (1987). Designs

for group sequential phase II clinical trials. Biometrics, 43, 865–874.

DeGroot, M.H. (1970). Optimal Statistical Decisions. McGraw-Hill, New

York.

Gehan, E.A. (1961). The determination of the number of patients required in

a follow-up trial of a new chemotherapeutic agent. Journal of Chronic

Diseases, 13, 346–353.

Jung, S.H., Carey, M., and Kim, K.M. (2001). Graphical search for two-stage

designs for phase II clinical trials. Controlled Clinical Trials, 22, 367–

372.

Simon, R. (1989). Optimal two-stage designs for phase II clinical trials. Con-

trolled Clinical Trials, 10, 1–10.

Therneau, T.M., Wieand, H.S., and Chang, M. (1990). Optimal designs for a

group sequential trial Biometrics, 46, 771–781.





Chapter 3

Inference on the Binomial Probability

in Single-Arm Multistage

Clinical Trials

Because of ethical and economical reasons, clinical trials are often designed

as sequential experiments, as discussed in Chapter 2. A multistage sequential

design can be described as follows: At each stage of the trial, a predetermined

number of patients are treated. Then the accumulated number of treatment

responses is compared to the stopping boundaries. If the accumulated number

of responders is smaller than or equal to the lower boundary, the trial is termi-

nated for lack of treatment efficacy. If the accumulated number of responders

is larger than or equal to the upper boundary, the trial may be terminated for

high treatment efficacy. Obviously, early termination for high efficacy in this

setting is not as ethically imperative. Otherwise, an additional fixed number

of patients will be treated at the next stage. This will continue until early

termination or until the predetermined number of stages. Multistage designs

have been described and investigated by Schultz, Nichol, Elfring, and Weed

(1973), Herson (1979), Fleming (1982), and Chang, Therneau, Wieand, and

Cha (1987), among others.

When a multistage trial is ended, we also want to estimate the true response

probability p of the new therapy. The most commonly used estimator is the

sample response rate, that is, the maximum likelihood estimator (MLE). How-

ever, in multistage designs, we observe only extreme cases by crossing either

the lower or upper boundary, and hence the MLE is biased. This is known as

the optional sampling effect. The bias of the MLE tends to be larger in studies

with lower stopping boundaries only (as in most multistage phase II studies)

than in studies with both upper and lower the stopping boundaries. Let M

denote the stage at which a trial is terminated, and S denote the cumulative

number of responders at stage M. We show that (M, S) is a complete and suf-

ficient statistic for p for the aforementioned multistage designs. Hence, noting

that the sample proportion after the first stage is an unbiased estimator, we

can obtain the uniformly minimum variance unbiased estimator (UMVUE)

by taking the conditional expectation of the first stage sample proportion

given (M, S) = (m, s) according to the Rao–Blackwell theorem, where m and

s denote specific observations of random variables M and S, respectively.

25

26

Randomized Phase II Cancer Clinical Trials

In multistage designs involving continuous observations, Liu and Hall (1999)

proved that the stopping stage and the cumulated sum of observations up to

the stopping stage are sufficient but not complete for the unknown mean.

Hence, in this case, the conditional expectation of the first stage sample mean

given the sufficient statistics is only an efficient estimator, but not necessarily

the UMVUE, contrary to Emerson and Fleming (1990). We will discuss a

general result developed by Jung and Kim (2004) for multistage designs for

phase II clinical trials in cancer drug screening. Specifically, we will derive the

UMVUE for the binomial probability following multistage testing.

Jennison and Turnbull (1983) and Duffy and Santner (1987) propose con-

fidence intervals for p based on (M, S). To construct a confidence interval,

we need a stochastic ordering among all possible (m, s) values. We show that

the ordering by the magnitude of the UMVUE is the same as that used by

Jennison and Turnbull (1983).

In analyzing phase II trials, investigators usually report an estimate of p and

its confidence interval, and whether the treatment is accepted or not. However,

none of these exactly tell us how significant evidence is against H 0 : p = p 0

that we observe from the data. We obtain this information by calculating the

p-value. Calculation of p-value for the testing associated with a multistage

phase II trial requires a linear ordering of the outcomes in the two-dimensional

sample space. Emerson and Fleming (1990) and Chang, Gould, and Snapinn

(1995) study p-values of sequential testings using continuous observations.

Usually, phase II trials have small sample sizes (about 50), so that these

continuous variable approaches do not provide a good approximation for these

trials with binary outcomes. In this chapter, we also investigate calculation of

p-values based on exact binomial sequential distributions. We will consider the

ordering by MLE and UMVUE. We also briefly investigate the performance

of the p-value based on the likelihood ratio ordering by Emerson and Fleming

(1990) as a normal approximation to binary data.

Lastly, we investigate application of the confidence interval and p-value

methods to the cases when the realized sample size of a multistage phase II

is different from that specified at the design stage.

3.1

Point Estimation

Let K be the number of stages, and nk and Xk denote the number of patients

accrued and the number of responders, respectively, during stage k, 1 ≤ k ≤ K .



And let S

k

k =

X

i =1

i denote the cumulative number of responders by stage

k. In designing a multistage phase II study to test hypotheses on response

probability, we usually select lower and upper boundaries ak and bk ( ak < bk)

to stop the study after stage k if Sk ≤ ak, concluding that the treatment under consideration is not very promising, or if Sk ≥ bk, concluding that it is very

Inference on the Binomial Probability

27

promising. We set aK = bK − 1 to make sure that the study terminates before

or at stage K . To allow early termination only for lack of clinical efficacy, we

choose any number larger than n 1 + · · · + nk as bk. This is justified as there is no compelling reason to terminate the trial early if the treatment appears to

have the desired effect and only terminate early if the treatment lacks such

an effect. There may be circumstances where the opposite is true.

Let M denote the stopping stage, and let S = SM denote the total number

of responders accumulated up to the stopping stage. The MLE of p is given



as ˜ p = p(m, s) = s/

m

n

k=1

k . As is derived in Appendix 3.A, the probability

mass function of the random vector (M, S) is given by

f (m, s| p) = cm,s ps( 1 − p)n 1+···+ nm− s

( 3 . 1 )

with support S = ∪ K S

m=1 m , where

Sm = { (m, s) : am−1 + 1 ≤ s ≤ am or bm ≤ s ≤ nm + bm−1 − 1}



and a

n 1

0 = −1 and b 0 = 1. Here c 1 ,s =

and, for m ≥ 2,

s





n 1

nm

cm,s =

· · ·

· · ·

x

x

x

1

m

1

xm

with the summations over the set

R(m, s) = { (x 1 , . . . , xm) : x 1 + · · · + xm = s,

ak + 1 ≤ x 1 + · · · + xk ≤ bk − 1 for k = 1 , . . . , m − 1} .

Note that the dimension of R(m, s) is m − 1.

In Appendix 3.A, we also prove that (M, S) is a complete and sufficient

statistic. Since ˜ p 1 = X 1 /n 1 is an unbiased estimator of p, the UMVUE of p is obtained as ˆ p = E{˜ p 1| (m, s)} by the Rao–Blackwell theorem. For observation

(m, s), the UMVUE is given by





· · ·

n 1

nm

n 1−1

n 2

nm

R(

· · ·

· · ·

· · ·

m,s) x 1

R(m,s)

ˆ p =

x 1

xm

=

x 1−1

x 2

xm





,

( 3 . 2 )

n

n 1

nm

1 cm,s

· · · R(

· · ·

m,s) x 1

xm



where we define n = 0 if x < 0. See Appendix 3.B for the detailed derivation.

x

Note that calculation of the UMVUE requires specification of the stopping

boundaries for stages up to m − 1, that is, (ak, bk) for 1 ≤ k ≤ m − 1, as well as the summary statistic value (m, s). At stage m, we may accrue slightly

more (or possibly fewer) patients than nm, especially in multicenter trials;

see Green and Dahlberg (1992) and Herndon (1998). In this case, we do not

have to delete the extra patients (or temporarily reopen the study to accrue

more patients) for the UMVUE calculation. Since UMVUE does not require

specification of the stopping boundaries at stage m, we can use all patients

accrued in the estimation.

28

Randomized Phase II Cancer Clinical Trials

Girshick, Mosteller, and Savage (1946) and Lehmann (1983) prove that

the number of successes X and the number of failures Y at the termination

of a study are jointly complete and sufficient statistics for p and derive the

UMVUE for a family of sequential binomial trials. Noting that the family

includes the multistage phase II study design and (M, S) and (X, Y ) are one-

to-one, the two UMVUE’s are identical.

It is easy but tedious to show that the ordering of the sample space for

(M, S) by the magnitude of the UMVUE is the same as that by Jennison and

Turnbull (1983). See also Armitage (1958) and Tsiatis, Rosner, and Mehta

(1984). In other words, we have

ˆ p( 1 , 0 ) < ˆ p( 1 , 1 ) < · · · < ˆ p( 1 , a 1 )

< ˆ p( 2 , a 1 + 1 ) < · · · < ˆ p( 2 , a 2 )

...

< ˆ p(K, aK−1 + 1 ) < · · · < ˆ p(K, aK )

<

( 3 . 3 )

ˆ p(K , bK ) < · · · < ˆ p(K , bK−1 − 1 + nK )

< ˆ p(K − 1 , bK−1 ) < · · · < ˆ p(K − 1 , bK−2 − 1 + nK−1 )

...

< ˆ p( 1 , b 1 ) < · · · < ˆ p( 1 , n 1 ) where ˆ p(m, s) is the UMVUE for (M, S) = (m, s). The stochastic ordering

for the distribution of the UMVUE is proved in Appendix 3.C in the case of

two-stage designs, as discussed in the next section.

3.1.1

Two-Stage Designs

Very often in cancer clinical trials, the number of stages is chosen to be 2. Let

p 0 denote the maximum unacceptable probability of response and p 1 denote

the minimum acceptable probability of response ( p 0 < p 1).

For two-stage designs, the UMVUE given in formula (3.2) simplifies to



 s



m = 1

n 1

ˆ p =



,

(

 s∧ (b 1−1 )

3 . 4 )



)( n 2 )

x 1= (a 1+1 )∨ (s− n 2 ) (n 1−1

x 1−1

s− x 1

s∧ (b 1−1 )

)( n 2 )

m = 2

x 1= (a 1+1 )∨ (s− n 2 ) (n 1

x 1

s− x 1

where a ∧ b = min (a, b) and a ∨ b = max (a, b). Note that ˆ p = ˜ p when m = 1.

In a two-stage design with lower and upper boundaries a 1 and b 1 for stage 1,

the MLE can be written specifically as

˜ p = X 1 I (X 1 ≤ a 1 or X 1 ≥ b 1 ) + X 1 + X 2 I (a 1 < X 1 < b 1 ) =

s



.

n

m

1

n 1 + n 2

n

k=1

k

Inference on the Binomial Probability

29

From formula (3.1), the probability mass function of (M, S) in a two-stage

design with lower stopping boundaries only is given as







n

 ps( 1 − p)n 1− s 1

m = 1 ,

0 ≤ s ≤ a

s

1





f (m, s| p) =

n

n

n



1 ∧ s

1

2

. ( 3 . 5 )

 ps( 1 − p)n 1+ n 2− s

m = 2 ,

a

x

1 + 1 ≤ s

1 = a 1 +1

x 1

s− x 1

≤ n 1 + n 2

As an example, we consider p 0 = 0 . 2 as the maximum unacceptable prob-

ability of response and p 1 = 0 . 4 as the minimum acceptable probability of

response. In this setting, we may consider a two-stage design with lower stop-

ping boundaries only. In the first stage, we treat n 1 = 13 patients, of which

if we observe a 1 = 3 or fewer responders, we conclude that the true response

probability is at most p 0 and stop the trial, and otherwise go on to the second

stage. In the second stage, we treat an additional n 2 = 30 patients. Out of the

total of n(= n 1 + n 2 ) = 43 patients treated, if we observe a(= a 2 ) = 12 or fewer responders, we also conclude that the true response probability is at most p 0,

and otherwise we conclude that the true response probability is at least p 1 and

we consider further investigation of the therapy. From Table 2.1 in Chapter 2,

this is Simon’s optimal design for ( p 0 , p 1 , α∗ , 1 − β∗ ) = ( 0 . 2 , 0 . 4 , 0 . 05 , 0 . 8 ).

Table 3.1 gives the UMVUE and the MLE for observations from a two-stage

design with n 1 = 13 and n 2 = 30 and lower boundaries a 1 = 3 and a 2 = 12 as given above. This design is optimal according to Simon (1989) for p 0 = 0 . 2

and p 1 = 0 . 4 with α∗ = 0 . 05 and β∗ = 0 . 2. When m = 1, two estimates are exactly the same as noted earlier. When m = 2, the MLE is much smaller than

UMVUE for small s values. We also calculated the probability mass function

f (m, s| p) of (M, S) for the true response probabilities p = 0 . 1 : 0 . 5 ( 0 . 1 ) according to formula (3.5).

The probability mass functions for the UMVUE and for the MLE follow-

ing termination of this two-stage design based on f (m, s| p) are plotted in

Figure 3.1. Note that for the observations for which the UMVUE and the

MLE are very different, the probability mass function has very small values.

The difference is largest at (m, s) = ( 2 , a 1 + 1 ), where ˜ p = (a 1 + 1 )/(n 1 + n 2 ) while ˆ p = (a 1 + 1 )/n 1 from formula (3.2). For ( 2 , s) with large s, the UMVUE

and the MLE are very similar. Overall, the UMVUE and the MLE tend to

be close to each other as p → 0 . 5. Most significantly, the distributions of the

UMVUE are stochastically increasing in p, whereas those for the MLE are not.

3.1.2

Numerical Studies

To understand the extent of the bias of the MLE following two-stage phase

II clinical trials and the relative efficiency of the UMVUE as compared to the

MLE defined as the ratio of the mean squared error (MSE) of the MLE to the

variance of the UMVUE, we conducted numerical studies based on two-stage

designs with lower stopping boundaries only as they are the most commonly

used designs.

30

Randomized Phase II Cancer Clinical Trials

Table 3.1

UMVUE, MLE, and probability mass for true p at each

observation in a two-stage design with n 1 = 13 and n 2 = 30 and lower

boundaries a 1 = 3 and a 2 = 12 to test H 0 : p 0 = 0 . 2 versus H 1 : p 1 = 0 . 4 with α = 0 . 05 and β = 0 . 2

f (m, s| p) for p

m

s

UMVUE

MLE

0.1

0.2

0.3

0.4

0.5

1

0

0.000

0.000

0.254

0.055

0.010

0.001

0.000

1

1

0.077

0.077

0.367

0.179

0.054

0.011

0.002

1

2

0.154

0.154

0.245

0.268

0.139

0.045

0.010

1

3

0.231

0.231

0.100

0.246

0.218

0.111

0.035

2

4

0.308

0.093

0.001

0.000

0.000

0.000

0.000

2

5

0.312

0.116

0.004

0.002

0.000

0.000

0.000

2

6

0.317

0.140

0.007

0.006

0.001

0.000

0.000

2

7

0.322

0.163

0.008

0.015

0.002

0.000

0.000

2

8

0.328

0.186

0.006

0.027

0.006

0.000

0.000

2

9

0.335

0.209

0.004

0.038

0.015

0.001

0.000

2

10

0.343

0.233

0.002

0.043

0.030

0.003

0.000

2

11

0.351

0.256

0.001

0.041

0.049

0.008

0.000

2

12

0.360

0.279

0.000

0.033

0.068

0.018

0.001

2

13

0.371

0.302

0.000

0.023

0.081

0.033

0.003

2

14

0.382

0.326

0.000

0.014

0.084

0.054

0.006

2

15

0.395

0.349

0.000

0.007

0.076

0.076

0.013

2

16

0.409

0.372

0.000

0.003

0.062

0.096

0.025

2

17

0.424

0.395

0.000

0.001

0.044

0.107

0.042

2

18

0.440

0.419

0.000

0.001

0.029

0.108

0.063

2

19

0.458

0.442

0.000

0.000

0.017

0.098

0.085

2

20

0.477

0.465

0.000

0.000

0.009

0.080

0.105

2

21

0.496

0.488

0.000

0.000

0.004

0.059

0.116

2

22

0.517

0.512

0.000

0.000

0.002

0.040

0.118

2

23

0.538

0.535

0.000

0.000

0.001

0.025

0.108

2

24

0.560

0.558

0.000

0.000

0.000

0.014

0.091

2

25

0.582

0.581

0.000

0.000

0.000

0.007

0.069

2

26

0.605

0.605

0.000

0.000

0.000

0.003

0.048

2

27

0.628

0.628

0.000

0.000

0.000

0.001

0.030

2

28

0.651

0.651

0.000

0.000

0.000

0.001

0.017

2

29

0.674

0.674

0.000

0.000

0.000

0.000

0.009

2

30

0.698

0.698

0.000

0.000

0.000

0.000

0.004

2

31

0.721

0.721

0.000

0.000

0.000

0.000

0.002

2

32

0.744

0.744

0.000

0.000

0.000

0.000

0.001

2

33

0.767

0.767

0.000

0.000

0.000

0.000

0.000

2

34

0.791

0.791

0.000

0.000

0.000

0.000

0.000

2

35

0.814

0.814

0.000

0.000

0.000

0.000

0.000

2

36

0.837

0.837

0.000

0.000

0.000

0.000

0.000

2

37

0.861

0.861

0.000

0.000

0.000

0.000

0.000

2

38

0.884

0.884

0.000

0.000

0.000

0.000

0.000

2

39

0.907

0.907

0.000

0.000

0.000

0.000

0.000

2

40

0.930

0.930

0.000

0.000

0.000

0.000

0.000

2

41

0.954

0.954

0.000

0.000

0.000

0.000

0.000

2

42

0.977

0.977

0.000

0.000

0.000

0.000

0.000

2

43

1.000

1.000

0.000

0.000

0.000

0.000

0.000

Inference on the Binomial Probability

31

for . 20= β

1.0

1.0

and

0.8

0.8

0.6

0.6

. 05

= 0.5

0

p

0.4

0.4

Estimate

=

0.2

0.2

α

0.0

0.0

0.3

0.2

0.1

0.0

0.3

0.2

0.1

0.0

with

1.0

1.0

0.8

0.8

Design

0.6

0.6

= 0.4 p

0.4

0.4

Estimate

0.2

0.2

Optimal

0.0

0.0

0.3

0.2

0.1

0.0

0.3

0.2

0.1

0.0

1.0

1.0

o-Stage

0.8

0.8

Tw

0.6

0.6

p = 0.3

0.4

0.4

Estimate

wing

0.2

0.2

0.0

0.0

follo

0.3

0.2

0.1

0.0

0.3

0.2

0.1

0.0

1.0

1.0

0.8

0.8

UMVUE

0.6

0.6

= 0.2 p

the

0.4

0.4

Estimate

0.2

0.2

and

0.0

0.0

0.3

0.2

0.1

0.0

0.3

0.2

0.1

0.0

MLE

1.0

1.0

the

0.8

0.8

of

0.6

0.6

= 0.1 p

0.4

0.4

Estimate

0.2

0.2

. 4.0

0.0

0.0

=

0.3

0.2

0.1

0.0

0.3

0.2

0.1

0.0

Distribution

p 1

UMVUE

MLE

3.1

and . 20=

Figure

p 0

32

Randomized Phase II Cancer Clinical Trials

Based on the probability mass function, we can evaluate the bias of the

MLE explicitly by



bias (˜ p| p) =

˜ p(m, s) f (m, s| p) − p.

(m,s)∈ S

However, noting that X 1 and X 2 are independent binomial random variables,

we can determine the bias explicitly as

b



1 −1



n 1

bias (˜ p| p) = −

n 2

(x 1 − n 1 p)

px 1 ( 1 − p)n 1− x 1 .

( 3 . 6 )

n 1 (n 1 + n 2 )

x

x

1

1 = a 1 +1

The MSE of the MLE can be determined directly using the probability mass

function of the sufficient statistics (M, S) according to formula (3.1) as follows:



MSE{˜ p(m, s)} =

{˜ p(m, s) − p}2 f (m, s| p).

(m,s)∈ S

The variance of the UMVUE is obtained by replacing ˜ p with ˆ p in this expres-

sion.

For various two-stage optimal and minimax designs according to Simon

(1989), we evaluate the bias of the MLE according to formula (3.6). We also

evaluate the MSE of the MLE and the variance of UMVUE for these designs.

Two sets of numerical studies have been performed; the first set (a) with fixed

type I and II error probabilities but with varying p 0 and p 1 and the second

set (b) with fixed p 0 and p 1 but with varying type I and II error probabilities.

In the first set of numerical studies (a), we consider Simon’s optimal and

minimax designs (a 1 /n 1 , a 2 /(n 1 + n 2 )) with α = 0 . 05 and β = 0 . 1 for the following binomial probabilities:

a.I p 0 = 0 . 1 and p 1 = 0 . 3: optimal = ( 2 / 18 , 6 / 35 ), minimax = ( 2 / 22 , 6 / 33 ) a.II p 0 = 0 . 2 and p 1 = 0 . 4: optimal = ( 4 / 19 , 15 / 54 ), minimax =

( 5 / 24 , 13 / 45 )

a.III p 0 = 0 . 3 and p 1 = 0 . 5: optimal = ( 8 / 24 , 24 / 63 ), minimax =

( 7 / 24 , 21 / 53 )

These numerical studies are conducted to evaluate the bias of the MLE and

the relative efficiency of the UMVUE as compared to the MLE for different

values of the true binomial probability.

In the second set of numerical studies (b), we consider Simon’s optimal and

minimax designs to test p 0 = 0 . 2 versus p 1 = 0 . 4 with the following type I and II error probabilities:

Inference on the Binomial Probability

33

b.I α = 0 . 1 and β = 0 . 1: optimal = ( 3 / 17 , 10 / 37 ), minimax = ( 3 / 19 , 10 / 36 ) b.II α = 0 . 05 and β = 0 . 2: optimal = ( 3 / 13 , 12 / 43 ), minimax =

( 4 / 18 , 10 / 33 )

b.III α = 0 . 05 and β = 0 . 1: optimal = ( 4 / 19 , 15 / 54 ), minimax =

( 5 / 24 , 13 / 45 )

These numerical studies are conducted to evaluate the bias of the MLE and

the relative efficiency of the UMVUE as compared to the MLE for different

values of the type I and II error probabilities.

Figures 3.2a and 3.2b display bias of the MLE for designs a.I, a.II, and a.III

and for designs b.I, b.II, and b.III, respectively, for a range of true p values,

including p 0 and p 1. The bias of the MLE is bigger at p values around the

middle of p 0 and p 1, but somewhat closer to p 0 rather than at the extreme

values. Overall, the bias of the MLE tends to be bigger with optimal designs

than with minimax designs.

Figures 3.3a and 3.3b display the relative efficiency of the UMVUE as com-

pared to the MLE, that is, the ratio of the MSE of the MLE to the variance

of the UMVUE, for designs a.I, a.II, and a.III and for designs b.I, b.II, and

b.III, respectively, for a range of true p values, including p 0 and p 1. For all designs, the MLE has smaller MSE for smaller p values than UMVUE, but

larger MSE for larger p values. There appears to be some efficiency loss with

Design a. I

Design a. II

Design a. III

0.0

0.0

0.0

–0.01

–0.01

–0.01

Optimal –0.02

–0.02

–0.02

–0.03

–0.03

–0.03

0.0

0.1

0.2

0.3

0.4

0.1

0.2

0.3

0.4

0.5

0.2

0.3

0.4

0.5

0.6

0.0

0.0

0.0

–0.01

–0.01

–0.01

Minimax –0.02

–0.02

–0.02

–0.03

–0.03

–0.03

0.0

0.1

0.2

0.3

0.4

0.1

0.2

0.3

0.4

0.5

0.2

0.3

0.4

0.5

0.6

p

p

p

Figure 3.2(a)

Bias of the MLE for Two-Stage Optimal and Minimax De-

signs with α = 0 . 05 and β = 0 . 1: I ( p 0 = 0 . 1 and p 1 = 0 . 3), II ( p 0 = 0 . 2 and p 1 = 0 . 4), III ( p 0 = 0 . 3 and p 1 = 0 . 5).

34

Randomized Phase II Cancer Clinical Trials

Design b. I

Design b. II

Design b. III

0.0

0.0

0.0

–0.01

–0.01

–0.01

Optimal –0.02

–0.02

–0.02

–0.03

–0.03

–0.03

0.1

0.2

0.3

0.4

0.5

0.1

0.2

0.3

0.4

0.5

0.1

0.2

0.3

0.4

0.5

0.0

0.0

0.0

–0.01

–0.01

–0.01

Minimax –0.02

–0.02

–0.02

–0.03

–0.03

–0.03

0.1

0.2

0.3

0.4

0.5

0.1

0.2

0.3

0.4

0.5

0.1

0.2

0.3

0.4

0.5

p

p

p

Figure 3.2(b)

Bias of the MLE for Two-Stage Optimal and Minimax

Designs for p 0 = 0 . 2 and p 1 = 0 . 4: I ( α = 0 . 1 and β = 0 . 1), II ( α = 0 . 5

and β = 0 . 2), III ( α = 0 . 05 and β = 0 . 1).

Design a. I

Design a. II

Design a. III

1.1

1.1

1.1

1.0

1.0

1.0

0.9

0.9

0.9

Optimal 0.8

0.8

0.8

0.7

0.7

0.7

0.6

0.6

0.6

0.0

0.1

0.2

0.3

0.4

0.1

0.2

0.3

0.4

0.5

0.2

0.3

0.4

0.5

0.6

1.1

1.1

1.1

1.0

1.0

1.0

0.9

0.9

0.9

Minimax 0.8

0.8

0.8

0.7

0.7

0.7

0.6

0.6

0.6

0.0

0.1

0.2

0.3

0.4

0.1

0.2

0.3

0.4

0.5

0.2

0.3

0.4

0.5

0.6

p

p

p

Figure 3.3(a)

Relative Efficiency of the UMVUE for Two-Stage Optimal

and Minimax Designs with α = 0 . 05 and β = 0 . 1: I ( p 0 = 0 . 1 and p 1 = 0 . 3), II ( p 0 = 0 . 2 and p 1 = 0 . 4), III ( p 0 = 0 . 3 and p 1 = 0 . 5).

Inference on the Binomial Probability

35

Design b. I

Design b. II

Design b. III

1.1

1.1

1.1

1.0

1.0

1.0

0.9

0.9

0.9

Optimal 0.8

0.8

0.8

0.7

0.7

0.7

0.6

0.6

0.6

0.1

0.2

0.3

0.4

0.5

0.1

0.2

0.3

0.4

0.5

0.1

0.2

0.3

0.4

0.5

1.1

1.1

1.1

1.0

1.0

1.0

0.9

0.9

0.9

Minimax 0.8

0.8

0.8

0.7

0.7

0.7

0.6

0.6

0.6

0.1

0.2

0.3

0.4

0.5

0.1

0.2

0.3

0.4

0.5

0.1

0.2

0.3

0.4

0.5

p

p

p

Figure 3.3(b)

Relative Efficiency of the UMVUE for Two-Stage Optimal

and Minimax Designs for p 0 = 0 . 2 and p 1 = 0 . 4: I ( α = 0 . 1 and β = 0 . 1), II ( α = 0 . 5 and β = 0 . 2), III ( α = 0 . 05 and β = 0 . 1).

the UMVUE as compared to the MLE, particularly for optimal designs, a

reasonable price for unbiasedness.

With a moderate n 1 (with n 1 p ≥ 5 as a rule of thumb), the binomial mass

function is approximately symmetric about n 1 p, so that the right-hand side

of formula (3.6) becomes very small for p such that n 1 p ≈ (a 1 + b 1 )/ 2. Similarly, the bias tends to be negative (positive) in studies with lower (upper)

boundaries only. Also, the MLE will be more biased in studies with one-sided

stopping boundaries than in those with lower and upper boundaries. Chang,

Wieand, and Chang (1989) provide a study of bias of the MLE in studies with

lower and upper boundaries proposed by Chang, Therneau, Wieand, and Cha

(1987).

3.2

Confidence Intervals

The confidence intervals determined according to Clopper and Pearson (1934)

and the stochastic ordering based on the magnitude of the UMVUE are the

same as those by Jennison and Turnbull (1983) by considering tail probabil-

ities. With the UMVUE ˆ p(m, s), an exact 100 ( 1 − α)% equal tail confidence

interval ( pL, pU ) for p is given by

Pr (ˆ p(M, S) ≥ ˆ p(m, s)| p = pL) = α/ 2

36

Randomized Phase II Cancer Clinical Trials

and

Pr (ˆ p(M, S) ≤ ˆ p(m, s)| p = pU ) = α/ 2 .

Confidence limits pL and pU can be obtained by a linear search procedure,

such as the bisection method, solving the equations.

For example, suppose that we observed (m, s) = ( 2 , 7 ) from a two-stage study with lower boundaries only, (n 1 , n 2 , a 1 , a 2 ) = ( 13 , 30 , 3 , 12 ). In this case, we have b 1 = 14, (a 1 + 1 ) ∨ (s − n 2 ) = ( 3 + 1 ) ∨ ( 7 − 30 ) = 4, and s ∧ (b 1 − 1 ) =

7 ∧ ( 14 − 1 ) = 7. From (3.2) or (3.4) in the following section, the UMVUE is





7

13−1

30

ˆ

x

p( 2 , 7 ) =

1 =4

x 1−1

7− x 1





= 0 . 322 .

7

13

30

x 1=4 x 1

7− x 1

Using (3.1), we have

Pr (ˆ p(M, S) ≥ . 322| p = . 103 ) = . 025 ,

Pr (ˆ p(M, S) ≤ . 322| p = . 538 ) = . 025 ,

so that a 95% confidence interval on p is given as (. 103 , . 538 ), which is the same as the one according to Jennison and Turnbull (1983). In contrast, a

naive 95% confidence interval by Clopper and Pearson (1934) ignoring the

group sequential aspect of the study is given as (. 068 , . 307 ). Note that the latter is narrower than the former by ignoring the group sequential aspect of

the study. Furthermore, the former is slightly shifted to the right from the

latter to reflect the fact that the study has been continued to stage 2 after

observing more responders than a 1 = 3 in stage 1.

3.3

P-Values

If one ignores the multistage design aspect of the study, S may be regarded as

a binomial random variable from Nm = n 1 + · · · + nm independent Bernoulli

trials. This leads to a naive p-value

N





m



v =

Nm

Pr (S ≥ s| p 0 ) =

pi ( 1 − p 0 )Nm− i

i

0

i = s

for observed values (M, S) = (m, s). However, the naive p-value does not

have the property that a proper p-value should have that is, the distribu-

tion of the naive p-value V = v(M, S) under H 0 does not have the property

Pr (V ≤ v| H 0 ) = v for the observable p-values, v ∈ [0 , 1]. This occurs because the assumed binomial distribution for S is incorrect under the two-stage

design.

The true null distribution of V = v(M, S) is calculated using the probability

mass function f (m, s| p 0 ) of (M, S). From (3.1), the probability mass function

Inference on the Binomial Probability

37

of the random vector (M, S) is given by

f (m, s| p) = cm,s ps( 1 − p)Nm− s

with support S = ∪ K S

m=1 m , where

Sm = { (m, s) : am−1 + 1 ≤ s ≤ am or bm ≤ s ≤ nm + bm−1 − 1}



and a

n 1

0 = −1 and b 0 = 1. Here c 1 ,s =

and, for m ≥ 2,

s





n 1

nm

cm,s =

· · ·

· · ·

x

x

x

1

m

1

xm

with the summations over the set

R(m, s) = { (x 1 , . . . , xm) : x 1 + · · · + xm

= s, ak + 1 ≤ x 1 + · · · + xk ≤ bk − 1

for k = 1 , . . . , m − 1} .



We define n = 0 if x < 0 or x > n.

x

Let ˆ

θ(M, S) denote an estimator of p. Then, a p-value may be defined as the

probability of obtaining more extreme estimates toward H 1 than the observed

one when H 0 is true. Hence, for testing H 0 : p = p 0 against H 1 : p > p 0, the p-value for an estimate ˆ

θ(m, s) will be given as

Pr (ˆ θ(M, S) ≥ ˆ θ(m, s)| p 0 ) =

f (i, j| p 0 ).

{ (i, j):ˆ θ(i, j)≥ˆ θ(m,s)}

We consider two estimators, MLE ˜ p(M, S) and UMVUE ˆ p(M, S), in this

section.

By minimizing f (m, s| p) with respect to p, we obtain the well-known MLE

as

˜ p(m, s) = s .

Nm

Note that the naive p-value is also based on the ordering of MLE, but without

using the correct probability density function f (m, s| p 0 ) for the outcomes.

As shown in Appendix 3.C, the UMVUE has a natural stochastic ordering

of

ˆ p( 1 , 0 ) < ˆ p( 1 , 1 ) < · · · < ˆ p( 1 , a 1 )

< ˆ p( 2 , a 1 + 1 ) < · · · < ˆ p( 2 , a 2 )

...

< ˆ p(K, aK−1 + 1 ) < · · · < ˆ p(K, aK )

< ˆ p(K, bK ) < · · · < ˆ p(K, bK−1 − 1 + nK )

< ˆ p(K − 1 , bK−1 ) < · · · < ˆ p(K − 1 , bK−2 − 1 + nK−1 )

...

< ˆ p( 1 , b 1 ) < · · · < ˆ p( 1 , n 1 ).

38

Randomized Phase II Cancer Clinical Trials

The probability mass function f (m, s| p) depends on the stopping boundaries

only up to stage m − 1, that is, { (ak, bk), 1 ≤ k ≤ m − 1}. This property combined with the monotonicity of the above stochastic ordering implies that,

given (M, S) = (m, s), the p-value based on UMVUE can be calculated if p 0

and the stopping boundaries up to stage m − 1 are given since



{ (

p-value =

i, j):ˆ p(i, j)≥ˆ p(m,s)} f (i, j | p 0 )

if s ≥ bm



1 −

{ (i, j):ˆ p(i, j)< ˆ p(m,s)} f (i, j | p 0 ) if s ≤ am In contrast, calculation of the p-value based on the MLE requires one to know

all stopping boundaries since there may be observations (i, j) with smaller or

larger MLE values than ˜ p(m, s) in the later stages. Cook (2002) discusses

similar issues for the cases with a continuous variable.

Whatever estimator is used, the p-values depend on the stochastic order-

ing, but not on the estimates. So, two estimators will result in exactly the

same p-values if they have the same stochastic ordering. Chang, Wieand, and

Chang (1989) correct the bias of the MLE using Whitehead’s (1986) approach.

The bias-corrected estimator has exactly the same ordering as the MLE (see

Appendix 3.D for the proof for two-stage designs), so that the two estimators

result in the same p-values. Further, both MLE and UMVUE increase in s

for each m. Hence, the two estimators will have the same ordering as long as

their ordering matches at the boundaries, that is, for all k = 1 , . . . , K − 1,

˜ p(k, ak) < ˜ p(k + 1 , ak + 1 ) and ˜ p(k, bk) > ˜ p(k + 1 , nk+1 + bk − 1 ).

3.3.1

P-Values under Two-Stage Designs

From Section 3.1.1, for a two-stage study, the probability mass function is

given as









n 1

 ps( 1 − p)n 1− s

m = 1 , 0 ≤ s ≤ a



s

1

or b 1 ≤ s ≤ n 1

f (m, s| p) =











b 1−1

n 1

n 2

 ps( 1 − p)n 1+ n 2− s

m = 2 , a



x

1 + 1 ≤ s

1 = a 1 +1

x 1

s− x 1

≤ b 1 + n 2 − 1

and the UMVUE of p given as to



 s



m = 1

n 1

ˆ p(m, s) =



 s∧ (b



1 −1 )

)( n 2 )

x 1= (a 1+1 )∨ (s− n 2 ) (n 1−1

x 1−1

s− x 1

s∧ (b 1−1 )

)( n 2 ) m = 2

x 1= (a 1+1 )∨ (s− n 2 ) (n 1

x 1

s− x 1

where a ∧ b = min (a, b) and a ∨ b = max (a, b). Note that ˆ p = ˜ p when m = 1.

Example 3.1 (Minimax design)

For H 0 : p 0 = . 4 versus H 1 : p 1 = . 6, the two-stage design (n 1 , n 2 , a 1 , b 1 , a 2 ) =

( 34 , 5 , 17 , 35 , 20 ) is the minimax design according to Simon (1989) among those with α ≤ 0 . 05, 1 − β ≥ 0 . 8 and a lower early stopping boundary only.

Inference on the Binomial Probability

39

Table 3.2

MLE and UMVUE, and p-values using these estimators for a

two-stage design with (n 1 , n 2 , a 1 , b 1 , a 2 ) = ( 34 , 5 , 17 , 35 , 20 ) and p 0 = . 4

Estimate

p-value

m

s

f ( m, s|p0)

UMVUE

MLE

UMVUE

MLE

Naive

1

0

0.0000

0.0000

0.0000

1.0000

1.0000

1.0000

1

1

0.0000

0.0294

0.0294

1.0000

1.0000

1.0000

1

2

0.0000

0.0588

0.0588

1.0000

1.0000

1.0000

1

3

0.0001

0.0882

0.0882

1.0000

1.0000

1.0000

1

4

0.0003

0.1176

0.1176

0.9999

0.9999

0.9999

1

5

0.0010

0.1471

0.1471

0.9997

0.9997

0.9997

1

6

0.0034

0.1765

0.1765

0.9986

0.9986

0.9986

1

7

0.0090

0.2059

0.2059

0.9952

0.9952

0.9952

1

8

0.0203

0.2353

0.2353

0.9862

0.9862

0.9862

1

9

0.0391

0.2647

0.2647

0.9659

0.9659

0.9659

1

10

0.0652

0.2941

0.2941

0.9268

0.9268

0.9268

1

11

0.0948

0.3235

0.3235

0.8617

0.8617

0.8617

1

12

0.1211

0.3529

0.3529

0.7669

0.7669

0.7669

1

13

0.1366

0.3824

0.3824

0.6458

0.6458

0.6458

1

14

0.1366

0.4118

0.4118

0.5092

0.5092

0.5092

1

15

0.1214

0.4412

0.4412

0.3726

0.3726

0.3726

1

16

0.0961

0.4706

0.4706

0.2512

0.2478

0.2512

1

17

0.0679

0.5000

0.5000

0.1550

0.1388

0.1550

2

18

0.0033

0.5294

0.4615

0.0872

0.2512

0.2653

2

19

0.0129

0.5337

0.4872

0.0838

0.1517

0.1713

2

20

0.0219

0.5403

0.5128

0.0709

0.0709

0.1021

2

21

0.0217

0.5508

0.5385

0.0490

0.0490

0.0559

2

22

0.0145

0.5672

0.5641

0.0273

0.0273

0.0280

2

23

0.0075

0.5897

0.5897

0.0128

0.0128

0.0128

2

24

0.0033

0.6154

0.6154

0.0053

0.0053

0.0053

2

25

0.0013

0.6410

0.6410

0.0020

0.0020

0.0020

2

26

0.0005

0.6667

0.6667

0.0007

0.0007

0.0007

2

27

0.0002

0.6923

0.6923

0.0002

0.0002

0.0002

2

28

0.0000

0.7179

0.7179

0.0001

0.0001

0.0001

2

29

0.0000

0.7436

0.7436

0.0000

0.0000

0.0000

2

30

0.0000

0.7692

0.7692

0.0000

0.0000

0.0000

2

31

0.0000

0.7949

0.7949

0.0000

0.0000

0.0000

2

32

0.0000

0.8205

0.8205

0.0000

0.0000

0.0000

2

33

0.0000

0.8462

0.8462

0.0000

0.0000

0.0000

2

34

0.0000

0.8718

0.8718

0.0000

0.0000

0.0000

2

35

0.0000

0.8974

0.8974

0.0000

0.0000

0.0000

2

36

0.0000

0.9231

0.9231

0.0000

0.0000

0.0000

2

37

0.0000

0.9487

0.9487

0.0000

0.0000

0.0000

2

38

0.0000

0.9744

0.9744

0.0000

0.0000

0.0000

2

39

0.0000

1.0000

1.0000

0.0000

0.0000

0.0000

40

Randomized Phase II Cancer Clinical Trials

Table 3.2 displays the p-values for MLE and UMVUE, the naive p-values,

and the probability mass function at p 0 = 0 . 4 for each sample point in the

descending order for UMVUE. For example, for (m, s) = ( 2 , 19 ), we have

˜ p = s/(n 1 + n 2 ) = 19 /( 34 + 5 ) = 0 . 4872

and





19∧ ( 35−1 )

34−1

5

33

5

+ 33 5

ˆ

x

p =

1 = ( 17+1 )∨ ( 19−5 )

x 1−1

19− x 1





= 17 1

18

0

= 0 . 5337 .

19∧ ( 35−1 )

34

5

34

5

+ 34 5

x 1= ( 17+1 )∨ ( 19−5 ) x 1

19− x 1

18

1

19

0

Also, when (m, s) = ( 2 , 19 ) is observed, we calculate the p-value based on MLE as

39



Pr (˜ p(M, S) ≥ . 4872| p 0 ) = f ( 1 , 17| p 0 ) +

f ( 2 , j| p 0 )

j =19

= . 0679 + (. 0129 + . 0219 + . 0217 + . 0145 + . 0075

+ . 0033 + . 0013 + . 0005 + . 0002 + . 0000 + · · ·

+ . 0000 )

= . 1517

and that based on UMVUE as

39



Pr (ˆ p(M, S) ≥ . 5337| p 0 ) =

f ( 2 , j| p 0 )

j =19

= . 0129 + . 0219 + . 0217 + . 0145 + . 0075 + . 0033

+ . 0013 + . 0005 + . 0002 + . 0000 + · · · + . 0000

= . 0838

In Table 3.2, the p-values that differ for MLE and UMVUE are boldfaced. The

p-values by the two estimators are different around the stopping boundary,

especially around (m, s) = (a 1 + 1 , 2 ). The naive p-values exactly match with those based on UMVUE in stage 1, but in stage 2 they are closer to those by

MLE than to those by UMVUE.

Example 3.2 (With both lower and upper stopping boundaries)

Under the same setting as in Example 3.1, ( p 0 , p 1 , α, 1 − β) = (. 4 , . 6 , . 05 , . 8 ), (n 1 , n 2 , a 1 , b 1 , a 2 ) = ( 20 , 27 , 9 , 13 , 24 ) minimizes ( EN0 + EN1 )/ 2 among the two stages with both lower and upper early stopping boundaries, where EN k

(k = 0 , 1 ) is the expected sample size when p = pk; see Chang et al. (1987).

Table 3.3 displays the p-values for the observations listed in descending or-

der for UMVUE. The p-values by the two estimators are different around

the upper and lower stopping boundaries. The stopping boundaries may be

Inference on the Binomial Probability

41

Table 3.3

MLE and UMVUE, and p-values using these estimators for a

two-stage design with (n 1 , n 2 , a 1 , b 1 , a 2 ) = ( 20 , 27 , 9 , 13 , 24 ) and p 0 = . 4

Estimate

p-value

m

s

f (m, s| p 0 )

UMVUE

MLE

UMVUE

MLE

Naive

1

0

0.0000

0.0000

0.0000

1.0000

1.0000

1.0000

1

1

0.0005

0.0500

0.0500

1.0000

1.0000

1.0000

1

2

0.0031

0.1000

0.1000

0.9995

0.9995

0.9995

1

3

0.0123

0.1500

0.1500

0.9964

0.9964

0.9964

1

4

0.0350

0.2000

0.2000

0.9840

0.9840

0.9840

1

5

0.0746

0.2500

0.2500

0.9490

0.9490

0.9490

1

6

0.1244

0.3000

0.3000

0.8744

0.8738

0.8744

1

7

0.1659

0.3500

0.3500

0.7500

0.7438

0.7500

1

8

0.1797

0.4000

0.4000

0.5841

0.5543

0.5841

1

9

0.1597

0.4500

0.4500

0.4044

0.2891

0.4044

2

10

0.0000

0.5000

0.2128

0.2447

0.9490

0.9980

2

11

0.0000

0.5016

0.2340

0.2447

0.9490

0.9947

2

12

0.0000

0.5034

0.2553

0.2447

0.8744

0.9871

2

13

0.0001

0.5055

0.2766

0.2446

0.8744

0.9721

2

14

0.0005

0.5077

0.2979

0.2445

0.8743

0.9450

2

15

0.0016

0.5101

0.3191

0.2440

0.7494

0.9012

2

16

0.0040

0.5128

0.3404

0.2425

0.7478

0.8370

2

17

0.0085

0.5156

0.3617

0.2385

0.5779

0.7514

2

18

0.0151

0.5188

0.3830

0.2300

0.5694

0.6472

2

19

0.0228

0.5221

0.4043

0.2149

0.3746

0.5316

2

20

0.0295

0.5256

0.4255

0.1921

0.3518

0.4139

2

21

0.0331

0.5294

0.4468

0.1625

0.3222

0.3040

2

22

0.0323

0.5334

0.4681

0.1294

0.1294

0.2098

2

23

0.0276

0.5375

0.4894

0.0970

0.0970

0.1356

2

24

0.0206

0.5418

0.5106

0.0695

0.0695

0.0819

2

25

0.0135

0.5462

0.5319

0.0489

0.0489

0.0460

2

26

0.0078

0.5508

0.5532

0.0354

0.0354

0.0241

2

27

0.0039

0.5553

0.5745

0.0276

0.0276

0.0117

2

28

0.0017

0.5599

0.5957

0.0237

0.0237

0.0052

2

29

0.0007

0.5644

0.6170

0.0220

0.0220

0.0022

2

30

0.0002

0.5689

0.6383

0.0213

0.0213

0.0008

2

31

0.0001

0.5733

0.6596

0.0211

0.0065

0.0003

2

32

0.0000

0.5775

0.6809

0.0210

0.0065

0.0001

2

33

0.0000

0.5815

0.7021

0.0210

0.0016

0.0000

2

34

0.0000

0.5853

0.7234

0.0210

0.0016

0.0000

2

35

0.0000

0.5888

0.7447

0.0210

0.0016

0.0000

2

36

0.0000

0.5920

0.7660

0.0210

0.0003

0.0000

2

37

0.0000

0.5950

0.7872

0.0210

0.0003

0.0000

2

38

0.0000

0.5976

0.8085

0.0210

0.0000

0.0000

2

39

0.0000

0.6000

0.8298

0.0210

0.0000

0.0000

1

13

0.0146

0.6500

0.6500

0.0210

0.0211

0.0210

1

14

0.0049

0.7000

0.7000

0.0065

0.0065

0.0065

1

15

0.0013

0.7500

0.7500

0.0016

0.0016

0.0016

1

16

0.0003

0.8000

0.8000

0.0003

0.0003

0.0003

1

17

0.0000

0.8500

0.8500

0.0000

0.0000

0.0000

1

18

0.0000

0.9000

0.9000

0.0000

0.0000

0.0000

1

19

0.0000

0.9500

0.9500

0.0000

0.0000

0.0000

1

20

0.0000

1.0000

1.0000

0.0000

0.0000

0.0000

42

Randomized Phase II Cancer Clinical Trials

interpreted as follows: using ˆ p(M, S) as the test statistic, we reject H 0 if

ˆ p(m, s) ≥ 0 . 5462 = ˆ p( 2 , b 2 ), where b 2 = a 2 + 1 = 25. Since the p-value for the critical value ˆ p( 2 , 25 ) is 0.0489, the exact type I error for the two-stage design is 0 . 0489, which satisfies the restriction of α ≤ 0 . 05. We can make a similar statement with respect to the MLE. However, with the MLE, the outcome

(m, s) = ( 1 , 9 ), on which the study will be stopped due to a low response rate after stage 1, has a smaller p-value than those between (m, s) = ( 2 , 10 ) and ( 2 , 21 ), which only occurs when the study proceeds to stage 2 after observing

a promising response rate from stage 1. In this sense, the UMVUE ordering

may be considered to be more in accordance with the multistage design for

phase II trials than the MLE ordering. As in the designs with a lower stopping

boundary only, the naive p-values exactly match those based on UMVUE in

stage 1, but they are closer to those by MLE in stage 2 than those by UMVUE.

Chang and O’Brien (1985) propose to use the likelihood-ratio





f (m, s|˜ p)

˜

s

Nm − s

=

p

1 − ˜ p

f (m, s| p 0 )

p 0

1 − p 0

to measure how far the MLE ˜ p = ˜ p(m, s) is from p 0. The ordering of the

sample space based on the likelihood-ratio is two-sided in nature, so that it

can be used to derive confidence intervals (Chang and O’Brien, 1987). As

discussed previously, phase II trials ordinarily have one-sided hypotheses, so

that this ordering is not appropriate to derive p-values for phase II trials.

Assuming the normal approximation of the binomial random variables, the

likelihood ratio ordering can be expressed as follows: (m, s) is more extreme

from H 0 : p = p 0 toward H 1 : p > p 0 than (m , s ) if and only if Nm|˜ p(m, s) − p 0| >

Nm |˜ p(m , s ) − p 0| .

Emerson and Fleming (1990) drop the absolute value signs and refer to the

linear ordering





Nm{˜ p(m, s) − p 0} >

Nm {˜ p(m , s ) − p 0}

( 3 . 7 )

as the likelihood ratio ordering. The latter has been used in the literature

under the name of the likelihood ratio ordering, including Chang, Gould,

and Snapinn (1995) and Cook (2002). The two orderings are different be-

cause pm(m, s) − p 0 can take negative values for some outcomes. Furthermore,

if ˜ p(m, s) = ˜ p(m , s ) < p 0 and m < m, then (m, s) is more in favor of H 1 : p > p 0 by (3.7). The p-value for (m, s) based on (3.7) is obtained by vr(m, s) =

I {

Ni (˜ p(i, j) − p 0 ) >

Nm(˜ p(m, s) − p 0 )} f (i, j| p 0 )

(i, j)∈ S

where I (· ) is the indicator function. As an example, we consider the de-

sign (n 1 , n 2 , a 1 , b 1 , a 2 ) = ( 30 , 30 , 9 , 31 ) with p 0 = 0 . 3. Under the design,

Inference on the Binomial Probability

43

both (m, s) = ( 1 , 9 ) and ( 2 , 18 ) have the same MLE of 0.3, but the p-value vr( 1 , 9 ) = 0 . 4602 is smaller than vr( 2 , 18 ) = 0 . 5037. This is against the concept of a group sequential testing with lower stopping boundaries only in the

sense that, between the two outcomes with the same MLE, the outcome which

accepts H 0 and stops after stage 1 is more supportive for H 1 than the other

which proceeds to stage 2.

It is obvious from (3.3) that UMVUE gives p-values satisfying the following

properties: (a) the p-values in the acceptance region of H 0 are larger than those

in the rejection region, and (b) the p-values for the critical value matches with

the type I error probability of the sequential testing. These properties may

not be satisfied by p-values defined by other orderings.

3.4

When Realized Sample Size Is Different

from That Specified in Design

At the design stage of a trial, we determine the required number of patients

(sample size) and a critical value for a specified type I error rate corresponding

to the sample size. When the study is over, however, the resulting sample size

is often different from the planned one due to ineligibilities and dropouts.

In this case, the prespecified critical value may not be appropriate anymore.

One of the common approaches to this problem is to assume that the realized

sample size is the planned one and recalculate the critical value corresponding

to the realized sample size and the prespecified type I error rate.

More specifically in a multistage phase II trial, the prespecified critical

values at the terminal stage is not applicable if the realized sample size is

different from the one determined at the design stage. In this case, we can use

the confidence interval or p-value approaches to test H 0 : p = p 0 against H 1 : p > p 0 based on the prespecified type I error rate α. This is possible because

the UMVUE-based calculation of confidence interval and p-value discussed in

this chapter does not require specification of the critical values at the terminal

stage.

For example, Simon’s optimal two-stage design for ( p 0 , p 1 , α∗ , 1 − β∗ ) =

( 0 . 4 , 0 . 6 , 0 . 1 , 0 . 9 ) is (a 1 /n 1 , a/n) = ( 7 / 18 , 22 / 46 ). Suppose that the study is completed with 23 responders from cumulative 48 eligible patients after

the second stage. Note that the statistical tests for phase II trials are one-

sided. Hence, we have to compare the lower confidence limit of 100 ( 1 − 2 α)%

two-sided confidence interval with p 0 if we want to use a confidence inter-

val method for testing. Using the resulting data (M, S) = ( 2 , 23 ) and the realized design (a 1 /n 1 , n) = ( 7 / 18 , 48 ), the 80% confidence interval is obtained as ( 0 . 387 , 0 . 599 ). Since the lower limit 0.387 of the confidence interval is smaller than p 0 = 0 . 4, we cannot reject H 0 : p 0 = 0 . 4 at α = 0 . 1 level.

Similarly, the p-value for (M, S) = ( 2 , 23 ) with respect to the realized design

44

Randomized Phase II Cancer Clinical Trials

(a 1 /n 1 , n) = ( 7 / 18 , 48 ) is given as p-value= 0 . 1360. Since the p-value is larger than α = 0 . 1, we fail to reject H 0, too. For a significant outcome of the study, we need at least S = 25 responders out of the realized n = 48 after the second

stage, for which case we have a 80% confidence interval of ( 0 . 423 , 0 . 628 ) and p-value = 0 . 0896.

APPENDIX 3.A: Completeness and Sufficiency of (M, S)

We consider a K -stage phase II trial design. The probability mass of a sample

path with x 1 , . . . , xm successes ( ak + 1 ≤ x 1 + · · · + xk ≤ bk − 1 for k =

1 , . . . , m − 1, and x 1 + · · · + xm ≤ am or ≥ bm) is given as px 1+···+ xm ( 1 − p)(n 1+···+ nm)− (x 1+···+ xm).

The sufficiency of (M, S) follows from the factorization theorem. In or-

der to prove completeness, we first derive the probability mass function

f (m, s| p) of random vector (M, S). For m = 1 , . . . , K and s = am−1 +

1 , . . . , am, bm, . . . , nm + bm−1 − 1,

f (m, s| p) = Pr (M = m, S = s| p)

= Pr (Sm = s, ak + 1 ≤ Sk ≤ bk − 1 , k = 1 , . . . , m − 1| p)





=

· · ·

Pr (X 1 = x 1 , . . . , Xm = xm| p),

x 1

xm

where the summations are subject to

R(m, s) = { (x 1 , . . . , xm) : x 1+· · ·+ xm = s, ak+1 ≤ sk ≤ bk−1 , k = 1 , . . . , m−1} .

Hence, we have





n 1

nm

f (m, s| p) =

· · ·

px 1 ( 1 − p)n 1− x 1 · · ·

pxm ( 1 − p)nm− xm

R(m,s) x 1

xm





=

n 1

nm

ps ( 1 − p)n 1+···+ nm− s

· · ·

· · ·

.

R(m,s) x 1

xm





Let c

n 1

nm

m,s =

· · · R(

· · ·

. Then the probability mass function of

m,s) x 1

xm

(M, S) is given as

f (m, s| p) = cm,s ps( 1 − p)n 1+ ··· + nm− s

( 3 .A. 1 )

with support S = ∪ K S

m=1 m where

Sm = { (m, s) : am−1 + 1 ≤ s ≤ am or bm ≤ s ≤ nm + bm−1 − 1} .

Inference on the Binomial Probability

45

Now we prove the completeness of (M, S). From (3.A.1), h( p) =

E p{ g(M, S)} is obtained as

K



am



K

nm+ bm−1−1



g(m, s) f (m, s| p) +

g(m, s) f (m, s| p)

m=1 s= am−1+1

m=1

s= bm



K



am



=

g(m, s)cm,s ps( 1 − p)n 1+ ··· + nm− s

m=1

s= am−1+1



nm + bm−1−1



+

g(m, s)cm,s ps( 1 − p)n 1+ ··· + nm− s .

(A. 2 )

s= bm

We need to show that h( p) = 0 for all p ∈ [0 , 1] ensures g(m, s) ≡ 0 for all (m, s) in the support of (M, S). If p = 0, then, from (A.2), we have g( 1 , 0 ) = 0.

If 1 − p = 0, then, also from (A.2), we have g( 1 , n 1 ) = 0. Now, for p ∈ ( 0 , 1 ), let Pk( p) = h( p)/ pk and Ql( p) = h( p)/( 1 − p)l. Each term, say, term i, in (A.2) has the factor pki ( 1 − p)li for some nonnegative integers ki and li . Since all terms have different factors, that is, (ki , li ) = (k j , l j ) if i = j, any subset of the terms in (A.2) has a unique minimum either among the ki ’s or the li ’s. If

ki ’s have a unique minimum k, then, since Pk( p) = 0 for all p ∈ ( 0 , 1 ), letting p → 0 shows g(m, s) = 0, where g(m, s) is the coefficient of the term with

pk factor. On the other hand, if li ’s have a unique minimum l, then, since

Ql ( p) = 0 for all p ∈ ( 0 , 1 ), letting p → 1 shows g(m, s) = 0, where g(m, s) is the coefficient of the term with ( 1 − p)l factor. Whichever coefficient is 0, we

remove that term from h( p) before next step. Starting from k = 1 and l = 1,

we continue this procedure until all terms in (A.2) are removed, concluding

that g(m, s) ≡ 0 for all (m, s) in the support of (M, S).

APPENDIX 3.B: UMVUE of p

Since (M, S) is complete and sufficient by Appendix 3.A, and ˜ p 1 = X 1 /n 1 is unbiased, by the Rao–Blackwell theorem, the UMVUE of p is given as ˆ p =

E{ X 1| (m, s)} /n 1. If M = 1, we have ˆ p = ˜ p 1. On the other hand, if 2 ≤ M ≤ K , the conditional probability mass function of X 1 given (M, S) = (m, s) in S is, for a 1 + 1 ≤ x 1 ≤ b 1 − 1,

Pr (X 1 = x 1 , M = m, S = s| p)

Pr (M = m, S = s| p)

= Pr (X 1 = x 1 , Sm = s, ak < Sk < bk for k = 2 , . . . , m − 1| p) f (m, s| p)





· · ·

n 1 px

n

1 ( 1 − p)n 1− x 1 · · ·

m

pxm ( 1 − p)nm− xm

=

x 2

xm

x 1

xm

f (m, s| p)

46

Randomized Phase II Cancer Clinical Trials

where the summations in the numerator are over the set

R(m, s| x 1 ) = { (x 2 , . . . , xm) : x 2 + · · · + xm = s − x 1 , ak + 1 ≤ sk ≤ bk − 1 , k = 2 , . . . , m − 1} .

Hence, the conditional probability mass function is simplified to





n 1

· · ·

n 2 · · · nm

x

R(

1

m,s| x 1 ) x 2

xm





.

· · ·

n 1

nm

R(

· · ·

m,s) x 1

xm

Therefore,





x n 1

· · ·

n 2 · · · nm

x

1

R(m,s| x

ˆ p = E{ X 1| (m, s)} =

1

x 1

1 )

x 2

xm





.

n

n 1

nm

1

n 1

· · · R(

· · ·

m,s) x 1

xm





Since

· · ·

· · ·

x 1

R(m,s| x 1 ) =

R(m,s),





· · ·

n 1−1

n 2 · · · nm

ˆ p =

x 1−1

x 2

xm





· · ·

n 1 · · · nm

x 1

xm

with the summations over R(m, s) in the numerator and in the denominator.

APPENDIX 3.C: Stochastic Ordering among ˆ p(m, s)

We consider a two-stage design with lower stopping boundaries only (that is,

b 1 = n 1 + 1) and assume that s ≤ n 1. The proof under other situations can be conducted similarly. We want to prove ˆ p( 1 , 0 ) < ˆ p( 1 , 1 ) < · · · < ˆ p( 1 , a 1 ) < ˆ p( 2 , a 1 + 1 ) < · · · < ˆ p( 2 , n 1 + n 2 ).

It is trivial that ˆ p( 1 , s) < ˆ p( 1 , s + 1 ) for 0 ≤ s ≤ a 1 − 1. Also, since ˆ p( 2 , a 1 + 1 ) = (a 1 + 1 )/n 1, ˆ p( 1 , a 1 ) = a 1 /n 1 < ˆ p( 2 , a 1 + 1 ). Now, we complete the proof by showing that ˆ p( 2 , s) < ˆ p( 2 , s + 1 ) for a 1 + 1 ≤ s ≤ n 1 + n 2 − 1.

Since





s+1

x n 1

n 2

s

n 1

n 2

1

x 1

ˆ

x

x

p( 2 , s + 1 ) − ˆ p( 2 , s) =

1 = a 1 +1

x 1

s+1− x 1





−

1 = a 1 +1

x 1

s− x 1





,

s

n

n

n

s+1

n 1

n 2

1

2

1

n

x

1

x

1 = a 1 +1

x

x

s− x

1

s+1− x 1

1 = a 1 +1

1

1

after reduction of the fractions to the common denominator, the numerator

of n 1{ˆ p( 2 , s + 1 ) − ˆ p( 2 , s)} is given as

s





s





n



1

n 2

n 1

n 1

n 2

x 1

+ (s + 1 )

x

s + 1 − x

s + 1

x

s − x

x

1

1

1

1

1 = a 1 +1

x 1= a 1+1

s





s





−

n 1

n 2

n 1

n 2

n 1

x 1

+

.

x

s − x

x

s + 1 − x

s + 1

x

1

1

1

1

1 = a 1 +1

x 1= a 1+1

Inference on the Binomial Probability

47





Noting that

n 2

= (n

n 2

, the numerator is expressed

s+1− x

2− s + x 1 )/(s +1− x 1 )

1

s− x 1

as

s





s





x



1 (n 2 − s + x 1 )

n 1

n 2

n 1

n 2

s + 1 − x

x

s − x

x

s − x

x

1

1

1

1

1

1 = a 1 +1

x 1= a 1+1





s





+ (

n 1

n 1

n 2

s + 1 ) s + 1

x

s − x

x

1

1

1 = a 1 +1

s





s





−

n 1

n 2

n 2 − s + x 1 n 1

n 2

x 1 x

s − x

s + 1 − x

x

s − x

x

1

1

1

1

1

1 = a 1 +1

x 1= a 1+1





s





−

n 1

n 1

n 2

x 1

.

s + 1

x

s − x

x

1

1

1 = a 1 +1

The difference between the first and the third terms can be expressed as

s



2





n 1

n 2

cov

X 1 , n 2 − s + X 1

x

s − x

s + 1 − X

x

1

1

1

1 = a 1 +1

where the covariance is taken with respect to X 1 with mass function





n 1

n 2

h(x

x 1

s− x 1



1 ) = s

n 1

n 2

x= a 1+1

x

s− x

for a 1 + 1 ≤ x 1 ≤ s. Since (n 2 − s + X 1 )/(s + 1 − X 1 ) increases in X 1, the covariance is positive. On the other hand, for the second and fourth terms,

s





s





(

n 1

n 2

n 1

n 2

s + 1 )

>

x 1

.

x

s − x

x

s − x

x

1

1

1

1

1 = a 1 +1

x 1= a 1+1

Hence, the numerator (as well as the denominator) of n 1{ˆ p( 2 , s + 1 ) − ˆ p( 2 , s)}

is positive.

APPENDIX 3.D: Bias-Corrected Estimator Has Same

Stochastic Ordering as MLE

We consider a two-stage design with design parameters (n 1 , n 2 , a 1 , b 1 , a 2 ). Let n = n 1 + n 2. By Whitehead (1986), the bias-corrected estimator is obtained

by solving

˜ p = p + B( p)

( 3 .A. 2 )

48

Randomized Phase II Cancer Clinical Trials

with respect to p, where B( p) is the bias of ˜ p when the true response proba-

bility is p, that is,

b



1 −1



n 1

B( p) = − n 2

(x 1 − n 1 p)

px 1 ( 1 − p)n 1− x 1;

n 1 n

x

x

1

1 = a 1 +1

see Jung and Kim (2004). From (3.A.2), it suffices to show that p + B( p) is

a strictly increasing function in p ∈ ( 0 , 1 ). The derivative of p + B( p) with respect to p is

b



1 −1



n 1

1 −

n 2

{ (x 1 − n 1 p) 2 − n 1 p( 1 − p)}

px 1 ( 1 − p)n 1− x 1 .

n 1 np( 1 − p)

x

x

1

1 = a 1 +1

We have a 1 + 1 ≤ b 1 − 1 for a two-stage design, so that the derivative for

p ∈ ( 0 , 1 ) is larger than

b



1 −1



n 1

1 −

n 2

(x 1 − n 1 p) 2

px 1 ( 1 − p)n 1− x 1 .

( 3 .A. 3 )

n 1 np( 1 − p)

x

x

1

1 = a 1 +1

Since

b





1 −1



n 1



(

n 1

n 1

x 1 − n 1 p) 2

px 1 ( 1 − p)n 1− x 1 <

(x 1 − n 1 p) 2

px 1 ( 1 − p)n 1− x 1

x

x

x

1

1

1 = a 1 +1

x 1=0

= n 1 p( 1 − p),

(3.A.3) is larger than 1 − n 2 /n, which is positive for a two-stage design. This

completes the proof.

References

Armitage, P. (1958). Numerical studies in the sequential estimation of a bi-

nomial parameter. Biometrika, 45, 1–15.

Chang, M.N., Gould, A.L., and Snapinn, S.M. (1995). P-values for group

sequential testing. Biometrika, 82, 650–654.

Chang, M.N. and O’Brien, PC. (1985). Confidence intervals following group

sequential trials. Controlled Clinical Trials, 7, 18–26.

Chang, M.N., Therneau, T.M., Wieand, H.S., and Cha, S.S. (1987). De-

signs for group sequential phase II clinical trials. Biometrics, 43,

865–874.

Inference on the Binomial Probability

49

Chang, M.N., Wieand, H.S., and Chang, V.T. (1989). The bias of the sample

proportion following a group sequential phase II clinical trials. Statistics

in Medicine, 8, 563–570.

Clopper, C.J. and Pearson, E.S. (1934). The use of confidence or fidu-

cial limits illustrated in the case of the binomial. Biometrika, 26,

404–413.

Cook, T.D. (2002). P-value adjustment in sequential clinical trials. Biomet-

rics, 58, 1005–1011.

Duffy, D.E. and Santner, T.J. (1987). Confidence intervals for a binomial

parameter based on multistage tests. Biometrics, 43, 81–93.

Emerson, S.S. and Fleming, T.R. (1990). Parameter estimation following

group sequential hypothesis testing. Biometrika, 77, 875–892.

Fleming, T.R. (1982). One sample multiple testing procedure for phase II

clinical trials. Biometrics, 38, 143–151.

Girshick, M.A., Mosteller, F., and Savage, L.J. (1946). Unbiased estimates for

certain binomial sampling problems with application. Annals of Mathe-

matical Statistics, 17, 13–23.

Green, S.J. and Dahlberg, S. (1992). Planned versus attained design in phase

II clinical trials. Statistics in Medicine, 11, 853–862.

Herndon, J. (1998). A design alternative for two-stage, phase II, multicenter

cancer clinical trials. Controlled Clinical Trials, 19, 440–450.

Herson, J. (1979). Predictive probability early termination plans for phase II

clinical trials. Biometrics, 35, 775–783.

Jennison, C. and Turnbull, B.W. (1983). Confidence intervals for a bino-

mial parameter following a multistage test with application to MIL-STD

105D and medical trials. Technometrics, 25, 49–58.

Jung, S.H. and Kim, K.M. (2004). On the estimation of the binomial

probability in multistage clinical trials. Statistics in Medicine, 23,

881–896.

Lehmann, E.L. (1983). Theory of Point Estimation. Wiley, New York.

Liu, A. and Hall, W.J. (1999). Unbiased estimation following a group sequen-

tial test. Biometrika, 86, 71–78.

Schultz, J.R., Nichol, F.R., Elfring, G.L., and Weed, S.D. (1973).

Multistage procedures for drug screening. Biometrics, 29, 293–300.

Simon, R. (1989). Optimal two-stage designs for phase II clinical trials. Con-

trolled Clinical Trials, 10, 1–10.

50

Randomized Phase II Cancer Clinical Trials

Tsiatis, A.A., Rosner, G.L., and Mehta, C.R. (1984). Exact confi-

dence intervals following a group sequential test. Biometrics, 40,

797–803.

Whitehead, J. (1986). On the bias of maximum likelihood estimation following

a sequential test. Biometrika, 73, 573–581.





Chapter 4

Single-Arm Phase II Clinical Trials

with Time-to-Event Endpoints

The most popular primary endpoint in phase II cancer clinical trials is tumor

response, resulting in a binary variable. Often, however, a time-to-event end-

point, such as time-to-disease progression or overall survival (meaning time to

death by any cause) starting from registration, may be chosen as the primary

endpoint of a phase II trial when a typical tumor response endpoint is not

applicable or is not clinically relevant. For example, in studies involving blood

cancers or in the case of surgical studies with adjuvant chemotherapies, where

the tumor is completely resected, so that tumor response is not a meaningful

endpoint. Also, cytostatic therapies are to prevent the growth of tumor rather

than to shrink it, so that tumor response cannot be a good endpoint for phase

II trials on experimental cytotoxic therapies. In these cases, a popular clinical

outcome of interest may be the time to a specific event, such as disease pro-

gression or death. Because of loss to follow-up or termination of study, event

times are subject to right censoring. Based on the standard terminology, we

use time-to-event and survival time together regardless of the type of event,

in this book.

Let T 1 , . . . , Tn, denoting the survival times for n patients who are treated by the experimental therapy of a single-arm phase II clinical trial, be independent

and identically distributed random variables with a survival function S(t) =

P(Ti ≥ t). Because of censoring, we observe { (Xi , δi ), i = 1 , . . . , n} instead of survival times, where Xi denotes the minimum of survival time Ti and

censoring time Ci , and δi = I (Ti ≤ Ci ) denotes the event indicator taking 1 if an event is observed and 0 otherwise. We assume that the survival and

censoring times are independent. In this chapter, we discuss some design and

analysis methods for single-arm phase II trials with a survival outcome as the

primary endpoint.

4.1

A Test Based on Median Survival Time

Let θ denote the true median survival time for the study population.

Then for the cumulative hazard function (t) = − log S(t), we have

(θ) = log 2. By Nelson (1969), a consistent estimator of (t) is given as

51

52

Randomized Phase II Cancer Clinical Trials





ˆ

(

t

t) =

Y −1 (t)d N (t), where Y (t) =

n

Y

n

N

0

i =1

i (t ), N (t ) =

i =1

i (t ), Yi (t ) =

I (Xi ≥ t), and Ni (t) = δi I (Xi ≤ t). Hence, a consistent estimator of θ is obtained by solving ˆ

(θ) = log 2, or ˆ S(θ) = 1 / 2, where ˆ S(t) denotes the

Kaplan–Meier (1958) estimator of S(t).

√

For large n,

n{ ˆ

(θ)−log 2} is approximately distributed as N( 0 , σ 2 ), where

θ

σ

1

2 =

d(t)

0

S(t)G(t)

and G(t) = P(C ≥ t) is the survivor function of the censoring variable C.

In deriving the asymptotic distribution of the test statistics on survival data

in this chapter, we use the following asymptotic results from Fleming and

Harrington (1991):

Theorem 4.1

Let Ln(t) be a predictable process ( i.e., a function generated by left-continuous

functions) uniformly convergent to a square integrable function (t). Then, as

n → ∞ , we have following results:

∞

∞

(a) n−1

L

(t)y(t)d(t), where

0

n (t )d N (t ) almost surely converges to

0

y(t) = G(t)S(t) is the limit of n−1 Y (t).

∞

(b) n−1 / 2

L

0

n (t )d M (t )

converges to N ( 0 , v), where d M(t) = d N (t)



−

∞

Y (t)d(t) and v =

2 (t)y(t)d(t), which can be consistently esti-

0

∞

∞

mated by ˆ

v = n−1

L 2 (t)Y (t)d ˆ

(t) = n−1

L 2 (t)d N (t).

0

n

0

n

4.1.1

Statistical Testing

For a chosen historical control with a median survival time θ 0, we want to test

if the experimental therapy has a larger median survival time than θ 0. So, the

associated statistical hypotheses are given as H 0 : θ = θ 0 and H 1 : θ > θ 0.

Let Sh(t) and h(t) denote the survivor function and the cumulative hazard

function, respectively, of the survival distribution under Hh (h = 0 , 1 ). A

cumulative hazard function is a monotonically increasing function, so that, if

H 1 is true, ˆ

(θ 0 ) → 1 (θ 0 ) < 1 (θ 1 ) = log 2, where θ 1 denotes the median survival time under H 1. Hence, we reject H 0 if

√ n{ˆ (θ 0 ) − log2} < − z 1− α,

ˆ

σ

where z 1− α is the 100 ( 1 − α) percentile of the standard normal distribution and

θ 0 dN(t)

ˆ

σ 2 = n

0

Y 2 (t)

is a consistent estimator of σ 2 under H 0 by Theorem 4.1(b), or refer to, for

example, Fleming and Harrington (1991).

Single-Arm Phase II Clinical Trials with Time-to-Event Endpoints

53

The test statistic is calculated by using

n



δ

ˆ

(θ

i I ( Xi ≤ θ 0 )

0 ) =

n I(Xj ≥ Xi)

i =1

j =1

and

n



δ

ˆ

σ 2 =

i I ( Xi ≤ θ 0 )

n



.

{ n I (X j ≥ Xi)}2

i =1

j =1

Note that, for this testing, the maximum follow-up period of the study should

be longer than θ 0. But a follow-up time longer than θ 0 does not have any

impact on the testing result either. In this sense, we may consider following

each subject for a period of θ 0 only, that is, Ci = θ 0, if we are interested in the median survival time only.

This is a nonparametric test since the test statistic and its null distribu-

tion do not require any parametric model assumption. However, at the design

stage, we have to assume a parametric survival model for sample size calcu-

lation as described in the following section.

4.1.2

Sample Size Calculation

The asymptotic distribution of median survival estimators has been widely

investigated in the literature, including Brookmeyer and Crowley (1982) and

Gardiner et al. (1986). Based on these results, a sample size formula for the

median survival test can be summarized as follows. Let us suppose that we

want to calculate a sample size n required for power 1 − β with respect to a

specific alternative hypothesis H 1 : θ = θ 1 (> θ 0 ). It is easy to show that, under

√

H 1, both the limit of ˆ

σ 2 and the variance of n{ ˆ (θ 0 ) − log 2} are identically

given as

θ 0

σ

d

2 =

1 (t ) .

0

S 1 (t)G(t)

Then, we have √



n{ ˆ

(θ 0 ) − log 2}

1 − β = P

< − z 1− α| H 1

ˆ

σ

√

√



≈

n{ ˆ

(θ 1 ) − log 2}

n{ ˆ

(θ 0 ) − ˆ (θ 1 )}

P

+

< − z

.

σ

σ

1− α | H 1

√

Let = 1 (θ 0 ) − 1 (θ 1 ) = 1 (θ 0 ) − log 2. Under H 1, n{ ˆ

(θ 0 ) − ˆ (θ 1 )} is

√

approximated by

n, and √ n{ˆ (θ 1 )−log2}

σ

54

Randomized Phase II Cancer Clinical Trials

is asymptotically N ( 0 , 1 ). Hence, by solving the above equation, we obtain

σ 2 (z 1− α + z 1− β) 2

n =

.

(4.1)

2

Formula (4.1) can be used to estimate a sample size based on any specified

censoring and survival distributions. In the next section, we consider sample

size calculation under some practical distributional assumptions.

4.1.2.1

Under Uniform Accrual and Exponential Survival

Models

For a sample size calculation, we have to specify a survival distribution that

is simple but well approximates the true distribution. Furthermore, we also

have to specify the censoring distribution based on the expected accrual pe-

riod and missing pattern. For a practical sample size, we may make following

assumptions:

(A) Exponential survival distribution: S(t) = exp (− λt) and (t) = λt for a specified hazard rate λ. Given a median survival time θ, we have

λ = θ−1 log 2.

(B) Uniform censoring distribution: Suppose that patients are expected to

be recruited at a constant rate during accrual period a and will be

followed for an additional period b after completion of the total accrual.

Then, the censoring distribution is U (b, a + b) with survivor function





 1

if t ≤ b

G(t) =

−

 t/a + (a + b)/a if b < t ≤ a + b .

 0

if t > a + b

We assume no loss to follow-up due to dropout here.

The variance σ 2 can be calculated only when G(θ 0 ) > 0. Thus, the follow-up period b should be chosen so that a + b ≥ θ 0. Under (A) and (B), we have σ 2 = eλ 1 θ 0 − 1

if θ 0 ≤ b. On the other hand, if b ≤ θ 0 ≤ a + b, then

θ 0

σ

eλ 1 t

2 = eλ 1 b − 1 + λ 1

dt.

(4.2)

b

(a + b)/a − t/b

The integration in the right-hand side can be calculated using a numerical

method.

Note that if the additional follow-up period b is longer than θ 0, then the

variance in (4.2), and consequently the sample size in (4.1), does not depend

on the accrual period a. So, we can conduct the final data analysis when

every patient is followed for θ 0 or experiences an event. If θ 0 is not too long,

Single-Arm Phase II Clinical Trials with Time-to-Event Endpoints

55

a reasonable choice for the additional follow-up period may be b = θ 0. In this

case, we have σ 2 = eλ 1 θ 0 − 1. If b < θ 0, however, the accrual period a should be so large that we need a + b ≥ θ 0. In this case, we may want to calculate the expected number of events at the time of data analysis: D = n × d, where d is the probability for a patient to experience an event during the study, that is,

∞

d = 1 − P (T > C| H 1 ) = 1 +

S 1 (t)dG(t) = 1 − exp (− bλ 1 ) {1 − exp (− aλ 1 )} , 0

aλ 1

where λ 1 = θ−1

1

log 2.

The assumptions (A) and (B) can be easily extended to a nonexponential

survival model and a nonuniform censoring distribution. Typically, in well-

designed and well-conducted clinical trials collecting survival times, we do

not observe many cases of loss to follow-up during the study, so that most

censored cases are administrative. In this sense, we assume no loss to follow-up

by (B). If one expects a large proportion of dropouts, it can be easily reflected

in the sample size calculation. Let E denote the time to loss to follow-up from

entry with a specific distribution, such as an exponential distribution, and ˜

C

denote the time to administrative censoring whose distribution is determined

by accrual and follow-up periods; then the censoring variable for each patient

is given as C = min (E, ˜

C) with a survivor function G(t) = P (E > t) P ( ˜

C > t)

since the loss to follow-up of a patient is usually independent of the admin-

istrative censoring. Suppose that ˜

C ˜

U (b, a + b) as in (B) and E follows an

exponential distribution with hazard rate λE . Then we have





 exp (− λEt)

if t ≤ b

G(t) =

(

 1 + b/a − t/b) exp (− λEt) if b < t ≤ a + b .

 0

if t > a + b

Example 4.1

Suppose that the median progression-free survival (PFS) for a standard ther-

apy is known to be θ 0 = 1 year. We will be interested in the experimental

therapy if its median PFS is θ 1 = 1 . 5 years or longer. Under the exponential

PFS model, we have corresponding hazard rates λ 0 = 0 . 693 and λ 1 = 0 . 462.

Assuming no loss to follow-up and b = 1 (= θ 0 ) year of follow-up for each patient, we need n = 73 patients for 1 − β = 90% power by the median survival

test with one-sided α = 10%. A simulation study is conducted to investi-

gate the small sample performance of the testing and sample size calculation

method. The test statistic was applied to each of B = 10 , 000 simulation sam-

ples with n = 73 that were generated under the design settings. The empirical

type I error rate and power were 11.8% and 86%, respectively. The sample

size for the median survival test seems to be slightly underpowered.

56

Randomized Phase II Cancer Clinical Trials

4.1.2.2

When Accrual Rate Is Given

Recall that, if the follow-up period of each patient is longer than θ 0 (that is,

b > θ 0), the required sample size does not depend on the the accrual period

a (or accrual rate). However, if the additional follow-up period b is not so

long that b < θ 0 (≤ a + b), then the variance in (4.2), and consequently the sample size in (4.1), depends on the accrual period a. In this case, the above

sample size formula is required to specify an accrual period a. When designing

a clinical trial, however, we usually can estimate an expected accrual rate r ,

rather than an accrual period a, based on the number of patients accrued from

the member sites recently. In this case, assumption (B) should be replaced by

(B) Patients are accrued following a Poisson distribution with rate r , and

are followed for a period b after the completion of accrual.

With (r, λ 0 , λ 1 , α, 1 − β, b) specified, σ = σ(a) is a function of a as given in (4.2). Hence, under (A) and (B), (4.1) is expressed as

σ 2 (a)(z 1− α + z 1− β) 2

n =

.

(4.3)

2

On the other hand, under the Poisson accrual distribution (B), we have

n = a × r.

(4.4)

Now, we have two equations (4.3) and (4.4) with two unknowns n and a.

Let a∗ denote the solution to the equation that is obtained by equating the

right-hand sides of (4.3) and (4.4), that is,

σ 2 (a)(z 1− α + z 1− β) 2

a × r =

.

2

Finally, given an accrual rate r (instead of an accrual period a), we obtain

the required sample size by n = a∗ × r. This equation is solved by a numerical

method such as the bisection method. Note that, at each replication, the

accrual period a should be large enough that the total study period is no

smaller than θ 0, that is, a + b ≥ θ 0, and σ 2 is calculable. If θ 0 is so large that the solution a∗ to the equation is too large, then the median survival method

is not appropriate for a phase II trial.

4.2

Maximum Likelihood Method for

Exponential Distribution

Since the family of exponential distributions is indexed by only one parameter

(hazard rate) and the distributions of most real survival data are closely ap-

proximated by exponential distributions, these distributions have been widely

Single-Arm Phase II Clinical Trials with Time-to-Event Endpoints

57

used for parametric analysis of survival data or as a hypothetical model in the

sample size calculation of nonparametric analysis method. In this section, we

discuss design and analysis methods of phase II trials based on exponential

maximum likelihood estimator (MLE). This approach can be easily extended

to other survival distribution models, such as Weibull distribution.

Suppose that the survival times of n subjects T 1 , . . . , Tn are IID random

variables with hazard rate λ whose survival and probability density functions

are given as f (t) = λ exp (− λt) and S(t) = exp (− λt) for t ≥ 0, respectively.

With the observed survival data { (Xi , δi ), i = 1 , . . . , n}, the log-likelihood

function is given by

n





n



n



l(λ) = log

f (Xi )δi S(Xi ) 1− δi

= log (λ)

δi − λ

Xi .

i =1

i =1

i =1

From this likelihood function, the MLE of λ is obtained as

ˆ

λ = D ,

X





where D =

n

δ

n

X

i =1 i denotes the total number of events and X =

i =1

i

denotes the total observed survival time. By the standard procedure on MLE,

ˆ

λ is asymptotically normal with mean λ and variance λ 2 /D.

By Miller (1981), the normality approximation is improved by taking a log-

transformation of the MLE. That is, by applying the delta method to this

result, we can show that log ˆ

λ is approximately normal with mean log λ and

variance 1 /D. Alternatively, Sprott (1973) proposes another transformation

ˆ

λ 1 / 3 to improve the normality. We consider the log-transformed estimator in

this section.

4.2.1

Statistical Testing

Suppose that the survival distribution of a chosen historical control is known

to have a hazard rate of λ 0. We want to test H 0 : λ = λ 0 versus H 1 : λ < λ 0.

√

By Miller (1981),

D( log ˆ λ − log λ 0 ) is approximately N ( 0 , 1 ) under H 0. So,

√

we reject H 0 in favor of H 1 if

D( log ˆ λ − log λ 0 ) < − z 1− α.

4.2.2

Sample Size Calculation

Let λ 1 (< λ 0 ) denote a hazard rate which is a clinically meaningful improvement from λ 0 for the experimental therapy. We want to estimate the required

sample size for a specified power under H 1 : λ = λ 1. Given a number of events

D, the power function is given as

√

1 − β = P{ D( log ˆ λ − log λ 0 ) < − z 1− α| H 1}

√

√

= P{ D( log ˆ λ − log λ 1 ) < D log − z 1− α| H 1} ,

58

Randomized Phase II Cancer Clinical Trials

√

where = λ 0 /λ 1 denotes the hazard ratio. Since

D( log ˆ λ − log λ 1 ) is ap-

proximately N ( 0 , 1 ) under H 1, the required number of events for power 1 − β

is obtained by

(z 1− α + z 1− β) 2

D =

.

(4.5)

( log ) 2

Let d = P(T ≤ C| λ 1 ) denote the probability that a patient has an event during the study. Since D = n × d, from (4.5), the required sample size is

obtained as

(z 1− α + z 1− β) 2

n =

.

(4.6)

d( log ) 2

For a specified survivor function of a specified censoring distribution G(t) =

P(C ≥ t), we calculate

∞

d = 1 − P (T > C| H 1 ) = E{1 − exp (− λ 1 C)} = 1 +

e− λ 1 t d G(t).

0

4.2.2.1

Under a Uniform Accrual Model

Suppose that patients are accrued at a constant rate during accrual period a

and followed for an additional period b. Then, the censoring distribution is

U (b, a + b) with



 1

if t ≤ b

G(t) =

−

 t/a + (a + b)/a if b < t ≤ a + b

0

if t > a + b

In this case, we have

d = 1 − e− λ 1 b ( 1 − e− λ 1 a).

(4.7)

λ 1 a

4.2.2.2

When Accrual Rate Is Known

Suppose that the accrual rate r is known instead of accrual period a. In this

case, the accrual period a is an unknown output variable at a sample size

calculation. From (4.7), d = d(a) = 1 − e− λb( 1 − e− λa)/(λa) is a function of the accrual period a. By replacing n = a × r in (4.6), we obtain the required accrual period a∗ by solving

(z 1− α + z 1− β) 2

a × r × d(a) =

(4.8)

( log ) 2

with respect to a. We solve the equation using a numerical method such as the

bisection method. Finally, the required sample size is calculated by n = a∗ × r.

Single-Arm Phase II Clinical Trials with Time-to-Event Endpoints

59

Example 4.2

Suppose that the median progression-free survival for a standard therapy is

known to be 1 year. We will be interested in the experimental therapy if its

median PFS is 1.5 years or longer. Under the exponential PFS model, we have

λ 0 = 0 . 693 and λ 1 = 0 . 462 ( = 1 . 5 ). For one-sided α = 10% test 1− β = 90%

power (z 1− α = 1 . 282 = z 1− β = 1 . 282 ), the required number of events at the analysis from (4.5) is given as

( 1 . 282 + 1 . 282 ) 2

D =

= 40 .

( log 1 . 5 ) 2

This trial is expected to accrue about 5 patients per month (or r = 60 pa-

tients per year) based on the recent accrual rate of patients at the study

institution. Assuming b = 1 year of additional follow-up after completion of

patient accrual, we have from (4.7)

d(a) = 1 − e−1 . 5 ( 1 − e−1 . 5 a).

1 . 5 a

By plugging this in (4.8), we solve





60 a 1 − e−1 . 5 ( 1 − e−1 . 5 a) = 40

1 . 5 a

to obtain a∗ = 1 . 272 years or n = 1 . 272 × 60 = 77 patients. The total study will take about 28 months for 16 months of patient accrual and 12 months of

additional follow-up period. A simulation study is conducted to investigate the

small sample performance of the testing and sample size calculation methods.

The test statistic was applied to each of B = 10 , 000 simulation samples with

n = 77 that were generated under the design settings. The empirical type I

error rate and power were 9% and 92.3%, respectively, which are close to their

nominal levels.

4.3

One-Sample Log-Rank Test

The median survival test in the previous section and the test on t-year survival

in Section 4.5 use the survival estimate at only one time point, so that they

may lose statistical efficiency by not fully using the entire information from

survival data. While the exponential MLE test uses the whole information on

the data, its performance strongly depends on the validity of the parametric

model assumption for given a data set. In order to tackle these issues, we

propose to use the one-sample log-rank test that was investigated by, for

example, Berry (1983) and Finkelstein et al. (2003).

60

Randomized Phase II Cancer Clinical Trials

4.3.1

Statistical Testing

Let 0 (t) denote the cumulative hazard function of a historical control that is

chosen for a new single-arm phase II trial. If the historical control data come

from a previous study, 0 (t) may be the Nelson–Aalen estimate (Nelson 1969;

Aalen 1978) from the data. Let (t) denote the cumulative hazard function

of an experimental therapy that will be observed from the new phase II trial.

We want to test H 0 : (t) = 0 (t) against H 1 : (t) < 0 (t) for t > 0.

Under H 0 for large n,

n

∞

W = n−1 / 2

{ d Ni(t) − Yi(t)d 0 (t)}

i =1

0

is approximately normal with mean 0 and its variance can be consistently

estimated by

n

∞

ˆ

σ 2 = n−1

Yi (t)d 0 (t).

i =1

0

Hence, we reject H 0 with one-sided type I error rate α if Z = W/ˆ

σ < − z 1− α

(Finkelstein et al. 2003).

Note that the standardized test statistic, W/ˆ

σ is expressed as

Z = O − E

√

,

E



∞



where O =

n

d N

n

δ

i =1 0

i (t ) =

i =1 i denotes the observed number of



events. On the other hand, under H

n

0, n−1

Y

i



=1 i (t) → S 0 (t)G(t) uniformly,



∞



so that E =

n

Y

n



i =1 0

i (t )d 0 (t ) =

i =1

0 ( Xi ) is asymptotically identi-

∞

cal to − n

G(t)d S

0

0 (t ), which is the expected number of events under H 0.

If the historical control has an exponential survival distribution, we have



˜

E = λ

n

0

X

i =1

i . Hence, the exponential MLE test with no transformation

in the previous section is similarly expressed as

O − ˜

E

√ .

˜

E/ O

Note that D and λ 0 X in the previous section are denoted as O and ˜

E in this

section, respectively.

4.3.2

Sample Size Calculation

We calculate the required sample size n for a specified power under a specific



alternative hypothesis H

n

1 : (t ) = 1 (t )(< 0 (t )). Under H 1, n−1

Y

i =1

i (t )

uniformly converges to G(t)S 1 (t), so that ˆ

σ 2 converges to

∞

σ 2 =

G(t)S

0

1 (t )d 0 (t ).

(4.9)

0

Single-Arm Phase II Clinical Trials with Time-to-Event Endpoints

61

On the other hand, we have

n

∞

n

∞

W = 1

√

{ d Ni(t) − Yi(t)d 1 (t)} + 1

√

Yi (t)d{ 1 (t) − 0 (t)} ,

n

n

i =1

0

i =1

0

so that, under H 1, W is approximately normal with mean

√

√ ∞

nω ≡

n

G(t)S 1 (t)d{ 1 (t) − 0 (t)}

0



and variance var (W ) = var (n−1 / 2

n



i =1 i ), where

∞

∞

i =

{ d Ni(t) − Yi(t)d 1 (t)} +

Yi (t)d{ 1 (t) − 0 (t)}

0

0

∞

=

{ d Ni(t) − Yi(t)d 1 (t)} + { 1 (Xi) − 0 (Xi)} .

0

In order to simplify the calculation of var (W ) under H 1, we assume that 1 (t) and 0 (t) are close. Under this assumption, the second term of i is ignorable

and var (W ) under H 1 is approximated by

∞

∞

σ 2 =

G(t)S

G(t)d S

1

1 (t )d 1 (t ) = −

1 (t )

(4.10)

0

0

by Theorem 4.1, note that σ 2 equals the probability that a patient has an

1

event during the study period when H 1 is true, and ω = σ 2 − σ 2.

1

0

Hence, we have the power function



√

√



W −

nω

σ 1

nω

1 − β = P(W/ˆ

σ < − z 1− α| H 1 ) = P

×

< −

− z

.

σ

1− α | H 1

1

σ 0

σ 0

By solving this equation and replacing ω = σ 2 − σ 2, we obtain the required

1

0

sample size

(σ 0 z 1− α + σ 1 z 1− β) 2

n =

.

(4.11)

(σ 2 − σ 2 ) 2

0

1

Although the one-sample log-rank test is nonparametric, its sample size cal-

culation requires specification of survival and censoring distributions. We now

derive sample size formulas under some practical design settings.

4.3.2.1

Under Proportional Hazards Model Assumption

Under a proportional hazards model assumption, 0 (t) = 1 (t), and from

(4.9) and (4.10), we have σ 2 = σ 2. Also, since σ 2 equals the probability

0

1

1

that a patient has an event during the study period, from (4.11), the required

number of events D = nσ 2 is expressed as

1

√

( z 1− α + z 1− β) 2

D =

.

(4.12)

( − 1 ) 2

62

Randomized Phase II Cancer Clinical Trials

Note that a calculation of the required number of events does not require

specification of any parametric models for the survival and censoring distri-

butions. However, calculation of a sample size n = D/σ 2 requires specification

1

of these distributions to calculate σ 2.

1

4.3.2.2

Under Uniform Accrual and Exponential Survival

Models

For a practical sample size calculation, we assume that the survival distri-

bution of the experimental therapy is exponential with hazard rate λ 0 under

H 0 and λ 1 under H 1. The survival functions are given as S 0 (t) = exp (− λ 0 t) and S 1 (t) = exp (− λ 1 t), respectively. Under exponential models for survival distributions, we have a proportional hazards model, = λ 0 /λ 1.

Assuming that patients are accrued at a constant rate during period a

and followed for an additional period of b, the censoring distribution is given

as U (b, a + b) with a survivor function G(t) = P(C ≥ t) = 1 if t ≤ b;

= (a + b)/a − t/a if b ≤ t ≤ a + b; = 0 otherwise.

Under a proportional hazards model, by using (4.12), a sample size estima-

tion requires to calculate only σ 2 based on the distributional assumptions:

1





b

λ

a+ b

λ

a+ b

σ 2 = λ

1 (a + b)

1

e− λ 1 t dt +

e− λ 1 t dt −

te− λ 1 t dt

1

1

0

a

b

a

b





= 1 − e− λ 1 b + 1 + b

e− λ 1 b − e− λ 1 (a+ b) − 1 { be− λ 1 b − (a + b)e− λ 1 (a+ b)}

a

a





− 1 e− λ 1 b − e− λ 1 (a+ b) = 1 − e− λ 1 b 1 − e− λ 1 a .

(4.13)

aλ 1

aλ 1

Hence, by combining n = D/σ 2, (4.12) and (4.13), we obtain

1 √

( z 1− α + z 1− β) 2

n =

.

(4.14)

σ 2 ( −

1

1 ) 2

4.3.2.3

When Accrual Rate Is Given

Now, we consider a sample size calculation when the accrual rate r is given

instead of the accrual period a. From (4.13), σ 2 = σ 2 (a) is a function of the un-1

1

known variable a. By replacing n with a × r in (4.14), we obtain an equation a,

√





2

z 1− α + z 1− β

a × r × σ 2 (a) =

1

− 1

or simply

a × r × σ 2 (a) = D

(4.15)

1

from nσ 2 = D. In order to use (4.15), we should calculate D using (4.12)

1

first. We solve one of these equations using a numerical method such as the

Single-Arm Phase II Clinical Trials with Time-to-Event Endpoints

63

bisection method. Let a∗ denote the solution to one of these equations. Then

the required sample size is obtained as n = a∗ × r.

Example 4.3

Suppose that the PFS for a standard therapy has the exponential distribution

with a median of θ 0 = 1 year. We will be interested in the experimental therapy

if its median PFS is θ 1 = 1 . 5 years or longer ( λ 0 = 0 . 693 and λ 1 = 0 . 462). So, we have = λ 0 /λ 1 = θ 1 /θ 0 = 1 . 5. We want to design a study to detect this improvement in PFS by the experimental therapy with 1 − β = 90% power

using the one-sample log-rank test with one-sided α = 10% (z 1− α = 1 . 282 =

z 1− β = 1 . 282 ). From (4.12), the required number of events is obtained as

√

( 1 . 282 1 . 5 + 1 . 282 ) 2

D =

= 32 . 5 .

( 1 . 5 − 1 ) 2

Further, suppose that this trial is expected to accrue about 5 patients per

month (or r = 60 per year) based on the recent accrual rate of patients

at the study institution. Assuming b = 1 year of additional follow-up after

completion of patient accrual, equation (4.15), combined with equation (4.13),

is expressed as





60 a

1 − e−0 . 462 ( 1 − e−0 . 462 a) = 32 . 5 .

0 . 462 a

By solving this equation with respect to a, we obtain an accrual period of

a∗ = 1 . 077 years (or 13 months), and a required sample size of n = a∗ × r =

1 . 077 × 60 = 65. The expected total study period is a∗ + b = 25 months. From

B = 10 , 000 simulations with n = 65, we observed an empirical type I error of

9.3% and power of 87.7%.

4.4

Two-Stage Trials Using One-Sample Log-Rank Test

The previous sections in this chapter consider single-stage designs. In this

section, we investigate design and analysis methods for two-stage phase II

trials using the one-sample log-rank test that was discussed in the previous

section. The other survival testing methods can be similarly extended to two-

stage designs. We consider an interim analysis only for futility testing as in

most traditional phase II trials, but one with efficacy only or with both futility

and efficacy can be similarly derived.

64

Randomized Phase II Cancer Clinical Trials

4.4.1

Two-Stage One-Sample Log-Rank Test

Suppose that nl patients are treated by the experimental therapy during stage

l(= 1 , 2 ). Let n = n 1 + n 2 denote the maximal sample size. We conduct an interim analysis at time τ , which may be determined in terms of number of

events or by calendar time. In order to avoid treating too many patients when

the experimental therapy is shown to be inefficacious, we assume that τ is

smaller than the planned accrual period a.

For subject i (= 1 , . . . , n), let Ti denote the survival time with survival

distribution Sh(t) and cumulative hazard function h(t) under Hh (h = 0 , 1 ), and ei denote the entering time (0 ≤ ei ≤ a). Let Ci denote the censoring time at the end of stage 2 with survivor function G(t) = P (Ci ≥ t) that is defined

by the accrual trend and additional follow-up period. The censoring time at

the interim analysis is denoted as C 1 i = max{min (τ − ei , Ci ), 0}. If patient i enters the study during stage 1 (that is, ei < τ ), then the censoring variable

at the interim analysis has a survivor function G 1 (t) = P{min (τ − ei , Ci ) ≥ t}.

The observed survival data are expressed as (X 1 i , δ 1 i ) at the interim analysis and (Xi , δi ) at the final analysis, where X 1 i = min (Ti , C 1 i ), δ 1 i = I (Ti ≤ C 1 i ), Xi = min (Ti , Ci ), and δi = I (Ti ≤ Ci ). We define at-risk processes Y 1 i (t) =

I (X 1 i ≥ t) and Yi (t) = I (Xi ≥ t), and event processes N 1 i (t) = δ 1 i I (X 1 i ≤ t) and Ni (t) = δi I (Xi ≤ t).

Test statistics at the interim and final analyses are expressed as

n

∞

−

W

1 / 2

1 = n

{

1

d N 1 i (t) − Y 1 i (t)d 0 (t)}

i =1

0

and

n

∞

W = n−1 / 2

{ d Ni(t) − Yi(t)d 0 (t)} ,

i =1

0

respectively. For large n 1 and n, the distribution of (W 1 , W ) under H 0 is approximately bivariate normal with means 0, and variances and covariance that

can be approximated by

n

∞

ˆ

σ 2 = n−1

Y

1

1

1 i (t )d 0 (t ),

i =1

0

n

∞

ˆ

σ 2 = n−1

Yi (t)d 0 (t),

i =1

0

and cov (W 1 , W ) = ˆ

σ 2, respectively; see, for example, Tsiatis (1982).

1

Note that n 1 denotes the number of patients who have entered the study



before the interim analysis time τ , that is, n

n

1 =

I (e

i =1

i ≤ τ). In the interim

Single-Arm Phase II Clinical Trials with Time-to-Event Endpoints

65

analysis, the patients who have not entered the study yet (that is, ei > τ )

have their survival times censored at time 0 (that is, X 1 i = 0 and δ 1 i = 0), so that they make no contributions to W 1 and ˆ

σ 2. A two-stage trial using the

1

one-sample log-rank test is conducted as follows:

• Design stage: Specify 0 (t) and α, together with an interim analysis

time and an early stopping value c 1.

• Stage 1: If W 1 /ˆ σ 1 ≥ c 1, then reject the experimental therapy and stop the trial. Otherwise, proceed to Stage 2.

• Stage 2: If W/ˆ σ < c, then accept the experimental therapy. Here, the

critical value c satisfies





α =

W 1

P

≤ c



1 , W ≤ c H 0

.

(4.16)

ˆ

σ 1

ˆ

σ

Noting that conditioning on W = w, W 1 is approximately normal with

mean ˆ

ρw and variance 1 − ˆ ρ, we approximate equation (4.16) by





c

α =

φ(w) c 1 − ˆ ρw



dw,

−∞

1 − ˆ

ρ 2

where ˆ

ρ = ˆ σ 1 /ˆ σ, and φ(· ) and (· ) are the probability density and cumulative distribution functions of the N ( 0 , 1 ) distribution, respectively.

4.4.2

Sample Size Calculation

At first we derive a power function given τ and c 1 together with the accrual

period a, follow-up period b, h(t) for h = 0 , 1, and (α, 1 − β). The interim analysis time τ may be determined in terms of calendar time or number of

events observed, but at the design stage, we should specify it as a calendar

time. If we want to specify it in terms of the number of events at the design

stage, we can convert it to a calendar time based on the expected accrual rate

and the specified survival distribution. We often choose c 1 = 0; that is, we stop

the trial early if the experimental therapy does no better than the historical

control. But we can choose any value for c 1, depending on how aggressively

we want to screen out the experimental therapy at the interim analysis.

The power function is given as





W 1

1 − β = P

≤ c 1 , W ≤ c| H 1 .

ˆ

σ 1

ˆ

σ

Before deriving a power function, we have to calculate c for a specified type I

error rate α, that is,





α =

W 1

P

≤ c 1 , W ≤ c| H 0 .

ˆ

σ 1

ˆ

σ

66

Randomized Phase II Cancer Clinical Trials

So, for a power calculation, we need to derive the limits of ˆ

σ 2 and ˆ σ 2 under

1

H 0 and H 1, and ω 1 = E(W 1 ), ω = E(W ), var (W 1 ) and var (W ) under H 1.

Under H 0, we have E(W 1 ) = E(W ) = 0, and ˆ

σ 2 and ˆ σ 2 converge to

1

∞

v 1 = −

G 1 (t)d S 0 (t)

0

and

∞

v = −

G(t)d S 0 (t),

0

respectively. Note that var (W 1 ) = v 1 and var (W ) = v under H 0. By independent increment of the one-sample log-rank statistic, corr (W 1 , W ) is given as

√

ρ 0 = v 1 /v.

√

√

Under H 1, we have E(W 1 ) =

n 1 ω 1 and E(W ) =

nω, where

∞

ω 1 =

G 1 (t)S 1 (t)d{ 1 (t) − 0 (t)}

0

and

∞

ω =

G(t)S 1 (t)d{ 1 (t) − 0 (t)} .

0

Further, ˆ

σ 2 and ˆ σ 2 converge to

1

∞

σ 2 = −

G

01

1 (t )S 1 (t )d 0 (t )

0

and

∞

σ 2 = −

G(t)S

0

1 (t )d 0 (t ),

0

respectively. The variances of W 1 and W are given as

∞

σ 2 = −

G

11

1 (t )d S 1 (t )

0

and

∞

σ 2 = −

G(t)d S

1

1 (t ),

0

respectively, under H 1. By independent increment of the one-sample log-rank

statistic, corr (W 1 , W ) is given as ρ 1 = σ 11 /σ 1. Note that ω 1 = σ 2 − σ 2 and 11

01

ω = σ 2 − σ 2, and σ 2 is the probability that a patient who is accrued during 1

0

11

stage 1 experiences an event before the interim analysis time, and σ 2 is the

1

probability that a patient in the study experiences an event before the final

analysis time. Hence, the expected numbers of events are calculated as D 1 =

n 1 σ 2 and D = nσ 2 at the two analysis times, respectively.

11

1

If (X, Y ) is a bivariate normal random vector with means µx and µy,

variances σ 2 and σ 2, and correlation coefficient ρ, then it is well known

x

y

Single-Arm Phase II Clinical Trials with Time-to-Event Endpoints

67

that the conditional distribution of X given Y = y is normal with mean

µx + (ρσx/σy)(y − µy) and variance σ 2 ( 1 − ρ 2 ). This result simplifies the x

calculation of type I error probability and power below.

If the interim analysis time τ and the stopping value c 1 are reasonably

chosen, the power of a two-stage design is not much lower than that of the

corresponding single-stage design. So, when searching for the required accrual

period (or sample size) of a two-stage design, we may start from the accrual

period for the single-stage design. Assuming an accrual pattern with a uniform

rate, the design procedure of two-stage designs can be summarized as follows:

• Given (α, 1− β, r, b, 0 (t), 1 (t)), calculate the sample size n and accrual period a 0 required for a single-stage design.

• Determine an interim analysis time τ during the accrual period a 0 of

the chosen single-stage design (that is, τ < a 0) and the stopping value

c 1 at the interim analysis.

• The accrual period required for a two-stage design is obtained around

a 0 as follows:

At a = a 0 (note that n 1 = rτ and n = ra 0),

(a) Obtain c by solving, the equation





c

α =

φ(

c 1 − ρ 0 z

z)



d z.

−∞

1 − ρ 20

(b) Given (n 1 , n, c 1 , c, α), calculate





¯

c

¯

c 1 − ρ 1 z

power =

φ(z)

d z

−∞

1 − ρ 21

where



√



√

σ

ω n

σ

ω n

¯

01

1

1

0

c 1 =

c

and

¯

c =

c −

.

σ

1 −

11

σ 01

σ 1

σ 0

• If the power is smaller than 1 − β, increase a slightly, and repeat the

above procedure until the power is close enough to 1− β. We may want to

change the interim analysis time τ when repeating the above procedure

with a different accrual period a.

4.4.2.1

Under Uniform Accrual and Exponential Survival

Models

Suppose that the survival distribution is exponential with a hazard rate λ 0

under H 0 and λ 1 under H 1. If patients are accrued at a constant rate during

period a and followed for an additional period of b, and the interim analysis

68

Randomized Phase II Cancer Clinical Trials

takes place before completion of patient accrual (that is, τ < a), then the cen-

soring distribution at the interim analysis is U ( 0 , τ ) and that at final analysis

is U (b, a + b), for which the survivor functions are given as



 1

if t ≤ 0

G 1 (t) =  1 − t/τ if 0 < t ≤ τ

0

if t > τ

and



 1

if t ≤ b

G(t) =

−

 t/a + (a + b)/a

if b < t ≤ a + b ,

0

if t > a + b

respectively. Note that we assume administrative censoring only. If loss to

follow-up is expected, then we may incorporate it in the calculation if its

distribution can be modeled as in Section 4.1, or we may increase the final

sample size by the expected proportion of loss to follow-up.

Under these assumptions, it is easy to show that

v 1 = 1 − ( 1 − e− λ 0 τ )/(τλ 0 ),

v = 1 − ( 1 − e− λ 0 a)e− λ 0 b/(aλ 0 ),

σ 2 = 1 − ( 1 − e− λ 1 τ )/(τλ

11

1 ),

σ 2 = 1 − ( 1 − e− λ 1 a)e− λ 1 b/(aλ

1

1 ), √

σ 2 = σ 2 , and σ 2 = σ 2, where = λ

v

01

11

0

1

0 /λ 1, ρ 0 =

1 /v, ρ 1 = σ 11 /σ 1,

√

√

√

√

¯

c 1 = c 1 − σ 11 ( 1 − ) n 1, and ¯ c = c − σ 1 ( 1 − ) n.

Example 4.4

Suppose that the PFS for a standard therapy (historical control) has the

exponential distribution with a median of 1 year ( λ 0 = 0 . 693). We will be

interested in the experimental therapy if its median PFS is 1.5 years ( λ 1 =

0 . 462) or longer. This trial is expected to accrue about 5 patients per month

(or r = 60 per year) based on the recent accrual rate of patients at the study

institution. Assuming b = 1 year of additional follow-up after completion of

patient accrual, a single-stage design for the one-sample log-rank test with

one-sided α = 5% requires an accrual period of a = 1 . 36 years or a sample

size of n = 82 for 1 − β = 90% power. If we conduct an interim futility testing

with c 1 = 0 at τ = 1 year, then the power of the two-stage design with one-

sided α = 5% decreases to 88% with n = 82. So, by increasing the accrual

period and sample size by about 5% for a = 1 . 43 years and n = 86, a two-stage

design with τ = 1 and c 1 = 0 has about 90% power. By the latter design,

under H 1, we will have about D 1 = 12 events at τ = 1 year and D = 47 at the final analysis. From B = 10 , 000 simulations on the design setting of the latter

two-stage design ( n = 86), we observed an empirical type I error of 4.6% and

power of 87%.

Single-Arm Phase II Clinical Trials with Time-to-Event Endpoints

69

4.5

Binomial Testing on t-Year Survival Probability

Suppose that t is a clinically relevant landmark time point for a specific dis-

ease, and a standard therapy is known to have a survival probability of p 0 at t.

Let S(t) denote the survival probability at time t for the experimental ther-

apy of a study. We want to test H 0 : S(t) = p 0 against H 1 : S(t) = p 1 (> p 0 ).

Considering the small sample sizes of regular single-arm phase II trials, Owzar

and Jung (2008) proposed using the exact binomial test on the total number of



patients whose event times are at least t, that is, X =

n

I (T

i =1

i ≥ t ). Through

extensive simulations, they claim that the methods on median survival time

and the exponential MLE do not perform well for phase II trials with small

sample sizes, and the exponential MLE method is sensitive to the validity of

a specified survival distribution. The methods discussed in Chapters 2 and

3 can be used for the design and statistical analysis for the binomial testing

method.

Example 4.5

Suppose that the median progression-free survival for a standard therapy is

known to be 1 year. We will be interested in the experimental therapy if its

median PFS is 1.5 years or longer. In this case, a reasonable choice for the

landmark time point is t = 1 year. Under the exponential PFS model, we

have p 0 = 0 . 5 and p 1 = 0 . 63. By the method in Chapter 2, a single-stage design requires n = 98 patients for (α, 1 − β) = ( 0 . 1 , 0 . 9 ). The sample size for the binomial test will depend on the chosen t. With t = 1 . 5 years, we

have p 0 = 0 . 35 and p 1 = 0 . 5 under the exponential PFS model, and we need n = 77 under the same design setting. With t = 1 . 5, the required sample size

is decreased, but we may have more missing observations (censoring before t)

due to the extended follow-up time.

For exact testing, the binomial testing will exclude the patients whose event

times are censored before t from analysis. If we want to use them, we may use

an asymptotic testing based on the Kaplan–Meier (1958) estimator at time t,

but this is not an exact test.

References

Aalen, O.O. (1978). Nonparametric inference for a family of counting pro-

cesses. Annals of Statistics, 6, 701–726.

Berry, G. (1983). The analysis of mortality by the subject-years methods.

Biometrics, 39, 173–184.

70

Randomized Phase II Cancer Clinical Trials

Brookmeyer, R. and Crowley, J. (1982). A confidence interval for the median

survival time. Biometrics, 38, 29–41.

Finkelstein, D.M., Muzikansky, A., and Schoenfeld, D.A. (2003). Comparing

survival of a sample to that of a standard population. Journal of the

National Cancer Institute, 95, 1434–1439.

Fleming, T.R. and Harrington, D.P. (1991). Counting Processes and Survival

Analysis, Wiley, New York.

Gardiner, J., Susarla, V., and Van Ryzin, J. (1985). On the estimation of the

median survival time under random censorship. In: Adaptive Statistical

Procedures and Related Topics, IMS Lecture Notes, 8, 350–364.

Kaplan, E.L. and Meier, P. (1958). Nonparametric estimation from incomplete

observations. Journal of the American Statistical Association, 53, 457–

481.

Miller, R.G. (1981). Survival Analysis, John Wiley & Sons, New York.

Nelson, W. (1969). Hazard plotting for incomplete failure data. Journal of

Quality Technology, 1, 27–52.

Owzar, K. and Jung, S.H. (2008). Designing phase II trials in cancer with

time-to-event endpoints (with discussion). Clinical Trials, 5, 209–221.

Sprott, D.A. (1973). Normal likelihoods and their relation to large sample

theory of estimation. Biometrika 60, 457–465.

Tsiatis, A.A. (1982). Repeated significance testing for a general class of statis-

tics used in censored survival analysis. Journal of American Statistical

Society, 77, 855–861.





Chapter 5

Single-Arm Phase II Trials with

Heterogeneous Patient Populations:

Binary and Survival Outcomes

The patient population for a phase II trial often consists of multiple subgroups,

called subpopulations, with different prognosis although the study therapy is

expected to be similarly beneficial for all subgroups. In this case, the final

decision on the study treatment should be adjusted for the heterogeneity of

the patient population.

Suppose that we want to evaluate the tumor response of CD30 antibody,

SGN-30, combined with GVD (Gemcitabine, Vinorelbine, Pegylated Lipo-

somal Doxorubicin) chemotherapy in patients with relapsed or refractory

classical Hodgkin lymphoma (HL) through a phase II trial. In a previous

study, GVD only (a historical control) has led to responses in 65% of pa-

tients with relapsed or refractory HL patients who never had a transplant

and 75% in the transplant group. About 50% of patients in the previous

study never had a transplant. Combining the data from the two subpopula-

tions, the response rate (RR) for the whole patient population is estimated as

70% (= 0 . 5 × 0 . 65 + 0 . 5 × 0 . 75 ).

A standard design to account for the heterogeneity of the patient population

is a single-arm trial based on a specified prevalence for each subpopulation

for testing hypotheses

H 0 : p ≤ 70%

against

Ha : p > 70% ,

where p denotes the true RR of the combination therapy in the patient popu-

lation combining the two subgroups, one for those with prior transplants and

the other for those without one. Suppose that we consider an increase in RR

by 15% or larger to be clinically significant for each subpopulation. So, we

will not be interested in the combination therapy if the true RR, p, is lower

than p 0 = 70% and will be strongly interested if the true RR is higher than

pa = 85%. Then, Simon’s (1989) two-stage optimal design for testing

H 0 : p 0 = 70%

against

Ha : pa = 85%

with type I error no larger than α∗ = 0 . 1 and power no smaller than 1 − β∗ =

0 . 9 is described as follows.

71

72

Randomized Phase II Cancer Clinical Trials

Stage 1 Accrue n 1 = 20 patients. If ¯ a 1 = 14 or fewer patients respond, then

we stop the trial, concluding that the combination therapy is ineffica-

cious. Otherwise, the trial proceeds to stage 2.

Stage 2 Accrue an additional n 2 = 39 patients. If more than ¯ a = 45 pa-

tients out of the total n = 59 (= n 1 + n 2 ) respond, then the combination therapy will be accepted for further investigation.

Using the fact that the number of responders from the two stages are inde-

pendent binomial random variables with an RR of p 0 under H 0 and pa under

Ha, we obtain the exact type I error rate and power of the two-stage design

as 0.0980 and 0.9029, respectively.

In developing such a standard design, an accurate specification of the preva-

lence of each subpopulation is critical. If the prevalence is erroneously speci-

fied, the type I error of the statistical testing cannot be accurately controlled.

Even though the prevalence is accurately specified, the observed proportion

of patients from each subpopulation may be quite different from the true one

when a study is over. This can easily happen in the standard phase II trials

because of their small sample sizes. If a new study accrues a larger number of

high-risk (low-risk) patients than expected, then the trial will have a higher

false negativity (positivity). This kind of bias will be increase as the difference

in RR increases between strata.

Stratified analysis is a popular statistical method to handle the heterogene-

ity of a study population. When the clinical outcome is binary as in the above

example, London and Chang (2005) propose to resolve this issue by choos-

ing rejection values based on a stratified analysis method. They adopt early

stopping boundaries for both low- and high-efficacy cases based on a type I

error rate and power spending function approach. Sposto and Gaynon (2009)

propose a two-stage design with a lower stopping value only based on large

sample approximations that may not hold well for phase II trials with small

sample sizes.

Noting that there usually exists no compelling reason to stop a phase II

trial due to high efficacy, Jung, Chang, and Kang (2011) propose two-stage

designs with early stopping based on futility testing only. In this chapter,

we investigate their method for binary clinical outcomes. We also discuss

stratified one-sample log-rank test for the studies with a survival endpoint.

5.1

Binary Outcome Case

Suppose that we want to design a phase II trial on a new therapy with re-

spect to a patient population with two subpopulations of patients, called the

high-risk subpopulation and the low-risk subpopulation. Cases with more than

Single-Arm Phase II Trials with Heterogeneous Patient Populations

73

two subpopulations will be discussed later. For subpopulation j (= 1 , 2 ), let

p j denote the RR of the therapy and γ j denote the prevalence ( γ 1 + γ 2 = 1).

The RR for the combined population is given as p = γ 1 p 1 + γ 2 p 2. Based on some historical control data, we will not be interested in the new therapy if

its RR for subpopulation j is p 0 j or lower, and will be highly interested in it if its RR is paj (= p 0 j + j for j > 0 ) or higher. Let p 0 = γ 1 p 01 + γ 2 p 02 and pa = γ 1 pa 1 + γ 2 pa 2.

We want to investigate the performance of unstratified and stratified designs

in terms type I error rate and power control.

5.1.1

Single-Stage Designs

At first we consider single-stage designs with a binary study endpoint.

5.1.1.1

Unstratified Testing

A standard single-stage design to test hypotheses H 0 : p ≤ p 0 versus Ha : p > p 0 is to accrue a certain number of patients, say, n, and to reject the

therapy (that is, to fail rejecting H 0), if the observed number of responders is

smaller than or equal to a chosen rejection value ¯

a. Given a prespecified type I

error rate α∗, power 1 − β∗, and clinically significant difference j = paj − p 0 j for subpopulation j (=1, 2), we choose the smallest n together with an integer

¯

a satisfying

α = P (X > ¯ a| p = p 0 ) ≤ α∗

and

1 − β = P (X > ¯ a| p = pa) ≥ 1 − β∗ ,

(5.1)

where X denotes the number of responders among n patients. Given ¯

a, we

usually calculate the exact type I error α and power 1 − β by regarding X as a binomial random variable with n independent trials and probability of success

p = γ 1 p 1 + γ 2 p 2, that is, α = B(¯

a + 1| n, p 0 ) and 1 − β = B(¯

a + 1| n, pa), where



B(x| n, p) =

n

b(x| n, p) and

i = x



n

b(x| n, p) =

px ( 1 − p)n− x

for x = 0 , 1 , . . . , n.

x

We call (n, ¯ a) a standard or unstratified design.

Let b(n, p) denote the binomial distribution with n independent trials and

probability of success p. Let M j be a random variable denoting the num-

ber of patients from subpopulation j among n patients. Assuming that the

population consists of infinitely many patients, we have M 1 ∼ b(n, γ 1 ) and

M 2 = n − M 1. Conditioning on M 1 = m 1, the number of responders X j among m j patients from subpopulation j follows b(m j , p 0 j ) under H 0. Hence, it is

74

Randomized Phase II Cancer Clinical Trials

easy to show that the above type I error for a standard design can be calcu-

lated also as

α = E M 1P (X 1 + X 2 > ¯ a| p 01 , p 02 , M 1 ) n

m 1

n− m 1



=

I (x 1 + x 2 > ¯

a)b(x 1| m 1 , p 01 )b(x 2| n − m 1 , p 02 )b(m 1| n, γ 1 ).

m 1=0 x 1=0 x 2=0

Power (5.1) can be calculated similarly.

5.1.1.2

Stratified Testing

For a stratified single-stage design, we propose to choose a value a satisfying

the α∗-condition given the observed m 1 value while fixing n(= m 1 + m 2 ) at the sample size of a standard design. Given M 1 = m 1 (m 2 = n − m 1 ), the conditional type I error for a rejection value a is calculated as

α(m 1 ) = P (X 1 + X 2 > a| p 01 , p 02 , m 1 ) m 1

n− m 1



=

I (x 1 + x 2 > a)b(x 1| m 1 , p 01 )b(x 2| n − m 1 , p 02 ).

x 1=0 x 2=0

Given m 1, we want to choose the maximal a = a(m 1 ) such that α(m 1 ) ≤ α∗.

For the chosen rejection value a = a(m 1 ), the conditional power is calculated

as

1 − β(m 1 ) = P (X 1 + X 2 > a| pa 1 , pa 2 , m 1 ) m 1

n− m 1



=

I (x 1 + x 2 > a)b(x 1| m 1 , pa 1 )b(x 2| n − m 1 , pa 2 ).

(5.2)

x 1=0 x 2=0

In summary, a stratified single-stage design for a population with two sub-

populations is chosen as follows:

Step 1. Specify γ 1, ( p 01 , p 02 , pa 1 , pa 2 ), and (α∗ , 1 − β∗ ).

Step 2. Choose a reasonable n as follows:

(a) Calculate p 0 = γ 1 p 01 + γ 2 p 02 and pa = γ 1 pa 1 + γ 2 pa 2.

(b) Choose a standard single-stage design (n, ¯ a) for testing

H 0 : p = p 0 vs. Ha : p = pa

under the (α∗ , 1 − β∗ )-condition. We choose this n (or a little larger number) as the sample size of the stratified design.

Step 3. For m 1 ∈ [0 , n], choose the maximum a = a(m 1 ) satisfying α(m 1 ) ≤

α∗.

Step 4. Given (n, m 1 , a), calculate the conditional power 1− β(m 1 ) by (5.2).

Single-Arm Phase II Trials with Heterogeneous Patient Populations

75

The study protocol using a stratified design may provide a table of

{ a(m 1 ), α(m 1 ), 1 − β(m 1 )} for 0 ≤ m 1 ≤ n. When the study is over, we observe m 1 and x(= x 1 + x 2 ), and reject the study therapy if x ≤ a(m 1 ).

Noting that M 1 ∼ b(n, γ 1 ), we can calculate the marginal type I error rate

and power of the stratified design by

n



α = E{ α(M 1 )} =

α(m 1 )b(m 1| n, γ 1 )

m 1=0

and

n



1 − β = E{1 − β(M 1 )} =

{1 − β(m 1 )} b(m 1| n, γ 1 ),

m 1=0

respectively. Since, for each m 1 ∈ [0 , . . . , n], we choose a = a(m 1 ) so that its conditional type I error does not exceed α∗, the marginal type I error will not

exceed α∗.

Example 5.1

Let’s consider the example study discussed at the beginning of this chapter

using 1 = 2 = 0 . 15. Under γ 1 = γ 2 = 0 . 5 and response rates ( p 01 , p 02 ) =

( 0 . 65 , 0 . 75 ), the hypotheses in terms of the population RR are expressed as H 0 : p 0 = 0 . 7 and Ha : p 1 = 0 . 85. For (α∗ , 1 − β∗ ) = ( 0 . 1 , 0 . 9 ), the standard (unstratified) design with the minimal sample size is (n, ¯ a) = ( 53 , 41 ), which has α = 0 . 0906 and 1 − β = 0 . 9093. The type I error and power are valid only when the true prevalence is γ 1 = γ 2 = 0 . 5.

Suppose that the study observed (x 1 , x 2 ) = ( 28 , 13 ) and m 1 = 36. Note that the observed prevalence for the high-risk subpopulation, ˆ

γ 1 = 36 / 53 = 0 . 68,

is much larger than the expected γ 1 = 0 . 5. By the unstratified design, x = 41

equals the rejection value ¯

a = 41, so that the therapy will be rejected. How-

ever, noting that m 1 = 36 is much larger than expected, the stratified design

lowers the rejection value to a = 40, so that, with observation x = 41, the

therapy will be accepted for further investigation. Similarly, the unstratified

Simon’s design may falsely accept the therapy if ˆ

γ 1 is much lower than the

specified prevalence γ 1 = 0 . 5.

Table 5.1 lists the conditional type I error rate and power of the standard

unstratified design for each m 1 ∈ [0 , n]. Note that if m 1 is much larger than nγ 1, that is, too many subpopulation 1 (high risk) patients are accrued, then the

standard rejection value ¯

a = 41 is so conservative that the conditional type I

error and power become smaller than the specified α∗ = 0 . 1 and 1 − β∗ = 0 . 9, respectively. On the other hand, if m 1 is too small compared to nγ 1, that is,

too many subpopulation 2 (low-risk) patients are accrued, then the standard

rejection value ¯

a = 41 is so anticonservative that the conditional type I error

becomes larger than the specified α∗ = 0 . 1 level. Figure 5.1(a) displays the

conditional type I error rate and power of the standard (unstratified) design.

76

Randomized Phase II Cancer Clinical Trials

Table 5.1

Conditional type I error and power of single-stage standard

(unstratified) and stratified designs with n = 53 for ( p 01 , p 02 , ) = ( 0 . 65 , 0 . 75 , 0 . 15 ) and (α∗ , 1 − β∗ ) = ( 0 . 1 , 0 . 9 ). The standard design has a fixed critical value ¯

a = 41

Unstratified

Stratified

Unstratified

Stratified

m1

α

1 − β a

α

1 − β

m1

α

1 − β a

α

1 − β

0 0.2961 0.9947 44 0.0606 0.9215

27 0.0869 0.9081 41 0.0869 0.9081

1 0.2852 0.9939 44 0.0569 0.9142

28 0.0823 0.9011 41 0.0823 0.9011

2 0.2746 0.9930 44 0.0535 0.9065

29 0.0780 0.8938 41 0.0780 0.8938

3 0.2641 0.9919 43 0.0972 0.9517

30 0.0738 0.8862 41 0.0738 0.8862

4 0.2540 0.9908 43 0.0920 0.9467

31 0.0699 0.8782 41 0.0699 0.8782

5 0.2440 0.9896 43 0.0870 0.9414

32 0.0661 0.8699 41 0.0661 0.8699

6 0.2343 0.9882 43 0.0822 0.9357

33 0.0625 0.8612 41 0.0625 0.8612

7 0.2249 0.9866 43 0.0776 0.9296

34 0.0590 0.8523 41 0.0590 0.8523

8 0.2157 0.9849 43 0.0733 0.9232

35 0.0557 0.8430 41 0.0557 0.8430

9 0.2067 0.9830 43 0.0691 0.9163

36 0.0526 0.8334 40 0.0961 0.9049

10 0.1980 0.9810 43 0.0651 0.9091

37 0.0496 0.8236 40 0.0913 0.8981

11 0.1895 0.9787 43 0.0614 0.9015

38 0.0468 0.8134 40 0.0867 0.8909

12 0.1813 0.9763 43 0.0578 0.8935

39 0.0441 0.8029 40 0.0822 0.8835

13 0.1734 0.9736 43 0.0544 0.8851

40 0.0415 0.7922 40 0.0780 0.8757

14 0.1656 0.9707 42 0.0969 0.9368

41 0.0391 0.7812 40 0.0739 0.8677

15 0.1582 0.9676 42 0.0919 0.9311

42 0.0367 0.7699 40 0.0701 0.8593

16 0.1510 0.9642 42 0.0870 0.9250

43 0.0346 0.7584 40 0.0664 0.8506

17 0.1440 0.9606 42 0.0823 0.9186

44 0.0325 0.7467 40 0.0628 0.8417

18 0.1373 0.9566 42 0.0779 0.9119

45 0.0305 0.7347 40 0.0594 0.8325

19 0.1308 0.9525 42 0.0736 0.9048

46 0.0287 0.7225 40 0.0562 0.8230

20 0.1245 0.9480 42 0.0696 0.8973

47 0.0269 0.7102 39 0.0955 0.8886

21 0.1185 0.9432 42 0.0657 0.8895

48 0.0252 0.6977 39 0.0908 0.8813

22 0.1127 0.9382 42 0.0620 0.8813

49 0.0237 0.6850 39 0.0864 0.8738

23 0.1071 0.9328 42 0.0585 0.8727

50 0.0222 0.6722 39 0.0820 0.8659

24 0.1017 0.9271 42 0.0551 0.8638

51 0.0208 0.6592 39 0.0779 0.8578

25 0.0966 0.9211 41 0.0966 0.9211

52 0.0195 0.6462 39 0.0739 0.8495

26 0.0916 0.9148 41 0.0916 0.9148

53 0.0182 0.6330 39 0.0701 0.8408

We observe that the conditional type I error of the standard design widely

varies between 0.0182 for m 1 = 53 and 0.2961 for m 1 = 0. Its conditional

power also widely varies around 1 − β∗ = 0 . 9.

The second part of Table 5.1 reports the conditional rejection value a(m 1 )

and its { α(m 1 ), 1 − β(m 1 )} for each m 1 ∈ [0 , n]. The conditional rejection value a(m 1 ) decreases from 44 to 39 as m 1 increases. Note that ¯

a = a(m 1 ) = 41

for m 1 values around nγ 1 = 26 . 5. Figure 5.1(a) displays the conditional type I error rate and power of the stratified design. While the conditional type I error

of the stratified design α(m 1 ) is closely controlled below α∗, the conditional power is also well controlled around 1 − β∗ = 0 . 9. If we want 1 − β to be larger than 1 − β∗ for all m 1 ∈ [0 , n], we have to choose a slightly larger n than 53.





Single-Arm Phase II Trials with Heterogeneous Patient Populations

77

(a) When (p01, p02) = (0.65, 0.75)

1.0

) 0.8

1

0.6

Unstratified

0.4

Stratified

) or 1 – β(m 1

0.2

α(m

0.0

0

10

20

30

40

50

m1

(b) When (p01, p02) = (0.6, 0.8)

1.0

) 1 0.8

0.6

Unstratified

Stratified

0.4

) or 1 – β(m 1

α(m 0.2

0.0

0

10

20

30

40

50

m1

Figure 5.1

Conditional type I error and power of standard (unstratified)

and stratified designs with n = 53 for (α∗ , 1 − β∗ , ) = ( 0 . 1 , 0 . 9 , 0 . 15 ). The standard design has a fixed critical value ¯

a = 41. The upper lines are condi-

tional powers and the lower lines are conditional type I error.

If the difference of the response probabilities between two subpopulations

| p 01 − p 02| is larger, then the range of the rejection values for the stratified

design will be wider, and the conditional type I error rate and power of the

unstratified design will fluctuate more wildly, depending on the m 1 value. Let’s

consider ( p 01 , p 02 ) = ( 0 . 6 , 0 . 8 ) and 1 = 2 = 0 . 15. Under (γ 1 , α∗ , 1 − β∗ ) =

( 0 . 5 , 0 . 1 , 0 . 9 ), the standard design will be the same as above, (n, ¯ a) = ( 53 , 41 ), but the stratified rejection value a(m 1 ) decreases from 47 to 37 as m 1 increases from 0 to 53. Figure 5.1(b) displays the conditional type I error rate and power

of the unstratified and stratified designs. Comparing Figures 5.1(a) and (b),

we observe that the stratified design controls its conditional type I error rate

and power closely to their nominal levels regardless of | p 01 − p 02| value, but

those of the standard design change farther away from their specified levels

78

Randomized Phase II Cancer Clinical Trials

with the larger difference between subpopulations. We also observe that with a

larger | p 01 − p 02| value, the conditional type I error and power of the stratified

design fluctuate more often because the conditional critical value changes more

frequently see Figure 5.1(b).

Let’s investigate the impact of an erroneously specified prevalence on the

study design. Suppose that the true prevalence is γ 1 = 0 . 3, but the study is

designed under a wrong specification of γ 1 = 0 . 5. Let’s assume ( p 01 , p 02 ) =

( 0 . 65 , 0 . 75 ), 1 = 2 = 0 . 15, and (α∗ , 1 − β∗ ) = ( 0 . 1 , 0 . 9 ) as above. Under the erroneously specified prevalence, the standard and stratified designs will be

the same as above, as shown in Table 5.1. The standard design has marginal

type I error and power (α, 1 − β) = ( 0 . 1530 , 0 . 9631 ) and the stratified design has (α, 1 − β) = ( 0 . 0767 , 0 . 9116 ). Under the true γ 1 = 0 . 3, p 0 = γ 1 p 01 +

γ 2 p 02 = 0 . 72 and p 1 = γ 1 pa 1 + γ 2 pa 2 = 0 . 87 are farther away from 1 / 2 than those under the specified γ 1 = 0 . 5, so that the marginal power for the stratified

design is still larger than 1 − β∗ even though the marginal type I error is much

below α∗ = 0 . 1. The marginal type I error for the standard design is much

larger than the specified α∗ = 0 . 1. Under a wrong projection of the prevalence,

the type I error of a standard design can be heavily biased, but that of the

stratified design will be always controlled below α∗.

Now, suppose that the true prevalence is γ 1 = 0 . 7, but the study is designed

under an erroneously specified γ 1 = 0 . 5. In this case, the standard design

has marginal type I error and power (α, 1 − β) = ( 0 . 0501 , 0 . 8209 ) and the stratified design has (α, 1 − β) = ( 0 . 0768 , 0 . 8762 ). The power for the stratified design is slightly smaller than 1− β∗ because of the conservative adjustment of

conditional type I error. However, the power for the standard design is much

smaller than 1 − β∗. The impact of an erroneously specified prevalence on the

bias of marginal type I error and power will be larger with a larger difference

between p 01 and p 02.

5.1.2

Two-Stage Designs

Because of ethical and economical issues, two-stage designs have been more

popular for phase II cancer clinical trials than single-stage designs. We may

stop a trial early when the RR of a study treatment turns out to be either too

low or too high (e.g., London and Chang, 2005), but we consider the more

popular design with an early stopping due to a low RR only here. If the exper-

imental treatment is efficacious, we usually do not have a compelling ethical

argument to stop the trial early and want to continue collecting more data

to be used in designing a future phase III trial. Furthermore, this simplifies

the computations and makes the statistical testing easier when the final sam-

ple size is different from a predetermined one. Under a two-stage design, we

treat nk patients during stage k(= 1 , 2 ). Let n = n 1 + n 2. For stage k(= 1 , 2 ) and subpopulation j (= 1 , 2 ), let Mkj and Xkj be random variables denoting the number of patients and the number of responders, respectively. Note that

nk = mk 1 + mk 2.

Single-Arm Phase II Trials with Heterogeneous Patient Populations

79

5.1.2.1

Unstratified Testing

An example standard (unstratified) two-stage design is demonstrated at the

beginning of this chapter. Given (α∗ , 1 − β∗ ), a standard design (n 1 , n 2 , ¯ a 1 , ¯ a) is chosen among the two-stage designs satisfying α ≤ α∗ and 1 − β ≥ 1 − β∗, where α and 1− β are obtained assuming that X 1 = X 11 + X 12 and X 2 = X 21 +

X 22 are independent binomial random variables with probability of success

p 0 (= γ 1 p 01 + γ 2 p 02 ) under H 0 and pa(= γ 1 pa 1 + γ 2 pa 2 ) under Ha as in Chapter 2. The unstratified analysis conducts statistical analysis ignoring the number

of patients from each subpopulation.

5.1.2.2

Stratified Testing

Given (M 11 , M 21 ) = (m 11 , m 21 ), a design (n 1 , n 2 , a 1 , a) has conditional type I error

α(m 11 , m 21 ) = P (X 11 + X 12 > a 1 , X 11 + X 12 + X 21 + X 22 > a| p 01 , p 02 ) m 11

n 1− m 11

m 21

n 2− m 21



=

I (x 11 + x 12 > a 1 , x 11 + x 12 + x 21 + x 22 > a) x 11=0 x 12=0 x 21=0 x 22=0

× b(x 11| m 11 , p 01 )b(x 12| n 1 − m 11 , p 02 )b(x 21| m 21 , p 01 )

× b(x 22| n 2 − m 21 , p 02 )

and power

1 − β(m 11 , m 21 ) = P (X 11 + X 12 > a 1 , X 11 + X 12 + X 21 + X 22 > a| pa 1 , pa 2 ) m 11

n 1− m 11

m 21

n 2− m 21



=

I (x 11 + x 12 > a 1 , x 11 + x 12 + x 21

x 11=0 x 12=0 x 21=0 x 22=0

+ x 22 > a)b(x 11| m 11 , pa 1 )b(x 12| n 1 − m 11 , pa 2 )

× b(x 21| m 21 , pa 1 )b(x 22| n 2 − m 21 , pa 2 ).

(5.3)

We want to find a two-stage stratified design { n 1 , n 2 , a 1 (m 11 ), a(m 11 , m 21 )}

whose conditional type I error is no larger than α∗ for each combination of

(m 11 , m 21 ) for mk 1 ∈ [0 , nk]. In order to simplify the computation associated with the search procedure, we fix (n 1 , n 2 ) at the first- and second-stage sample sizes for a standard two-stage design based on a specified prevalence γ 1,

such as Simon’s (1989) minimax or optimal design, or admissible design by

Jung et al. (2004). Given M 11 = m 11, we also propose to fix a 1 = a 1 (m 11 ) at

[ m 11 p 01 + m 12 p 02], where [ c] denotes the largest integer not exceeding c. In other words, we reject the experimental therapy after stage 1 if the observed

number of responders from stage 1 is no larger than the expected number of

responders under H 0. Now, the only design parameter we need to choose is a,

the rejection value at stage 2. At stage 2, given { α∗ , n 1 , n 2 , m 11 , m 21 , a 1 (m 11 )}, we choose the largest a = a(m 11 , m 21 ) satisfying α(m 11 , m 21 ) ≤ α∗. Its conditional power, 1 − β(m 11 , m 21 ), is calculated by (5.3).

80

Randomized Phase II Cancer Clinical Trials

If the observed prevalence is close to the specified one (i.e., m 11 /n 1 ≈ γ 1 and m 21 /n 2 ≈ γ 1), then the conditional rejection values { a 1 (m 11 ), a(m 11 , m 21 )} will be the same as the unstratified rejection values (¯ a 1 , ¯ a) of the unstratified two-stage design by Simon (1989) or Jung et al. (2004). As in single-stage designs,

the conditional power may be smaller than 1 − β∗ for some (m 11 , m 21 ). If we want to satisfy 1− β ≥ 1− β∗ for all combinations of { (m 11 , m 21 ), 0 ≤ m 11 ≤ n 1 , 0 ≤ m 21 ≤ n 2}, then we have to choose a slightly larger n than that of a

standard unstratified design.

If the true prevalence of subpopulation 1 is γ 1, Mk 1 for k = 1 , 2 are independent random variables following b(nk, γ 1 ). Given (M 11 , M 21 ) = (m 11 , m 21 ), let α(m 11 , m 21 ) and 1 − β(m 11 , m 21 ) denote the conditional type I rate and power for conditional rejection values { a 1 (m 11 ), a(m 11 , m 21 )}, respectively. Then, the marginal (unconditional) type I error rate and power are obtained by

n 1

n 2



α =

α(m 11 , m 21 )b(m 11| n 1 , γ 1 )b(m 21| n 2 , γ 1 ) m 11=0 m 21=0

n 1

n 2



1 − β =

{1 − β(m 11 , m 21 )} b(m 11| n 1 , γ 1 )b(m 21| n 2 , γ 1 ), m 11=0 m 21=0

respectively. In summary, a phase II trial with a stratified two-stage design is

conducted as follows:

• Specify (p 01 , p 02 , pa 1 , pa 2 ) and (α∗ , 1 − β∗ ).

• Choose sample sizes for the two stages (n 1 , n 2 ) as follows.

(a) Specify γ 1, the prevalence for subpopulation 1.

(b) For p 0 = γ 1 p 01 + γ 2 p 02 and pa = γ 1 pa 1 + γ 2 pa 2, choose a standard (unstratified) two-stage design for testing

H 0 : p = p 0

vs.

Ha : p = pa

that satisfies the (α∗ , 1 − β∗ )-condition. We use (n 1 , n 2 ) for the chosen standard design as the stage 1 and 2 sample sizes of the

stratified design.

• Conduct the trial.

(a) Stage 1: Treat n 1 patients and observe m 11 , x 11 , x 12. Calculate a 1 =

a 1 (m 11 ) = [ m 11 p 01 + m 12 p 02] based on the observed m 11. Reject the experimental therapy if x 1 = x 11 + x 12 is smaller than or equal to

a 1 (m 11 ). Otherwise, we proceed to stage 2.

(b) Stage 2: Treat n 2 patients and observe m 21 , x 21 , x 22. Choose the largest integer a = a(m 11 , m 21 ) satisfying α(m 11 , m 21 ) ≤ α∗ conditioning on (m 11 , m 21 ). Accept the therapy if x = x 11 + x 12 + x 21 + x 22

is larger than a(m 11 , m 21 ).

• The conditional power 1 − β(m 11 , m 21 ) for the two-stage trial with (n 1 , n 2 , m 11 , m 21 , a 1 , a) is calculated by (5.3).

Single-Arm Phase II Trials with Heterogeneous Patient Populations

81

In designing a two-stage phase II trial with stratified analysis, we should

include the description of the whole procedure described above as well as the

design parameter values in the study protocol.

Chang, Jung, and Wu (2012) propose to drop the subpopulations with low

efficacy after stage 1 using interim futility testing.

Example 5.2

We consider the design setting of Example 5.1 with ( p 01 , p 02 , 1 , 2 ) =

( 0 . 65 , 0 . 75 , 0 . 15 , 0 . 15 ), γ 1 = 0 . 5, and (α∗ , 1 − β∗ ) = ( 0 . 1 , 0 . 9 ). For this setting, Simon’s optimal two-stage design is given as (n 1 , n 2 , ¯ a 1 , ¯ a) = ( 20 , 39 , 14 , 45 ).

We choose (n 1 , n 2 ) = ( 20 , 39 ) for our stratified two-stage design.

Suppose that the study observed (m 11 , m 21 ) = ( 14 , 28 ) and (x 1 , x) =

( 15 , 45 ). Note that much larger number of patients than expected are ac-

crued from the high-risk group, subpopulation 1, that is, m 11 /n 1 = 0 . 70 and

m 21 /n 2 = 0 . 72 compared to the specified γ 1 = 0 . 5. By Simon’s design, x = 45

equals ¯

a = 45, so that the therapy will be rejected. However, the stratified

critical values for (m 11 , m 21 ) = ( 14 , 28 ) are given as (a 1 , a) = ( 13 , 44 ), so that, with observations (x 1 , x) = ( 15 , 45 ), the therapy will be accepted for further investigation. Similarly, the unstratified Simon’s design may falsely accept

the therapy if the trial accrues too many patients from the low-risk group

compared to the projected γ 2 = 0 . 5.

Figure 5.2(a) displays the conditional type I error and power of Simon’s

optimal design (marked as Unstratified) and the stratified design under the

design settings. While the conditional type I error rate of the stratified design

is closely controlled below α∗, that of the unstratified design wildly fluctuates

between 0.0185 and 0.3110, depending on (m 11 , m 21 ). Also, the conditional

power of the stratified design is closely maintained around 1 − β∗, but that

of Simon’s design widely changes between 0.6447 and 0.9876. In the x-axis of

Figure 5.2(a) (Figure 5.2(b) also), only m 11 values are marked, but actually m 21

values run from 0 to n 2 = 39 between consecutive m 11 values. Consequently,

the conditional type I error rate and power, especially for the standard un-

stratified design, regularly fluctuate between consecutive m 11 values.

Figure 5.2(b) displays the conditional type I error rate and power of the

two designs when the two subpopulations have a larger difference in RR,

(p 01 , p 02 ) = ( 0 . 6 , 0 . 8 ), with other parameters fixed at the same values as above.

Note that with γ 1 = 0 . 5, Simon’s optimal design will be identical to that for

(p 01 , p 02 ) = ( 0 . 65 , 0 . 75 ), that is, (n 1 , n 2 , ¯ a 1 , ¯ a) = ( 20 , 39 , 14 , 45 ). As in the single-stage design case (Figure 5.1(b)), we observe that the conditional type

I error rate and power of the the unstratified design fluctuate more wildly than

those with ( p 01 , p 02 ) = ( 0 . 65 , 0 . 75 ), whereas the performance of the stratified design is almost unaffected. In conclusion, unstratified analysis can be more

problematic when the difference in response rates between subpopulations is

large.





82

Randomized Phase II Cancer Clinical Trials

Unstratified

Stratified

1.0

) 21 0.8

m, 11 m 0.6

) or 1 – β(

0.4

21 m, 11 0.2

mα(

0.0

0

5

10

15

20

m 11 ( m 21)

(a) When ( p 01, p 02) = (0.65, 0.75)

Unstratified

Stratified

1.0

) 21 m 0.8

, 11 m

0.6

) or 1 – β( 0.4

21 m, 11 0.2

mα(

0.0

0

5

10

15

20

m 11 ( m 21)

(b) When ( p 01, p 02) = (0.6, 0.8)

Figure 5.2

Conditional type I error and power of two-stage standard (un-

stratified) and stratified designs under (α∗ , 1 − β∗ , ) = ( 0 . 1 , 0 . 9 , 0 . 15 ). The unstratified design has (n 1 , n, ¯ a 1 , ¯ a) = ( 20 , 59 , 14 , 45 ). The upper lines are conditional powers and the lower lines are conditional type I error.

If the true prevalence is accurately specified, then Simon’s optimal design

has marginal type I error rate and power of (α, 1 − β) = ( 0 . 0954 , 0 . 9010 ), and the stratified design has (α, 1− β) = ( 0 . 0792 , 0 . 9044 ) if ( p 01 , p 02 ) = ( 0 . 65 , 0 . 75 ) and (α, 1 − β) = ( 0 . 0788 , 0 . 9159 ) if ( p 01 , p 02 ) = ( 0 . 6 , 0 . 8 ). Both designs using

Single-Arm Phase II Trials with Heterogeneous Patient Populations

83

stratified analysis satisfy the condition of (α∗ , 1 − β∗ ) = ( 0 . 1 , 0 . 9 ). However, if the true prevalence of subpopulation 1 is γ 1 = 0 . 3 but γ 1 = 0 . 5 is specified in designing the study, then Simon’s design based on unstratified analysis

has (α, 1 − β) = ( 0 . 1618 , 0 . 9521 ) if ( p 01 , p 02 ) = ( 0 . 65 , 0 . 75 ) and (α, 1 − β) =

( 0 . 2548 , 0 . 9798 ) if (p 01 , p 02 ) = ( 0 . 6 , 0 . 8 ). Note that Simon’s design has a more biased marginal type I error rate when two subpopulations are more different

in terms of RR. On the other hand, the stratified design always controls the

marginal type I error below α∗ and power close to 1 − β∗ even under an

erroneously specified prevalence, for example, (α, 1 − β) = ( 0 . 0776 , 0 . 9203 ) if ( p 01 , p 02 ) = ( 0 . 65 , 0 . 75 ) and (α, 1 − β) = ( 0 . 0782 , 0 . 9481 ) if ( p 01 , p 02 ) =

( 0 . 6 , 0 . 8 ).

5.1.3

Some Extensions

In this section, we present some extended concepts of stratified designs that

are discussed above.

5.1.3.1

Conditional P-Value

In the previous sections, a stratified two-stage design is determined by the

sample sizes (n 1 , n 2 ) and the rejection value (a 1 , a) conditioning on the number of patients from each subpopulation during each stage. When the trial is

completed, however, the number of patients accrued to the study may be

slightly different from the predetermined sample size. This happens since often

some patients drop out or turn out to be ineligible after registration. Because

of this, we usually accrue a slightly larger number of patients than the planned

sample size, say, 5% more. As a result, the total number of eligible patients

at the end of a trial tends to be different from the planned n. In this case, the

sample size of a study is a random variable, and the rejection value chosen for

the planned sample size may not be valid anymore if the realized sample size

is different from that chosen at the design stage. As a flexible testing method

for two-stage phase II trials, we propose to calculate the p-value conditioning

on the observed sample size as well as the observed number of patients from

each subpopulation, and to reject H 0 (or equivalently accept the experimental

therapy) when the conditional p-value is smaller than the prespecified α∗

level.

If a trial is stopped due to lack of efficacy after stage 1, then we usually are

not interested in p-value calculation. Suppose that the trial has proceeded to

stage 2 to observe (x 1 , x) together with (n 1 , n 2 , m 11 , m 21 ). Then, the interim testing after stage 1 will be conducted using the rejection value a 1 = [ m 11 p 01 +

m 12 p 02]. Given mkj (mk 1+ mk 2 = nk), Xkj is a b(mkj , p 0 j ) random variable under H 0. Hence, the p-value for an observation (x 11 , x 12 , x 21 , x 22 ) conditioning on

84

Randomized Phase II Cancer Clinical Trials

(n 1 , n 2 , m 11 , m 21 ) is obtained by

m 11

m 12

m 21

m 22



p-value =

I (i 11 + i 12 > a 1 , i 11 + i 12 + i 21 + i 22 ≥ x) i 11=0 i 12=0 i 21=0 i 22=0

2

2



×

b(ikj | mkj , p 0 j ),

j =1 k=1

where mk 2 = nk − mk 1. We reject H 0 if p-value < α∗. Note that the calculation of a conditional p-value does not require specification of the true prevalence.

In order to avoid the informative sampling issue, the final sample size should

be determined without looking at the response data from stage 2 patients.

Example 5.3

Let’s revisit Example 5.2 with ( p 01 , p 02 ) = ( 0 . 65 , 0 . 75 ). Suppose that, at the design stage, we chose (n 1 , n 2 ) = ( 20 , 39 ) based on Simon’s optimal design, but the study accrued a slightly larger number of patients (n 1 , n 2 ) = ( 20 , 40 ), among whom (m 11 , m 21 ) = ( 12 , 25 ) were from subpopulation 1 and (x 1 , x) =

( 15 , 46 ) responded. For the original sample size (n 1 , n 2 ) = ( 20 , 39 ), the stratified rejection values are (a 1 , a) = ( 13 , 45 ) with respect to (m 11 , m 21 ) = ( 12 , 24 ) or ( 12 , 25 ). Hence, we could accept the therapy if the number of responders (x 1 , x) = ( 15 , 46 ) was observed from the design as originally planned, (n 1 , n) = ( 20 , 59 ). However, by having one more eligible patient from stage 2, it became unclear whether we should accept the therapy or not by

the testing rule of the original design. To resolve this issue, we calculate

the p-value for (x 1 , x) = ( 15 , 46 ) conditioning on (n 1 , n 2 ) = ( 20 , 40 ) and (m 11 , m 21 ) = ( 12 , 25 ), p-value = 0 . 1089. The conditional p-value is marginally larger than α∗ = 0 . 1, so that we may consider accepting the therapy for further

investigation.

5.1.3.2

When There Are More Than Two Subpopulations

Suppose that there are J (≥ 2 ) subpopulations with RR p j for subpopula-

tion j (= 1 , . . . , J ). We consider two-stage designs here. We accrue n 1 and n 2

patients during stages 1 and 2, respectively. The response rates for J subpopu-

lations are specified as p0 = ( p 01 , . . . , p 0 J ) under H 0 and p a = ( pa 1 , . . . , paJ ) under Ha. Let M k = (Mk 1 , . . . , Mk J ) denote the random vector representing the numbers of patients from the J subpopulations among nk patients accrued



during stage k (

J

M

j =1

k j = nk , k = 1 , 2), and m k = (mk 1 , . . . , mk J ) denote their observed values. Let Xkj denote the number responders among Mkj patients from subpopulation j during stage k. Then, given mkj , Xkj is a random variable with b(mkj , p j ).

Single-Arm Phase II Trials with Heterogeneous Patient Populations

85

Given (m1 , m2 ), the conditional type I error rate and power for chosen rejection values (a 1 , a) are calculated as





 J



J





α(m1 , m2 ) = P  X 1 j > a 1 , (X 1 j + X 2 j) > a|p0 , m1 , m2

j =1

j =1





m 11



m 1 J

m 21



m 2 J

 J



J





=

· · ·

· · ·

I  x 1 j > a 1 , (x 1 j + x 2 j) > a

x 11=0

x 1 J =0 x 21=0

x 2 J =0

j =1

j =1

J



×

b(x 1 j | m 1 j , p 0 j )b(x 2 j | m 2 j , p 0 j ) j =1

and





 J



J





1 − β(m1 , m2 ) = P  X 1 j > a 1 , (X 1 j + X 2 j) > a|p a, m1 , m2

j =1

j =1





m 11



m 1 J

m 21



m 2 J

 J



J





=

· · ·

· · ·

I  x 1 j > a 1 , (x 1 j + x 2 j) > a

x 11=0

x 1 J =0 x 21=0

x 2 J =0

j =1

j =1

J



×

b(x 1 j | m 1 j , paj )b(x 2 j | m 2 j , paj ),

(5.4)

j =1

respectively. A phase II trial with a stratified two-stage design on a heteroge-

neous population with J subpopulations is conducted as follows:

• Specify p0, p a, and (α∗ , 1 − β∗ ).

• Choose the sample sizes for two stages (n 1 , n 2 ) as follows:

(a) Specify the prevalence for each subpopulation, (γ 1 , . . . , γJ ).





(b) For p

J

J

0 =

γ

γ

j =1

j p 0 j and pa =

j =1

j pa j , choose a standard

(unstratified) two-stage design for testing

H 0 : p = p 0

vs.

Ha : p = pa

that satisfies the (α∗ , 1 − β∗ ) condition. We choose (n 1 , n 2 ) for the standard design as the stage 1 and 2 sample sizes of our stratified

design.

• Conduct the trial.

(a) Stage 1: Treat n 1 patients and observe (m 11 , . . . , m 1 J ) and (x

J

11 , . . . , x 1 J ). Calculate a 1 = [

m

j =1

1 j p 0 j ]. Reject the experi-



mental therapy if x

J

1 =

x

j =1 1 j is smaller than or equal to a 1.

Otherwise, proceed to stage 2.

86

Randomized Phase II Cancer Clinical Trials

(b) Stage 2: Treat n 2 patients and observe (m 21 , . . . , m 2 J ) and (x 21 , . . . , x 2 J ). Choose the largest integer a satisfying α(m1 , m2 ) ≤

α∗ conditioning on the observed (m1 , m2 ). Accept the experimental therapy for further investigation,if x > a where x =

2

J

x

k=1

j =1 1 j .

• Calculate the conditional power 1 − β(m1 , m2 ) for the two-stage testing with (n 1 , n 2 , m1 , m2 , a 1 , a) using (5.4).

Given sample sizes n 1 and n 2, M1 and M2 are independent multinomial

random vectors with probabilities of “success” for the J subpopulations

(γ 1 , . . . , γJ ) and n 1 and n 2 independent trials, respectively. Hence, the marginal type I error rate and power can be calculated by taking the expectations of α(M1 , M2 ) and 1 − β(M1 , M2 ) with respect to M1 and M2.

5.2

Survival Outcome Case: Stratified One-Sample

Log-Rank Test

In this section, we introduce a stratified analysis method for the one-sample

log-rank test that was discussed in Section 4.3 and derive its sample size

calculation method.

5.2.1

Statistical Testing

Suppose that there are J subpopulations, or strata, with different survival dis-

tributions because of different risk levels. For subpopulation j (= 1 , . . . , J ), let

0 j(t) denote the cumulative hazard function of a selected historical control.

Let j (t) denote the cumulative hazard function of the experimental therapy

for subpopulation j . We want to test

H 0 : j (t) = 0 j (t)

for j = 1 , . . . , J

against

H 1 : j (t) < 0 j (t)

for j = 1 , . . . , J.

Let n j denote the number of patients from subpopulation

j , and



n

=

J

n

j =1

j

the total sample size. For patient i (=

1 , . . . , n j )

in subpopulation

j , Tji and C ji denote the survival and censoring

times, respectively. For X ji

= min (Tji, C ji) and δji = I (Tji ≤

C ji ), we define N ji (t)

= δji I (X ji ≤ t), Yji(t) = I (X ji ≥ t),

n

n

N

j

j

j (t ) =

N

Y

i =1

j i (t ) and Y j (t ) =

i =1

j i (t ).

Under H 0 for large n,

J

∞

W = n−1 / 2

{ d N j(t) − Yj(t)d 0 j(t)}

j =1

0

Single-Arm Phase II Trials with Heterogeneous Patient Populations

87

is approximately normal with mean 0 and its variance can be consistently

estimated by

J

∞

ˆ

σ 2 = n−1

Y j (t)d 0 j (t).

j =1

0

Hence, we reject H 0 with one-sided α level if Z = W/ˆ

σ < − z 1− α, where z 1− α

denotes the 100 ( 1 − α) percentile of the standard normal distribution.

Note that we have the standardized test statistic is expressed as

J

Oj − E j

W/ˆ

σ =



,

E

j =1

j

∞

where, for subpopulation j , O j =

d N

0

j (t ) is the observed number of events

∞

and E j =

Y

0

j (t )d 0 j (t ) is the expected number of events under H 0.

5.2.2

Sample Size Calculation



We calculate the required sample size n =

J

n

j =1

j for a specified power

under a specific alternative hypothesis H 1 : j (t) = 1 j (t) for j = 1 , . . . , J .

Let γ j = n j /n denote the expected prevalence of subpopulation j ( γ j > 0



and

J

γ

j =1

j = 1), S 1 j (t ) = exp{− 1 j (t )} denote the survivor function of T ji under H 1, and G(t) denote the survivor function of C ji . Under H 1, n−1 Y j (t) uniformly converges to γ j G(t)S 1 j (t), so that ˆ

σ 2 converges to

J

∞

σ 2 =

γ

G(t)S

0

j

1 j (t )d 0 j (t ).

j =1

0

Under H 1, W is approximately normal with mean

√

√ J

∞

nω ≡

n

γj

G(t)S 1 j (t)d{ 1 j (t) − 0 j (t)}

j =1

0

and variance

J

∞

J

∞

σ 2 =

γ

G(t)S

γ

G(t)d S

1

j

1 j (t )d 1 j (t ) = −

j

1 j (t ).

j =1

0

j =1

0

Note that σ 2 equals the probability that a patient has an event during the

1

study period when H 1 is true, and ω = σ 2 − σ 2.

1

0

Hence, we have the power function



√

√



W −

nω

σ 1

nω

1 − β = P(W/ˆ

σ < − z 1− α| H 1 ) = P

×

< −

− z

.

σ

1− α | H 1

1

σ 0

σ 0

88

Randomized Phase II Cancer Clinical Trials

By solving this equation and replacing ω = σ 2 − σ 2, we obtain the required

1

0

sample size

(σ 0 z 1− α + σ 1 z 1− β) 2

n =

.

( 5 . 5 )

(σ 2 − σ 2 ) 2

1

0

5.2.2.1

Under Uniform Accrual and Exponential Survival Models

Suppose that the survival distribution is exponential with hazard rate λhj

under Hh for h = 0 , 1. The survival and cumulative hazard functions are

given as Shj (t) = exp (− λhj t) and hj (t) = λhj t, respectively. Assuming patient accrual at a constant rate during period a and an additional follow-up period

of b, the censoring distribution is U (b, a + b) with a survival function G(t) =

P(C ≥ t) = 1 if t ≤ b; = (a + b)/a − t/a if b ≤ t ≤ a + b; = 0 otherwise. Under these assumptions, we have

J



σ

e− bλ 1 j

2 = 1 −

γ

( 1 − e− aλ 1 j ).

( 5 . 6 )

1

j aλ 1 j

j =1

Similarly, we can show that

J





λ

σ 2 =

γ 0 j 1 − e− bλ 1 j ( 1 − e− aλ 1 j ) .

0

j λ 1 j

aλ 1 j

j =1

By plugging σ 2 and σ 2 in (5.5), we calculate a sample size under uniform

0

1

accrual and exponential survival model.

If we expect similar efficacy improvement among subpopulations, we may

assume a common hazard ratio = λ 0 j /λ 1 j . In this case, we have σ 2 = σ 2

0

1

and ω = σ 2 − σ 2 = ( 1 − )σ 2. Hence, (5.5) is expressed as

1

0

1

√

( z 1− α + z 1− β) 2

n =

.

( 5 . 7 )

σ 2 ( −

1

1 ) 2

Since σ 2 is the probability of observing an event from each patient in the

1

study, the required number of events D = nσ 2 is given as

1

√

( z 1− α + z 1− β) 2

D =

.

( 5 . 8 )

( − 1 ) 2

5.2.2.2

When Accrual Rate Is Given

We assume (i) uniform accrual, (ii) exponential survival model, and (iii) con-

stant a common hazard ratio = λ 01 /λ 11 = · · · = λ 0 J /λ 1 J . Now, we further consider a sample size calculation when the accrual rate r is given instead

of the accrual period a. From (5.6), σ 2 = σ 2 (a) is a function of an unknown 1

1

variable a. By replacing n with a × r in the left side of (5.7), we obtain an

Single-Arm Phase II Trials with Heterogeneous Patient Populations

89

equation on a,

√





2

z 1− α + z 1− β

a × r × σ 2 (a) =

1

− 1

or, simply

a × r × σ 2 (a) = D

( 5 . 9 )

1

from nσ 2 = D. To use (5.9), we should calculate D by (5.8) first. We solve one 1

of these equations using a numerical method such as the bisection method.

Let a∗ denote the solution to the equations. Then, the required sample size is

obtained as n = a∗ × r.

References

Chang, M., Jung, S.H., and Wu, S.S. (2012). Two-stage designs with addi-

tional futility tests for phase II clinical trials with heterogeneous patient

populations. Sequential Analysis, in press.

Jung, S.H., Chang, M., and Kang, S. (2012). Phase II cancer clinical trials

with heterogeneous patient populations. Journal of Biopharmaceutical

Statistics, 22, 312–328.

Jung, S.H., Lee, T.Y., Kim, K.M., and George, S. (2004). Admissible two-

stage designs for phase II cancer clinical trials. Statistics in Medicine,

23, 561–569.

London, W.B. and Chang, M.N. (2005). One- and two-stage designs for strat-

ified phase II clinical trials. Statistics in Medicine, 24, 2597–2611.

Simon, R. (1989). Optimal two-stage designs for phase II clinical trials. Con-

trolled Clinical Trials, 10, 1–10.

Sposto, R. and Gaynon, P.S. (2009). An adjustment for for patient hetero-

geneity in the design of two-stage phase II trials. Statistics in Medicine,

28, 2566–2579.





Chapter 6

Randomized Phase II Trials

for Selection: No Prospective

Control Arms

Often, phase II protocols have multiple experimental therapies for efficacy

screening with respect to the same patient population. Usually, the resources

for clinical trials are limited, so that we may want to choose only a small num-

ber of therapies, ideally one therapy, to be compared with a standard therapy

through a phase III trial. In this setting, we may take one of two approaches:

(i) conduct multiple separate phase II trials, one for each experimental ther-

apy, and evaluate them independently using a standard phase II trial design

method for a single-arm phase II trial; (ii) conduct a single phase II trial with

multiple experimental arms, randomize patients into the arms, and choose

the best arm(s) using a selection method. The former approach requires more

research resources due to the multiplicity of the studies. Also, the individual

phase II trials may potentially have different patient characteristics, and the

comparison among different therapies can be biased.

Because of these issues, the second approach is more attractive. However,

the statistical approaches for analyzing randomized phase II trials are lim-

ited. Simon, Wittes, and Ellenberg (1985) consider randomizing n patients to

each of K treatment arms through a single stage and picking the winner, the

arm with the largest estimated response rate, among them. This approach is

based on the statistical methods of ranking and selection, the basic concepts

of which were introduced more than 50 years ago by Beckhofer (1954), with

a substantial literature since that time. They show that, depending on the

design setting, n = 16 to 70 patients per arm are required for a correct se-

lection probability of 0.9 when there exists a difference of 0.15 in response

rate among the K arms. Liu, LeBlanc, and Desai (1999) point out that this

approach has a high selection probability even when the treatment arms have

the same response rates. Sargent and Goldberg (2001) consider a similar ap-

proach by allowing selection based on other factors when the difference in

observed response rates is small.

Palmer (1991) proposes a two-stage design for selection of the best of three

treatments. In stage 1, cohorts of three patients are randomized to arms A,

91

92

Randomized Phase II Cancer Clinical Trials

B, and C, and a decision is made to continue to accrue the next cohort or

to stop and choose the best two arms. In stage 2, cohorts of two patients

are randomized to the two arms chosen at stage 1, and a decision is made to

continue to accrue the next cohort or to stop and choose the winner. Given

the maximum number of patients available for the study, the stopping time

for each stage is chosen to minimize the number of future failures using a

Bayesian approach. This method requires rapid determination of responses

to be able to apply the sequential tests. As an extension of Palmer (1991),

Cheung (2008) proposes a fully sequential approach that can accommodate

more than three arms.

Steinberg and Venzon (2002) propose two-stage designs for a phase II trial

with two experimental arms. In stage 1, n 1 patients are randomized to each

arm. The trial is stopped after stage 1 if the difference in number of responders

between the two arms are larger than d, which is chosen so that, when the

two arms have a difference of 0.15 in response rate, the probability of selecting

the inferior arm is controlled at a specified level. Otherwise, the trial proceeds

to stage 2 to randomize an additional n 2 patients to each arm. After stage

2, the winner is chosen based on the cumulative responses through the two

stages. Given n = n 1 + n 2, one can choose n 1 = n 2 = n/ 2 or to minimize the expected sample size for the specified response rates with 0.15 of difference.

This approach does not control the overall error probabilities through the

two-stage selection procedure.

Most of these existing methods do not accurately control the type I er-

ror and the power for the whole selection procedure. Furthermore, they do

not allow unequal designs among different arms. In this chapter, we discuss

Jung and George (2009). They propose exact and efficient methods for se-

lecting a small number of experimental therapies for further investigation

through a randomized phase II trial. If there exists a historical control, it

is reasonable to choose an experimental arm that beats both the histori-

cal control and the other experimental arms. In this sense, at first, each

of the parallel experimental arms is compared to a historical control by

a single-arm phase II trial design called independent evaluation, and then

between-arm comparisons are performed among the experimental arms that

are accepted from the independent evaluation through single-arm phase II

trial designs, called between-arm comparison. In a between-arm compari-

son, we use the uniformly minimum variance unbiased estimator (UMVUE)

of response rate of each arm since, as shown in Chapter 3, for two-stage

phase II trial designs, the maximum likelihood estimator (MLE) can be

seriously biased, and the efficiency of UMVUE is comparable to that of

MLE.

If there exists no historical control, we conduct between-arm comparisons

at each stage, so that we can stop the trial early when a significant difference

in efficacy is observed among the experimental arms.

Randomized Phase II Trials for Selection: No Prospective Control Arms 93

6.1

With a Historical Control

We consider two-arm randomized phase II studies, each arm with a two-stage

design for independent evaluation as the primary objective.

Example 6.1

Suppose that we randomize non-Hodgkin’s lymphoma patients who relapsed

from a rituximab-containing combination regimen to rituximab alone (Arm

R, n = 90) or rituximab+lenalidomide (Arm R+L, n = 45) with 2-to-1 prob-

ability, each arm will go through independent evaluation with the following

two-stage design:

Arm R: (a 1 /n 1 , a/n) = ( 10 / 57 , 19 / 90 ) for 4% type I error at p 0 = 0 . 15

and 95% power at p 1 = 0 . 30.

Arm R+L: (a 1 /n 1 , a/n) = ( 4 / 21 , 10 / 45 ) for 5% type I error at p 0 = 0 . 15 and 89% power at p 1 = 0 . 35.

Arm R is a potential control arm for a future phase III trial in case Arm R+L

is accepted in this trial, but it is included in this phase II trial because there

is not enough historical data on the regimen. Twice as many patients will be

accrued to Arm R than to Arm R+L to allow more precise estimation of the

clinical parameters to be used in designing a future phase III trial. Arm R+L

may not be investigated further if it does not seem to be more efficacious

than Arm R. We want to compare the two arms accounting for the two-stage

design for each arm.

In general, we call the two arms arm x and arm y, respectively. For arm

k(= x, y), let Mk(= 1 or 2 ) denote the terminating stage and Sk the number of responders at stage Mk during independent evaluation. For an outcome

(mk, sk), let ˆ pk = ˆ pk(mk, sk) denote the UMVUE for the true response proba-

bilities pk; see Chapter 3.

6.1.1

When Both Arms Have Identical Two-Stage Designs

In this section, we assume that patients are randomized between two arms

with the same two-stage design (a 1 /n 1 , a/n) for independent evaluation, see

Chapter 2.

6.1.1.1

One-Sided Test

Suppose that patients are randomized between two experimental arms, arm x

and arm y, and consider selection of arm y compared to arm x. Usually, the

selection procedure is bilateral, so that the associated test is two-sided. But

94

Randomized Phase II Cancer Clinical Trials

we discuss one-sided test in this section, and expand the results to two-sided

selection problems in the following section.

At first, each arm will be evaluated compared to a common historical control

using a standard two-stage design for phase II trials. When such a trial is

completed, we want to test whether the arm y is better than arm x or not.

The hypotheses associated with this type of comparison are

H 0 : py ≤ px vs. Ha : py > px .

This is a one-sided test. So in this case, we usually would not want to accept

the experimental arm y if it is not accepted in the independent evaluation.

Thus, we want to select arm y for further investigation (or, reject H 0) if it is

accepted in the independent evaluation, that is, m y = 2 and sy > a, and it has

a higher response risponse rate than arm x, that is, ˆ py − ˆ px ≥ c for a chosen critical value c. Let ˆ pk = ˆ p(mk, sk) for given (Mk, Sk), and D = { (m, s) : m =

1 , 0 ≤ s ≤ a 1} ∪ { (m, s) : m = 2 , a 1 + 1 ≤ s ≤ n} denote the sample space of each arm defined by the common two-stage design (a 1 /n 1 , a/n). Given a true

response rate px = py = p under H 0, the probability of rejecting H 0 is h(c| p) = P(ˆ py − ˆ px ≥ c, my = 2 , sy > a| p)





=

I {ˆ p(my, sy) − ˆ p(mx , sx ) ≥ c, my = 2 , sy > a}

(mx ,sx )∈ D (my,sy)∈ D

× f (mx, sx| p) f (my, sy| p),

(6.1)

where I (· ) is the indicator function and f (m, s| p) denotes the probability mass function of (M, S) under the common two-stage designs,

f (m, s| p)





ps ( 1 − p)n

n

1 − s

1

m = 1 ,

0 ≤ s ≤ a

=

s

1





ps ( 1 − p)n

n

n

n

1 + n 2 − s

1 ∧ s

1

2

m = 2 ,

a

x

1 + 1 ≤ s ≤ n 1 + n 2

1 = a 1 +1

x 1

s− x 1

for (m, s) ∈ D, see Chapter 3. More generally, the probability of an event A

in D 2 is calculated by





P(A| px , py) =

I { (mx , sx ), (my, sy)} ∈ A

(mx ,sx )∈ D (my,sy)∈ D

× f (mx, sx| px) f (my, sy| py).

In contrast to asymptotic tests, such as the two-sample t-test, the operating

characteristics of this exact test depend on the null response probability p,

an unknown nuisance parameter. In order to remove the nuisance parameter,

we control the type I error rate by maximizing the probability in (6.1) over

the whole parameter space p ∈ [0 , 1], or over a subset of interest I ⊂ [0 , 1].

See Berger and Boos (1994) for the rationale for such an approach. Given α,

Randomized Phase II Trials for Selection: No Prospective Control Arms 95

we want to choose a critical value c = cα so that the probability of accepting

arm y is no larger than α under H 0, that is,

P{ˆ p(My, Sy) − ˆ p(Mx , Sx ) ≥ cα, My = 2 , Sy > a| H 0}

= max P{ˆ p(My, Sy) − ˆ p(Mx, Sx) ≥ cα, My = 2 , Sy > a| px = py = p} ≤ α.

p∈ I

We will refer to probability (6.2) as the type I error rate. Let p 0 denote the

response rate of a historical control. Then, we may choose a small interval

around p 0, such as I = [ p 0 − 0 . 2 , p 0 + 0 . 2]. If we want the type I error rate to be controlled under any true response rate value, we have to choose I = [0 , 1].

We use the latter in this chapter.

Let H (c) = max p∈ I h(c| p). Obviously, h(c| p) is monotone in c. Given c, however, h(c| p) can have local maxima over p ∈ I. For example, when both arms have the same design as that of Arm R+L in Example 6.1, (a 1 /n 1 , a/n) =

( 4 / 21 , 10 / 45 ), Figure 6.1 displays h(c = 0 . 1| p) over p ∈ [0 , 1]. Note that there are two local maxima, one around p = 0 . 25 and the other around 0.3. So,

given α, calculation of the critical value cα requires a two-stage numerical

search procedure. For a given critical value c, H (c) is calculated by the grid

search for the maximum of h(c| p) in the range of p ∈ [0 , 1]. For any p ∈

[0 , 1], h(c| p) is monotone in c, so that H (c) is also monotone in c. Hence, the critical value c = cα satisfying H(cα) = α can be obtained by the bisection method.

Let (> 0 ) denote a clinically significant difference in response rate. Given

px and py = px + , the probability of correct comparison, called the power, is calculated as

1 − β = P(ˆ py − ˆ px ≥ cα, My = 2 , Sy > a| px , py = px + ).

0.20

0.15

0.10

h(0.1|p)

0.05

0 0

0.2

0.4

0.6

0.8

1.0

p

Figure 6.1

Plot of h(c| p) for c = 0 . 1 and p between 0 and 1.

96

Randomized Phase II Cancer Clinical Trials

Suppose that arm y is accepted in the independent evaluation, and ˆ

c = ˆ py − ˆ px

denotes the observed difference from the data. Then, one may want to see how

significant the evidence is against H 0. To this end, we propose to calculate a

p-value by

p-value = max P{ˆ p(My, Sy) − ˆ p(Mx , Sx ) ≥ ˆ c, My = 2 , Sy > a| px = py = p} .

0≤ p≤1

Example 6.2

Suppose that we want to test if arm y has a higher response rate than arm

x. The two arms have the same two-stage design (a 1 /n 1 , a/n) = ( 4 / 21 , 10 / 45 ) as in Arm R+L of Example 6.1. With α = 0 . 1, we have cα = 0 . 1520, and the type I error rate is maximized at px = py = 0 . 2692. With = 0 . 2, the power is 0.669 for ( px , py) = ( 0 . 15 , 0 . 35 ), 0.649 for ( px , py) = ( 0 . 2 , 0 . 4 ), and 0.639

for ( px , py) = ( 0 . 25 , 0 . 45 ). With = 0 . 25, the power is 0.809 for ( px , py) =

( 0 . 15 , 0 . 4 ), 0.796 for (px, py) = ( 0 . 2 , 0 . 45 ), and 0.800 for (px, py) = ( 0 . 25 , 0 . 5 ).

When we have (mx , sx ) = ( 2 , 12 ) (ˆ px = 0 . 295 ), we have p-value = 0 . 3064

if (my, sy) = ( 2 , 15 ) (ˆ py = 0 . 342 ); p-value = 0 . 1123 if (my, sy) = ( 2 , 20 ) (ˆ py = 0 . 445); and p-value = 0 . 0145 if (my, sy) = ( 2 , 25 ) (ˆ py = 0 . 556).

Note that the above comparison rule controls the type I error rate of select-

ing one experimental arm when both arms have an equal response rate. One

may want to somewhat loosen the type I error control by allowing a selection

of the inferior experimental arm whose response rate is smaller than the other

only by a clinically negligible margin. Let δ(> 0 ) denote the maximum of clin-

ically insignificant differences in response rate, for example, δ = 0 . 05. Suppose

that we do not care about falsely accepting arm y as far as py is within δ of px , that is, py > px − δ. In this case, the hypotheses may be modified to

H 0 : py ≤ px − δ

vs.

Ha : py > px − δ.

We choose a critical value c = cα satisfying

max P{ˆ p(My, Sy) − ˆ p(Mx , Sx ) ≥ cα, My = 2 , Sy > a| px , py = px − δ} ≤ α.

px , py ∈ I

Given px and py = px + , the power is calculated as

1 − β = P{ˆ p(My, Sy) − ˆ p(Mx , Sx ) ≥ cα, My = 2 , Sy > a| px , py = px + } .

For an observed difference ˆ

c = ˆ py − ˆ px , the p-value is calculated as

p-value = max P{ˆ p(My, Sy)−ˆ p(Mx , Sx ) ≥ ˆ c, My = 2 , Sy > a| px , py = px − δ} .

px , py ∈ I

We will consider a selection procedure allowing the maximum clinically in-

significant difference δ in the remainder of this chapter if not stated otherwise.

Randomized Phase II Trials for Selection: No Prospective Control Arms 97

Example 6.3

Consider Example 6.2 with δ = 0 . 05. With δ = 0 . 05 and α = 0 . 1, we have cα = 0 . 0925, and the Type I error rate is maximized at ( px , py) =

( 0 . 3138 , 0 . 2638 ). With = 0 . 2, the power is 0.799 for (px, py) = ( 0 . 15 , 0 . 35 ), 0.820 for ( px , py) = ( 0 . 2 , 0 . 4 ), and 0.827 for ( px , py) = ( 0 . 25 , 0 . 45 ). If we observe (mx , sx ) = ( 2 , 12 ), we have p-value = 0 . 1640 if (my, sy) = ( 2 , 15 ); p-value = 0 . 0529 if (my, sy) = ( 2 , 20 ); and p-value = 0 . 0051 if (my, sy) =

( 2 , 25 ).

6.1.1.2

Two-Sided Test

We now want to compare two experimental arms and choose one that will be

investigated further in a phase III trial. We would not care much if we select

an inferior arm when its response rate is smaller than that of the other arm

only by a clinically insignificant margin δ. In this case, the associated testing is

two-sided. As in the one-sided case, we do not want to select an experimental

arm if it is not accepted in the independent evaluation. That is, we want to

select an experimental arm if it is accepted in the independent evaluation and

its UMVUE is significantly larger than that of the other arm.

For arm k(= x, y), let Ak = (Mk = 2 , Sk > a) denote the event that arm k is accepted from an independent evaluation through a two-stage design. We

select arm x if {arm x is accepted in the independent evaluation, but arm y is not} or {both arms are accepted in the independent evaluation and arm x has

a significantly higher response rate than arm y}. That is, for a chosen critical

value c, we select arm x if

Sx(c) = (Ax ∩ ¯

Ay) ∪ { Ax ∩ Ay ∩ (ˆ p(Mx, Sx) − ˆ p(My, Sy) ≥ c)}

is true, and arm y if

Sy(c) = ( ¯

Ax ∩ Ay) ∪ [ Ax ∩ Ay ∩ {ˆ p(My, Sy) − ˆ p(Mx, Sx) ≥ c)}]

is true, where ¯

A denotes the complement of event A. Since the two arms have

the same two-stage design, (a 1 /n 1 , a/n), the error probabilities P(Ax | px , py =

px + δ) and P(Ay| px , py = px − δ) are identical. Hence, for specified px and py with δ = | px − py|, the false selection probability is expressed as 1 [P{ Sx(c)| py = px + δ} + P{ Sy(c)| px = py + δ}] = P{ Sy(c)| px = py + δ} .

2

Using this result, we obtain the critical value c = cα so that the false selection

probability under H 0, also called the type I error rate, does not exceed α, that

is,

max P{ Sy(c)| px , py = px − δ} ≤ α.

px , py ∈ I

Noting that ¯

Ax ∩ Ay ⊂ Sy(c) for any c > 0, so that we should choose an α larger than max px,py∈ I P{ Sy(c)| px = py + δ}. The probabilities of Sx (c) and Sy(c) will

98

Randomized Phase II Cancer Clinical Trials

be unequal if the two arms have different designs. Cases with different designs

will be discussed in the next section.

Given px and py = px + , the true selection probability, also called the power, is calculated as

1 − β = P{ Sy(cα)| px , py = px + }

with respect to a clinically significant difference . Suppose that both arms

are accepted in the independent evaluation and ˆ

c = ˆ py − ˆ px (> 0 ) denotes the

observed difference in UMVUE from a randomized phase II trial. Then, we

calculate the p-value by

p-value =

max

P[ ¯

Ax ∩ Ay ∩{ˆ p(My, Sy)−ˆ p(Mx, Sx) ≥ ˆ c}| px, py = px − δ] .

px , py = px − δ∈ I

We select neither arm if both arms are rejected in the independent evaluation,

and select both arms if both arms are accepted in the independent evaluation

and |ˆ px − ˆ py| < cα.

Example 6.4

Suppose that two experimental arms have the same two-stage design

(a 1 /n 1 , a/n) = ( 4 / 21 , 10 / 45 ). With δ = 0 . 05, we have max px,py∈ I P{ Sy(c)| px =

py + δ} = 0 . 1333. For α = 0 . 2, we have cα = 0 . 0444 and the actual type I error rate is 0.1701, which is attained at ( px , py) = ( 0 . 567 , 0 . 617 ), where the order is unimportant. With = 0 . 15, the power is 0.830 for ( px , py) = ( 0 . 25 , 0 . 4 ), 0.827 for ( px , py) = ( 0 . 3 , 0 . 45 ), and 0.822 for ( px , py) = ( 0 . 35 , 0 . 5 ). When we observe (mx , sx ) = ( 2 , 12 ), we have p-value = 0 . 1701 if (my, sy) = ( 2 , 15 ); p-value = 0 . 1337 if (my, sy) = ( 2 , 20 ); and p-value = 0 . 0013 if (my, sy) =

( 2 , 25 ).

6.1.2

When Two Arms Have Different Two-Stage Designs

In a randomized phase II trial, we may want to use a different design for

independent evaluation of each experimental arm. If we want to compare two

experimental therapies evaluated by separate single-arm phase II trials, it

is very likely that the two trials have different designs. In this section, we

consider selection problems when two arms have different two-stage designs.

In the previous section, we have considered phase II trials randomizing

patients to two arms with exactly the same two-stage designs for independent

evaluation. In this case, we do not want to select an arm that is rejected in

the independent evaluation. However, when the two arms have different two-

stage designs, the probability of accepting an arm will be different from that

of the other. So, a between-arm comparison incorporating the independent

evaluation result may be unfair to the arm with a higher rejection probability.

Randomized Phase II Trials for Selection: No Prospective Control Arms 99

As such, the selection rules in this section are based only on the comparison

of the estimators of the response rates.

6.1.2.1

One-Sided Test

As before, we consider selection of arm y compared to arm x by testing

H 0 : py ≤ px − δ

vs.

Ha : py > px − δ

for a maximal clinically negligible difference δ. We choose a critical value

c = cα satisfying

max

P(ˆ py − ˆ px ≥ cα| px = py + δ)

0≤ px < py ≤1





= max

I {ˆ py(mx , sx ) − ˆ px (my, sy) ≥ cα}

0≤ px < py ≤1 (mx,sx)∈ Dx (my,sy)∈ Dy

× fx(mx, sx| py + δ) fy(my, sy| py) ≤ α,

where Dk, ˆ pk(· , · ), and fk(· , ·|· ) are design-specific sample space, UMVUE of the response rate, and probability mass function of (M, S), respectively, for

arm k(= x, y).

The power for and px ( py = px + ) is calculated by

1 − β = P(ˆ py − ˆ px ≥ cα| px , py = px + )





=

I {ˆ py(mx , sx ) − ˆ px (my, sy) ≥ cα} fx (mx , sx | px )

(mx ,sx )∈ Dx (my,sy)∈ Dy

× fy(my, sy| px + ).

For an observed difference, ˆ

c = ˆ py − ˆ px , the p-value is calculated as

p-value =

max

P(ˆ py − ˆ px ≥ ˆ c| px = py + δ)

0≤ px , py ≤1





=

max

I {ˆ py(mx , sx ) − ˆ px (my, sy) ≥ ˆ c}

0≤ px < py ≤1 (mx,sx)∈ Dx (my,sy)∈ Dy

× fx(mx, sx| py + δ) fy(my, sy| py).

Example 6.5

Consider δ = 0 . 05 in Example 6.1. Then with α = 0 . 1, we have cα = 0 . 0717

and the type I error rate is maximized at ( px , py) = ( 0 . 2185 , 0 . 1685 ). With

= 0 . 2, the power is 0.933 for (px, py) = ( 0 . 25 , 0 . 45 ), 0.926 for (px, py) =

( 0 . 30 , 0 . 50 ), and 0.922 for (px, py) = ( 0 . 35 , 0 . 55 ). Table 6.1 displays p-values for this exact method.

100

Randomized Phase II Cancer Clinical Trials

Table 6.1

p-values for some chosen outcomes for comparing arm x

(control) with (a 1 /n 1 , a/n) = ( 10 / 57 , 19 / 90 ) and arm y (experimental) with (a 1 /n 1 , a/n) = ( 4 / 21 , 10 / 45 ) at α = 0 . 1 and δ = . 05

Arm x

Arm y

m

s

ˆ p(m, s)

m

s

ˆ p(m, s)

p-value

2

20

0.230

2

11

0.283

0.1413

2

20

0.230

2

12

0.295

0.1169

2

20

0.230

2

13

0.309

0.0904

2

20

0.230

2

14

0.325

0.0675

2

20

0.230

2

15

0.342

0.0447

2

20

0.230

2

20

0.445

0.0017

6.1.2.2

Two-Sided Test

Suppose that two experimental arms have different two-stage designs for in-

dependent evaluation with respect to a historical control. We choose a critical

value c = cα satisfying

max { P(ˆ py−ˆ px ≥ cα| px = py+ δ)+ P(ˆ px −ˆ py ≥ cα| py = px + δ)} ≤ α. ( 6 . 3 ) 0≤ px , py ≤1

Note that the two misselection errors in the left-hand side of (6.3) are not the

same if the two arms have different designs. We fail to select one arm against

the other if |ˆ px − ˆ py| < cα.

The power for and px ( py = px + ),

1 − β = P(ˆ py − ˆ px ≥ cα| px , py = px + ).

For an observed difference, ˆ

c = |ˆ px − ˆ py|, the p-value is calculated as

p-value =

max { P(ˆ py − ˆ px ≥ ˆ c| px = py + δ, py)

0≤ px , py ≤1

+ P(ˆ px − ˆ py ≥ ˆ c| px, py = px + δ)} .

Example 6.6

Suppose that both arms in Example 6.1 are experimental. Then with δ = 0 . 05

and α = 0 . 1, we have cα = 0 . 1174, and the type I error is maximized at (px, py) = ( 0 . 2775 , 0 . 2275 ), where the order is unimportant. With = 0 . 2, the power is 0.826 for ( px , py) = ( 0 . 25 , 0 . 45 ), 0.831 for ( px , py) = ( 0 . 30 , 0 . 50 ), and 0.838 for ( px , py) = ( 0 . 35 , 0 . 55 ). Table 6.2 reports p-values for some chosen outcomes for the exact method.

Randomized Phase II Trials for Selection: No Prospective Control Arms 101

Table 6.2

Shown are p-values for some chosen outcomes for comparing

two experimental arms with two-stage designs (a 1 /n 1 , a/n) =

( 10 / 57 , 19 / 90 ) and (a 1 /n 1 , a/n) = ( 4 / 21 , 10 / 45 ) at α = 0 . 1 and δ = . 05

Arm x

Arm y

m

s

ˆ p(m, s)

m

s

ˆ p(m, s)

p-value

2

33

0.333

2

20

0.407

0.2180

2

33

0.333

2

25

0.500

0.0277

2

33

0.333

2

30

0.600

0.0019

2

33

0.333

2

35

0.700

0.0001

2

33

0.333

2

40

0.800

0.0000

6.2

When No Historical Control Exists

In this section, we assume that there exist no historical control for comparison

with experimental arms. In this case, we propose a two-stage design conduct-

ing a between-arm comparison at each stage. No independent evaluation of

each experimental arm is conducted in this case.

Suppose that equal number of patients are randomized to each arm at each

stage. During stage l(= 1 , 2 ), nl patients are randomized to each arm, and Xl and Yl denote the number of responders from arms x and y, respectively.

Let n = n 1 + n 2, X = X 1 + X 2, and Y = Y 1 + Y 2. Given integers c 1 and c, we propose to select arm x if X 1 − Y 1 > c 1 or X − Y > c. The type I error probability for a clinically negligible difference δ is given as

α = max P{ (X 1 − Y 1 > c 1 ) ∪ (X − Y > c)| px = py − δ}

px , py ∈ ( 0 , 1 )

= P{ (X 1 − Y 1 > c 1 ) ∪ (X − Y > c)| px = 0 . 5 − δ/ 2 , px = 0 . 5 + δ/ 2}

and the power for a clinically meaningful difference is given as

1 − β =

min

P{ (X 1 − Y 1 > c 1 ) ∪ (X − Y > c)| px = py + , py}

px , py ∈ ( 0 , 1 )

= P{ (X 1 − Y 1 > c 1 ) ∪ (X − Y > c)| px = 0 . 5 + / 2 , px = 0 . 5 − / 2} .

These probabilities are calculated using Xl and Yl are independent B(nl, px )

and B(nl, py) random variables, respectively.

Given type I error α∗ and power 1 − β∗, a candidate design (n 1 , n, c 1 , c) should satisfy

α = P{ (X 1 − Y 1 > c 1 ) ∪ (X − Y > c)| px = 0 . 5 − δ/ 2 , px = 0 . 5 + δ/ 2} ≤ α∗

and

1− β = P{ (X 1− Y 1 > c 1 )∪ (X − Y > c)| px = 0 . 5+ / 2 , px = 0 . 5− / 2} ≥ 1− β∗ .

102

Randomized Phase II Cancer Clinical Trials

A search for a good two-stage selection design may be conducted to go

through all combinations of (n 1 , n, c 1 , c). Among the candidate designs satis-

fying a (α∗ , 1 − β∗ )-condition, the minimax design has the smallest n.

So far we assume that equal number of patients are randomized to each arm

during each stage. If different numbers of patients are randomized between

two arms, we may set up a selection rule based on the difference in sample

proportions. Suppose that during stage l(= 1 , 2 ), ml and nl patients are randomized to arms x and y, respectively, and Xl and Yl denote the numbers of responders from these arms. We select arm x if X 1 / − Y 1 > c 1 or X − Y > c.

Let m = m 1 + m 2, n = n 1 + n 2, X = X 1 + X 2, and Y = Y 1 + Y 2. Given integers c 1 and c, we may select arm x if X 1 /m 1 − Y 1 /n 1 > c 1 or X/m − Y/n > c.

The type I error rate and power are similarly calculated as in the balanced

randomization case.

6.3

Extension to More Than Two Arms

In this section, we consider two-stage designs with balanced allocation. It can

be easily extended to the cases with unbalanced allocation as in the two-

arm cases. Suppose that, during stage l(= 1 , 2 ), we randomize nl patients are randomized to each of K arms and observe the number of responders Xkl

from arm k(= 1 , . . . , K ). Let Xk = Xk 1 + Xk 2 and n = n 1 + n 2. Suppose that arm 1 has the highest response rate. We choose arm 1 if its response rate is

significantly higher than that of the second best arm.

6.3.1

When a Historical Control Exists

When a historical control exists, each arm is independently evaluated com-

pared to the common historical control at first. For arm k(= 1 , . . . , K ), let Mk

and Sk denote the terminating stage and the cumulative number of responders

at the terminating stage, respectively, that will be observed from a two-stage

design (a 1 /n 1 , a/n). By controlling the type I error rate accounting for the

multiplicity of experimental arms, we choose a critical value c = cα satisfying

max

P{ˆ p(M 1 , S 1 ) − max ˆ p(Mk, Sk) ≥ cα,

p 1 ,..., pK ∈ ( 0 , 1 )

2≤ k≤ K

M 1 = 2 , S 1 > a| p 1 = p 2 − δ, p 2 = · · · = pK } ≤ α

with respect to a clinically negligible difference δ. Given p 1 and a clinically

meaningful difference (> δ), the power is calculated as

1 − β = P{ˆ p(M 1 , S 1 ) − max ˆ p(Mk, Sk) ≥ cα,

2≤ k≤ K

M 1 = 2 , S 1 > a| p 1 = p 2 + , p 2 = · · · = pK } .

Randomized Phase II Trials for Selection: No Prospective Control Arms 103

6.3.2

When No Historical Control Exists

If there no historical control exists, there will be no independent evaluation of

each experimental arm. A two-stage selection proceeds as follows. For chosen

critical values (c 1 , c), we select arm 1 if X 11 − max2≤ k≤ K Xk 1 > c 1 or X 1 −

max2≤ k≤ K Xk > c. Accounting for the multiplicity of experimental arms, we

calculate the type I error rate for a clinically negligible difference δ by

α = P{ (X 11 − max Xk 1 > c 1 ) ∪ (X 1 − max Xk > c)| p 1 = 0 . 5 − δ/ 2 , 2≤ k≤ K

2≤ k≤ K

p 2 = · · · = pK = 0 . 5 + δ/ 2}

and the power for a clinically meaningful difference by

1 − β = P{ (X 11 − max Xk 1 > c 1 ) ∪ (X 1 − max Xk > c)| p 1 = 0 . 5 + / 2 , 2≤ k≤ K

2≤ k≤ K

p 2 = · · · = pK = 0 . 5 − / 2} .

Given (α∗ , 1− β∗ ), a candidate design (n 1 , n, c 1 , c) satisfies α ≤ α∗ and 1− β ≥

1− β∗. A search for the minimax design can be conducted as in the K = 2-arm

case.

References

Beckhofer, R.E. (1954). A single-sample multiple decision procedure for rank-

ing means of normal populations with known variances. Annals of Math-

ematical Statistics, 25, 16–39.

Berger, R. and Boos, D.D. (1994). P values maximized over a confidence set

for the nuisance parameter. Journal of American Statistical Association,

89, 1012–1016.

Cheung, Y.K. (2008). Simple sequential boundaries for treatment selection in

multi-armed randomized clinical trials with a control. Biometrics, 64,

940–949.

Jung, S.H. and George, S.L. (2009). Between-arm comparisons in randomized

phase II trials. Journal of Biopharmaceutical Statistics, 19, 456–468.

Liu, P.Y., LeBlanc, M., and Desai, M. (1999). False positive rates of random-

ized phase II designs. Controlled Clinical Trials, 20, 343–352.

Palmer, C.R. (1991). A comparative phase II clinical trials procedure for

choosing the best of three treatments. Statistics in Medicine, 20, 1051–

1060.

Sargent, D.J. and Goldberg, R.M. (2001). A flexible design for multiple armed

screening trials. Statistics in Medicine, 20, 1051–1060.

104

Randomized Phase II Cancer Clinical Trials

Simon, R., Wittes, R.E., Ellenberg, S.S. (1985). Randomized phase II clinical

trials. Cancer Treatment Reports, 69, 1375–1381.

Steinberg, S.M. and Venzon, D.J. (2002). Early selection in a randomized

phase II clinical trial. Statistics in Medicine, 21, 1711–1726.





Chapter 7

Randomized Phase II Cancer Clinical

Trials with a Prospective Control on

Binary Endpoints (I): Two-Sample

Binomial Test

As an effort to speed the assessment of new therapies, a phase II clinical trial

traditionally recruits a small number of patients only to the experimental

therapy arm to be compared to a historical control. This implies that the tra-

ditional single-arm phase II trials are appropriate only when reliable and valid

data for an existing standard therapy are available for the same patient pop-

ulation. Furthermore, the response assessment method used for the historical

control should be identical to the one that will be used for a new study.

If no historical control data satisfying these conditions exist or the existing

data are too small to represent the whole patient population, we have to

consider a randomized phase II clinical trial with a prospective control to be

compared with the experimental therapy under investigation. Pointing out

that the success rate of phase III trials based on the outcomes from single-

arm phase II trials is very low, Cannistra (2009) recommends a randomized

phase II trial if a single-arm design is subject to any of these issues. Readers

may refer to Gan et al. (2010) about more issues associated with which design

to choose between a single-arm phase II trial and a randomized phase II trial.

In Chapter 6, we considered randomized phase II clinical trials with exper-

imental arms only. In this chapter, we focus on randomized phase II trials

for evaluating the efficacy of an experimental therapy compared to a prospec-

tive control. We discuss a statistical testing method for designing and an-

alyzing randomized phase II clinical trials with a prospective control based

on a two-sample binomial test (Jung, 2008). The following chapter discusses

randomized phase II trials based on Fisher’s (1935) exact test. Although we

demonstrate these methods using tumor response as the endpoint, it can be

applied to any binomial endpoint, for example, the proportion of patients

progression-free at a fixed time point, say, 6 months, as in Section 4.5. Other

types of randomized phase II trial designs have been proposed by many in-

vestigators, including Thall, Simon, and Ellenberg (1989), and Steinberg and

105

106

Randomized Phase II Cancer Clinical Trials

Venzon (2002). Rubinstein et al. (2005) discuss the strengths and weaknesses

of some of these methods and propose a method for randomized phase II

screening designs based on the usual large-sample approximation. The de-

signs based on the large-sample theory usually do not control the type I error

accurately with typically small sample sizes for phase II trials.

7.1

Two-Sample Binomial Test

7.1.1

Single-Stage Design

If patient accrual is fast or it takes long (say, longer than 6 months) for

response assessment of each patient, we may consider using a single-stage

design. Suppose that n patients are randomized to each arm, and let X and

Y denote the number of responders in arms x (experimental) and y (control),

respectively. Let p x and p y denote the true response rates for arms x and

y, respectively. We want to test whether the experimental arm has a higher

response rate than the control or not, that is, H 0 : p x ≤ p y against H 1 : p x > p y. A single-stage randomized phase II trial is conducted as follows.

• Randomize n patients to each arm, and observe the number of respon-

ders X and Y from arms x and y, respectively.

• Given a prespecified critical value a, accept the experimental arm x if

X − Y ≥ a.

In order to conduct a single-stage randomized phase II trial, we have to de-

termine (n, a) at the design stage. Let p 0 denote the projected response rate

for the historical control and a clinically significant increase in response

rate for arm x. For the purpose of type I and II error calculation, we specify

a simple null hypothesis H 0 : p x = p y = p 0 and an alternative hypothesis H 1 : p x = p 0 + , p y = p 0. Given (n, a), the type I error rate and power of the single-stage design are calculated as

α = P (X − Y ≥ a| p x = p y = p 0 )

and

1 − β = P (X − Y ≥ a| p x = p 0 + , p y = p 0 ), respectively. Let B(n, p) denote the binomial distribution with n independent

trials and a probability of success p for each trial. These probabilities are

calculated assuming that X ∼ B(n, p x ) and Y ∼ B(n, p y ) are independent

Randomized Phase II Cancer Clinical Trials with a Prospective Control 107

random variables. That is,

n 1

n 1−max ( 0 ,k 1 )



n 2



n 2−max ( 0 ,k 2 )



α =

b(y 1| n 1 , p 0 )b(k 1 + y 1| n 1 , p 0 )

k 1= a 1 y 1=max ( 0 , − k 1 ) k 2= a− k 1 y 2=max ( 0 , − k 2 )

× b(y 2| n 2 , p 0 )b(k 2 + y 2| n 2 , p 0 )

and

n

n−max ( 0 ,k)



1 − β =

b(y| n, p 0 )b(k + y| n, p x )b(y| n, p 0 )b(k + y| n, p x ), k= a y=max ( 0 , − k)



where b(x| n, p) = n px ( 1 − p)n− x for x = 0 , 1 , . . . , n denotes the probability x

mass function of the B(n, p) distribution.

Suppose that we want to choose a single-stage design with type I error

rate smaller than or equal to α∗ and power larger than or equal to 1 − β∗.

There exist many single-stage designs satisfying the (α∗ , 1− β∗ )-restriction. We choose design (n, a), which has the smallest n among those designs. Tables 7.1

to 7.9 list single-stage designs under various combinations of (α∗ , 1 − β∗ , ).

7.1.2

Two-Stage Designs with Interim Futility Test

Because of ethical and economical reasons, clinical trials usually are conducted

as a multistage design, so that we can terminate the trials when an experi-

mental arm is believed to be significantly low (futility) or high (superiority)

efficacy compared to the comparative control. Because of its small sample size,

a typical phase II trial has two stages. In this section, we consider two-stage

designs for randomized phase II trials between an experimental arm (arm

x) and a control arm (arm y) with a futility stopping rule under balanced

allocation. Trials with two or more experimental arms and a prospective con-

trol, with both futility and superiority stopping rules, or under unbalanced

allocation will be investigated in the following sections. A two-stage random-

ized phase II trial with a futility stopping rule under balanced allocation will

proceed as follows.

• Stage 1: Accrue n 1 patients to each arm, and observe X 1 and Y 1 denoting the number of responders among the n 1 first-stage patients for arms x

and y, respectively.

(a) Proceed to the second stage if X 1 − Y 1 ≥ a 1 for a chosen integer

a 1 ∈ [− n 1 , n 1].

(b) Otherwise, we reject arm x (or fail to reject H 0) and stop the trial.

• Stage 2: Accrue an additional n 2 patients to each arm, and let X 2 and

Y 2 denote the number of responders among the second-stage patients of

arms x and y, respectively. Let X = X 1 + X 2 and Y = Y 1 + Y 2 denote the

108

Randomized Phase II Cancer Clinical Trials

EN

48.01

24.49

18.17

35.55

23.28

46.49

28.01

54.58

31.03

61.70

34.73

66.09

38.56

69.78

39.49

72.23

39.81

74.59

40.20

73.92

39.56

70.31

38.10

66.37

36.81

63.54

34.77

55.85

29.31

47.18

24.30

37.59

68.77

) and8 ,.

β−

(. 1

1

.8010

.8078

.8097

.8018

.8083

.8001

.8026

.8005

.8025

.8001

.8014

.8000

.8006

.8001

.8000

.8005

.8003

.8003

.8014

.8004

.8013

.8004

.8005

.8000

.8025

.8018

.8006

.8011

.8012

.8005

.8008

.8014

.8008

= )∗

Design

β−

.0789

.0799

.0613

.0991

.0993

.0860

.0779

.0909

.0991

.0893

.0940

.0997

.0999

.0951

.0938

.0991

.0996

.0897

.1000

.0900

.0995

.0994

.0982

.0960

.0930

.0882

.0843

.0926

.0908

.0927

.0982

.0889

.0922

, 1∗

)α

) )

) ) ) ) ) ) ) ) ) ) ) ) ) ) ) ) ) ) ) ) ) ) ) ) ) ) ) ) ) )

(α

Optimal

,a

)

, 4 , 3 , 3 , 4 , 3 , 6 , 5 , 7 , 5 , 8 , 6 , 8 , 6 , 9 , 7 , 9 , 7 , 10 , 7 , 10 , 7 , 9 , 7 , 9 , 7 , 9 , 7 , 8 , 6 , 7 , 5 , 6 , 7

, 2

, 3

, 2

, 3

, 3

, 2

, 2

, 1

,a 1

, 1 , 1 , 1 , 2 , 2 , 1 , 1 , 1 , 2

, 1

, 3

, 1

, 1 , 2 , 2 , 2 , 2

, 1

, 1

, 1 , 1 , 1 , 1 , 1 , 1

1

, 32 , 15 , 9 , 29 , 18 , 27 , 16 , 31 , 24 , 41 , 21 , 50 , 31 , 46 , 22 , 53 , 21 , 47 , 26 , 46 , 26 , 50 , 21 , 41 , 19 , 39 , 16 , 28 , 15 , 25 , 10 , 18 , 33

under

,n(n ( 74 ( 45 ( 45 ( 55 ( 45 ( 73 ( 46 ( 85 ( 48 ( 100 ( 53 ( 105 ( 62 ( 110 ( 62 ( 115 ( 64 ( 120 ( 68 ( 120 ( 66 ( 116 ( 60 ( 110 ( 60 ( 107 ( 60 ( 91 ( 49 ( 76 ( 46 ( 65 ( 116

value

EN

56.55

24.49

18.17

40.36

23.28

56.58

28.30

61.03

33.98

78.57

36.77

83.81

49.34

78.83

45.45

90.60

42.21

94.21

52.56

93.21

49.43

96.22

41.14

70.42

41.72

84.45

42.04

67.89

30.79

54.58

24.67

44.27

78.77

stopping

β

y

−1 .8000 .8078 .8097 .8033 .8083 .8013 .8060 .8005 .8024 .8025 .8003 .8003 .8045 .8002 .8003 .8017 .8015 .8021 .8013 .8000 .8029 .8037 .8012 .8000 .8004 .8025 .8002 .8000 .8044 .8003 .8145 .8003 .8001

futilit

Design

a

.0739

.0799

.0613

.0986

.0993

.0994

.0779

.0894

.0966

.0992

.0930

.0996

.0979

.0968

.0940

.0999

.0994

.0997

.0992

.0996

.0999

.0998

.0999

.0982

.0946

.0990

.0993

.0958

.0922

.0967

.0998

.0940

.0965

with

)α

) ) ) ) ) ) ) ) ) ) ) ) ) ) ) ) ) ) ) ) ) ) ) ) ) ) )

Minimax

) )

) ) )

,a

)

, 4 , 3

, 8

, 3 , 4 , 3 , 5 , 5 , 7 , 5 , 7 , 6 , 8 , 6 , 9 , 7 , 9 , 7 , 9 , 7 , 9 , 7 , 9 , 7 , 9 , 7 , 8 , 6 1 , 6 , 7 , 5 , 6 , 7

, 0 , 1 , 1 , 3 , 2 , 5 , 1 , 0 , 3 , 7 , 1 , 7 , 6 , 0 , 0 , 7 , 1 , 8 , 6 , 8 , 5 , 9 , 0 , 0 , 0 , 8 , 5 , − , 1 , 0 , 1 , 0 , 0

designs

,a 11

, 9

, 93

, 92

, 51

,n

, 47 , 15

, 39 , 18 , 56 , 17 , 45 , 31 , 78 , 28 , 83 , 49 , 60 , 35 , 89 , 31

, 52

, 48 , 96 , 25 , 41 , 29 , 84 , 41 , 49 , 20 , 38 , 11 , 29

n

( 63 ( 45 ( 45 ( 47 ( 45 ( 61 ( 45 ( 74 ( 45 ( 83 ( 48 ( 89 ( 52 ( 95 ( 54 ( 99 ( 56 ( 102 ( 56 ( 101 ( 56 ( 98 ( 54 ( 95 ( 52 ( 88 ( 48 ( 79 ( 45 ( 68 ( 45 ( 56 ( 101

o-stage

tw

β(−1 .8009 .8955 .9734 .8081 .9231 .8046 .8576 .8052 .8431 .8029 .8039 .8037 .8063 .8036 .8025 .8044 .8078 .8044 .8008 .8022 .8046 .8023 .8025 .8002 .8043 .8017 .8083 .8006 .8175 .8032 .8474 .8027 .8043

optimal

Design

) 1

and

.0740

.0524

.0524

.0695

.0656

.0843

.0610

.0904

.0840

.0905

.0720

.0879

.0859

.0979

.0947

.0893

.0827

.0927

.0842

.0927

.0853

.0905

.0825

.0851

.0965

.0919

.0884

.0963

.0777

.0987

.0663

.0964

.0996

=

(γ

)α

) ) ) ) ) ) ) ) ) ) ) ) ) ) ) ) ) ) ) ) ) ) ) ) ) ) ) ) ) ) ) ) )

,a

, 4 , 4 , 4 , 5 , 5 , 6 , 6 , 7 , 6 , 8 , 7 , 9 , 7 , 9 , 7 , 10 , 8 , 10 , 8 , 10 , 8 , 10 , 8 , 10 , 7 , 9 , 7 , 8 , 7 , 7 , 7 , 6 , 7

Single-Stage

(n

( 63 ( 50 ( 50 ( 52 ( 50 ( 63 ( 50 ( 74 ( 50 ( 84 ( 53 ( 94 ( 54 ( 95 ( 54

( 61

( 60

( 60

( 59

( 52 ( 90 ( 51 ( 79 ( 50 ( 68 ( 50 ( 56

Minimax

( 104

( 104

( 103

( 102

( 100

( 101

cation

allo

x

7.1

p

.15

.2

.25

.25

.3

.3

.35

.35

.4

.4

.45

.45

.5

.5

.55

.55

.6

.6

.65

.65

.7

.7

.75

.75

.8

.8

.85

.85

.9

.9

.95

.95

.95

y

able

p

.05

.1

.15

.2

.25

.3

.35

.4

.45

.5

.55

.6

.65

.7

.75

.8

.85

T balanced

Randomized Phase II Cancer Clinical Trials with a Prospective Control 109

EN

56.31

28.18

18.69

43.99

26.12

54.12

32.57

66.28

38.35

73.76

43.51

78.89

44.91

84.81

49.00

86.13

49.40

90.13

49.12

89.38

48.41

83.41

47.09

80.65

44.49

72.75

39.74

66.44

34.18

57.17

29.56

42.39

83.27

) and

β

85

−

,.

1

.8501

.8510

.8507

.8512

.8509

.8503

.8514

.8502

.8514

.8502

.8506

.8504

.8507

.8500

.8500

.8507

.8508

.8501

.8500

.8505

.8507

.8502

.8502

.8504

.8509

.8501

.8523

.8509

.8506

.8506

.8524

.8501

.8503

(. 1= Design

)∗ β

.0917

.0897

.0604

.0843

.0810

.0988

.0885

.0986

.0887

.0994

.0854

.0985

.0977

.0930

.0879

.0989

.0926

.0984

.0955

.0985

.0947

.0991

.0905

.0934

.0995

.0990

.0948

.1000

.0991

.0993

.0822

.0986

.0985

−

)α

)

)

)

)

)

)

)

)

)

)

)

)

, 1

)

)

)

) ) ) )

Optimal

) ) ) ) ) ) )

)

)

)

)

)

)

)

, 9

, 9

, 8

, 7

∗

,a

, 4 , 3 , 3 , 5 , 4 , 6 , 5 , 7 , 6 , 8 , 7

, 7 , 10 , 8 , 10 , 8 , 10 , 8 , 10 , 8 , 10 , 8 , 10 , 7

, 7

, 6 , 7 , 6 , 6

(α

, 3

, 3

, 2

, 2

, 3

, 3

,a 1

, 1 , 1 , 1 , 1 , 1 , 1 , 1

, 1

, 1

, 1 , 2 , 1 , 2 , 1 , 4 , 1 , 4 , 1 , 2 , 2 , 2 , 3

, 1

, 2 , 3 , 1 , 1

1

, 52

, 57

, 53

, 46

, 49

, 65

,n

, 39 , 19 , 12 , 28 , 18 , 33 , 21

, 23

, 24

, 26 , 55 , 26 , 56 , 28 , 72 , 26 , 71 , 27 , 53 , 30 , 52 , 35

, 21

, 24 , 44 , 15 , 22

(n

( 83 ( 46 ( 35 ( 67 ( 39 ( 82 ( 49 ( 105 ( 59 ( 114 ( 69 ( 122 ( 69 ( 133 ( 78 ( 134 ( 76 ( 137 ( 78 ( 137 ( 75 ( 132 ( 79 ( 127 ( 70 ( 118 ( 64 ( 109 ( 56 ( 93 ( 50 ( 70 ( 133

under

value

EN

62.67

30.76

18.69

49.54

28.43

59.54

36.22

77.14

44.38

88.84

54.22

82.00

50.53

96.82

62.22

90.63

57.84

56.03

52.95

91.41

51.84

96.93

59.22

79.04

44.40

90.33

41.13

67.04

34.75

43.42

110.69

109.69

105.99

β

stoppingy

−1 .8502 .8515 .8507 .8506 .8517 .8500 .8501 .8519 .8502 .8510 .8536 .8504 .8500 .8501 .8522 .8502 .8500 .8512 .8501 .8504 .8500 .8509 .8501 .8500 .8541 .8501 .8505 .8539 .8508 .8504 .8502 .8504 .8508

Design

futilita

.0876

.0831

.0604

.0803

.0784

.0965

.0855

.0995

.0859

.0995

.0997

.0989

.0967

.0937

.0996

.0995

.0926

.0997

.0955

.0998

.0950

.0997

.0918

.0962

.0997

.0994

.0964

.1000

.0991

.0997

.0989

.0993

.0995

with

)α

)

)

)

)

)

)

)

)

)

Minimax

) ) ) ) ) ) ) ) ) ) )

)

)

)

)

)

)

)

) ) ) ) ) )

,a

, 4 , 3 , 3 , 5 , 4 , 6 , 5 , 7 , 6 , 8 , 6 , 9 , 7 , 10 , 7 , 10 , 8 , 10 , 8 , 10 , 8 , 10 , 8 , 10 , 7 , 9 , 7 , 8 , 6 , 7 , 5 , 6 , 7

, 1

, 8

, 8

1

, 3

, 6

,a 1

, 0 , 0 , 1 , 0 , 0 , 0 , 0 , 5 , 0 , 6 , 6

, 0 , 0 , 7 , 1 , 0

, 0

, 0 , 3 , 1 , − , 7

, 0 , 8 , 4 , 5 , 4 , 1

designs

1

, 59

, 67

,n

, 49 , 21 , 12 , 38 , 18 , 45 , 27 , 75 , 36 , 87 , 54

, 39 , 76 , 62 , 66 , 47 , 109 , 43 , 108 , 36 , 78 , 40 , 76 , 59

, 30 , 90 , 39 , 64 , 33 , 27 , 104

n

( 72 ( 36 ( 35 ( 58 ( 35 ( 71 ( 43 ( 87 ( 51 ( 98 ( 56 ( 109 ( 60 ( 115 ( 64 ( 119 ( 67

( 67

( 67

( 66

( 61

( 56 ( 93 ( 50 ( 81 ( 44 ( 65

( 120

( 119

( 117

( 111

( 104

( 118

o-stage

tw

β(−1 .8530 .8909 .9665 .8532 .9041 .8540 .8534 .8544 .8511 .8526 .8523 .8537 .8524 .8521 .8521 .8512 .8508 .8512 .8521 .8502 .8560 .8518 .8563 .8504 .8527 .8542 .8544 .8503 .8580 .8552 .8606 .8543 .8505

optimal

Design

) 1

and

.0880

.0952

.0952

.0806

.0940

.0974

.0860

.0831

.0861

.0855

.0832

.0848

.0974

.0944

.0870

.0867

.0929

.0900

.0963

.0902

.0974

.0883

.0946

.0965

.0879

.0886

.0987

.0902

.0859

.0905

.0898

.0844

.0899

=

(γ

)α

) ) ) ) ) ) ) ) ) ) ) ) ) ) ) ) ) ) ) ) ) ) ) ) ) ) ) ) ) ) ) ) )

,a

, 4 , 3 , 3 , 5 , 4 , 6 , 5 , 8 , 6 , 9 , 7 , 10 , 7 , 10 , 8 , 11 , 8 , 11 , 8 , 11 , 8 , 11 , 8 , 10 , 8 , 10 , 7 , 9 , 7 , 8 , 6 , 7 , 8

Single-Stage

(n

( 72 ( 40 ( 40 ( 58 ( 40 ( 71 ( 43 ( 92 ( 51

( 59

( 60

( 67

( 67

( 67

( 67

( 66

( 64

( 56 ( 96 ( 54 ( 84 ( 45 ( 70

Minimax

( 103

( 114

( 115

( 124

( 124

( 123

( 122

( 111

( 109

( 123

cation

allo

x

7.2

p

.15

.2

.25

.25

.3

.3

.35

.35

.4

.4

.45

.45

.5

.5

.55

.55

.6

.6

.65

.65

.7

.7

.75

.75

.8

.8

.85

.85

.9

.9

.95

.95

.95

y

able

p

.05

.1

.15

.2

.25

.3

.35

.4

.45

.5

.55

.6

.65

.7

.75

.8

.85

T balanced

110

Randomized Phase II Cancer Clinical Trials

EN

75.20

37.92

26.56

52.83

33.83

69.54

42.45

80.47

48.82

90.19

51.62

98.19

56.81

58.43

61.57

61.33

60.28

58.43

99.29

52.83

89.97

49.61

79.64

42.19

67.36

34.09

53.57

97.40

105.17

106.61

111.66

109.15

103.15

β

) and9

−

,.

1

.9007

.9004

.9024

.9007

.9037

.9001

.9004

.9003

.9009

.9001

.9001

.9000

.9002

.9002

.9000

.9003

.9001

.9010

.9003

.9001

.9002

.9005

.9001

.9001

.9001

.9000

.9006

.9005

.9002

.9007

.9016

.9010

.9004

(. 1

Design

= )∗

.0740

.0950

.0940

.0993

.0946

.0904

.0754

.0990

.0977

.0994

.0985

.0982

.0924

.0938

.0996

.1000

.0885

.0901

.0912

.0999

.0907

.0999

.0876

.0938

.0986

.0982

.0887

.0994

.0927

.0984

.0937

.0900

.0970

β−

)

)

)

)

)

)

)

)

Optimal

)α

) ) ) ) ) ) ) ) ) ) )

)

)

)

)

)

)

)

) ) ) ) ) ) )

, 1

,a

, 5 , 3 , 2 , 5 , 4 , 7 , 6 , 8 , 6 , 9 , 7 , 10 , 8 , 11 , 8 , 11 , 9 , 12 , 9 , 11 , 9 , 11 , 9 , 11 , 8 , 10 , 8 , 9 , 7 , 8 , 6 , 7 , 8

∗

, 1 , 2 , 2 , 1 , 2 , 1 , 1 , 1 , 3 , 2 , 1 , 2 , 1 , 2 , 2 , 2 , 2 , 2 , 2 , 4 , 2 , 2 , 2 , 2 , 1 , 2 , 1 , 2 , 1 , 1 , 1 , 1 , 1

(α

,a 11 , 50

, 44

, 49

, 64

, 53

, 37

, 52

,n

, 33 , 22 , 36 , 27

, 28

, 41

, 33 , 66 , 34 , 70 , 43 , 70 , 42 , 75 , 41 , 86 , 40 , 67 , 38 , 65 , 30 , 58 , 27

, 23

, 18 , 28

(n

( 112 ( 59 ( 55 ( 76 ( 55 ( 102 ( 62 ( 119 ( 73 ( 133 ( 75 ( 149 ( 85 ( 159 ( 85 ( 162 ( 95 ( 166 ( 96 ( 164 ( 95 ( 158 ( 94 ( 152 ( 81 ( 141 ( 78 ( 124 ( 67 ( 105 ( 56 ( 87 ( 154

under

value

EN

86.76

38.06

26.56

58.38

33.83

77.96

43.23

89.42

60.10

93.42

56.31

62.80

66.85

75.10

78.45

77.45

76.33

55.97

94.37

64.46

90.26

47.10

70.20

34.32

59.47

99.19

109.00

125.11

112.04

144.21

143.21

111.81

119.70

β

stopping

−

y

1

.9009

.9032

.9024

.9002

.9037

.9001

.9000

.9001

.9029

.9006

.9004

.9001

.9004

.9000

.9002

.9002

.9009

.9018

.9005

.9019

.9001

.9004

.9028

.9000

.9010

.9003

.9004

.9007

.9003

.9011

.9036

.9003

.9010

Design

futilita

.0955

.0971

.0940

.0960

.0946

.0877

.0979

.0969

.0985

.0996

.0976

.0982

.0910

.0940

.0995

.0999

.0996

.0994

.0996

.0997

.0992

.0998

.0984

.0959

.0993

.0990

.0989

.0997

.0948

.0988

.0939

.0924

.0971

)

with

)α

)

)

)

)

)

)

)

)

)

)

)

Minimax

) ) ) ) ) ) )

)

)

)

)

)

)

)

)

)

)

) ) ) )

,a

, 11

, 4 , 3 , 2 , 5 , 4 , 7 , 5 , 8 , 6 , 9 , 7 , 10 , 8 1 , 8 , 11 , 8 , 11 , 8 , 11 , 8 , 11 , 8 , 11 , 8 , 10 , 7 , 9 , 7 , 8 , 6 , 7 , 8

, 0

, 1

1

, 4

, 1

,a 1

, 4 , 2 , 2 , 0 , 2 , 0 , 3

, 6

, 0 , 0 , 0 , − , 4 , 1 , 7 , 11 , 8 , 11 , 8 , 3 , 8 , − , 0 , 1 , 7

, 0 , 1 , 1 , 0

1

, 82

, 61

designs

, 71

, 69

,n

, 86 , 34 , 22 , 47 , 27 , 62 , 40

, 60

, 42 , 85 , 47

, 77 , 95 , 76

, 34 , 67 , 64

, 31 , 48 , 19 , 36

, 104 , 63 , 83 , 74 , 144 , 78 , 143

, 98

n

( 93 ( 55 ( 55 ( 67 ( 55 ( 91 ( 55 ( 105 ( 61 ( 122 ( 68 ( 130 ( 76

( 78

( 82

( 82

( 81 ( 142 ( 79

( 74 ( 126 ( 68 ( 112 ( 60 ( 97 ( 55 ( 78 ( 146

( 140

( 145

( 146

( 145

( 135

o-stage

tw

β(−1 .9018 .9434 .9896 .9019 .9621 .9017 .9205 .9020 .9037 .9024 .9037 .9024 .9031 .9002 .9010 .9006 .9039 .9005 .9010 .9006 .9004 .9006 .9023 .9002 .9027 .9004 .9039 .9001 .9033 .9001 .9307 .9040 .9020

optimal

Design

) 1

and

.0688

.0691

.0691

.0963

.0842

.0881

.0791

.0976

.0782

.0842

.0987

.0992

.0920

.0941

.0832

.0876

.0902

.0910

.0923

.0913

.0921

.0888

.0896

.0960

.0836

.0868

.0918

.0875

.0974

.0845

.0850

.0962

.0851

=

(γ

)α

) ) ) ) ) ) ) ) ) ) ) ) ) ) ) ) ) ) ) ) ) ) ) ) ) ) ) ) ) ) ) ) )

,a

, 5 , 4 , 4 , 5 , 5 , 7 , 6 , 8 , 7 , 10 , 7 , 10 , 8 , 11 , 9 , 12 , 9 , 12 , 9 , 12 , 9 , 12 , 9 , 11 , 9 , 11 , 8 , 10 , 7 , 9 , 7 , 7 , 9

Single-Stage

(n

( 98 ( 60 ( 60 ( 67 ( 60 ( 91 ( 60

( 66

( 68

( 76

( 83

( 84

( 83

( 82

( 81

( 79

( 70

( 60

( 60 ( 78

Minimax

( 105

( 127

( 130

( 140

( 150

( 150

( 149

( 147

( 135

( 131

( 117

( 102

( 151

cation

allo

x

7.3

p

.15

.2

.25

.25

.3

.3

.35

.35

.4

.4

.45

.45

.5

.5

.55

.55

.6

.6

.65

.65

.7

.7

.75

.75

.8

.8

.85

.85

.9

.9

.95

.95

.95

y

able

p

.05

.1

.15

.2

.25

.3

.35

.4

.45

.5

.55

.6

.65

.7

.75

.8

.85

T balanced

Randomized Phase II Cancer Clinical Trials with a Prospective Control 111

) and

41.62

19.55

14.02

31.94

19.18

37.78

23.81

45.68

26.75

52.95

29.85

54.98

32.43

59.21

33.03

61.58

33.25

61.62

34.50

61.05

33.19

59.87

31.63

55.77

30.29

50.67

28.57

47.28

23.20

38.99

20.53

29.67

56.50

8

EN

,.

β

(. 15

−

=

1

.8011

.8015

.8143

.8007

.8006

.8004

.8025

.8006

.8024

.8004

.8013

.8002

.8004

.8005

.8001

.8001

.8010

.8001

.8007

.8003

.8011

.8007

.8001

.8004

.8002

.8004

.8007

.8001

.8003

.8021

.8008

.8014

.8003

)∗ β Design

−

.1232

.1395

.1068

.1499

.1118

.1479

.1461

.1407

.1369

.1324

.1486

.1468

.1345

.1497

.1429

.1387

.1489

.1416

.1476

.1416

.1497

.1386

.1465

.1496

.1404

.1460

.1300

.1321

.1475

.1400

.1268

.1449

.1379

, 1∗ (α

)α

) ) ) ) ) ) ) ) ) ) ) ) ) ) ) ) ) ) )

Optimal

) ) ) ) ) ) ) ) ) ) ) ) ) )

,a

, 3 , 2 , 2 , 3 , 3 , 4 , 3 , 5 , 4 , 6 , 4 , 6 , 5 , 6 , 5 , 7 , 5 , 7 , 5 , 7 , 5 , 7 , 5 , 6 , 5 , 6 , 5 , 6 , 4 , 5 , 4 , 4 , 5

,a 1

, 1 , 1 , 1 , 1 , 1 , 1 , 2 , 1 , 1 , 1 , 2 , 1 , 1 , 2 , 1 , 1 , 1 , 1 , 2 , 1 , 1 , 1 , 1 , 2 , 1 , 1 , 1 , 1 , 1 , 1 , 1 , 1 , 1

under

1

, 23 , 12 , 18 , 32

,n

, 31 , 16 , 10 , 17 , 14 , 28 , 21 , 30 , 18 , 33 , 24 , 37 , 22 , 39 , 20 , 38 , 21 , 38 , 27 , 37 , 18 , 35 , 19 , 37 , 19 , 31 , 17 , 27 , 14

(n

( 59 ( 27 ( 25 ( 56 ( 28 ( 51 ( 32 ( 66 ( 39 ( 78 ( 43 ( 77 ( 46 ( 95 ( 50 ( 90 ( 49 ( 90 ( 49 ( 90 ( 53 ( 90 ( 48 ( 89 ( 45 ( 75 ( 44 ( 73 ( 36 ( 60 ( 33 ( 46 ( 89

value

EN

45.30

19.96

14.02

32.04

20.07

38.12

27.50

48.59

28.74

61.87

35.33

55.84

35.25

72.67

33.82

69.87

43.16

69.83

40.06

66.61

37.00

66.00

38.84

69.68

31.05

52.02

32.69

57.06

25.42

39.68

21.76

30.19

56.83

stoppingy

β−1 .8001 .8071 .8143 .8022 .8016 .8001 .8115 .8006 .8009 .8033 .8017 .8011 .8002 .8026 .8015 .8001 .8068 .8001 .8005 .8000 .8026 .8003 .8002 .8002 .8005 .8010 .8001 .8009 .8003 .8030 .8003 .8027 .8004

futilita

Design

with

.1208

.1417

.1068

.1479

.1107

.1484

.1460

.1436

.1388

.1499

.1488

.1497

.1376

.1488

.1474

.1437

.1494

.1474

.1498

.1472

.1493

.1447

.1483

.1496

.1451

.1492

.1382

.1499

.1490

.1447

.1340

.1495

.1395

)α

) ) ) ) ) ) ) ) ) ) ) ) ) ) ) ) ) ) ) ) ) ) ) ) ) ) ) ) )

Minimax

) ) ) )

,a

, 3 , 2 , 2 , 3 , 3 , 4 , 3 , 5 , 4 , 5 , 4 , 6 , 5 , 6 , 5 , 7

, 7

, 7

, 7

1

, 5 1 , 5 1 , 5 1 , 5 , 6 , 5 , 6 , 5 , 5 , 4 , 5 , 4 , 4 , 5

designs

,a 1

, 0 , 1 , 1 , 2 , 1 , 1 , 3 , 0 , 0 , 5 , 4 , 0 , 0 , 6 , 0 , − , 5 , − , 4 , − , 3 , − , 4 , 6 , 0 , 1 , 0 , 5 , 2 , 0 , 0 , 0 , 1

1

, 11 , 10 , 36

,n

, 38 , 17 , 10 , 30 , 17 , 30 , 27 , 38 , 23 , 61 , 35 , 36 , 28 , 72 , 22 , 57 , 43 , 57 , 39 , 48 , 34 , 48 , 38 , 69 , 18 , 38 , 26 , 56 , 22 , 19

n

( 50 ( 26 ( 25 ( 38 ( 25 ( 49 ( 30 ( 57 ( 33 ( 66 ( 37 ( 72 ( 41 ( 76 ( 43 ( 78 ( 44 ( 78 ( 44 ( 78 ( 45 ( 77 ( 42 ( 73 ( 41 ( 69 ( 38 ( 62 ( 33 ( 55 ( 29 ( 43 ( 84

o-stage

tw

β(−1 .8018 .8025 .9096 .8041 .8796 .8010 .8060 .8060 .8040 .8027 .8100 .8029 .8034 .8032 .8052 .8008 .8040 .8008 .8052 .8032 .8090 .8029 .8063 .8053 .8064 .8052 .8014 .8046 .8087 .8049 .8279 .8042 .8058

optimal

Design

) 1

and

=

.1211

.0685

.0654

.1022

.1375

.1117

.1086

.1454

.1397

.1360

.1250

.1263

.1388

.1375

.1194

.1440

.1258

.1477

.1295

.1490

.1307

.1462

.1270

.1409

.1208

.1312

.1394

.1423

.1265

.1228

.1477

.1248

.1235

(γ

)α

) ) ) ) ) ) ) ) ) ) ) ) ) ) ) ) ) ) ) ) ) ) ) ) ) ) ) ) ) ) ) ) )

,a

, 3 , 3 , 3 , 4 , 3 , 5 , 4 , 5 , 4 , 6 , 5 , 7 , 5 , 7 , 6 , 7 , 6 , 7 , 6 , 7 , 6 , 7 , 6 , 7 , 6 , 7 , 5 , 6 , 5 , 6 , 4 , 5 , 6

Minimax

Single-Stage

(n

( 50 ( 31 ( 30 ( 43 ( 30 ( 54 ( 32 ( 57 ( 33 ( 67 ( 41 ( 77 ( 41 ( 78 ( 48 ( 78 ( 48 ( 78 ( 48 ( 78 ( 48 ( 77 ( 47 ( 76 ( 46 ( 74 ( 38 ( 63 ( 37 ( 60 ( 30 ( 48 ( 89

cation

allo

x

7.4

p

.15

.2

.25

.25

.3

.3

.35

.35

.4

.4

.45

.45

.5

.5

.55

.55

.6

.6

.65

.65

.7

.7

.75

.75

.8

.8

.85

.85

.9

.9

.95

.95

.95

y

able

p

.05

.1

.15

.2

.25

.3

.35

.4

.45

.5

.55

.6

.65

.7

.75

.8

.85

T balanced

112

Randomized Phase II Cancer Clinical Trials

)

57.26

33.22

62.24

36.74

69.64

38.16

71.45

42.36

74.24

42.71

76.58

42.45

75.88

41.72

71.75

40.53

67.40

37.22

63.90

33.20

54.88

30.40

47.26

23.50

37.83

68.57

85

EN

49.49

27.66

16.07

39.09

22.75

49.63

29.22

,.

(. 15

β−

=

.8502

.8519

.8520

.8500

.8500

.8503

.8502

.8506

.8501

.8504

.8500

.8502

.8510

.8505

.8503

.8504

.8507

.8503

.8503

.8504

.8502

.8512

.8507

.8506

.8520

.8506

.8514

.8503

.8525

.8510

.8505

.8510

.8503

)

1

∗ β

Design

− , 1

.1399

.1469

.1195

.1499

.1276

.1271

.1238

.1493

.1466

.1477

.1354

.1377

.1495

.1475

.1298

.1498

.1356

.1499

.1378

.1496

.1373

.1499

.1336

.1468

.1499

.1371

.1439

.1458

.1283

.1494

.1385

.1495

.1469

∗ (α

)α

) ) ) ) ) ) ) ) ) ) ) ) ) ) ) ) ) ) ) )

Optimal

) ) ) ) ) ) ) ) ) ) ) ) )

,a

, 3 , 2 , 2 , 3 , 3 , 5 , 4 , 5 , 4 , 6 , 5 , 7 , 5 , 7 , 6 , 7 , 6 , 7 , 6 , 7 , 6 , 7 , 6 , 7 , 5 , 7 , 5 , 6 , 5 , 5 , 4 , 4 , 5

, 1

, 2

, 3

, 3

, 2

, 2

,a 1

, 1 , 2 , 1 , 2 , 1 , 1 , 1 , 2 , 2 , 1 , 1 , 1 , 1

, 1

, 1

, 1

, 1

, 1 , 1 , 2 , 1 , 1 , 1 , 1 , 2 , 1 , 2

under

1

, 45

, 51

, 61

, 60

, 50

, 36 , 14 , 28 , 51

,n

, 37 , 27 , 12 , 32 , 17 , 32 , 19 , 41 , 28 , 42 , 25 , 46 , 25

, 26

, 28

, 26

, 27

, 25 , 41 , 28 , 39 , 21 , 33 , 18

(n

( 69 ( 31 ( 26 ( 59 ( 32 ( 73 ( 44 ( 89 ( 45 ( 87 ( 52 ( 98 ( 55 ( 103 ( 63 ( 112 ( 61 ( 109 ( 63 ( 109 ( 60 ( 107 ( 60 ( 99 ( 55 ( 94 ( 49 ( 82 ( 47 ( 69 ( 37 ( 60 ( 103

value

EN

52.79

27.66

16.60

43.12

23.78

56.04

33.43

67.50

36.36

64.18

39.81

78.86

45.84

73.04

49.68

88.58

47.86

92.84

46.54

92.84

44.53

90.50

43.55

69.58

46.51

69.91

33.75

55.69

32.74

55.37

24.15

43.39

81.23

stoppingy

β−1 .8502 .8519 .8627 .8505 .8516 .8527 .8501 .8515 .8513 .8512 .8506 .8500 .8533 .8502 .8517 .8508 .8502 .8505 .8501 .8532 .8506 .8524 .8508 .8507 .8528 .8502 .8515 .8502 .8501 .8505 .8525 .8503 .8512

futilita

Design

with

.1388

.1469

.1232

.1169

.1276

.1487

.1225

.1489

.1484

.1496

.1378

.1408

.1496

.1493

.1472

.1500

.1395

.1482

.1425

.1493

.1416

.1497

.1381

.1499

.1484

.1428

.1482

.1500

.1342

.1489

.1451

.1334

.1494

)α

) ) ) ) ) ) ) ) ) ) ) ) ) ) ) ) ) ) ) ) ) ) ) ) ) ) ) ) )

Minimax

) ) ) )

,a

, 3 , 2 , 2 , 4 , 3 , 4 , 4 , 5 , 4 , 6 , 5 , 7

, 6

, 6

, 7

1

, 5 , 7 , 5 , 7 1 , 7 1 , 7 , 6 , 7 , 6 , 7 , 5 1 , 5 , 6 , 5 , 5 , 4 , 5 , 5

designs

,a 1

, 0 , 2 , 1 , 0 , 0 , 4 , 0 , 5 , 3 , 1 , 0 , − , 4 , 1 , 5 , 6 , − , 7 , − , 7 , 0 , 7 , 0 , 1 , 5 , − , 0 , 0 , 0 , 4 , 0 , 0 , 4

1

, 11 , 31 , 78

,n

, 45 , 27 , 13 , 35 , 17 , 55 , 30 , 67 , 35 , 51 , 32 , 66 , 45 , 56 , 49 , 87 , 37 , 92 , 33 , 92 , 33 , 90 , 32 , 53 , 46 , 48 , 19 , 33 , 22 , 53

n

( 58 ( 31 ( 25 ( 49 ( 28 ( 61 ( 36 ( 70 ( 41 ( 80 ( 46 ( 87 ( 49 ( 93 ( 53 ( 95 ( 54 ( 97 ( 54 ( 97 ( 54 ( 93 ( 53 ( 89 ( 49 ( 83 ( 45 ( 74 ( 41 ( 64 ( 33 ( 53 ( 93

o-stage

tw

β(

)

−

.8518

.8581

.9096

.8527

.8796

.8534

.8502

.8523

.8557

.8502

.8533

.8504

.8561

.8537

.8522

.8512

.8510

.8512

.8522

.8537

.8561

.8511

.8559

.8511

.8511

.8531

.8576

.8502

.8551

.8551

.8517

.8524

.8516

1

1

optimal

=

Design

and

(γ

.1391

.0837

.0654

.1173

.1375

.1280

.1225

.1287

.1171

.1246

.1388

.1410

.1238

.1306

.1334

.1370

.1399

.1408

.1437

.1420

.1449

.1383

.1414

.1320

.1331

.1450

.1243

.1294

.1388

.1360

.1161

.1366

.1350

)α

) ) ) ) ) ) ) ) ) ) ) ) ) ) ) ) ) ) ) ) ) ) ) ) ) ) ) ) ) ) ) ) )

cation

,a

, 3 , 3 , 3 , 4 , 3 , 5 , 4 , 6 , 5 , 7 , 5 , 7 , 6 , 8 , 6 , 8 , 6 , 8 , 6 , 8 , 6 , 8 , 6 , 8 , 6 , 7 , 6 , 7 , 5 , 6 , 5 , 5 , 6

Minimax

allo

Single-Stage

(n

( 58 ( 36 ( 30 ( 49 ( 30 ( 62 ( 36 ( 74 ( 45 ( 85 ( 46 ( 87 ( 54 ( 98 ( 54 ( 98 ( 54 ( 98 ( 54 ( 98 ( 54 ( 96 ( 53 ( 94 ( 51 ( 83 ( 50 ( 79 ( 41 ( 67 ( 38 ( 53 ( 98

x

7.5

p

.15

.2

.25

.25

.3

.3

.35

.35

.4

.4

.45

.45

.5

.5

.55

.55

.6

.6

.65

.65

.7

.7

.75

.75

.8

.8

.85

.85

.9

.9

.95

.95

.95

balanced

y

able

p

.05

.1

.15

.2

.25

.3

.35

.4

.45

.5

.55

.6

.65

.7

.75

.8

.85

T and

Randomized Phase II Cancer Clinical Trials with a Prospective Control 113

EN

66.24

34.39

23.57

48.01

29.14

60.14

35.47

70.90

42.20

80.54

46.24

88.31

49.97

91.31

51.04

93.77

52.81

96.51

54.77

95.50

52.65

89.20

49.94

85.80

46.11

79.22

43.11

70.31

35.81

58.43

30.47

45.08

84.34

) and9 ,.

β−

(. 15

1

.9005

.9004

.9003

.9002

.9004

.9004

.9001

.9001

.9003

.9002

.9000

.9001

.9006

.9001

.9003

.9001

.9009

.9003

.9009

.9004

.9001

.9001

.9000

.9004

.9003

.9005

.9004

.9001

.9001

.9003

.9040

.9001

.9005

= )

Design

∗ β−

.1496

.1034

.1412

.1369

.1487

.1452

.1415

.1449

.1330

.1406

.1484

.1497

.1377

.1440

.1494

.1480

.1495

.1480

.1307

.1479

.1494

.1500

.1485

.1431

.1428

.1499

.1314

.1385

.1438

.1415

.1491

.1394

.1393

, 1∗

)α

) ) ) ) ) ) ) ) ) ) ) ) ) ) ) ) ) ) ) ) ) ) ) ) ) ) ) ) ) ) ) ) )

(α

Optimal

,a

, 3 , 3 , 2 , 4 , 3 , 5 , 4 , 6 , 5 , 7 , 5 , 7 , 6 , 8 , 6 , 8 , 6 , 8 , 7 , 8 , 6 , 8 , 6 , 8 , 6 , 7 , 6 , 7 , 5 , 6 , 4 , 5 , 6

, 1

, 3

, 1

, 2

, 3

, 3

, 1

, 1

, 2

, 1

, 1

,a 1

, 2 , 1 , 1 , 1 , 1 , 1 , 1 , 1 , 1

, 2

, 1

, 0

, 2

, 1

, 2

, 2

, 1

, 1

, 1 , 1 , 2 , 1

1

, 55

, 73

, 59

, 68

, 76

, 75

, 60

, 54

, 53

, 44

, 37 , 24 , 29 , 51

,n

, 59 , 27 , 14 , 35 , 19 , 43 , 27 , 48 , 30

, 36

, 33

, 30

, 40

, 34

, 36

, 40

, 30

, 28

, 24

under

(n

( 87 ( 47 ( 45 ( 66 ( 45 ( 82 ( 47 ( 99 ( 58 ( 111 ( 66 ( 120 ( 71 ( 129 ( 68 ( 133 ( 75 ( 136 ( 80 ( 135 ( 82 ( 123 ( 67 ( 123 ( 66 ( 122 ( 62 ( 102 ( 51 ( 85 ( 45 ( 66 ( 126

value

EN

73.16

34.99

23.57

50.35

29.14

63.22

35.82

80.95

45.62

91.17

52.27

54.47

51.93

62.22

61.64

60.63

99.25

56.49

92.74

47.12

98.66

51.88

77.41

36.70

59.16

30.47

45.81

85.01

105.49

101.50

102.25

113.53

112.53

stopping

β

y

−1 .9021 .9014 .9003 .9001 .9004 .9001 .9011 .9000 .9000 .9000 .9002 .9018 .9001 .9000 .9004 .9000 .9021 .9006 .9007 .9006 .9001 .9002 .9016 .9002 .9007 .9011 .9025 .9002 .9010 .9004 .9040 .9020 .9002

futilit

Design

a

.1469

.1024

.1412

.1365

.1487

.1463

.1438

.1468

.1337

.1427

.1491

.1498

.1397

.1474

.1497

.1497

.1497

.1497

.1489

.1497

.1481

.1498

.1496

.1479

.1461

.1483

.1495

.1446

.1482

.1446

.1491

.1429

.1418

with

)α

) ) )

) ) )

)

)

)

)

)

)

)

)

Minimax

) ) ) ) ) ) )

)

)

)

)

)

)

)

)

) ) ) )

,a

, 8

, 8

, 3 , 3 , 2 , 4 , 3 , 5 , 4 , 6 , 5 , 7

, 7 , 6

, 8

, 8

, 7

, 6

2

1

1

, 5

1

2

, 6 , 8 , 6

, 6

, 6 , 8 , 6 1 , 6 , 7 , 5 1 , 5 , 6 , 4 , 5

, 3 , 1 , 1 , 0 , 1 , 0 , 0

, 4 , 7

, 7

, 7

, − , 0 , 4 , 5

, 5

, 5 , 4 , 4 , − , 0 , 7 , 5

, 0 , 0 , 2 , 0 , 0

designs

,a 1

, − , − , −

, −

, −

1

, 95

, 92

, 98

, 24 , 21 , 40

,n

, 72 , 29 , 14 , 40 , 19 , 51 , 23 , 69 , 32 , 79 , 51 , 105 , 41 , 79 , 36

, 61 , 112 , 60 , 111 , 59

, 54 , 68 , 30

, 51 , 55 , 22 , 33

n

( 79 ( 45 ( 45 ( 58 ( 45 ( 73 ( 45 ( 86 ( 52 ( 99 ( 57 ( 108 ( 62

( 68

( 67

( 64

( 61

( 56

( 48 ( 80 ( 45 ( 64

( 113 ( 65 ( 119 ( 67 ( 120

( 119

( 116

( 109

( 102

( 91

( 120

o-stage

tw

β(−1 .9017 .9430 .9874 .9036 .9541 .9034 .9043 .9000 .9019 .9002 .9029 .9002 .9013 .9006 .9028 .9003 .9016 .9003 .9028 .9001 .9020 .9024 .9037 .9024 .9037 .9020 .9053 .9017 .9003 .9017 .9483 .9022 .9020

optimal

Design

) 1

and

=

.1052

.1211

.1211

.1376

.1197

.1477

.1028

.1468

.1343

.1428

.1247

.1359

.1404

.1477

.1246

.1343

.1310

.1380

.1347

.1382

.1342

.1360

.1312

.1499

.1240

.1389

.1399

.1464

.1216

.1246

.1489

.1204

.1244

(γ

)α

) ) ) ) ) ) ) ) ) ) ) ) ) ) ) ) ) ) ) ) ) ) ) ) ) ) ) ) ) ) ) ) )

,a

, 4 , 3 , 3 , 4 , 4 , 5 , 5 , 6 , 5 , 7 , 6 , 8 , 6 , 8 , 7 , 9 , 7 , 9 , 7 , 9 , 7 , 9 , 7 , 8 , 7 , 8 , 6 , 7 , 6 , 7 , 5 , 6 , 7

Minimax

Single-Stage

(n

( 84 ( 50 ( 50 ( 58 ( 50 ( 73 ( 50 ( 86 ( 52 ( 99 ( 61 ( 111 ( 62 ( 113 ( 70 ( 123 ( 70 ( 123 ( 70 ( 122 ( 69 ( 121 ( 68 ( 109 ( 66 ( 105 ( 57 ( 91 ( 53 ( 85 ( 50 ( 69 ( 125

cation

allo

x

7.6

p

.15

.2

.25

.25

.3

.3

.35

.35

.4

.4

.45

.45

.5

.5

.55

.55

.6

.6

.65

.65

.7

.7

.75

.75

.8

.8

.85

.85

.9

.9

.95

.95

.95

y

able

p

.05

.1

.15

.2

.25

.3

.35

.4

.45

.5

.55

.6

.65

.7

.75

.8

.85

T balanced

114

Randomized Phase II Cancer Clinical Trials

) and

EN

34.33

19.55

13.08

28.95

16.67

32.75

21.44

40.21

22.57

43.20

24.58

48.61

28.66

50.49

29.00

51.13

29.14

51.10

28.93

50.40

28.54

49.44

27.60

47.81

26.68

43.79

23.47

37.25

19.73

34.02

17.69

24.76

49.23

8 ,.(. 2

β−

=

.8008

.8015

.8109

.8073

.8063

.8017

.8002

.8002

.8021

.8009

.8001

.8010

.8013

.8000

.8012

.8004

.8013

.8004

.8012

.8000

.8021

.8008

.8002

.8003

.8023

.8014

.8005

.8005

.8016

.8014

.8055

.8013

.8006

)

1

∗ β

Design

− , 1

.1946

.1395

.1835

.1980

.1798

.1972

.1566

.1811

.1912

.1980

.1992

.1976

.1947

.1886

.1843

.1942

.1895

.1969

.1924

.1973

.1916

.1944

.1872

.1887

.1807

.1995

.1981

.1984

.1976

.1789

.1716

.1927

.1994

∗ (α

)α

) ) ) ) ) ) ) ) ) ) ) ) ) )

) )

)

Optimal

) )

) ) ) ) ) ) ) ) ) ) )

,a

)

)

)

, 2 , 2 , 1 , 2 , 2 , 3 , 3 , 4 , 3 , 4 , 3 , 4 , 3 , 5 , 4 , 5 , 4 , 5 , 4 , 5 , 4 , 5 , 4 , 5 , 4 , 4 , 3 , 4 , 3 , 4 , 3 , 3 , 3

,a 1

, 1 , 1 , 1 , 2 , 1 , 1 , 1 , 0 , 0 , 1 , 1 , 2 , 2 , 0 , 0 , 0 , 0 , 0 , 0 , 0 , 0 , 0 , 0 , 0 , 0 , 1 , 1 , 0 , 0 , 0 , 1 , 0 , 2

under

1

, 9

, 6 , 16 , 12 , 7 , 40

,n

, 28 , 16

, 27 , 12 , 26 , 17 , 23 , 13 , 33 , 17 , 38 , 23 , 30 , 17 , 29 , 16 , 29 , 17 , 30 , 16 , 29 , 15 , 29 , 14 , 24 , 13 , 19

(n

( 45 ( 27 ( 25 ( 35 ( 25 ( 42 ( 28 ( 53 ( 29 ( 56 ( 35 ( 68 ( 41 ( 67 ( 38 ( 69 ( 39 ( 69 ( 38 ( 67 ( 38 ( 66 ( 37 ( 63 ( 36 ( 69 ( 38 ( 51 ( 28 ( 47 ( 26 ( 35 ( 69

value

EN

34.33

19.63

13.08

30.75

16.67

32.93

23.33

42.10

22.69

45.88

29.45

51.91

29.77

56.44

30.36

51.46

30.54

51.43

29.16

50.88

29.00

49.90

29.07

52.42

28.42

51.39

24.45

38.44

20.23

36.42

17.90

24.76

55.42

stoppingy

β−1 .8008 .8018 .8109 .8004 .8063 .8031 .8000 .8005 .8032 .8016 .8089 .8002 .8019 .8000 .8005 .8013 .8002 .8013 .8021 .8006 .8028 .8010 .8002 .8001 .8007 .8016 .8025 .8001 .8040 .8001 .8153 .8013 .8001

futilita

Design

with

.1946

.1397

.1835

.1524

.1798

.1991

.1586

.1835

.1919

.1998

.2000

.1825

.1769

.1944

.1878

.1968

.1944

.1997

.1939

.1998

.1946

.1968

.1932

.1961

.1868

.1974

.1988

.1987

.1997

.1867

.1786

.1927

.1886

)α

) ) ) ) ) ) ) ) ) ) ) ) ) ) ) ) ) ) ) ) ) ) ) ) ) )

)

Minimax

) )

)

,a

)

) )

, 2 , 2

, 3 , 4

, 5

, 5 , 4

, 4

, 4 , 5 , 4

, 4

, 1 , 3 , 2 , 3 1 1 , 3 , 4 , 3 1 , 4 2 1 , 5 1 , 5 , 4 , 5 , 4 , 5 1 2 1 , 4 , 3 , 4 , 3 , 4 , 3 , 3 1

designs

,a 1

, 1 , 1 , 1 , 0 , 1 , 1 , − , − , 0 , 2 , 3 , − , 0 , − , − , 0 , − , 0 , 0 , 0 , 0 , 0 , − , − , − , 4 , 2 , 1 , 1 , 0 , 0 , 0 , −

1

, 9

, 5 , 7

,n

, 28 , 17

, 26 , 12 , 27 , 18 , 29 , 15 , 42 , 29 , 37 , 23 , 48 , 20 , 35 , 21 , 35 , 19 , 35 , 20 , 34 , 18 , 38 , 18 , 50 , 21 , 30 , 16 , 28

, 39

n

( 45 ( 25 ( 25 ( 34 ( 25 ( 41

( 25 ( 35

( 25 ( 48 ( 28 ( 53 ( 31 ( 60 ( 35 ( 60 ( 35 ( 65 ( 35 ( 65 ( 37 ( 64 ( 36 ( 63 ( 34 ( 58 ( 33 ( 56 ( 32 ( 49 ( 26 ( 43

( 63

o-stage

tw

β(−1 .8018 .8892 .9586 .8023 .8796 .8065 .8589 .8050 .8040 .8009 .8052 .8051 .8090 .8001 .8052 .8043 .8040 .8043 .8092 .8012 .8034 .8006 .8052 .8009 .8040 .8060 .8060 .8010 .8129 .8041 .8279 .8079 .8009

optimal

Design

) 1

and

=

.1211

.1773

.1773

.1529

.1375

.1521

.1810

.1852

.1397

.1670

.1629

.1848

.1804

.1945

.1901

.1713

.1966

.1751

.1618

.1746

.1601

.1716

.1969

.1969

.1896

.1884

.1794

.1722

.1657

.1913

.1477

.1631

.1903

(γ

)α

) ) ) ) ) ) ) ) ) ) ) ) ) ) ) ) ) ) ) ) ) ) ) ) ) ) ) ) ) ) ) ) )

,a

, 3 , 2 , 2 , 3 , 3 , 4 , 3 , 4 , 4 , 5 , 4 , 5 , 4 , 5 , 4 , 6 , 4 , 6 , 5 , 6 , 5 , 6 , 4 , 5 , 4 , 5 , 4 , 5 , 4 , 4 , 4 , 4 , 4

Minimax

Single-Stage

(n

( 50 ( 30 ( 30 ( 34 ( 30 ( 46 ( 30 ( 48 ( 33 ( 58 ( 34 ( 60 ( 35 ( 60 ( 35 ( 70 ( 35 ( 70 ( 42 ( 69 ( 41 ( 68 ( 34 ( 58 ( 33 ( 57 ( 32 ( 54 ( 31 ( 43 ( 30 ( 40 ( 63

cation

allo

x

7.7

p

.15

.2

.25

.25

.3

.3

.35

.35

.4

.4

.45

.45

.5

.5

.55

.55

.6

.6

.65

.65

.7

.7

.75

.75

.8

.8

.85

.85

.9

.9

.95

.95

.95

y

able

p

.05

.1

.15

.2

.25

.3

.35

.4

.45

.5

.55

.6

.65

.7

.75

.8

.85

T balanced

Randomized Phase II Cancer Clinical Trials with a Prospective Control 115

) and

EN

47.84

23.45

16.07

34.30

19.50

43.85

25.25

47.90

28.42

56.64

32.79

58.73

33.83

61.54

34.98

65.19

35.62

66.12

36.24

65.47

34.92

62.70

33.29

57.39

31.05

53.53

29.19

48.96

25.71

39.47

19.68

30.31

57.20

85 ,.

β

(. 2

−

=

1

.8522

.8516

.8520

.8509

.8500

.8508

.8512

.8509

.8523

.8505

.8504

.8500

.8504

.8500

.8500

.8502

.8516

.8509

.8519

.8507

.8503

.8508

.8500

.8501

.8500

.8510

.8504

.8503

.8500

.8505

.8516

.8510

.8509

)∗ β Design

−

.1989

.1618

.1195

.1732

.1981

.1955

.1787

.1990

.1988

.1811

.1769

.1951

.1909

.1993

.1971

.1985

.1995

.1993

.1988

.1984

.1984

.1994

.1976

.1997

.1959

.1941

.1844

.1975

.1978

.1933

.1906

.1974

.1901

, 1∗ (α

)α

) ) ) ) ) ) ) ) ) ) ) ) ) ) ) )

) )

Optimal

) ) ) ) ) ) ) ) ) ) ) ) ) )

,a

)

, 2 , 2 , 2 , 3 , 2 , 3 , 3 , 4 , 3 , 5 , 4 , 5 , 4 , 5 , 4 , 5 , 4 , 5 , 4 , 5 , 4 , 5 , 4 , 5 , 4 , 5 , 4 , 4 , 3 , 4 , 3 , 3 , 4

,a 1

, 2 , 0 , 1 , 0 , 1 , 2 , 0 , 0 , 1 , 0 , 0 , 0 , 0 , 1 , 1 , 2 , 1 , 2 , 1 , 2 , 1 , 2 , 1 , 1 , 0 , 0 , 0 , 2 , 1 , 0 , 0 , 1 , 0

under

1

, 20 , 8 , 19 , 26

,n

, 46 , 16 , 12 , 21 , 15 , 37 , 15 , 31 , 20 , 35 , 19 , 35 , 19 , 42 , 27 , 50 , 25 , 49 , 23 , 48 , 23 , 49 , 24 , 41 , 18 , 32 , 16 , 38 , 14

(n

( 54 ( 27 ( 26 ( 43 ( 27 ( 59 ( 32 ( 61 ( 40 ( 74 ( 43 ( 78 ( 45 ( 85 ( 45 ( 90 ( 49 ( 94 ( 53 ( 94 ( 50 ( 85 ( 45 ( 77 ( 41 ( 71 ( 39 ( 69 ( 42 ( 54 ( 27 ( 46 ( 80

value

EN

47.84

23.93

16.60

35.47

22.66

47.39

25.89

48.16

32.43

62.46

34.91

59.26

35.45

70.12

37.16

75.13

42.44

72.38

42.44

69.59

39.25

73.13

38.68

67.12

31.28

53.69

32.99

52.91

30.18

39.65

19.68

33.03

57.20

stoppingy

β−1 .8522 .8502 .8627 .8505 .8602 .8547 .8521 .8519 .8506 .8500 .8501 .8501 .8503 .8506 .8504 .8510 .8508 .8502 .8522 .8503 .8513 .8510 .8559 .8525 .8506 .8504 .8501 .8502 .8588 .8518 .8516 .8506 .8509

futilita

Design

with

.1989

.1588

.1232

.1717

.1942

.1980

.1785

.1999

.1953

.1843

.1788

.1985

.1949

.1995

.1983

.1988

.1967

.1905

.1999

.1898

.1974

.1988

.1995

.1999

.1976

.1953

.1932

.1854

.1973

.1948

.1906

.1976

.1901

)α

) ) ) ) ) ) ) ) ) ) ) ) ) ) ) ) ) ) ) ) ) ) ) ) ) )

) )

Minimax

) ) ) )

,a

)

, 2 , 2 , 2 , 3 , 2 , 3 , 3 , 4 , 3 , 5 , 4 , 5 , 4

, 6

, 6

, 4 , 5

2

1

1

1

, 5 , 4 , 5 , 4 2 , 4 1 , 4 , 5 , 4 , 5 , 4 , 5 1 1 , 3 , 4 , 3 , 3 , 4

designs

,a 1

, 2 , 0 , 1 , 0 , 2 , 3 , 0 , 0 , 3 , − , − , − , − , 4 , 2 , 5 , 4 , − , 4 , − , 3 , 5 , 3 , 4 , 0 , 0 , − , − , 3 , 0 , 0 , 2 , 0

1

, 8 , 29 , 26

,n

, 46 , 20 , 13 , 29 , 22 , 46 , 20 , 33 , 32 , 51 , 26 , 33 , 26 , 68 , 34 , 74 , 42 , 56 , 42 , 53 , 37 , 72 , 37 , 65 , 20 , 35 , 27 , 36 , 29 , 22

n

( 54 ( 26 ( 25 ( 40 ( 25 ( 52 ( 30 ( 60 ( 34

( 27

( 67 ( 39 ( 73 ( 40 ( 76 ( 43 ( 79 ( 44 ( 80 ( 44 ( 80 ( 45 ( 77 ( 43 ( 73 ( 40 ( 69 ( 36 ( 62 ( 34 ( 53

( 42 ( 80

o-stage

tw

β(−1 .8518 .8892 .9586 .8544 .8796 .8541 .8589 .8524 .8537 .8502 .8518 .8503 .8529 .8535 .8501 .8510 .8558 .8510 .8501 .8535 .8539 .8503 .8533 .8542 .8557 .8523 .8502 .8534 .8503 .8532 .8568 .8582 .8515

optimal

Design

) 1

and

=

.1391

.1773

.1773

.1729

.1375

.1694

.1810

.1614

.1569

.1844

.1795

.1682

.1963

.1809

.1651

.1874

.1742

.1911

.1754

.1923

.1767

.1881

.1728

.1828

.1664

.1715

.1935

.1888

.1769

.1670

.1555

.1774

.1662

(γ

)α

) ) ) ) ) ) ) ) ) ) ) ) ) ) ) ) ) ) ) ) ) ) ) ) ) ) ) ) ) ) ) ) )

,a

, 3 , 2 , 2 , 3 , 3 , 4 , 3 , 5 , 4 , 5 , 4 , 6 , 4 , 6 , 5 , 6 , 5 , 6 , 5 , 6 , 5 , 6 , 5 , 6 , 5 , 6 , 4 , 5 , 4 , 5 , 4 , 4 , 5

Minimax

Single-Stage

(n

( 58 ( 30 ( 30 ( 40 ( 30 ( 53 ( 30 ( 65 ( 38 ( 67 ( 39 ( 78 ( 40 ( 80 ( 47 ( 80 ( 48 ( 80 ( 47 ( 80 ( 47 ( 78 ( 46 ( 77 ( 45 ( 74 ( 36 ( 62 ( 34 ( 58 ( 32 ( 45 ( 85

cation

allo

x

7.8

p

.15

.2

.25

.25

.3

.3

.35

.35

.4

.4

.45

.45

.5

.5

.55

.55

.6

.6

.65

.65

.7

.7

.75

.75

.8

.8

.85

.85

.9

.9

.95

.95

.95

y

able

p

.05

.1

.15

.2

.25

.3

.35

.4

.45

.5

.55

.6

.65

.7

.75

.8

.85

T balanced

116

Randomized Phase II Cancer Clinical Trials

60.58

30.85

23.57

42.27

29.14

54.11

32.59

65.15

38.12

70.19

39.94

78.15

44.72

80.03

46.75

81.46

46.99

82.16

46.68

81.15

45.70

78.08

44.33

74.85

41.83

70.10

35.87

59.70

32.04

51.59

27.48

39.92

71.17

) and

EN

9 ,.

β

(. 2

−

=

1

.9004

.9011

.9003

.9001

.9004

.9002

.9013

.9000

.9006

.9001

.9002

.9004

.9014

.9001

.9006

.9003

.9003

.9000

.9006

.9002

.9002

.9007

.9008

.9002

.9007

.9007

.9001

.9005

.9000

.9001

.9048

.9004

.9009

)∗ β Design

−

.1636

.1786

.1412

.1953

.1487

.1883

.1912

.1792

.1758

.1968

.1972

.1844

.1997

.1947

.1815

.2000

.1876

.1998

.1896

.1995

.1885

.1999

.1842

.1924

.1974

.1988

.1984

.1968

.1831

.2000

.1946

.1789

.1999

, 1∗ (α

)α

)

) ) ) ) ) ) ) ) ) ) ) ) ) ) ) ) ) ) ) )

Optimal

) ) ) ) ) ) ) ) ) ) )

)

,a

, 3 , 2 , 2 , 3 , 3 , 4 , 3 , 5 , 4 , 5 , 4 , 6 , 4 , 6 , 5 , 6 , 5 , 6 , 5 , 6 , 5 , 6 , 5 , 6 , 4 , 5 , 4 , 5 , 4 , 4 , 3 , 4 , 4

, 0

, 0

, 0

, 1

, 1

, 0

, 0

, 1

,a 1

, 0 , 1 , 1 , 0 , 1 , 0 , 1 , 0 , 0 , 1 , 0

, 2

, 0

, 0

, 0

, 0

, 0

, 2 , 2 , 1 , 0 , 0 , 1 , 1 , 0

1

, 51

, 53

, 49

, 59

, 58

, 50

, 45

, 46

under

, 30 , 15 , 19

,n

, 40 , 23 , 14 , 25 , 19 , 36 , 23 , 43 , 25 , 52 , 27

, 38

, 29

, 31

, 29

, 28

, 26

, 33 , 53 , 27 , 36 , 14

(n

( 74 ( 45 ( 45 ( 54 ( 45 ( 68 ( 46 ( 83 ( 48 ( 92 ( 50 ( 101 ( 57 ( 103 ( 61 ( 109 ( 60 ( 109 ( 61 ( 108 ( 60 ( 102 ( 59 ( 100 ( 58 ( 98 ( 47 ( 79 ( 45 ( 79 ( 45 ( 55 ( 103

value

EN

62.65

30.85

23.57

42.38

29.14

56.80

32.80

69.08

40.03

73.25

40.21

82.53

50.67

80.55

49.21

91.54

50.14

95.03

49.10

94.03

48.79

89.25

46.54

75.70

44.98

80.43

36.00

59.87

32.04

60.14

27.48

43.28

87.59

stoppingy

β−1 .9004 .9011 .9003 .9021 .9004 .9002 .9047 .9001 .9003 .9003 .9006 .9002 .9032 .9000 .9003 .9002 .9001 .9002 .9003 .9001 .9000 .9017 .9001 .9005 .9000 .9000 .9001 .9003 .9000 .9000 .9048 .9000 .9009

futilita

Design

.1614

.1786

.1412

.1959

.1487

.1895

.1935

.1811

.1765

.1993

.1980

.1879

.1985

.1972

.1847

.1987

.1917

.1988

.1944

.1986

.1940

.1999

.1892

.1962

.1815

.1895

.2000

.1980

.1831

.1995

.1946

.1882

.1991

with

)α

) ) ) ) ) ) ) ) ) ) ) ) ) ) ) ) ) ) ) ) ) ) ) ) ) ) ) ) )

Minimax

) ) ) )

,a

, 3 , 2 , 2 , 3 , 3 , 4

, 5 , 4

, 6

, 6 , 5

, 5

, 5

, 5

, 5 , 6 , 5 , 6

, 4

1

, 3 1 1 , 5 , 4 1 , 4 1 1 , 6

, 6

, 6

, 6

, 4 , 5 , 4 , 4 , 3

, 4

, 4 1 , 5 1 , 5 1

1

1

1

2

1

, 4

, 1 , 0 , 0 , 4 , 1

, 4

designs

,a 1

, 0 , 1 , 1 , 0 , 1 , − , 1 , − , − , 2 , 0 , − , 4 , − , −

, −

, −

, −

, − , − , − , −

, −

1

, 88

, 93

, 92

, 15

, 86

,n

, 52 , 23 , 14 , 27 , 19 , 44 , 24 , 55 , 29 , 66 , 29 , 66 , 50 , 50 , 37

, 40

, 37

, 38 , 86 , 33 , 45 , 32 , 69 , 28 , 39 , 14 , 59

, 25

n

( 70 ( 45 ( 45 ( 53 ( 45 ( 63 ( 45 ( 77 ( 45 ( 85 ( 49 ( 93 ( 53 ( 99 ( 56 ( 100 ( 56 ( 101 ( 56 ( 100 ( 55 ( 97 ( 54 ( 94 ( 52 ( 86 ( 46 ( 77 ( 45 ( 64 ( 45 ( 51 ( 93

o-stage

tw

β(−1 .9034 .9430 .9874 .9036 .9541 .9019 .9386 .9016 .9266 .9012 .9027 .9021 .9013 .9014 .9024 .9016 .9013 .9016 .9024 .9014 .9013 .9009 .9028 .9002 .9019 .9000 .9043 .9022 .9231 .9019 .9483 .9017 .9018

optimal

Design

) 1

and

=

.1623

.1211

.1211

.1376

.1197

.1903

.1623

.1819

.1901

.1717

.1583

.1893

.1744

.1723

.1863

.1799

.1927

.1836

.1964

.1837

.1955

.1802

.1921

.1728

.1839

.1896

.1726

.1742

.1628

.1844

.1489

.1925

.1834

(γ

)α

) ) ) ) ) ) ) ) ) ) ) ) ) ) ) ) ) ) ) ) ) ) ) ) ) ) ) ) ) ) ) ) )

,a

, 3 , 3 , 3 , 4 , 4 , 4 , 4 , 5 , 4 , 6 , 5 , 6 , 5 , 7 , 5 , 7 , 5 , 7 , 5 , 7 , 5 , 7 , 5 , 7 , 5 , 6 , 5 , 6 , 5 , 5 , 5 , 4 , 5

Minimax

Single-Stage

(n

( 70 ( 50 ( 50 ( 58 ( 50 ( 63 ( 50 ( 77 ( 50 ( 90 ( 54 ( 93 ( 55 ( 104 ( 56 ( 105 ( 56 ( 105 ( 56 ( 104 ( 55 ( 102 ( 54 ( 99 ( 52 ( 86 ( 50 ( 82 ( 50 ( 67 ( 50 ( 51 ( 98

cation

allo

x

7.9

p

.15

.2

.25

.25

.3

.3

.35

.35

.4

.4

.45

.45

.5

.5

.55

.55

.6

.6

.65

.65

.7

.7

.75

.75

.8

.8

.85

.85

.9

.9

.95

.95

.95

y

able

p

.05

.1

.15

.2

.25

.3

.35

.4

.45

.5

.55

.6

.65

.7

.75

.8

.85

T balanced

Randomized Phase II Cancer Clinical Trials with a Prospective Control 117

total number of responders among the cumulative n = n 1 + n 2 patients

for arms x and y, respectively.

(a) For an integer a ∈ [ a 1 − n 2 , n], accept arm x (or reject H 0) for further investigation if X − Y ≥ a.

(b) Otherwise, we reject arm x.

Now we discuss how to determine (n 1 , n 2 , a 1 , a) using the exact two-sample binomial test for a randomized phase II clinical trial with a prospective control

arm. Let p 0 denote the projected response rate for the historical control and

a clinically significant increase in response rate for arm x. For the purpose

of type I and II error calculation, we specify a point null hypothesis H 0 : p x =

p y = p 0 and an alternative hypothesis H 1 : p x = p 0 + , p y = p 0. For a two-stage design defined by (n 1 , n, a 1 , a), the type I error rate and power of the two-stage design are calculated as

α = P (X 1 − Y 1 ≥ a 1 , X − Y ≥ a| p x = p y = p 0 ) and

1 − β = P (X 1 − Y 1 ≥ a 1 , X − Y ≥ a| p x = p 0 + , p y = p 0 ), respectively. These probabilities are calculated assuming that X 1 ∼ B(n 1 , p x ), X 2 ∼ B(n 2 , p x ), Y 1 ∼ B(n 1 , p y ), and Y 2 ∼ B(n 2 , p y ) are independent random variables. That is,

n 1

n 1−max ( 0 ,k 1 )



n 2

n 2−max ( 0 ,k 2 )



α =

b(y 1| n 1 , p 0 )b(k 1 + y 1| n 1 , p 0 )b(y 2| n 2 , p 0 ) k 1= a 1 y 1=max ( 0 , − k 1 ) k 2= a− k 1 y 2=max ( 0 , − k 2 )

× b(k 2 + y 2| n 2 , p 0 )

and

n 1

n 1−max ( 0 ,k 1 )



n 2

n 2−max ( 0 ,k 2 )



1 − β =

b(y 1| n 1 , p 0 )b(k 1 + y 1| n 1 , p x )

k 1= a 1 y 1=max ( 0 , − k 1 ) k 2= a− k 1 y 2=max ( 0 , − k 2 )

× b(y 2| n 2 , p 0 )b(k 2 + y 2| n 2 , p x ).

Suppose that we want to choose a two-stage design with type I error rate

smaller than or equal to α∗ and power larger than or equal to 1− β∗. There exist

many two-stage designs satisfying the (α∗ , 1 − β∗ )-restriction. We next define two reasonable two-stage designs for a randomized phase II trial, mimicking

the designs for single-arm trials by Simon (1989).

7.1.2.1

Optimal Design

We want to find the two-stage design with the smallest expected sample size

when the experimental therapy has a low response rate specified under H 0.

118

Randomized Phase II Cancer Clinical Trials

The probability of early termination (PET) under H 0 : p x = p y = p 0 is calculated as

a 1−1

n 1−max ( 0 ,k 1 )



PET = P (X 1 − Y 1 < a 1| p 0 ) =

b(y 1| n 1 , p 0 )b(k 1 + y 1| n 1 , p 0 ).

k 1=− n 1 y 1=max ( 0 , − k 1 )

Since under H 0 the sample size per arm is n 1 with probability PET and n with

probability 1 − PET, the expected sample size per arm under H 0 is obtained

as

EN = n 1 × PET + n × ( 1 − PET ).

Among the two-stage randomized phase II trial designs satisfying the (α∗ , 1 −

β∗ )-restriction, the optimal design is defined as the one with the smallest EN.

7.1.2.2

Minimax Design

Among the two-stage designs satisfying the (α∗ , 1 − β∗ )-restriction, the minimax design is defined as the one with the smallest maximal sample size n

per arm. For the chosen n, there may be more than one two-stage designs

satisfying the (α∗ , β∗ )-restriction. In this case, we choose the design with the smallest EN as the minimax design.

Given n, the designs satisfying the (α∗ , 1− β∗ )-restriction can be determined by an exhaustive enumeration of (α, 1 − β, EN ) by changing n 1, a 1, and a (1 ≤ n 1 ≤ n − 1, − n 1 ≤ a 1 ≤ n 1, a 1 − n 2 ≤ a ≤ n). Among these designs, the one that minimizes EN is identified. For the given n, this design dominates

all other designs in terms of EN. Let D(n) = (n 1 , n, a 1 , a) denote the design with the smallest EN, denoted as EN (n), among the designs with maximal

sample size n while satisfying the (α∗ , 1 − β∗ )-restriction. If n is too small, there may exist no designs satisfying the (α∗ , 1 − β∗ )-restriction. The design D(n) with the smallest n is the minimax design. If n exceeds a certain limit, the two-stage design practically becomes identical to the single-stage design

in the sense that the critical value of the first stage of the two-stage design

is the same as that of the corresponding single-stage designs and no decision

is made in the second stage. Hence, as n increases beyond the limit, EN (n)

increases linearly. The search for the optimal design continues by checking

EN (n) until n becomes so large that EN (n) starts to linearly increase in n.

Tables 7.1 to 7.9 report the minimax and optimal designs under α∗ = 0 . 1,

0.15, 0.2; 1 − β∗ = 0 . 8, 0.85, 0.9; p y = p 0 = 0 . 05 : 0 . 85 ( 0 . 05 ); = p x − p y =

0 . 1, 0.15, 0.2 ( = 0 . 1 also for p y = 0 . 05 and 0.85). Note that the maximal sample size for α = 0 . 1 or 1 − β = 0 . 9 is too large, especially when combined with a small effect size = 0 . 15. Under each setting, the maximal sample

size for the minimax design is smaller than or equal to the sample size of the

single-stage design. Under some settings, the single-stage design requires more

patients than the maximal sample size of the optimal design.

Randomized Phase II Cancer Clinical Trials with a Prospective Control 119

Example 7.1

We consider a randomized phase II trial to evaluate the antitumor activity of

CD30 antibody, SGN-30, combined with GVD chemotherapy (arm x) com-

pared with GVD plus placebo (arm y) in patients with relapsed/refractory

classical Hodgkin’s lymphoma. The primary objective of this study is for test-

ing H 0 : p x ≤ p y against H 1 : p x > p y. For the purpose of type I error rate and power calculation, the hypotheses are specified as H 0 : p x = p y = 0 . 7

and H 1 : p x = 0 . 85 , p y = 0 . 7, that is, p 0 = 0 . 7 and = 0 . 15. The design parameters are chosen based on a small study on GVD alone. Under

(α∗ , 1− β∗ , p 0 , p x ) = ( 0 . 15 , 0 . 8 , 0 . 7 , 0 . 85 ), the minimax design is (n 1 , n, a 1 , a) =

( 56 , 62 , 5 , 5 ), which has (α, 1 − β, EN ) = ( 0 . 1499 , 0 . 8009 , 57 . 06 ), and the optimal design is (n 1 , n, a 1 , a) = ( 27 , 73 , 1 , 6 ), which has (α, 1 − β, EN ) =

( 0 . 1321 , 0 . 8001 , 47 . 28 ). Compared to the minimax design, the optimal design requires 11 (= 73 − 62 ) more patients per arm in maximal sample size, but

saves almost 10 (≈ 57 . 06 − 47 . 28 ) patients per arm in expected sample size when arm x is inefficacious. When minimax and optimal designs are very

different in terms of n and EN, we can find a compromise design that has

n close to that of the minimax design and EN close to that of the optimal

design. Under the design setting, the design (n 1 , n, a 1 , a) = ( 29 , 65 , 0 , 6 ), which has (α, 1 − β, EN ) = ( 0 . 1367 , 0 . 8007 , 49 . 05 ), requires only 3 (= 65 − 62 ) more maximal sample size than the minimax design and 1 . 77 (= 49 . 05 − 47 . 28 ) more expected sample size under H 0 than the optimal design. The single-stage

design under the same design parameters requires n = 63 patients to reject H 0

when X − Y ≥ 6, for which (α, 1 − β) = ( 0 . 1423 , 0 . 8046 ). Note that, compared to the sample size of this single-stage design, the compromise two-stage design

requires a maximal sample size of only by 2, but its expected sample under

H 0 is much smaller (49.05 vs. 63). If we slightly increase the type I error rate

to α∗ = 0 . 16, the optimal design is given as (n 1 , n, a 1 , a) = ( 27 , 63 , 1 , 5 ), which has (α, 1 − β, EN ) = ( 0 . 1593 , 0 . 8006 , 42 . 87 ). With an increase of 1% in α∗, we drastically reduce EN and n.

7.1.3

Extensions

So far, we have considered two-arm randomized phase II trials allocating an

equal number of patients to each arm. Also, we have controlled type I and

II error rates under point null and alternative hypotheses. In this section, we

investigate some extensions from these standard design settings.

7.1.3.1

Unbalanced Randomized Trials

One may want to allocate more patients to one arm than the other for some

reasons, for example, to collect more information on one arm than the other

or to collect enough specimens for a correlative study on one arm. Suppose

that we want to randomize a different number of patients between two arms.

120

Randomized Phase II Cancer Clinical Trials

Let ml and nl denote the sample sizes at stage l(= 1 , 2 ) of arms x and y, respectively (m = m 1 + m 2 , n = n 1 + n 2 ). Also, let Xl and Yl denote the number of responders among stage l patients of arms x and y, respectively

(X = X 1 + X 2 , Y = Y 1 + Y 2 ). If we want to assign γ times larger number of patients to arm x than to arm y, then we have ml = γ × nl and m = γ × n.

Note that a choice of γ = 1 corresponds to the balanced two-stage designs

considered in the previous section. When γ = 1, it does not make sense to

directly compare the numbers of responders between arms at each stage. We

propose to compare the sample response rates between two arms in this case.

A two-stage design under an unbalanced allocation scheme proceeds as

follows.

• Stage 1: Accrue m 1 patients to arm x and n 1 patients to arm y, and

observe X 1 and Y 1.

(a) Proceed to the second stage if X 1 /m 1 − Y 1 /n 1 ≥ a 1 for a chosen constant a 1 ∈ [−1 , 1].

(b) Otherwise, reject arm x (or fail to reject H 0) and stop the trial.

• Stage 2: Accrue an additional m 2 patients to arm x and n 2 patients to

arm y, and observe X 2 and Y 2.

(a) For a constant a ∈ [−1 , 1], accept arm x (or reject H 0) for further

investigation if X/m − Y/n ≥ a.

(b) Otherwise, reject arm x.

Given H 0 : p x = p y = p 0 and H 1 : ( p x , p y ) = ( p 0 + , p 0 ), the type I error rate and power of a two-stage design, defined by (m 1 , n 1 , m 2 , n 2 , a 1 , a), are calculated as

α = P (X 1 /m 1 − Y 1 /n 1 ≥ a 1 , X/m − Y/n ≥ a| p x = p y = p 0 ) and

1 − β = P (X 1 /m 1 − Y 1 /n 1 ≥ a 1 , X/m − Y/n ≥ a| p x = p 0 + , p y = p 0 ), respectively.

When H 0 is true, the probability of early termination and the expected

sample size for arm x are calculated as

m 1

n 1



PET = P (X 1 /m 1 − Y 1 /n 1 < a 1| p 0 ) =

I (x 1 /m 1 − y 1 /n 1 < a 1 )

x 1=0 y 1=0

× b(x 1| m 1 , p 0 )b(y 1| n 1 , p 0 ),

and

ENx = m 1 × PET + m × ( 1 − PET ),

respectively. Similarly, the expected sample size for arm y under H 0 is obtained

as ENy = n − n 2 × PET. So, the expected total sample size is EN = ENx +

Randomized Phase II Cancer Clinical Trials with a Prospective Control 121

ENy = (m + n)− (m 2 + n 2 )×PET, or approximately EN = (γ +1 ) ENy. Among the two-stage designs satisfying the (α∗ , 1 − β∗ )-restriction, the optimal design is defined as the one with the smallest EN.

The minimax design is defined as the one with the smallest m (or m + n) among the two-stage designs satisfying the (α∗ , 1 − β∗ )-restriction.

Example 7.2

In Example 7.1, suppose that we want to assign twice as many patients

to SGN-30 plus GVD arm (arm x), that is, γ = 2. Under the same de-

sign setting as in Example 7.1, ( p 0 , p x , α∗ , 1 − β∗ ) = ( 0 . 7 , 0 . 85 , 0 . 15 , 0 . 8 ), the minimax design is (m 1 , m, n 1 , n, a 1 , a) = ( 31 , 93 , 16 , 47 , −0 . 0081 , 0 . 0721 ), which has (α, 1 − β, EN ) = ( 0 . 1463 , 0 . 8014 , 92 . 36 ), and the optimal design is (m 1 , m, n 1 , n, a 1 , a) = ( 35 , 99 , 18 , 50 , 0 . 0206 , 0 . 0677 ), which has (α, 1 −

β, EN ) = ( 0 . 1459 , 0 . 8027 , 92 . 21 ). Unbalanced designs usually require larger sample sizes than balanced designs. For example, for the minimax designs,

the total maximal sample size for this unbalanced design, m + n = 140, is

larger than that for the balanced design, 126 from Example 7.1. Since our

search program for minimax and optimal designs goes through all possible

combinations of m = 2 n and m = 2 n ± 1, we actually have m ≈ γ × n.

7.1.3.2

Strict Type I and II Error Control

So far, we have considered a simple null hypothesis H 0 : p x = p y = p 0 based on the response rate of a historical control, p 0. However, possibly due to a slightly

different patient population or the variability of the estimated response rate

for a historical control, the true response rate for the prospective control of

a randomized trial may be different from p 0. In this case, the chosen critical

values (a 1 , a) under the point null hypothesis may not control the type I error

rate accurately under the composite null hypothesis H 0 : p x = p y. In this

section, we consider the balanced randomization case, but extension to the

unbalanced case is straightforward. In order to protect the type I error rate

accurately under the composite null hypothesis, we calculate type I error by

α = max P (X 1 − Y 1 ≥ a 1 , X − Y ≥ a| p x = p y = p 0 ).

( 7 . 1 )

p 0∈[0 , 1]

Because B(n, p) has the largest variance with p = 1 / 2, the probability in (7.1) is maximized at p 0 = 1 / 2. Hence, (7.1) is simplified to

α = P (X 1 − Y 1 ≥ a 1 , X − Y ≥ a| p x = p y = 1 / 2 ).

We also have considered a simple alternative hypothesis for power calcula-

tion. So, a chosen two-stage design based on the point alternative hypothesis

may be underpowered although the experimental arm really has a higher re-

sponse rate than the control by , that is, H 1 : p x = p y + . In order to

122

Randomized Phase II Cancer Clinical Trials

guarantee a certain power level over the composite alternative hypothesis, we

may calculate the power by

1 − β =

min

P (X 1 − Y 1 ≥ a 1 , X − Y ≥ a| p x = p 0 + , p y = p 0 ), p 0∈[0 , 1− ]

which can be simplified to

1 − β = P (X 1 − Y 1 ≥ a 1 , X − Y ≥ a| p x = 1 / 2 + / 2 , p y = 1 / 2 − / 2 ).

In summary, given , if a design (n 1 , n, a 1 , a) has type I error α under H 0 : p x = p y = 1 / 2 and power 1 − β under H 1 : p x = 1 / 2 + / 2 , p y = 1 / 2 − / 2, its type I error and power are given as α and 1 − β under the composite

hypotheses H 0 : p x = p y and H 1 : p x = p y + .

Given (α∗ , β∗ , ), the optimal and minimax designs are defined as in Section

7.1.2. We do not specify p 0 in designing a study controlling the type I error

and power under composite hypotheses. For example, for (α∗ , 1 − β∗ , ) =

( 0 . 15 , 0 . 8 , 0 . 15 ) as in Example 7.1, the minimax design is (n 1 , n, a 1 , a) =

( 54 , 78 , −2 , 7 ), which has (α, 1 − β, EN ) = ( 0 . 1487 , 0 . 8000 , 70 . 43 ), and the optimal design is (n 1 , n, a 1 , a) = ( 39 , 89 , 1 , 7 ), which has (α, 1 − β, EN ) =

( 0 . 1428 , 0 . 8001 , 61 . 75 ). Note that these sample sizes are larger than those in Example 7.1, which are calculated under point null and alternative hypotheses. Table 7.10 lists the minimax and the optimal designs when controlling the

type I error rate and power over p 0 ∈ [0 , 1] for α∗ = 0 . 15 , 0 . 2, 1− β∗ = 0 . 8 , 0 . 85, and = 0 . 15 , 0 . 2. Note that the minimax designs for some design settings have n 1 too close to n, for example, (α∗ , 1 − β∗ , ) = (. 1 , . 8 , . 2 ). They are not appropriate as two-stage designs.

7.1.3.3

Randomized Trials with One Control

and K Experimental Arms

Suppose that there are K (≥ 2 ) experimental arms and one control arm. We

want to identify the experimental arms whose response rate is significantly

higher than that of the control arm. We consider balanced allocations here,

but the following results can be easily modified for an unbalanced allocation

case.

In the first stage, we accrue n 1 patients to each of K +1 arms. For stage 1, let

Xk 1 denote the number of responders from experimental arm k(= 1 , . . . , K )

and Y 1 the number of responders from the control arm. For an integer a 1 ∈

[− n 1 , n 1], experimental arm k with Xk 1 − Y 1 ≥ a 1 proceeds to the second stage together with the control. All experimental arms with Xk 1 − Y 1 < a 1 will

be dropped because of lack of efficacy. If no experimental arm survives over

stage 1, then the whole trial will be terminated after stage 1. In the second

stage, patients are randomized to the experimental arms surviving over stage 1

and the control arm.

In the second stage, we accrue an additional n 2 patients to each of the

control and the experimental arms that survived over the first stage. Let

Randomized Phase II Cancer Clinical Trials with a Prospective Control 123

EN

74.68

42.11

90.19

49.45

61.71

61.75

34.81

77.18

42.75

96.58

54.91

51.09

29.31

66.68

36.24

82.91

46.96

110.92

strict

β

for

−1 .8005 .8007 .8502 .8508 .9001 .9001 .8001 .8009 .8500 .8507 .9002 .9002 .8000 .8023 .8504 .8503 .9006 .9003

value

Design

α

.0909

.0979

.0898

.0964

.0918

.0923

.1428

.1473

.1369

.1396

.1495

.1318

.1978

.1930

.1854

.1996

.1999

.1917

stopping

Optimal

)

)

)

)

)

)

)

y

)

)

)

) )

)

)

) ) ) )

)

, a

, 8

, 8

, 6

1

, 10 , 7 , 11 , 8 , 12 , 9

, 7 , 5

, 6

, 7

, 5 , 4 , 6 , 4

, 5

, 1

, 3

, 1

, a

, 2 , 3 , 2 , 1 , 2 , 2

, 1 , 2

, 1

, 1

, 0 , 0 , 0 , 1

, 0

futilit

1

, 46 , 32 , 56 , 28 , 69 , 42

, 39 , 26 , 46 , 28 , 77 , 35

, 29 , 15 , 40 , 23 , 57 , 31

a

, n

( 70

( 76

( 95

( 89 ( 52

( 61

( 79

( 69 ( 40 ( 89 ( 53

( 60

( n

( 122

( 144

( 174

( 114

( 134

( 113

with

test

) 1=

84.95

55.11

57.82

67.46

70.43

40.28

92.84

47.82

65.50

52.50

29.31

72.91

43.68

98.65

50.10

(γ

EN

105.81

131.99

113.73

binomial

β

for

cation

−1

allo

.8003

.8007

.8513

.8500

.9000

.9000

.8000

.8011

.8502

.8502

.9007

.9021

.8002

.8023

.8500

.8567

.9003

.9001

designs

Design

α

.0925

.0997

.0997

.0971

.0919

.0930

.1487

.1496

.1493

.1444

.1499

.1495

.1991

.1930

.1917

.1990

.1982

.1965

balanced

o-stage

)

)

tw

)

)

and

Minimax

)

)

)

)

) )

, a

)

) , 12 ) , 7 ) ) , 6 , 8 ) ) ) , 6 )

, 5

1

, 10 , 7 , 10 , 8 1 , 9

2

, 5 , 7 1

, 6

, 5 , 4 1 , 4 , 6 1

, 1]

, 7

, a

, 0 , 7 , 7 , 0 , − , 0

, 6

, − , 4 , 7 , −

, 6

, 1 , 0 , − , 4

, −

[0

1

, 63 , 55 , 102 , 47

, 48

, 98

, 54 , 39 , 92 , 37 , 112 , 65

, 42 , 15 , 62 , 43

, 40

optimal

∈

, n

, 107

( 56

( 67

( 84

( 45 ( 97

( 68

( 65 ( 40

( 46 ( 101

p 0

( n

( 104

( 123

( 78

( 54 ( 121

( 80

( 56

( 150

and

r

) ove∗

∆

.15

.2

.15

.2

.15

.2

.15

.2

.15

.2

.15

.2

.15

.2

.15

.2

.15

.2

β

Minimax

− , 1 ∗ β

∗ (α

−1 .8 .85 .9

.8

.85

.9

.8

.85

.9

7.10 of

trol

∗

able

α

.1

.15

.2

T con

124

Randomized Phase II Cancer Clinical Trials

Xk 2 and Y 2 denote the number of responders from the second-stage patients

of experimental arm k and the control, respectively. Note that the number

of experimental arms in the second stage will be smaller than K if some

experimental arms are rejected after stage 1. Also, let Xk = Xk 1 + Xk 2 and

Y = Y 1 + Y 2 denote the total number of responders from the cumulative

n = n 1 + n 2 patients for experimental arm k and the control, respectively.

For an integer a ∈ [ a 1 − n 2 , n], we accept experimental arm k for further investigation if Xk − Y ≥ a.

Let pk denote the response rate for experimental arm k(= 1 , . . . , K ), and

p y that for the control arm. Also, let p 0 denote the response rate for a his-

torical control. We consider the point null hypothesis H 0 : p 1 = · · · = pK =

p y = p 0. We propose to control the probability of erroneously accepting any

inefficacious experimental arm, called the family-wise error rate (FWER),

α = P{∪ K (X

k=1

k 1 − Y 1 ≥ a 1 , X k − Y ≥ a)| p 0}

n 1

n 1



n 1

n 2

n 2



n 2



=

· · ·

· · ·

I {∪ K (x

k=1

k 1 − y 1 ≥ a 1 , xk 1

y 1=0 x 11=0

xK 1=0 y 2=0 x 12=0

xK 2=0

+ xk 2 − y 1 − y 2 ≥ a)} b(y 1| n 1 , p 0 )b(y 2| n 2 , p 0 ) K



×

b(xk 1| n 1 , p 0 )b(xk 2| n 2 , p 0 ).

(7.2)

k=1

The family-wise power under a specified alternative hypothesis

H 1 : p y = p 0 , pk = p 0 + for k = 1 , . . . , K

is calculated by

1 − β = P{∪ K (X

k=1

k 1 − Y 1 ≥ a 1 , X k − Y ≥ a)| p 1 = · · · = pK = p 0 + , p y = p 0}

n 1

n 1



n 1

n 2

n 2



n 2



=

· · ·

· · ·

I {∪ K (x

k=1

k 1− y 1 ≥ a 1 , xk 1+ xk 2− y 1− y 2 ≥ a)}

y 1=0 x 11=0

xK 1=0 y 2=0 x 12=0

xK 2=0

K



× b(y 1| n 1 , p 0 )b(y 2| n 2 , p 0 )

b(xk 1| n 1 , p 0 + )b(xk 2| n 2 , p 0 + ).

( 7 . 3 )

k=1

Given ( p 0 , , α∗ , 1 − β∗ ), the optimal and minimax designs are defined as in a two-arm trial case. Let’s consider the case where K = 2. There are two

types of early termination: (i) when only one experimental arm is rejected,

or (ii) when both experimental arms are rejected after stage 1. For type (i),

the required sample size is 3 n 1 + 2 n 2, and the probability of early termination

under H 0 is

PET1 = 2 × P (X 11 − Y 1 < a 1 , X 21 − Y 1 ≥ a 1| p 0 )

Randomized Phase II Cancer Clinical Trials with a Prospective Control 125

and, for type (ii), the required sample size is 3 n 1 and the probability of early

termination under H 0 is

PET2 = P (X 11 − Y 1 < a 1 , X 21 − Y 1 < a 1| p 0 ).

Hence, the expected sample size under H 0 is obtained as

EN = ( 3 n 1 + 2 n 2 ) × PET1 + 3 n 1 × PET2 + 3 n × ( 1 − PET1 − PET2 )

= 3 n − n 2 × PET1 − 3 n 2 × PET2 ,

and 1 / 3 of which is the expected sample size per arm.

Even with K = 2, the search for the optimal and minimax designs requires

heavy computations. For an expedited search, we may choose a reasonable n,

for example, an integer slightly larger than that for a two-arm design, and

find (n 1 , a 1 , a) satisfying the (α∗ , 1 − β∗ )-condition in a narrow space, such as n 1 ∈ [0 . 3 n, 0 . 7 n], a 1 ∈ [−2 , 2], and a ∈ [ n/ 2 − 2 , n/ 2 + 2]. This suggestion is based on our experience that an n 1 of around n/ 2 provides a convenient time

schedule for the interim analysis, and, for reasonable two-stage designs, a 1 is

chosen around 0 and a is chosen around n/ 2.

Example 7.3

Let’s consider (α∗ , 1 − β∗ , p 0 , ) = ( 0 . 15 , 0 . 8 , 0 . 7 , 0 . 15 ) and K = 2. We may choose n = 70 per arm, which is slightly larger than that for the minimax

design for two-arm trials, 62 from Example 7.1, n 1 ∈ [21 , 49], a 1 ∈ [−2 , 2], and a ∈ [3 , 8]. Within the range, we choose the design with the smallest EN

among those satisfying the (α∗ , 1 − β∗ )-condition. From the expedited search, we find design (n 1 , n, a 1 , a) = ( 23 , 70 , 2 , 7 ), which has operating characteristics (α, 1 − β) = ( 0 . 1382 , 0 . 8003 ) and EN = 40 . 01 per arm.

In order to adjust for the multiplicity of statistical tests, we propose to

control the FWER in testing and to choose a design satisfying the family-

wise power 1 − β given in (7.3). However, one may want to choose a design

satisfying the marginal power to accept each efficacious experimental therapy

with a certain probability. Given (n 1 , n), suppose that the critical values (a 1 , a) are chosen to control the FWER given in (7.2) below α∗ level. Then, the

marginal power for experimental arm k with pk = p 0 + will be calculated as

1 − ˜

β = P (Xk 1 − Y 1 ≥ a 1 , Xk − Y ≥ a| p 0 , pk) n 1

n 1

n 2

n 2



=

I (xk 1 − y 1 ≥ a 1 , xk 1 + xk 2 − y 1 − y 2 ≥ a) y 1=0 xk 1=0 y 2=0 xk 2=0

× b(y 1| n 1 , p 0 )b(y 2| n 2 , p 0 )b(xk 1| n 1 , pk)b(xk 2| n 2 , pk)

126

Randomized Phase II Cancer Clinical Trials

or

n 1

n 1−max ( 0 ,k 1 )



n 2

n 2−max ( 0 ,k 2 )



1 − ˜

β =

b(y 1| n 1 , p 0 )b(k 1 + y 1| n 1 , pk)

k 1= a 1 y 1=max ( 0 , − k 1 ) k 2= a− k 1 y 2=max ( 0 , − k 2 )

× b(y 2| n 2 , p 0 )b(k 2 + y 2| n 2 , pk).

In Example 7.3 with K = 2, the design (n 1 , n, a 1 , a) = ( 23 , 70 , 2 , 7 ) has a marginal power of 1 − ˜

β = 0 . 6654 for (p 0 , ) = ( 0 . 7 , 0 . 15 ). Suppose that we want to control the marginal power at 1 − ˜

β∗ = 0 . 8 while controlling the

FWER at α∗ = 0 . 15 for each experimental arm with ( p 0 , ) = ( 0 . 7 , 0 . 15 ).

Then we need a larger trial, such as (n 1 , n, a 1 , a) = ( 44 , 88 , 0 , 9 ), which has (α, 1 − ˜ β) = ( 0 . 1293 , 0 . 8007 ).

7.2

Two-Stage Designs with Both Upper

and Lower Stopping Values

In a regular multistage clinical trial, we have to consider stopping or continu-

ing the trial depending on the outcome of the study therapy at each interim

analysis. In a traditional single-arm phase II cancer trial, we usually con-

sider stopping the trial early only for futility, but not for efficacy (also called

superiority), since there are no ethical issues in treating future patients with

an efficacious therapy. So far, we have considered early stopping for futility

only. In a randomized phase II trial, however, we may also want to stop the

trial early if the experimental therapy is shown to be more efficacious than the

prospective control therapy. In this section, we investigate two-arm ( k = 1)

two-stage randomized trials with both lower (futility) and upper (efficacy)

early stopping values.

We consider balanced allocations, but an extension to unbalanced ran-

domization can be easily derived. A two-stage phase II trial with design

{ (a 1 , b 1 )/n 1 , a/n} proceeds as follows:

Stage 1: Randomize n 1 patients to each arm, and observe the number of

responders X 1 and Y 1.

(a) If X 1 − Y 1 ≤ a 1, reject the experimental therapy and stop the trial.

(b) If X 1 − Y 1 ≥ b 1, accept the experimental therapy and stop the trial.

(c) If a 1 < X 1 − Y 1 < b 1, continue to stage 2.

Stage 2: Treat n 2 patients, and observe the number of responders X 2

and Y 2. Let X = X 1 + X 2 and Y = Y 1 + Y 2.

(a) If X − Y ≤ a, reject the experimental therapy.

(b) If X − Y > a, accept the experimental therapy.

Randomized Phase II Cancer Clinical Trials with a Prospective Control 127

We want to test H 0 : p x = p y against H 0 : p x > p y. For a two-stage design

{ (a 1 , b 1 )/n 1 , a/n}, we reject the experimental therapy (or fail to reject H 0) if (X 1 − Y 1 ≤ a 1 ) or (a 1 < X 1 − Y 1 < b 1 , X − Y ≤ a), the probability of which is calculated by

n 1−0∨ b 1



n 1



R( p x , p y ) =

b(x 1| n 1 , p x )b(y 1| n 1 , p y )

y 1=0

x 1=0∨ (y 1+ b 1 )

n 1−0∨ (a 1+1 )



n 1∧ (y 1+ b 1−1 )



n 2−0∨ (a+1− x 1+ y 1 )



+

y 1=0∨ ( 1− b 1 ) x 1=0∨ (y 1+ a 1+1 )

y 2=0

n 2



×

b(x 1| n 1 , p x )b(y 1| n 1 , p y )b(x 2| n 2 , p x )b(y 2| n 2 , p y ) x 2=0∨ (y 2+ a+1− x 1+ y 1 )

for given p x and p y, where a ∧ b = min (a, b) and a ∨ b = max (a, b). Under H 0 : p x = p y = p 0 and H 1 : p x = p 0 + , p y = p 0, the constraint on type I error probability and power is expressed as R( p x = p y = p 0 ) ≥ 1 − α∗ and R( p x = p 0 + , p y = p 0 ) ≤ β∗.

Given ( p 0 , ), there are many designs satisfying a type I error rate and

power constraint (α∗ , 1 − β∗ ). Among them, the minimax design minimizes the maximum number of patients n = n 1 + n 2. For a combination of response

probabilities ( p x , p y ), the expected sample size per arm is given as

EN ( p x , p y ) = PET ( p x , p y ) × n 1 + {1 − PET ( p x , p y )} × n, where

PET ( p x , p y ) = 1 − P(a 1 < X 1 − Y 1 < b 1| p x , p y ) n 1−0∨ (a 1+1 )



n 1∧ (y 1+ b 1−1 )



= 1 −

b(x 1| n 1 , p x )b(y 1| n 1 , p y )

y 1=0∨ ( 1− b 1 ) x 1=0∨ (y 1+ a 1+1 )

is the probability of early termination after stage 1. Let EN0 = EN ( p 0 , p 0 )

and EN1 = EN ( p 0 + , p 0 ). The optimal design minimizes the average of the expected sample sizes for p 0 and given as

EN = ( EN0 + EN1 )/ 2

among the designs satisfying the (α∗ , 1 − β∗ ) condition. On the other hand, the minimax design minimizes the maximal sample size n.

Tables 7.11–7.19 list minimax and optimal two-stage designs with both

upper and lower stopping values under various design settings of (α∗ , 1 −

β∗ , p x , p y ).

128

Randomized Phase II Cancer Clinical Trials

1

EN

40.86

21.87

19.14

35.02

22.36

46.60

28.35

56.44

32.52

63.72

36.94

71.45

41.29

75.27

43.05

79.30

44.71

81.20

46.01

81.28

46.29

79.69

44.03

75.86

41.93

71.80

40.06

65.41

36.61

57.19

32.54

48.43

91.51

0

EN

46.54

23.25

17.50

34.99

21.74

45.14

26.96

52.91

31.05

60.65

34.37

66.69

36.80

71.37

39.70

74.10

41.01

73.72

40.54

72.99

39.85

72.45

40.45

68.76

38.87

63.55

33.76

57.70

30.47

50.28

27.17

37.62

68.20

under

β−1 .8001 .8017 .8149 .8006 .8046 .8015 .8005 .8016 .8032 .8005 .8008 .8008 .8014 .8001 .8016 .8006 .8006 .8011 .8025 .8004 .8009 .8001 .8018 .8001 .8006 .8019 .8004 .8007 .8003 .8026 .8004 .8017 .8018

values

Design

.0994

.1000

.0923

.0898

.0956

.0972

.0896

.0997

.0970

.0991

.0989

.0999

.0996

.0988

.0991

.0991

.0973

.0999

.0998

.0999

.0989

.0997

.1000

.0997

.0996

.0996

.0995

.0999

.0986

.0999

.0983

.0987

.0998

stopping

Optimal

)α

)

)

)

)

)

)

)

)

)

)

,a

)

)

)

)

)

) ) ) ) ) )

, 3 ) ) ) ) ) ) ) ) ) )

)

)

, 4

, 4 , 4 , 6 , 5 , 7 , 5 , 8 , 6 , 10 , 6 , 10 , 7 , 11 , 7 , 10 , 7 , 10 , 7 , 11 , 7 , 9 , 8 , 9 , 6 , 8 , 6 , 8 , 5 , 5 , 6

early

, 2

,b 1

, 3

, 9

, 8

, 7

1

, 2 , 2 , 4 , 3 , 5 , 4 , 6 , 5 , 7 , 5 , 7 , 6 , 8 , 6 , 8 , 7 , 9 , 7 , 9 , 7 , 8 , 7

, 6

, 6 , 7 , 5 , 6 , 5 , 6

er

, 0 , 0 , 0 , 1 , 1 , 1 , 1 , 1 , 1 , 0 , 1 , 0 , 1 , 0 , 1 , 1 , 2 , 1 , 2 , 1 , 1 , 2 , 2 , 1 , 2 , 0 , 0 , 0 , 1 , 2 , 1 , 0

w

,a 1

, −

, 9

, 55

, 49

, 39

lo

1

, 15

, 25 , 18 , 35 , 21 , 38 , 25 , 45 , 20 , 44 , 22 , 51 , 24 , 50 , 31 , 56 , 29 , 55 , 28 , 48 , 34

, 29

, 21 , 36 , 18 , 36 , 23 , 28

,n

, 27

( 50

(n

( 61 ( 52

( 53 ( 50 ( 77 ( 52 ( 92 ( 50 ( 97 ( 58 ( 120 ( 59 ( 115 ( 64 ( 126 ( 64 ( 123 ( 67 ( 123 ( 67 ( 125 ( 64 ( 107 ( 65 ( 109 ( 53 ( 90 ( 51 ( 88 ( 54 ( 63 ( 109

and

er

upp

1

EN

41.49

27.11

19.14

35.26

22.36

44.97

28.26

57.14

32.52

74.41

38.70

78.08

40.12

79.47

44.87

83.11

48.06

95.71

52.75

96.56

51.48

89.83

49.84

84.91

43.37

85.38

40.28

68.87

36.87

60.10

34.82

48.64

90.18

with

)

0

1

EN

designs

=

54.39

25.72

17.50

36.36

21.74

53.06

27.39

59.56

31.05

74.41

35.31

79.83

44.81

77.99

45.69

85.95

43.95

95.64

52.37

96.51

49.31

89.40

41.25

77.90

39.88

85.31

38.15

64.08

32.66

53.84

25.69

43.71

78.91

(γ

β−

o-stage

1

.8022

.8001

.8003

.8011

.8001

.8078

.8007

.8005

Design

.8007

.8065

.8149

.8040

.8046

.8004

.8062

.8001

.8032

.8025

.8013

.8002

.8013

.8001

.8001

.8002

.8003

.8001

.8020

.8014

.8029

.8001

.8015

.8002

.8004

tw

cation

allo

.0993

.0802

.0923

.0933

.0956

.0994

.0920

.0998

.0970

.0998

.0962

.0981

.0993

.0998

.0989

.1000

.0998

.0995

.0998

.0997

.0999

.0999

.0998

.0999

.0991

.0989

.0964

.0997

.0908

.0985

.0926

.0987

.0988

optimal

Minimax

)α

)

)

)

)

)

)

)

)

)

)

)

) ) ) ) )

) ) ) )

)

, 8

, 9 )

)

) ) ) , 8 ) ) )

) ) ) )

and

balanced

,a

, 3 , 2

, 6

, 6

, 6

, 9

, 9

, 7

, 2 , 4 , 4 , 5 , 5

, 5 , 7 , 5 , 8

, 6

, 6

, 6 , 9 , 6

, 6 , 8 , 6

, 6 , 6 , 5 , 5 , 6

,b 1

, 3

, 5

, 7

, 6

, 8 , 10

, 9

, 9

3

, 3 , 2 , 4 , 3 3 , 4 1 , 5 , 8 , 7 , 9 3 , 11 1 1 , 10 , 10 , 9 , 10 , 11 , 10 , 11 , 14 , 8 , 9 , 7 2 , 6 , 9 , 5 , 7

, 1

, 0 , 1

, 1

, 1 , 3 , 1 , 0

1

, 5 , 5 , 5

1

, 0 , 5 , 0

, 1 , 0 , 1 , 0 , 0

) and

,a 1

, −

, 0

, −

, −

, − , − , − , − , 1

, 4 , 5 , 0 , −

, −

8

1

, 23 , 9 , 29 , 18

, 22

, 25 , 73 , 29 , 73

, 95 , 52 , 96

, 31 , 85 , 30

, 26 , 43 , 18 , 35 , 62

,.

, 38

, 48 , 88 , 31

,n

, 29

, 27

, 48

, 23

, 38 , 73

, 39

( 50

, 61

, 62

Minimax

( 50

( 50 ( 50

( 50

( 50 ( 81 ( 50 ( 90

( 56

( 52 ( 88 ( 50

( 50 ( 68 ( 50 ( 56 ( 101

(. 1

(n

( 58

( 60

( 71

( 52 ( 94 ( 53

( 56 ( 99 ( 54

( 100 ( 55 ( 100

( 100

( 92

( 79

= )∗

x

7.11 β

p

.15

.2

.25

.25

.3

.3

.35

.35

.4

.4

.45

.45

.5

.5

.55

.55

.6

.6

.65

.65

.7

.7

.75

.75

.8

.8

.85

.85

.9

.9

.95

.95

.95

− , 1

y

able ∗

p

.05

.1

.15

.2

.25

.3

.35

.4

.45

.5

.55

.6

.65

.7

.75

.8

.85

T (α

Randomized Phase II Cancer Clinical Trials with a Prospective Control 129

1

EN

53.02

26.43

16.95

40.06

23.27

52.95

30.62

65.39

36.97

75.90

41.88

82.94

46.00

87.38

49.93

91.00

51.34

93.19

51.71

93.44

51.69

93.53

50.46

87.28

51.02

84.67

45.36

74.62

41.62

64.70

34.96

53.17

96.44

0

EN

53.66

26.54

18.16

43.43

25.09

55.95

31.84

64.69

38.47

72.78

43.68

79.61

47.56

85.44

48.74

89.40

49.65

89.86

50.82

89.22

50.14

85.80

48.37

82.72

43.69

73.43

41.11

68.30

34.71

58.97

31.02

45.79

86.90

under

β− .8507 .8514 .8576 .8519 .8511 .8514 .8516 .8503 .8526 .8511 .8517 .8511 .8536 .8503 .8506 .8504 .8502 .8506 .8504 .8511 .8507 .8501 .8512 .8505 .8520 .8504 .8507 .8504 .8502 .8501 .8543 .8517 .8501

Design

1

values

.0995

.0949

.0838

.0997

.0988

.0996

.0980

.0986

.0973

.0998

.0996

.0997

.0995

.0999

.0959

.0997

.0983

.0998

.0995

.0999

.0989

.0996

.0994

.0999

.0994

.0998

.0987

.0986

.0988

.0988

.0989

.0993

.0988

Optimal

stopping

)α

)

) ) )

)

)

)

)

)

)

)

)

)

,a

) ) )

) ) ) ) )

)

)

)

)

)

)

)

)

) ) ) )

, 3 , 2 , 3 , 4

, 8 , 6 , 9

, 9 , 12 , 9 , 10 , 8 , 11 , 7 , 9 , 8 , 9 , 6 , 8 , 6 , 6 , 8

, 4 , 4 , 7 , 5 , 7 , 6

, 6

, 8 , 10 , 8 , 11 , 8 , 12

, 9

, 8

, 7

early

,b 1

, 4 , 3 , 2 1 , 3 , 5 , 4 , 7 , 5 , 8 1 , 9 , 6 , 9 , 7 , 9 , 7 , 9 , 7 , 9 , 7 , 10 , 7 , 9 , 7

, 6

, 6 , 7 , 5 , 6

, 0 , 0 , 0

, 0 , 0 , 0 , 0 , 0 , 0

, 1 , 0 , 0 , 1 , 0 , 0 , 1 , 1 , 1 , 1

, 0 , 2 , 0 , 1 , 1 , 2 , 1 , 2 , 1 , 1 , 2

er

,a 1

, −

, −

, 0

w

1

, 40 , 20 , 12

, 47

, 59

, 50

, 54

, 71

, 22 , 18 , 37 , 21 , 44 , 27

, 27

, 32 , 56 , 37 , 57 , 32 , 61 , 38 , 60 , 37 , 55 , 32 , 64 , 26

, 29

, 25 , 48 , 24 , 35

lo

,n(n ( 78 ( 41 ( 40 ( 60 ( 41 ( 89 ( 52 ( 95 ( 58 ( 109 ( 59 ( 120 ( 73 ( 127 ( 76 ( 136 ( 76 ( 148 ( 81 ( 148 ( 81 ( 73 ( 69 ( 73 ( 60 ( 99 ( 53 ( 74

( 127

( 135

( 119

( 113

( 145

and

er

upp

1

EN

54.30

26.47

16.95

38.68

26.71

56.05

31.79

80.71

39.06

89.29

54.22

91.34

54.28

90.99

52.60

54.99

60.44

55.80

52.90

56.24

93.36

48.27

83.94

44.27

72.05

35.49

59.04

106.42

110.74

113.06

105.65

104.94

108.15

with

) 1

0

=

EN

59.48

26.94

18.16

50.10

25.30

59.61

34.23

80.46

40.28

88.35

54.13

87.53

54.45

99.59

54.29

99.66

57.06

60.41

55.03

92.29

51.79

52.04

83.27

44.11

80.34

40.93

66.77

33.73

49.72

designs

111.13

113.21

104.90

105.54

(γ

β−

o-stage

cation

Design

1

.8502

.8551

.8576

.8512

.8542

.8505

.8511

.8501

.8508

.8500

.8536

.8501

.8501

.8501

.8500

.8500

.8501

.8505

.8500

.8521

.8501

.8503

.8501

.8503

.8520

.8508

.8509

.8508

.8509

.8504

.8502

.8517

.8509

tw

allo

.0959

.0953

.0838

.0993

.0891

.0997

.0943

.0995

.0966

.0999

.0997

.0999

.0998

.0999

.0979

.1000

.0983

.0999

.0996

.0998

.0981

.1000

.0981

.0996

.0999

.0999

.0984

.0998

.0996

.1000

.0980

.0996

.1000

optimal

Minimax

)α

)

)

)

)

) ) )

)

)

)

balanced

) ) ) ) ) ) ) ) ) ) ) , 8 ) , 9 )

)

)

)

)

)

, 9

, 10 ) , 10 , 7 , 9 ) , 9

, 8 )

)

)

, 6

and

,a

, 3 , 2 , 3 , 4 , 3 , 5 , 4 , 6 , 5 , 7 , 5

, 6

, 7

, 7

, 7

, 7

, 6

, 6 , 7 , 5 , 6 , 5 , 5

,b 1

, 4

, 4

, 7 , 5

, 13

, 11

, 9

, 11

, 10

1

, 3 , 2 3 , 4 2 1 , 9 , 6 , 11 , 8 1 , 8 4 , 8 , 17 1 , 11 , 9 , 11 , 101 , 17 , 9

, 12 , 15 , 9 , 12 , 9 , 11 , 6 , 10

) and

, 0 , 0

, 0

, 5 , 0

, 5

, 2

, 0 , 2

, 4 , 3 , 5

, 2 , 0 , 5

, 3 , 0

, 3

, 0

, 5

,a 1

, −

, −

, − , −

, 5

, −

, −

, −

, −

, 4

, 5

, 4

, 2

85

1

, 21 , 12

, 17

, 80 , 34

, 54

, 53

, 47 , 91

, 59

, 80 , 42 , 104 , 50 , 76 , 35 , 78 , 39 , 64 , 27 , 45 , 104

,.

, 87

,n

, 48

, 25

, 39 , 25

, 68

, 67

, 48 , 109

, 112 , 43

Minimax

( 40 ( 40

( 40

( 85 ( 50 ( 97 ( 56

( 59

( 65

( 66

( 65

( 62

( 56 ( 94 ( 50 ( 81 ( 44 ( 64

(. 1

(n

( 69

( 55

( 70 ( 42

( 105

( 113

( 116 ( 66 ( 120

( 120 ( 66 ( 116

( 110

( 103

( 118

= )∗

x

7.12 β

p

.15

.2

.25

.25

.3

.3

.35

.35

.4

.4

.45

.45

.5

.5

.55

.55

.6

.6

.65

.65

.7

.7

.75

.75

.8

.8

.85

.85

.9

.9

.95

.95

.95

− , 1

y

able ∗

p

.05

.1

.15

.2

.25

.3

.35

.4

.45

.5

.55

.6

.65

.7

.75

.8

.85

T (α

130

Randomized Phase II Cancer Clinical Trials

1

EN

63.63

32.80

20.67

50.93

29.99

63.71

37.91

76.11

45.31

87.22

49.15

95.36

53.76

58.26

61.11

60.46

61.29

59.75

56.59

98.48

52.01

85.50

46.12

75.83

42.51

63.73

104.86

107.93

110.39

110.72

105.67

102.03

111.77

0

EN

69.23

35.62

25.04

53.82

34.89

68.66

40.16

82.59

45.96

92.01

53.44

57.00

59.70

60.70

62.45

59.35

58.40

54.88

90.80

49.95

84.27

44.51

69.40

35.86

52.92

101.48

104.86

109.30

109.68

108.21

108.41

101.49

102.33

under

β−

Design

1

.9003

.9008

.9045

.9001

.9012

.9003

.9030

.9001

.9003

.9006

.9014

.9006

.9000

.9009

.9006

.9010

.9005

.9001

.9010

.9005

.9003

.9000

.9004

.9001

.9016

.9011

.9016

.9002

.9005

.9000

.9012

.9006

.9005

values

.0950

.0855

.0966

.0873

.0992

.0969

.0946

.0983

.0995

.0997

.0999

.0998

.0998

.1000

.0992

.1000

.0974

.1000

.0998

.0998

.0997

.0995

.0995

.0998

.0994

.0999

.0991

.0994

.0996

.0983

.0997

.0998

.0996

Optimal

)α

)

)

)

)

)

)

)

stopping

)

)

)

)

)

)

)

)

,a

) ) ) )

)

)

)

)

)

)

)

)

)

)

)

)

) )

, 4 , 3 , 5 , 5 , 6 , 7 , 5 , 9 , 6 , 10 , 8 , 11 , 8 , 11 , 8 , 12 , 9 , 12 , 9 , 12 , 9 , 13 , 9 , 12 , 8 , 10 , 8 , 11 , 8 , 8 , 7 , 6 , 8

,b 1

, 4 , 3 , 2 , 5 , 3 , 6 , 5 , 7 , 6 , 8 , 6 , 9 , 7 , 10 , 8 , 10 , 8 , 11 , 8 , 11 , 8 , 10 , 8 , 10 , 8 , 10 , 7 , 8 , 6 , 8 , 5 , 7 , 8

early

, 0 , 0 , 0 , 0 , 0 , 0 , 0 , 0 , 1 , 0 , 0 , 0 , 0

, 0

, 1

, 0

, 1

, 2

, 1

, 1 , 1 , 1 , 1 , 1 , 1 , 2

,a 1

, 0

, 0

, 2

, 2

, 1

, 2

, 1

er

1

, 49 , 24 , 15 , 37 , 19 , 47 , 28 , 56 , 36 , 59 , 36 , 69 , 40 , 66 , 42 , 68 , 44 , 85 , 43 , 82 , 42 , 78 , 47 , 79 , 42 , 63 , 37 , 59 , 33 , 51 , 24 , 39 , 83

w

,n

lo

(n

( 106 ( 61 ( 60 ( 81 ( 71 ( 103 ( 60 ( 124 ( 72 ( 141 ( 82 ( 149 ( 83

( 85

( 96

( 91

( 96

( 94

( 82

( 80

( 75

( 73 ( 85

( 158

( 167

( 168

( 170

( 167

( 159

( 142

( 139

( 108

( 163

and

er

1

upp

EN

70.64

32.81

20.67

51.35

32.54

69.13

37.91

83.30

54.44

54.47

70.23

72.93

73.85

65.27

66.00

72.63

64.73

65.26

49.94

84.25

42.36

69.39

102.17

105.84

107.67

126.39

112.02

116.90

124.38

115.77

112.93

100.94

127.33

with

0

) 1

EN

78.50

36.00

25.04

58.27

33.25

75.45

40.16

89.14

53.59

98.78

58.10

70.29

72.68

74.19

69.06

69.93

72.71

57.07

65.36

94.68

46.57

74.19

36.14

70.20

110.86

119.71

118.51

129.15

123.96

118.77

118.40

106.78

107.12

designs

=

(γ

β−1 .9000 .9048 .9045 .9000 .9046 .9002 .9030 .9001 .9001 .9000 .9000 .9001 .9012 .9003 .9000 .9002 .9004 .9001 .9002 .9001 .9001 .9004 .9003 .9000 .9001 .9000 .9005 .9002 .9012 .9004 .9009 .9001 .9001

o-stage

Design

tw

cation

allo

.0980

.0870

.0966

.0982

.0909

.0988

.0946

.0992

.0992

.0998

.0992

.1000

.0990

.0998

.0999

.1000

.0994

.1000

.0984

.0988

.0986

.1000

.0986

.0999

.0995

.0999

.0989

.1000

.0996

.0999

.0902

.0998

.0997

optimal

Minimax

)

)α

)

)

)

)

)

)

)

)

)

) ) )

)

)

)

) )

) ) )

)

,a

)

)

)

) )

, 4 ) ) , 4 ) , 6 ) , 7 ) , 8 , 6 , 9 ) , 10

, 11

, 7 , 10

, 11 , 8

, 8 , 10

, 10 , 7 , 9

, 8 , 6 , 7

, 7

and

balanced

, 3 , 5

, 4

, 5

, 5

, 7

, 8

, 8

, 7

, 6 , 6

,b 1

, 4

, 6

, 7

, 10

, 14 , 9 , 13

, 13

, 17

, 8

1

, 3 , 2 2 , 4 1 , 5 2 , 9 1 2 3 , 8 , 12

, 12 , 10

, 10

, 12

4

, 11 , 18 , 9 5 1 1 1 , 17 , 9 , 13 , 12

, 8 , 15

, 6 , 8

, 3

1

, 12

, − , 0 , 0 , − , 1 , − , 0 , − , 3 , − , − , − , 5

, 5 , 2 , 4

, −

, 4 , 5 , 1 , 0

, 4 , 4 , − , 1 , 1 , 1 , 0

) and

,a 1

, −

, − , −

, −

1

, 65 , 90

, 27 , 67 , 81

9

, 67 , 25 , 15 , 41 , 27 , 63 , 28 , 66 , 52 , 77 , 43 , 76 , 70

, 72

, 74 , 72 , 105 , 73 , 76 , 56

, 59 , 111

, 109 , 44 , 100

, 31 , 62

,.

,n

( 60 ( 60

( 60

( 60

( 61

( 74

, 102

( 77

( 81

( 79

( 73

( 68

( 95 ( 60 ( 77

Minimax

(n

( 90

( 66

( 88

( 67

( 82

( 81

( 111 ( 60

( 139

(. 1

( 104

( 118

( 129

( 139

( 143

( 148

( 123

( 147

( 141

( 134

= )∗

x

7.13 β

p

.15

.2

.25

.25

.3

.3

.35

.35

.4

.4

.45

.45

.5

.5

.55

.55

.6

.6

.65

.65

.7

.7

.75

.75

.8

.8

.85

.85

.9

.9

.95

.95

.95

− , 1

y

able ∗

p

.05

.1

.15

.2

.25

.3

.35

.4

.45

.5

.55

.6

.65

.7

.75

.8

.85

T (α

Randomized Phase II Cancer Clinical Trials with a Prospective Control 131

1

EN

33.23

18.71

14.19

27.45

18.99

35.99

20.23

45.26

26.38

50.97

28.72

54.89

31.93

59.17

33.15

61.80

35.07

63.10

35.12

63.29

35.05

61.56

34.65

61.45

32.10

54.74

31.42

53.33

28.23

43.30

24.33

36.87

66.80

0

EN

41.71

19.46

13.36

28.54

18.02

36.95

22.58

44.38

26.78

48.78

29.18

54.94

31.91

59.53

32.64

60.46

34.17

60.33

34.75

59.77

33.69

58.69

33.24

55.47

31.12

53.00

26.79

44.44

23.65

39.53

19.74

30.65

55.50

under

β−

values

.8001

.8001

.8024

.8025

.8018

.8002

.8021

.8016

.8015

.8012

.8005

.8004

.8016

.8003

.8012

.8002

.8006

.8000

.8001

.8000

.8072

.8024

.8013

Design

1

.8015

.8016

.8076

.8012

.8010

.8001

.8040

.8014

.8014

.8000

.1499

.1214

.1199

.1447

.1253

.1472

.1482

.1499

.1336

.1500

.1438

.1497

.1495

.1497

.1478

.1484

.1493

.1494

.1469

.1492

.1499

.1487

.1468

.1497

.1492

.1496

.1480

.1489

.1492

.1493

.1483

.1487

.1500

stopping

Optimal

)α

) )

)

)

)

)

) ) ) ) ) ) ) ) )

)

) )

) ) ) ) ) )

) ) ) ) ) ) ) ) )

early

,a

, 3

, 3

, 6

, 7

, 5

, 6 , 6 , 5 , 7 , 4 , 5 , 4 , 5 , 3 , 4 , 4

, 2 , 2 , 1 , 3 , 2 , 4

, 4 , 4 , 5 , 5

, 6

, 5 , 7

, 7 , 6 , 7 , 6 , 7

, 3 , 3 , 4 , 3 , 6 , 4 , 6 , 4 , 6 , 4 , 6 , 5 , 7 , 5 , 7 , 5 , 7 , 5 , 7 , 5 , 7 , 5 , 6 , 5 , 6 , 4 , 5 , 4 , 4 , 6

er

,b 1

1

, 2 , 2

1

1

1

1

1

w

, 0

, 0 , 0 , 0

, 0 , 0 , 0 , 0

, 0

, 0 , 1

, 0 , 0 , 0 , 1 , 1 , 1

, 0 , 1 , 0 , 0 , 0 , 1 , 0 , 0 , 0

,a 1

, −

, 0

, −

, −

, −

, −

, −

lo

1

, 15 , 9 , 22 , 12 , 28

, 35 , 20 , 33 , 20

, 19

, 23 , 48

, 40 , 24 , 39 , 26 , 45 , 26

, 23 , 42 , 17 , 26 , 14 , 31 , 13 , 19 , 38

,n

, 18

, 15

, 32

, 33

, 18

, 30

( 35 ( 30 ( 44 ( 31 ( 55

( 59 ( 40 ( 74 ( 48

( 59

( 50 ( 91 ( 50 ( 93 ( 55 ( 93 ( 59 ( 92 ( 57 ( 80 ( 46 ( 84 ( 43 ( 73 ( 42 ( 67 ( 32 ( 53 ( 82

and

(n

( 61

( 30

( 79

( 89

er

upp

1

with

EN

34.57

19.07

14.19

35.10

16.41

42.48

20.23

46.86

25.55

58.10

35.33

64.53

31.89

70.65

36.39

65.31

40.10

67.35

41.01

72.12

42.13

65.21

38.94

69.72

34.15

66.06

31.81

51.35

29.34

46.98

25.60

38.84

72.32

) 1

0

=

designs

(γ

EN

44.69

19.89

13.36

35.08

20.69

40.27

22.58

48.35

29.32

58.24

35.20

62.62

35.03

70.71

36.22

68.18

39.72

66.20

39.93

72.27

42.10

67.32

38.57

69.40

31.76

66.04

30.36

50.84

25.24

42.24

20.82

30.36

63.39

β−

o-stage

cation

Design

1

.8035

.8041

.8076

.8047

.8168

.8006

.8040

.8001

.8010

.8011

.8017

.8001

.8008

.8035

.8001

.8001

.8004

.8001

.8005

.8000

.8015

.8000

.8008

.8002

.8004

.8006

.8005

.8006

.8004

.8009

.8010

.8013

.8003

tw

allo

.1457

.1245

.1199

.1495

.1422

.1500

.1482

.1496

.1488

.1493

.1488

.1499

.1499

.1496

.1500

.1486

.1480

.1493

.1498

.1498

.1480

.1499

.1492

.1496

.1489

.1486

.1447

.1497

.1495

.1486

.1364

.1499

.1497

optimal

Minimax

balanced

)α

)

)

)

) ) ) ) ) ) ) ) ) ) ) ) ) )

) ) ) ) ) ) ) ) ) ) ) ) ) ) )

and

,a

, 2

)

, 3

, 3 , 4 , 3

, 5 , 4

, 6

, 6

, 6 , 4 , 5 , 4 , 5 , 4 , 5 , 3 , 4 , 3 , 3 , 4

, 2 , 2 , 1 , 2

, 3

, 5 , 3

, 6 , 4

, 4

, 4 , 6 , 4

, 2

, 4 , 2 , 8 , 3 , 6 , 4 , 6 , 6

, 5

, 9

, 9

, 6 , 7

, 9

3

, 7 , 7 3 , 7 , 10 , 9 , 9 , 6 4 , 7 , 9 , 7 , 7 1 1 , 7 , 8 , 5 , 7 1

) and

,b 1

3

, 2

1

1

3

, 11

, 0

, 2 1 , 0

, 2 , 3

, 3 , 0

, 3 2 , 3 , 1 , 4

, 3 , 5 , 0 , 5

, 1 , 0 , 0 , 0

8

, −

, 0

, −

, − , − , −

, 2 , −

, −

, −

, −

, − , −

, −

,.

,a 11 , 10 , 17 , 9 , 35 , 9 , 36 , 15 , 42 , 12 , 57 , 35 , 60 , 16 , 70 , 33 , 52 , 39

, 69 , 26 , 66

, 22 , 35 , 15 , 22

, 49 , 39 , 70 , 42 , 41 , 38

, 22 , 40

, 48

Minimax

,n

( 30

(. 15

(n

( 47 ( 30

( 36 ( 30 ( 46 ( 30 ( 55 ( 32 ( 64 ( 37 ( 69 ( 40 ( 75 ( 41 ( 77 ( 44

( 73 ( 40 ( 67

( 33 ( 52 ( 30 ( 42

( 78 ( 44 ( 77 ( 44 ( 76 ( 42

( 38 ( 62

( 76

= )∗

x

7.14 β

p

.15

.2

.25

.25

.3

.3

.35

.35

.4

.4

.45

.45

.5

.5

.55

.55

.6

.6

.65

.65

.7

.7

.75

.75

.8

.8

.85

.85

.9

.9

.95

.95

.95

− , 1

y

able ∗

p

.05

.1

.15

.2

.25

.3

.35

.4

.45

.5

.55

.6

.65

.7

.75

.8

.85

T (α

132

Randomized Phase II Cancer Clinical Trials

1

EN

41.17

21.46

14.96

33.36

20.22

42.30

24.19

51.82

29.25

60.03

33.38

67.64

36.71

70.63

39.63

73.38

41.30

76.93

42.58

76.16

42.96

72.02

39.98

68.93

37.91

65.26

35.39

58.41

32.20

51.06

26.99

40.97

76.09

0

EN

50.77

22.96

15.34

36.26

21.04

48.05

28.63

54.78

32.12

62.01

38.06

67.19

38.39

72.02

39.84

74.95

42.11

74.06

41.58

73.73

40.32

74.54

40.28

69.14

36.93

63.27

33.17

57.33

28.93

47.57

25.05

38.14

70.08

under

β−

values

.8519

.8504

.8503

.8511

.8505

.8517

.8523

.8504

.8510

.8504

.8503

.8517

.8513

.8501

.8503

.8508

.8507

.8513

.8535

.8500

.8517

.8503

.8501

Design

1

.8507

.8506

.8510

.8511

.8529

.8505

.8537

.8507

.8515

.8508

.1497

.1452

.1380

.1492

.1450

.1466

.1499

.1497

.1479

.1498

.1489

.1494

.1494

.1499

.1494

.1494

.1495

.1483

.1499

.1489

.1480

.1494

.1496

.1476

.1494

.1474

.1488

.1492

.1493

.1487

.1474

.1495

.1469

stopping

Optimal

)α

)

)

) ) ) ) ) ) ) ) ) ) ) ) ) ) , 8 ) ) ) ) ) ) ) ) ) ) ) ) ) ) ) ) )

early

,a

, 2

, 5 , 4

, 4 , 6 , 6

, 5 , 8

, 7

, 7

, 9 , 7 , 8 , 6 , 7 , 5 , 7 , 4 , 6 , 4 , 4 , 5

, 3 , 2 , 1 , 4 , 2

, 6

, 6

, 5 , 7 , 7

, 5

, 5

, 3 , 3 , 4 , 3 , 5 , 4 , 6 , 4 , 8 , 5 , 7 , 6 1 , 5 , 9 , 7 , 9 , 7 , 7 , 5 , 7 , 5 , 7 , 5 , 6 , 5 , 5 , 4 , 5 , 6

er

,b 1

2

, 2 , 2

1

1

1

1

1

1

, 1

, 0

, 0

, 0

, 0

, 0

w

, 0 , 0 , 0 , 0

, 0

, 0

, 0

, 0

, 0

, 0

, 0

, 0 , 1 , 0 , 1 , 0 , 0 , 0 , 0

,a 1

, −

, − , −

, − , − , −

, −

, −

lo

1

, 19 , 11 , 24 , 17

, 39

, 51

, 57 , 30 , 42 , 26 , 53 , 32 , 54 , 29 , 53 , 26 , 48 , 24 , 49 , 22 , 45 , 20 , 30 , 18 , 29 , 51

,n

, 22

, 29 , 17

, 19 , 35 , 22

, 22

( 37 ( 31 ( 66 ( 30

( 85

( 91

( 110 ( 56

( 73 ( 104 ( 56 ( 102 ( 57 ( 113 ( 68 ( 105 ( 61 ( 98 ( 53 ( 92 ( 44 ( 80 ( 39 ( 54 ( 101

and

(n

( 57

( 69 ( 41

( 45 ( 90 ( 57

( 55

( 112

er

upp

1

with

EN

40.20

23.33

15.18

31.06

20.22

45.27

26.32

67.31

36.37

70.11

41.30

72.85

46.02

87.51

39.53

89.25

42.99

92.27

46.92

84.46

43.67

89.39

41.65

78.34

46.38

68.33

40.30

66.08

38.13

56.66

28.51

49.37

85.86

) 1=

0

designs

(γ

EN

53.34

26.07

15.96

41.78

21.04

50.88

28.72

67.26

36.06

67.17

41.41

75.77

45.67

87.38

46.66

88.28

45.90

92.36

47.33

86.29

45.31

89.48

42.42

74.18

46.26

69.78

34.98

58.95

38.12

54.87

25.45

49.41

80.79

β−

o-stage

cation

Design

1

.8500

.8527

.8664

.8520

.8529

.8501

.8505

.8516

.8522

.8503

.8506

.8505

.8534

.8509

.8502

.8508

.8504

.8509

.8503

.8501

.8502

.8510

.8507

.8502

.8530

.8501

.8514

.8500

.8504

.8506

.8501

.8515

.8500

tw

allo

.1499

.1478

.1445

.1477

.1450

.1431

.1378

.1490

.1492

.1498

.1494

.1499

.1496

.1497

.1499

.1500

.1486

.1500

.1495

.1498

.1494

.1490

.1481

.1497

.1488

.1490

.1491

.1496

.1471

.1498

.1495

.1490

.1500

optimal

balanced

Minimax

)α

) ) ) ) ) ) ) ) ) ) ) ) ) ) ) ) ) ) ) ) ) ) ) ) ) ) ) ) ) ) ) ) )

and

,a

, 2 , 2 , 1 , 3 , 2 , 4 , 3 , 4 , 3 , 5 , 4 , 6 , 4 , 6 , 5 , 6 , 5 , 7 , 5 , 7 , 5 , 7 , 5 , 6 , 4 , 6 , 4 , 5 , 4 , 4 , 3 , 4 , 4

) and

,b 1

, 3 , 2

, 3

, 5 , 4

, 8

, 6

, 7

, 7

, 7

, 9

5

1

, 2 3 , 3 2 1 , 7 , 6 , 11 , 5 1 , 8 , 10 4 , 12 2 , 8 , 7 , 9 3 , 8 1 , 12 , 7 2 , 9 , 11 , 5 , 8 , 6 , 5 , 10

, 0

, 0

, 4 , 2

, 2

, 3

, 4 , 1 , 0

, 4

, 4

, 0

, 3 , 3 , 0 , 2

85

, − , −

, −

, − , −

, 1

, −

, 5 , − , 5 , −

, −

, − , 2

, −

, 1

, 3

,.

,a 11 , 27 , 22 , 12 , 17 , 17 , 38 , 22 , 67 , 35 , 61 , 41 , 68 , 45 , 87 , 29 , 87 , 36 , 92 , 45 , 81 , 24 , 89 , 33 , 68 , 46 , 53 , 28 , 51 , 38 , 53 , 21 , 49 , 78

Minimax

,n

(. 15

(n

( 55 ( 30 ( 30 ( 46 ( 30 ( 59 ( 35 ( 70 ( 41 ( 78 ( 44 ( 85 ( 49 ( 90 ( 52 ( 95 ( 53 ( 95 ( 53 ( 95 ( 53 ( 93 ( 52 ( 88 ( 49 ( 82 ( 44 ( 73 ( 40 ( 64 ( 32 ( 52 ( 92

= )∗

x

7.15 β

p

.15

.2

.25

.25

.3

.3

.35

.35

.4

.4

.45

.45

.5

.5

.55

.55

.6

.6

.65

.65

.7

.7

.75

.75

.8

.8

.85

.85

.9

.9

.95

.95

.95

− , 1

y

able ∗

p

.05

.1

.15

.2

.25

.3

.35

.4

.45

.5

.55

.6

.65

.7

.75

.8

.85

T (α

Randomized Phase II Cancer Clinical Trials with a Prospective Control 133

1

EN

50.38

25.12

19.08

38.86

25.55

53.70

31.98

64.09

36.32

73.06

41.41

76.96

43.81

82.26

48.55

86.18

48.97

88.56

48.41

88.14

49.99

87.16

47.58

84.10

45.27

77.20

41.28

69.06

37.32

60.25

31.74

48.26

87.76

0

EN

61.42

35.60

22.02

49.96

28.47

58.35

34.84

68.52

41.87

77.97

45.37

88.54

50.57

93.76

51.24

94.21

52.01

95.27

53.36

94.31

50.46

89.23

50.09

85.02

45.50

79.18

43.19

70.08

35.87

58.41

30.49

46.21

85.51

under

β−1 .9001 .9021 .9007 .9010 .9016 .9005 .9004 .9000 .9006 .9000 .9003 .9001 .9000 .9008 .9016 .9009 .9010 .9003 .9006 .9001 .9000 .9002 .9024 .9002 .9006 .9011 .9004 .9003 .9006 .9018 .9037 .9000 .9004

Design

values

.1475

.1318

.1305

.1489

.1414

.1473

.1382

.1498

.1495

.1472

.1457

.1497

.1466

.1498

.1493

.1500

.1489

.1479

.1500

.1478

.1491

.1499

.1488

.1499

.1496

.1500

.1489

.1482

.1486

.1493

.1488

.1490

.1491

Optimal

stopping

)α

) )

)

)

) ) )

) )

) )

) ) )

)

)

)

)

)

,a

)

)

)

)

)

) ) ) )

, 3 , 3 ) , 5 ) ) )

)

, 6 , 5 , 7

, 8 , 7 , 10 , 6 , 9

, 8

, 7 , 10 , 7 , 10 , 6 , 9 , 7

, 6 , 9 , 7 , 7 , 5 , 6 , 5 , 5 , 6

, 2 , 2 , 3 , 3 , 5 , 4

, 4

, 6 , 7 , 5 , 7 , 6 , 8

, 6

, 8

early

,b 1

, 3

, 8

, 7

, 7

, 6

1

1

, 2 1 , 3 , 5 , 4 , 6 1 , 7 , 5 2 1 1 1 1 , 6 , 8 1 , 8 , 7

, 6 1 , 6

, 5

, 5 , 6 , 4 , 5

, 0

, 0 , 0 , 0 , 0

, 0 , 0

, 0 , 0

, 0 , 0 , 0 , 0 , − , 0 , 1 , 0 , 0 , 0 , 0 , 0 , 1 , 0

er

,a 1

, − , −

, −

, −

, − , − , − , − , −

, −

w

1

, 14

, 19 , 42 , 25 , 47

, 57

, 58

, 50

, 60

, 20 , 56 , 33 , 50 , 29 , 58 , 28 , 60 , 35 , 66 , 33 , 65 , 36

, 35 , 49 , 31

, 29

, 24 , 39 , 20 , 37

lo

,n

, 40 , 17

, 25

(n

( 82 ( 50 ( 50 ( 77 ( 50 ( 88 ( 54 ( 105 ( 64 ( 114 ( 69

( 82

( 73

( 77

( 70

( 71

( 57 ( 91 ( 52 ( 76

( 120 ( 76

( 141

( 133

( 103

( 129

( 140 ( 75 ( 135

( 145 ( 77 ( 144

( 124

and

er

upp

1

EN

53.28

25.12

19.08

49.70

25.55

57.73

32.38

72.26

35.88

87.13

52.22

83.63

58.12

93.84

56.22

62.38

92.15

60.88

97.97

59.79

57.26

95.63

49.97

80.53

53.14

85.61

41.52

67.89

33.84

54.11

98.21

107.36

106.60

with

) 1

0

=

EN

69.41

35.60

22.02

50.89

28.47

62.97

35.29

74.69

45.91

90.32

52.01

94.16

58.21

97.97

53.48

61.98

61.93

60.15

56.16

99.06

49.00

87.01

53.21

85.87

35.42

64.27

31.04

49.92

90.37

designs

105.73

102.59

102.34

102.95

(γ

β−

o-stage

cation

Design

1

.9001

.9021

.9007

.9007

.9016

.9002

.9015

.9001

.9001

.9001

.9003

.9002

.9001

.9000

.9006

.9000

.9021

.9000

.9005

.9003

.9001

.9001

.9017

.9001

.9002

.9000

.9008

.9002

.9002

.9000

.9053

.9001

.9001

tw

allo

.1492

.1318

.1305

.1490

.1414

.1486

.1397

.1496

.1499

.1498

.1493

.1467

.1488

.1488

.1498

.1499

.1498

.1499

.1495

.1499

.1485

.1500

.1499

.1499

.1498

.1497

.1487

.1497

.1480

.1496

.1411

.1497

.1485

optimal

Minimax

)α

)

)

)

)

)

)

)

)

balanced

) ) ) ) ) ) ) ) ) ) )

)

)

)

)

, 7 ) , 7 ) , 7 ) , 8 )

)

) , 7

, 7 ) ) ) , 5 )

, 5

and

,a

, 3 , 3 , 2 , 3 , 3 , 4 , 4 , 5 , 4 , 6 , 4

, 8

, 7

, 5

, 4

, 9 , 5

, 5

, 5

, 6

, 6

, 5

, 9 , 5 , 6 , 4

, 4

, 9

,b 1

, 3 , 2

, 7

, 5 , 8

, 12

, 10

, 12 , 9

, 8

3

1

, 2 , 4 , 3 2 , 4 , 8 4 1 , 8 3 , 6 3 , 11 , 14 , 10 3 , 7 , 10 , 7 , 16 , 10 2 1 2 , 6 , 8 , 7 , 10

1

1

, 5 1

) and

, 0 , 0 , 0

, 0 , 0

, 3 , − , 3

, 0 , 4 , 4

, 1 , 0 , 3 , 4 , 3

, − , 3 , 3 , 0

, 1 , − , −

9

,a 1

, − , −

, −

, − , −

, −

, −

, − , −

, −

,.

1

, 14 , 49 , 19

, 28 , 67

, 51 , 70 , 58

, 45 , 102 , 61

, 60 , 91 , 59 , 99 , 54

, 68 , 53 , 85 , 25

, 25

, 66

,n

, 47 , 17

, 47

, 27 , 85

, 70

, 75

, 88 , 38

, 51

, 38

Minimax

( 50 ( 55 ( 50

( 50 ( 86

( 57

( 60

( 67

( 67

( 55 ( 90 ( 50

( 50

(. 15

(n

( 76 ( 50

( 72

( 50 ( 97

( 109

( 64

( 113 ( 64 ( 118 ( 67 ( 121

( 120

( 115

( 108 ( 59 ( 103

( 76

( 60 ( 112

= )∗

x

7.16 β

p

.15

.2

.25

.25

.3

.3

.35

.35

.4

.4

.45

.45

.5

.5

.55

.55

.6

.6

.65

.65

.7

.7

.75

.75

.8

.8

.85

.85

.9

.9

.95

.95

.95

− , 1

y

able ∗

p

.05

.1

.15

.2

.25

.3

.35

.4

.45

.5

.55

.6

.65

.7

.75

.8

.85

T (α

134

Randomized Phase II Cancer Clinical Trials

1

EN

30.13

17.21

14.19

21.79

14.57

28.40

17.26

37.20

20.91

39.82

22.65

46.25

25.85

46.92

27.32

49.11

27.55

49.67

28.09

49.38

27.76

48.83

26.85

47.41

26.53

44.74

24.15

39.76

21.87

35.02

19.43

29.62

55.08

0

EN

31.81

17.56

13.36

26.46

15.37

31.31

20.60

38.31

21.58

43.17

25.11

46.56

25.52

48.24

27.76

50.07

27.67

51.42

28.52

50.93

28.02

48.82

26.69

46.48

25.97

43.84

22.85

39.94

20.69

33.66

17.81

24.10

45.71

under

β−1 .8003 .8019 .8148 .8041 .8012 .8017 .8061 .8012 .8000 .8001 .8000 .8008 .8021 .8016 .8018 .8003 .8013 .8010 .8032 .8004 .8015 .8003 .8014 .8027 .8002 .8010 .8039 .8005 .8003 .8006 .8021 .8010 .8008

values

Design

.1941

.1579

.1824

.1972

.1790

.1993

.1970

.1873

.1908

.1986

.1959

.1934

.1992

.1999

.1928

.1992

.1995

.1995

.1990

.2000

.1985

.1991

.1996

.1996

.1960

.1920

.1970

.1985

.1972

.1919

.1862

.1984

.1997

stopping

Optimal

)α

)

)

) ) )

)

) ) ) )

) )

)

,a

) ) )

)

) )

) ) ) ) )

, 3 ) , 3

) )

)

) ) )

) )

, 3

, 5 , 4 , 4

, 5

, 6 , 4 , 6 , 4

, 5 , 3

, 5

early

, 2 , 1 , 0

, 2

, 4 , 3

, 3

, 4 , 6 , 4

, 6 , 4

, 5 , 3

, 4 , 4 , 3 , 2 , 3

,b 1

, 2 , 2

, 4 , 3 , 6

, 5

, 5 , 4 , 5 , 4

, 5 , 5

, 4

, 2 , 2

, 3

1

, 2 1 , 2 , 4 , 3 1 1 1 , 4 1 , 4 , 5 , 4 1 1 1 1 , 5 , 4 1 1 , 5 , 4 1 , 3 , 4 , 3 , 4 , 4

er

, 0 , 0

1

, 0

, 0

, 0 , 0

, 0

, 0 , 0 , 0

, 0 , 0

, 0 , 0

, 0 , 0 , 0 , 0 , 0

w

,a 1

, −

, − , −

, − , − , −

, −

, − , − , − , −

, − , −

, −

lo

1

, 26 , 14 , 9

, 11

, 8 , 29 , 16

, 18

, 21 , 36 , 20

, 34 , 20

, 32 , 17

, 14 , 25 , 13 , 16 , 27

,n

, 13

, 18

, 29 , 15 , 33

, 29

, 31 , 16 , 31 , 16

, 26 , 19

, 23

( 30

(n

( 54 ( 30

( 41 ( 31 ( 46 ( 33 ( 59 ( 36 ( 63 ( 38 ( 61 ( 41 ( 72 ( 43 ( 81 ( 45 ( 79 ( 43 ( 78 ( 42 ( 81 ( 42 ( 71 ( 33 ( 68 ( 35 ( 62 ( 39 ( 53 ( 30 ( 39 ( 83

and

er

upp

1

37.13

17.21

14.19

21.37

14.91

36.02

19.12

41.52

21.94

48.47

29.36

52.55

27.69

49.42

27.31

54.23

29.71

58.07

30.37

55.70

29.30

54.02

28.94

50.77

26.53

45.32

26.12

43.76

22.14

41.08

19.43

30.73

52.36

with

EN

)

0

1

designs

=

EN

37.12

17.56

13.36

28.37

15.86

35.37

19.50

41.69

21.54

48.08

29.28

52.64

29.19

50.49

28.73

51.87

29.50

57.12

30.04

53.74

28.24

51.76

28.15

50.29

25.97

46.95

26.07

38.11

21.10

41.08

17.81

24.43

50.71

(γ

β−

o-stage

Design

1

.8024

.8019

.8148

.8032

.8153

.8036

.8102

.8002

.8003

.8005

.8089

.8013

.8003

.8004

.8002

.8002

.8010

.8003

.8002

.8001

.8004

.8014

.8010

.8004

.8002

.8001

.8008

.8002

.8020

.8019

.8021

.8032

.8003

tw

cation

allo

.1982

.1579

.1824

.1948

.1863

.1998

.1840

.1992

.1931

.1993

.2000

.1994

.1994

.1996

.1980

.2000

.1978

.1993

.1987

.1995

.1992

.1999

.1966

.1981

.1960

.1995

.1978

.1993

.1995

.1998

.1862

.1997

.1983

optimal

Minimax

)α

) )

) ) ) ) )

)

) ) ) )

) )

) ) ) ) ) ) ) ) ) )

) ) )

)

) ) ) ) )

and

balanced

,a

, 1 , 1

, 3 , 4 , 3 , 4 , 3

, 3

, 3 , 4 , 3 , 4

, 2 , 3

, 0 , 2 , 2 , 2 , 2 , 3 , 2 , 3 , 2 , 4

, 4 , 3 , 4

, 4

, 3 , 3 , 2 , 3 , 3

,b 1

, 3 , 2

, 4 , 7 , 5 , 9 , 6

, 6

, 6 , 8 , 5 , 6

, 5 , 5

, 2 , 23 , 2 , 6 , 3 , 4 , 4 , 7 , 5 , 5 2 2 2 1 2 , 9 , 6 , 9 1 , 9 1 2 1 2 , 4 , 8 , 4 , 4 , 3 1 1

) and

, 1 , 0

, 0 , 1 , 0 , 1 , 0 , 2 , 2 , 2

, 2 , 0 , 1

, 0

, 1 , 0 , 1 , 2 , 0

,a 1

, 0 , −

, − , − , − , − , −

, −

, − , − , − , −

, − , −

8

1

, 9

, 12 , 34 , 15 , 41 , 17 , 47 , 29 , 52

, 55 , 27 , 49

, 45

, 25 , 30 , 19 , 41 , 13

,.

, 37 , 14

, 8

,n

, 26 , 37 , 20 , 41 , 19

, 21

, 22 , 39 , 19 , 37

, 12 , 39

Minimax

( 38 ( 30 ( 30

( 30 ( 39 ( 30 ( 45 ( 30 ( 52 ( 31 ( 57

( 63 ( 35 ( 63

( 61

( 31 ( 49 ( 30 ( 42 ( 30

(. 2

(n

( 31

( 32 ( 60 ( 34 ( 62 ( 35

( 35

( 34 ( 58 ( 33 ( 55

( 33 ( 63

= )∗

x

7.17 β

p

.15

.2

.25

.25

.3

.3

.35

.35

.4

.4

.45

.45

.5

.5

.55

.55

.6

.6

.65

.65

.7

.7

.75

.75

.8

.8

.85

.85

.9

.9

.95

.95

.95

− , 1

y

able ∗

p

.05

.1

.15

.2

.25

.3

.35

.4

.45

.5

.55

.6

.65

.7

.75

.8

.85

T (α

Randomized Phase II Cancer Clinical Trials with a Prospective Control 135

1

EN

32.26

19.92

14.96

27.18

17.43

35.42

21.46

44.15

25.43

49.86

28.72

53.34

29.74

56.42

32.58

60.12

33.35

60.23

33.63

60.29

33.29

59.39

32.54

58.63

31.03

51.59

28.41

47.78

25.91

40.92

22.45

33.51

62.83

0

EN

43.72

20.88

15.34

30.57

19.05

41.05

25.54

47.33

27.50

54.18

31.76

58.57

32.59

65.08

34.34

62.40

35.82

63.14

35.09

62.69

34.59

60.57

34.33

56.64

31.83

54.73

28.67

48.05

24.54

40.84

20.07

31.50

57.64

under

β−

values

.8532

.8504

.8506

.8503

.8516

.8501

.8507

.8516

.8510

.8521

.8500

.8507

.8527

.8507

.8516

.8501

.8509

.8504

.8530

.8503

.8524

.8504

.8510

Design

1

.8515

.8509

.8510

.8500

.8505

.8501

.8583

.8503

.8509

.8502

.1996

.1801

.1380

.1947

.1908

.1999

.1985

.1958

.1989

.1906

.1995

.1977

.1994

.1978

.1997

.1976

.1985

.1997

.1992

.1996

.1987

.1973

.1991

.1998

.1976

.1989

.1977

.1938

.1952

.1967

.1981

.1920

.1982

stopping

Optimal

)α

) ) ) ) ) ) ) ) ) ) ) ) ) ) ) ) ) ) ) ) ) ) ) ) ) ) ) ) ) ) ) ) )

early

,a

, 2

, 2

, 4 , 2

, 5 , 3 , 6 , 4 , 7

, 5 , 6 , 4 , 6 , 4

, 5 , 5 , 5 , 6 , 4 , 5 , 3 , 5 , 3 , 3 , 3

, 2 , 1 , 1 , 3 , 3

, 5 , 4

, 5 , 6

, 6

, 2 , 3 , 3 , 4 , 3 , 5 , 4 , 5 , 4 , 5 , 4 , 6 , 4 , 6 , 5 , 6 , 5 , 6 , 4 , 6 , 4 , 5 , 4 , 5 , 4 , 4 , 3 , 4 , 6

er

,b 1

2

, 2 , 2 1

1

2

1

2

1

1

2

1

1

1

1

1

1

1

1

w

, 0 , 0

, 0

, 0 , 0

, 0 , 0

, 0

, 0

, 0 , 0 , 0 , 0 , 0 , 0 , 0

,a 1

, −

, −

, − , −

, − , − , − , − , −

, − , − , − , − , −

, − , −

, −

lo

1

, 18 , 11

, 15

, 35 , 19

, 24 , 47

, 44

, 23

, 22 , 36 , 18 , 29 , 13 , 24 , 46

,n

, 22

, 19

, 20 , 10

, 37 , 14 , 40 , 22 , 38

, 19 , 40 , 24 , 39 , 24

, 19 , 31

, 36

( 31 ( 31

( 35

( 77 ( 51

( 59 ( 93 ( 57 ( 93 ( 48 ( 93 ( 47 ( 93 ( 54 ( 85 ( 53 ( 81 ( 44 ( 73 ( 38 ( 69 ( 38 ( 47 ( 76

and

(n

( 52

( 41

( 66 ( 30

( 76 ( 40 ( 85 ( 46 ( 92

er

upp

1

with

EN

32.45

20.50

15.18

28.55

16.33

36.94

21.46

50.92

32.14

60.47

32.80

62.26

32.76

68.93

37.35

74.22

39.67

71.62

42.24

64.01

39.05

67.01

37.50

67.89

35.15

58.27

30.89

48.87

29.58

46.34

23.00

36.38

65.80

) 1

0

=

designs

(γ

EN

45.84

21.42

15.96

32.79

20.69

42.14

25.54

49.37

32.16

60.82

33.43

60.49

34.01

69.32

36.72

74.30

39.29

72.65

42.22

69.76

38.51

68.94

37.27

66.77

32.68

56.18

30.99

50.12

29.70

40.53

19.62

32.58

58.68

β−

o-stage

cation

Design

1

.8509

.8572

.8664

.8500

.8673

.8505

.8583

.8511

.8519

.8506

.8524

.8500

.8507

.8502

.8511

.8504

.8501

.8500

.8522

.8501

.8501

.8501

.8512

.8525

.8512

.8502

.8501

.8506

.8504

.8506

.8566

.8506

.8503

tw

allo

.1978

.1818

.1445

.1924

.1961

.1912

.1985

.1995

.1967

.1996

.1999

.1997

.1983

.1981

.1993

.1996

.1998

.1993

.1999

.1992

.1997

.1995

.1988

.1999

.1994

.1994

.1961

.1999

.1968

.1998

.1974

.1985

.1996

optimal

Minimax

balanced

)α

)

)

) ) ) ) ) ) ) ) ) )

) ) ) ) ) ) ) ) ) ) ) ) ) ) ) ) ) ) ) ) )

and

,a

, 2

, 2 , 2 , 3 , 2

, 4 , 3

, 5

, 5 , 3 , 4 , 3 , 4 , 3 , 4 , 3 , 3 , 2 , 2 , 3

, 2 , 1 , 1

, 3 , 2 , 4 , 3

, 5 , 3 , 5 , 3 , 5 , 3

, 3

, 2 , 2 , 3 , 2 , 4 , 3 , 8 , 4 , 5 , 4 , 10 , 6

, 8

, 7

, 6 , 6

, 8

, 7

2

, 6 , 7 , 6 , 7 , 7 , 6 4 , 7 1 , 6

, 8 , 9 2 1 , 4 1 , 4 , 6 1

) and

,b 1

3

2

1

2

2

1

, 10

, − , 0 , 0 , − , − , − , − , 0 , 2 , 1 , 0

, 0 , 3

, 2

, 2

, 0 , 0

, 1

, 0 , 1

, − , − , 2 , 1 , 3 , 2

, −

, −

, 3

, − , −

, −

, −

85

,a 1

,.

1

, 22 , 19 , 12 , 25 , 10 , 30 , 10 , 43 , 32 , 60 , 32

, 70 , 42

, 37

, 36

, 28 , 49

, 29

, 14 , 29

, 50 , 23 , 68 , 34 , 74 , 38

, 52

, 64

, 65

, 22 , 41

, 29

, 42

Minimax

,n

(. 2

(n

( 51 ( 30 ( 30 ( 37 ( 30 ( 50 ( 30 ( 58 ( 34 ( 64 ( 37

( 78 ( 44

( 44

( 43

( 39 ( 66

( 33

( 30 ( 42

( 70 ( 40 ( 76 ( 43 ( 77 ( 44

( 78

( 76

( 73

( 36 ( 61

( 50

( 73

= )∗

x

7.18 β

p

.15

.2

.25

.25

.3

.3

.35

.35

.4

.4

.45

.45

.5

.5

.55

.55

.6

.6

.65

.65

.7

.7

.75

.75

.8

.8

.85

.85

.9

.9

.95

.95

.95

− , 1

y

able ∗

p

.05

.1

.15

.2

.25

.3

.35

.4

.45

.5

.55

.6

.65

.7

.75

.8

.85

T (α

136

Randomized Phase II Cancer Clinical Trials

1

EN

46.53

25.49

19.08

34.18

23.27

44.80

28.04

51.05

29.63

60.01

33.51

65.87

37.60

69.61

40.12

72.03

40.17

72.00

41.82

74.55

40.64

70.80

39.11

67.37

37.76

63.66

34.13

56.02

30.72

49.13

26.73

40.07

73.59

0

EN

54.60

28.89

22.02

41.01

28.90

52.02

31.43

64.90

38.58

68.77

40.71

73.58

41.45

78.39

45.01

81.94

44.78

84.35

45.08

81.26

43.97

79.61

42.92

74.18

41.52

66.81

37.13

60.75

31.00

52.91

26.67

39.86

70.06

under

β−

values

.9015

.9004

.9003

.9010

.9008

.9008

.9002

.9001

.9002

.9001

.9004

.9011

.9007

.9011

.9000

.9002

.9025

.9010

.9004

.9008

.9015

.9022

.9002

Design

1

.9000

.9002

.9026

.9001

.9003

.9005

.9014

.9003

.9005

.9001

.1841

.1780

.1725

.1895

.1995

.1929

.1876

.1989

.1993

.1994

.1990

.1996

.1990

.1996

.1924

.1996

.1999

.1992

.1993

.1940

.1998

.1996

.1982

.1999

.1976

.1994

.1990

.1999

.1957

.1992

.1963

.1926

.1998

stopping

Optimal

)α

)

)

)

)

)

)

)

)

)

) ) ) ) ) ) ) )

)

)

)

)

)

)

)

)

) )

)

)

, 6

, 6

, 7

, 8

, 8

, 7

, 8

, 7

)

)

) )

early

,a

, 2

, 3

, 4

, 6 , 4

, 4

, 4

, 5

, 5

, 5

, 5

, 5

, 6 , 6 , 5 , 6 , 4 , 6 , 5 , 4 , 4

, 3 , 2 , 1 , 3 , 7

, 4

, 6

, 6

, 6

, 6

, 7

, 6

, 6

, 2 , 4 , 3 , 4 , 3 , 51 , 4 1 , 5 1 , 5 1 , 5 2 , 5 1 , 5 1 , 5 1 , 4 , 6 , 4 , 5 , 4 , 4 , 3 , 4 , 5

er

,b 1

1

, 2 , 2 1

1

2

2

2

1

1

1

1

1

1

1

, 0 1 1

1

, 0

w

, 0 , 0

, 0

, 0

, 0

, 0 , 0

,a 1

, −

, −

, −

, − , − , − , − , − , − , − , − , − , − , − , − , − , − , − , − , − , −

, − , −

, −

lo

1

, 22 , 14

, 18

, 24

, 40

, 51

, 50

, 54

, 48

, 55

, 52

, 48

, 49

, 22

, 17 , 29 , 48

,n

, 38

, 27

, 35

, 34 , 14

, 20

, 28

, 31

, 30

, 25

, 26

, 29

, 21

, 21 , 37

, 28

( 54 ( 50

( 75

( 52

( 63

( 64

( 69

( 66

( 61

( 69 ( 102 ( 58 ( 93 ( 51 ( 87 ( 54 ( 64 ( 112

and

(n

( 70

( 57

( 73

( 92 ( 52 ( 107 ( 54 ( 104 ( 57 ( 118

( 124

( 122

( 116

( 121

( 111

er

upp

1

with

EN

42.57

25.73

19.08

39.24

21.59

45.81

26.98

66.78

33.04

82.07

38.59

78.53

41.72

80.89

52.12

88.97

49.95

94.03

47.28

93.05

44.23

87.77

43.00

82.04

47.28

74.96

35.06

68.11

30.56

59.94

29.33

41.72

87.43

) 1

0

designs

=

EN

60.83

28.76

22.02

41.22

30.77

56.25

32.83

68.05

37.83

82.09

39.54

81.75

46.79

82.46

52.25

87.62

50.98

94.19

50.84

93.19

46.12

87.68

49.42

79.83

47.61

76.21

37.11

62.24

31.28

59.72

28.09

41.71

87.01

(γ

β−

o-stage

Design

1

.9014

.9032

.9026

.9003

.9159

.9000

.9078

.9003

.9014

.9012

.9013

.9004

.9001

.9003

.9019

.9000

.9010

.9007

.9001

.9005

.9001

.9002

.9000

.9000

.9007

.9006

.9019

.9009

.9024

.9000

.9045

.9010

.9009

tw

cation

allo

.1967

.1786

.1725

.1955

.1907

.1994

.1987

.2000

.1787

.1993

.2000

.1998

.1996

.1999

.1984

.1998

.2000

.2000

.1999

.1998

.1993

.1989

.1972

.1998

.1999

.1999

.1948

.1998

.1979

.1996

.1853

.1999

.1993

optimal

Minimax

)α

)

)

)

) ) ) ) ) ) ) ) ) ) ) )

) ) ) ) ) ) ) ) )

) ) ) ) ) ) ) ) )

and

balanced

,a

, 2

, 5

, 5

, 2 , 1 , 2 , 4 , 3 , 3 , 4 , 4 , 4 , 3 , 5 , 4

, 4 , 5 , 4 , 5 , 4 , 5 , 4 , 5 , 4

, 4 , 5 , 4 , 4 , 4 , 3 , 3 , 3 , 3

,b 1

, 2

, 5 , 2 , 5 , 3

, 4

, 7 , 5

, 7

, 7

, 7

, 5

, 5

4

, 2 , 2 1 1 4 1 , 5 1 , 7 , 6 1 3 , 11

, 9

, 9

, 13

2

, 5 , 12 , 6

, 5 , 7

, 4 , 7 , 4

, 7

, 4 3 , 4 1 , 10 5 2

1

, 11

2

) and

, − , 0 , 0 , − , − , − , − , 0 , − , 4 , 0 , − , −

, 1 , 1

, 0 , 3 , 1

, 3

, − , 2 , 2 , 0

, −

, − , 3 , − , −

, − , 0

, −

9

,a 1

, 93

, 92

,.

1

, 13 , 23 , 14 , 30 , 14 , 36 , 16 , 66 , 28 , 82 , 33 , 76 , 39

, 47 , 73

, 23 , 59 , 23

, 86

, 65 , 52 , 82 , 49

, 44

, 38 , 85 , 35 , 65

, 26 , 52

, 24

Minimax

,n

(. 2

(n

( 65 ( 50 ( 50 ( 50 ( 50 ( 61 ( 50 ( 73 ( 50 ( 83 ( 50 ( 90 ( 52

( 50 ( 85

( 50 ( 64 ( 50

( 93

( 95 ( 54 ( 100 ( 55 ( 101 ( 55 ( 100 ( 55 ( 97 ( 53 ( 90

( 50 ( 75

( 51

= )∗

x

7.19 β

p

.15

.2

.25

.25

.3

.3

.35

.35

.4

.4

.45

.45

.5

.5

.55

.55

.6

.6

.65

.65

.7

.7

.75

.75

.8

.8

.85

.85

.9

.9

.95

.95

.95

− , 1

y

able ∗

p

.05

.1

.15

.2

.25

.3

.35

.4

.45

.5

.55

.6

.65

.7

.75

.8

.85

T (α

Randomized Phase II Cancer Clinical Trials with a Prospective Control 137

1

EN

80.61

46.04

94.91

52.52

61.99

63.54

35.08

76.91

41.97

88.56

49.36

50.05

28.68

61.00

34.46

75.01

42.79

111.04

0

stopping

EN

74.86

41.75

89.21

50.43

62.22

60.25

34.83

74.10

42.53

95.37

53.79

51.60

28.87

63.39

34.91

82.30

46.49

y

110.62

β

eriorit

−

Design

1

.8002

.8015

.8501

.8500

.9012

.9015

.8005

.8002

.8501

.8503

.9000

.9005

.8003

.8013

.8509

.8507

.9001

.9003

supa

.1000

.0996

.0991

.0991

.0999

.0997

.1499

.1484

.1496

.1462

.1494

.1498

.1997

.1981

.1997

.1998

.1957

.1934

andy

Optimal

)

)α )

)

)

)

) ) ) ) )

)

1

)

)

) ) )

)

)

)

,a

, 7

, 10 , 7 , 11 , 9 , 12 , 9 , 7 , 6 , 7 , 6 , 10 , 7 , 6 , 4 , 6

, 6 , 5 , 4 , 6 , 4 , 7 , 6

futilit

=

,b 1 , 9 , 7 , 10 , 7 , 11 , 8 , 7 , 5 , 9 , 6 , 8 1 1 1 1 , 5 1 , 5

a

(γ

, 1 , 0

, 1

, 0 , 0 , 0 , 0 , 0 , 0

, 0

, 0

,a 1

, 2

, 1

, − , − , − , −

, −

1

, 54 , 27

, 36

, 40 , 39 , 24 , 53 , 31 , 66

, 26

, 33

,n

, 68

, 79

, 31 , 30 , 15 , 38

, 56

with

(n ( 116 ( 63

( 84

( 94 ( 94 ( 55 ( 104 ( 62 ( 145 ( 79 ( 80 ( 44 ( 95 ( 52 ( 117 ( 75

cation

( 143

( 167

test

allo

1

EN

98.40

52.57

56.25

69.27

69.53

40.86

87.35

44.87

63.42

59.96

31.25

77.04

39.29

98.28

46.27

100.16

117.63

104.68

binomial

0

balanced

EN

for

98.39

49.50

54.75

72.14

68.27

40.01

88.46

45.23

63.72

59.70

30.03

77.05

40.15

98.31

48.43

103.74

125.01

107.55

and

, 1]

β−

designs

[0

1

.8025

.8006

.8500

.8500

.9000

.9003

.8001

.8013

.8507

.8506

.9010

.9024

.8003

.8000

.8501

.8513

.9003

.9002

∈

Design

p 0r

o-stage

.0997

.0999

.0980

.0992

.0997

.1000

.1495

.1500

.1496

.1479

.1499

.1497

.1997

.1998

.1993

.1999

.1982

.1987

tw

) ove

)

∗

)

β

Minimax

)α ) )

)

)

) )

)

)

, 10 , 7 , 11 ) , 6 ) )

, 8 ) )

) ) )

−

,a , 9 , 6

, 8

, 4 , 7 , 5

, 6 , 4 , 3 , 5 , 4 , 5 , 4

, 10

, 12 , 10 , 13

, 11 , 8 , 9 , 8 , 10 , 7 , 8 , 7 , 6 , 5 , 9 , 8

optimal

, 1

,b 1

, 12 1 1 1 , 10 2

1

, 1

2

, 5 2

∗

, 5 , 4

, 3 , 1

, 3 , 3

, 4 , 0

, − , − , − , 0 , −

, −

, −

, −

(α

,a 11 , 98

, 39 , 85

, 63 , 59

, 77 , 38 , 98

and

,n

, 48 , 86 , 41

, 101

, 103 , 65 , 54

, 36

, 20

, 37

of

n

( 101 ( 57

( 82

( 45 ( 96 ( 54

( 68 ( 63 ( 35 ( 78 ( 45 ( 101 ( 56

( 122 ( 67

( 78

( 121

( 148

trol

Minimax

con

( .15 .2 .15 .2 .15 .2 .15 .2 .15 .2 .15 .2 .15 .2 .15 .2 .15 .2

∗

strict

β

7.20

−

for

1

.8

.85

.9

.8

.85

.9

.8

.85

.9

∗

able

α .1

.15

.2

T values

138

Randomized Phase II Cancer Clinical Trials

7.2.1

Strict Control of Type I Error Rate and Power

The designs reported in Tables 7.11–7.19 are valid only when the response

rate of the control arm, p y, is accurately controlled. Now we consider a strict

control of type I error rate and power to maintain type I error rate and

power at the specified level regardless of the true p y value. To this end, we

control the type I error rate at p x = p y = 0 . 5 and calculate the power at

(p x , p y ) = ( 0 . 5 − / 2 , 0 . 5 + / 2 ) for given H 1 : p x − p y = . Table 7.20 lists minimax and optimal two-stage designs with both upper and lower stopping

values under various design settings of (α∗ , 1 − β∗ , ) when type I error rate and power are strictly controlled.

7.3

Discussions

While the number of randomized phase II trials is rapidly growing (Lee and

Feng, 2005), we largely lack efficient design and analysis methods for them.

This chapter proposes optimal and minimax designs for two-stage randomized

phase II trials using two-sample binomial test. Given a design setting, the

maximal sample size for the minimax two-stage design is usually smaller than

or equal to the sample size for the single-stage design as in single-arm trial de-

signs (Simon, 1989). The ratio of stage 1 sample size to the maximal size, n 1 /n,

for the minimax design is usually large, so that its operating characteristics

and the maximal sample size are similar to those of the single-stage design.

However, the ratio for the optimal design is usually small so that we can

terminate the trial early and minimize the expected sample size when the

experimental arm is inefficacious.

We have considered minimax and optimality criteria in this chapter. But

often these two criteria conflict with each other, so that the minimax design

may have an excessively large expected sample size under H 0 compared to the

optimal design, and the optimal design may have an excessively large maximal

sample size compared to the minimax design. In order to address this issue,

we may combine these two criteria to derive a compromise design; refer to

Jung, Carey, and Kim (2001) and Jung et al. (2004) for the single-arm design

case. We have focused on two-stage designs, but the methods can be easily

extended to designs with any number of stages.

A randomized phase II trial may look similar to a phase III trial in the

sense that both include a prospective control and carry out statistical tests

to compare between the control and an experimental arm. However, we do

not want a phase II trial to be more than an efficacy screening study, while a

phase III trial is to finalize scientific questions on an experimental regimen. As

a result, we want phase II trials to be as simple as possible. In order to keep

the sample size small and the study period short for a randomized phase II

Randomized Phase II Cancer Clinical Trials with a Prospective Control 139

trial, we use a relatively large one-sided α, such as 15% or 20% (rather than

the conventional two-sided α = 5% level), and a moderate power, such as 80%

or 85% (rather than 90%), and a short-term outcome variable as the primary

endpoint, such as tumor response or time to progression (rather than overall

survival). As shown in Tables 7.11–7.19 and 7.20, in most cases, the sample

sizes for 10% α or 90% power are too big for a phase II trial.

It is claimed that a two-arm randomized phase II trial requires about

four times the sample size of a single-arm phase II trial. This can be eas-

ily proved for single-stage trials by using normal approximation to binomial

distributions. For a single-arm phase II trial with m patients, we will reject

H 0 : p x = p 0 (or accept the experimental therapy x) if

ˆ p x − p 0

√

> z 1− α,

p 0 ( 1 − p 0 )/m

where z 1− α denotes the 100 ( 1 − α) percentile of the standard normal distribution. Using the standard procedure for sample size calculation, it is easy to

show that, for power 1 − β with respect to H 1 : p x = p 0 + using one-sided α, the required sample size is

m = p 0 ( 1 − p 0 )(z 1− α + z 1− β) 2 .

2

For a randomized trial with n patients per arm, we will reject H 0 : p x =

p y (= p 0 ) (or accept the experimental arm x) if

ˆ p x − ˆ p y

√

> z 1− α.

2 p 0 ( 1 − p 0 )/n

Similarly, we can show that, for power 1 − β with respect to H 1 : p x − p y =

using one-sided α, the required sample size per arm per arm is

n = 2 p 0 ( 1 − p 0 )(z 1− α + z 1− β) 2 .

2

So, the total sample size N for a randomized trial is

N = 2 n = 4 p 0 ( 1 − p 0 )(z 1− α + z 1− β) 2 = 4 m.

2

We also observe this by comparing the design tables in Chapter 2 and this

chapter, for example, Table 2.4 and Table 7.3, especially for the designs with

response rates around 50% for which the normal approximation holds well.

The sample size of a typical single-arm phase II trial is about 50. So, if we

want to design a two-arm randomized phase II trial with a total sample size

of about 100, then we will have to increase α and lower the power. Otherwise,

the required sample size for a randomized phase II trial will be around 200,

which is too large for a phase II trial.

140

Randomized Phase II Cancer Clinical Trials

References

Cannistra, S.A. (2009). Phase II trials in Journal of Clinical Oncology. Journal

of Clinical Oncology, 27 (19), 3073–3076.

Fisher, R.A. (1935). The logic of inductive inference (with discussion). Journal

of Royal Statistical Society, 98, 39–82.

Gan, H.K., Grothey, A., Pond, G.P., Moore, M.J., Siu, L.L., and Sargent, D.J.

(2010). Randomized phase II trials: Inevitable or inadvisable? Journal

of Clinical Oncology, 28 (15), 2641–2647.

Jung, S.H. (2008). Randomized phase II trials with a prospective control.

Statistics in Medicine, 27, 568–583.

Jung S.H., Carey, M., and Kim, K.M. (2001). Graphical search for two-stage

designs for phase II clinical trials. Control Clinical Trials, 22, 367–372.

Jung, S.H., Lee, T.Y., Kim, K.M., and George, S. (2004). Admissible two-

stage designs for phase II cancer clinical trials. Statistics in Medicine,

23, 561–569.

Lee, J.J. and Feng, L. (2005). Randomized phase II designs in cancer clinical

trials: Current status and future directions. Journal of Clinical Oncology,

23 (19), 4450–4457.

Rubinstein, L.V., Korn, E.L., Freidlin, B., Hunsberger, S., Ivy, S.P., and

Smith, M.A. (2005). Design issues of randomized phase II trials and

a proposal for phase II screening trials. Journal of Clinical Oncology,

23 (28), 7199–7206.

Simon, R. (1989). Optimal two-stage designs for phase II clinical trials. Con-

trolled Clinical Trials, 10, 1–10.

Steinberg, S.M. and Venzon, D.J. (2002). Early selection in a randomized

phase II clinical trial. Statistics in Medicine, 21, 1711–1726.

Thall, P.F., Simon, R., and Ellenberg, S.S. (1989). A two-stage design for

choosing among several experimental treatments and a control in clinical

trials. Biometrics, 45, 537–547.





Chapter 8

Randomized Phase II Cancer Clinical

Trials with a Prospective Control on

Binary Endpoints (II): Fisher’s

Exact Test

In Chapter 7, we have considered randomized phase II trials for comparing

the efficacy of an experimental therapy (arm x) with that of a prospective

control (arm y) in terms of a binary endpoint, such as tumor response, using

a two-sample binomial test. Let p x and p y denote the true response rates for

arms x and y, respectively. We want to test whether the experimental arm has

a higher response rate than the control or not, that is, H 0 : p x ≤ p y against Ha : p x > p y. The null distribution of the binomial test that was discussed in Chapter 7 depends on the common response probability p x = p y (= p 0 ).

Consequently, if the true response probabilities are different from the specified

ones, the testing based on binomial distributions may not maintain the type

I error rate close to the specified value. In order to avoid this issue, we have

considered controlling the type I error rate over the whole range of p x = p y

values, that is, [0 , 1]. This conservative control of the type I error rate is

equivalent to controlling the type I error rate at p x = p y = 1 / 2. This results in an overly strong conservativeness when the true response probability is very

different from 50%.

An alternative approach to avoiding specification of the nuisance parameter

p 0 is to condition the null distribution of the two-sample binomial test on a

sufficient statistic of p 0. This results in Fisher’s (1935) exact test, which is

derived by conditioning on the total number of responders from two arms. In

this chapter, we investigate single-stage and two-stage randomized phase II

trial designs using Fisher’s exact test. Using some example designs, we show

that Fisher’s exact test accurately controls the type I error rate over a wide

range of p 0 values, and is more powerful than the binomial test of Chapter 7

if the true response rates p x and p y are different from 50%. If we can project

the true response rates accurately at the design stage, we can identify efficient

designs by adopting Simon’s (1989) optimal and minimax design concepts that

were proposed for single-arm phase II trials.

141

142

Randomized Phase II Cancer Clinical Trials

8.1

Single-Stage Design

As was stated in the previous chapter, if patient accrual is fast or it takes long

(say, longer than 6 months) for response assessment of each patient, we may

consider using a single-stage design. Suppose that n patients are randomized

to each arm, and let X and Y denote the number of responders in arms x

(experimental) and y (control), respectively. Let qk = 1− pk for arm k(= x , y ).

Then the frequencies (and response probabilities in the parentheses) can be

summarized as in Table 8.1.

At the design stage, n is determined. Fisher’s exact test is based on the

conditional distribution of X given the total number of responders Z = X + Y

with a probability mass function



n

n

θx

f (x| z, θ) =

x

z− x





m+

n

n

θi

i = m−

i

z− i

for m− ≤ x ≤ m+, where m− = max ( 0 , z − n), m+ = min (z, n), and θ =





p

m+

n

n

x q y /( p y q x ) denotes the odds ratio. It is easy to show that

=

i = m−

i

z− i



2 n .

z Suppose that we want to control the type I error rate below α∗. Then, given

X + Y = z, we reject H 0 : p x = p y = p 0 (that is, θ = 1) in favor of Ha : p x > p y (that is, θ > 1) if X − Y ≥ a, where a is the smallest integer satisfying m+



α(z) ≡ P (X− Y ≥ a| z, H 0 ) = P ( 2 X ≥ z + a| z, H 0 ) =

f (x| z, θ = 1 ) ≤ α∗ ,

x= (z+ a)/ 2

where c is the round-up integer of c. Hence, the critical value a depends on

the total number of responders z. However, the conditional type I error rate

α(z) does not depend of the common response rate p x = p y under H 0. Under Ha : θ = θa(> 1 ), the conditional power on X + Y = z is given by m+



1 − β(z) ≡ P (X − Y ≥ a| z, Ha) =

f (x| z, θa).

x= (z+ a)/ 2

Table 8.1

Frequencies (and response probabilities in the parentheses)

of a single-stage randomized phase II trial

Arm x

Arm y

Total

Response

Yes

x ( p x)

y ( p y)

z

No

n − x ( q x)

n − y ( q y)

2 n − z

Total

n

n

Randomized Phase II Cancer Clinical Trials

143

We propose to choose n so that the marginal power is no smaller than a

specified power level 1 − β∗, that is,

2 n



E{1 − β(Z)} =

{1 − β(z)} g(z) ≥ 1 − β∗

z=0

where g(z) is the probability mass function of Z = X + Y under Ha : p x > p y which is given by

m





+

n

n

g(z) =

px

pz− x

x

x qn− x

x

z − x

y

qn− z+ x

y

x= m−

for z = 0 , 1 , . . . , 2 n. Since the conditional type I error rate is controlled below α∗ for any z value, the marginal type I error rate

2 n



E{ α(Z)} =

α(z)g 0 (z)

z=0

is controlled below α∗ too. Here, g 0 (z) is the probability mass function g(z) under H 0 : p x = p y = p 0, that is,

m





+

n

n

g 0 (z) = pzq 2 n− z

.

0 0

x

z − x

x= m−

Given the type I error rate α∗, power 1 − β∗ and a specific alternative hypoth-

esis Ha : ( p x , p y ), we find a sample size n as follows.

8.1.1

Algorithm for Single-Stage Design

1. For n = 1 , 2 , . . . ,

a. For z = 0 , 1 , . . . , 2 n, find the smallest integer a = a(z) such that α(z) = P (X − Y ≥ a| z, θ = 1 ) ≤ α∗

and calculate the conditional power for the chosen a = a(z)

1 − β(z) = P (X − Y ≥ a| z, θa).

b. Calculate the marginal power 1 − β = E{1 − β(Z)}.

2. Find the smallest integer n such that 1 − β ≥ 1 − β∗.

Fisher’s test which is based on the conditional distribution of X given Z =

X + Y , is valid under θ = 1 (that is, controls the type I error rate exactly), and its conditional power depends only on the odds ratio θa under Ha. However,

144

Randomized Phase II Cancer Clinical Trials

the marginal power, and hence the sample size n, depends on ( p x , p y ), so that we need to specify ( p x , p y ) at the design stage. If ( p x , p y ) are misspecified, the trial may be over- or underpowered, but the type I error rate in data analysis

will always be appropriately controlled. Tables 8.2 to 8.10 list single-stage

designs under various design settings.

8.2

Two-Stage Design

For ethical and economical reasons, clinical trials are often conducted using

multiple stages. Phase II trials usually enter a small number of patients, so

that practically the number of stages is two at the most.

Suppose that nl(l = 1 , 2 ) patients are randomized to each arm during stage

l(= 1 , 2 ). Let n 1 + n 2 = n denote the maximal sample size for each arm, and let Xl and Yl denote the number of responders during stage l in arms x and

y, respectively ( X = X 1 + X 2 and Y = Y 1 + Y 2).

We choose nl at the design stage. Note that X 1 and X 2 are independent,

and, given Xl + Yl = zl, Xl has the conditional probability mass function nl

nl

θxl

f

xl

zl − xl





l (xl | zl , θ ) = ml+

nl

nl

θi

i = ml−

i

zl − i

for ml− ≤ xl ≤ ml+, where ml− = max ( 0 , zl − nl) and ml+ = min (zl, nl).

8.2.1

Two-Stage Designs with a Futility Interim Test Only

At first, we consider designs with the same features as popular two-stage phase

II trial designs with an early stopping rule when the experimental therapy has

a low efficacy, that is, an interim futility test. The rejection values (a 1 , a) are

chosen conditional on z 1 and z 2 as follows:

Stage 1: Randomize n 1 patients to each arm, and observe X 1 = x 1 and Y 1 = y 1.

a. Given z 1 (= x 1 + y 1 ), find a stopping value a 1 = a 1 (z 1 ).

b. If x 1 − y 1 ≥ a 1, proceed to stage 2. Otherwise, stop the trial.

Stage 2: Randomize n 2 patients to each arm, and observe x 2 and y 2 (z 2 =

x 2 + y 2 ).

a. Given (z 1 , z 2 ), find a rejection value a = a(z 1 , z 2 ).

b. Accept the experimental arm if x − y ≥ a, where x = x 1 + x 2 and y = y 1 + y 2.

Now, we discuss how to choose the rejection values (a 1 , a) conditioning on

(z 1 , z 2 ).

Randomized Phase II Cancer Clinical Trials

145

EN

72.58

41.44

35.39

50.90

33.04

59.45

37.59

66.89

41.01

73.44

43.90

76.56

45.02

81.35

47.04

82.33

47.28

82.26

46.89

81.15

44.76

76.23

43.38

72.89

40.34

66.16

36.56

58.32

31.13

49.14

30.66

37.52

68.74

Design

β− .8003 .8008 .8861 .8001 .8028 .8005 .8020 .8004 .8009 .8010 .8007 .8000 .8004 .8000 .8003 .8000 .8004 .8000 .8007 .8007 .8010 .8001 .8009 .8005 .8016 .8005 .8028 .8010 .8683 .8005 .8005

1

0.8004

0.8007

with

o-Stage

test

Tw

α

.0538

.0354

.0312

.0615

.0543

.0709

.0623

.0749

.0683

.0780

.0720

.0780

.0713

.0813

.0770

.0788

.0767

.0791

.0769

.0785

.0756

.0810

.0804

.0828

.0717

.0783

.0728

.0751

.0666

.0724

.0676

.0664

.0724

exact

)

) ) ) ) ) ) ) ) ) ) ) ) ) ) ) ) ) ) ) ) ) ) ) ) ) ) ) ) ) ) ) ) )

1

, 31

, 34

, 34

, 34

, 34

, 34

, 34

, 28

, 11 , 18 , 7 , 13 , 24

Optimal

, n

, 28 , 19 , 13 , 22 , 11 , 24 , 16 , 29 , 17

, 16

, 20

, 18

, 19

, 18

, 20

, 16

, 17 , 26 , 12 , 24

( 45

( n

( 99 ( 53 ( 45 ( 70 ( 45 ( 85 ( 52 ( 96 ( 58 ( 107 ( 64 ( 111 ( 64 ( 120 ( 69 ( 122 ( 69 ( 122 ( 69 ( 120 ( 64 ( 111 ( 64 ( 109 ( 58 ( 98 ( 54 ( 85 ( 45 ( 72

( 54 ( 101

Fisher’s

for

EN

76.35

41.65

42.91

52.30

33.04

79.54

39.87

70.84

43.87

81.68

47.89

80.22

48.37

93.31

56.87

91.08

52.12

91.06

56.83

93.25

48.25

80.04

47.71

81.48

43.52

70.46

39.39

79.53

31.13

51.26

36.75

39.63

74.60

designs

Design

β−1 .8002 .8008 .8716 .8002 .8028 .8006 .8004 .8000 .8001 .8001 .8005 .8004 .8003 .8000 .8000 .8001 .8007 .8001 .8000 .8000 .8003 .8004 .8005 .8001 .8001 .8000 .8004 .8006 .8028 .8002 .8716 .8008 .8002

o-stage

o-Stage

tw

Tw

α

.0507

.0337

.0274

.0587

.0543

.0668

.0612

.0733

.0669

.0764

.0696

.0759

.0693

.0768

.0718

.0757

.0698

.0782

.0685

.0788

.0816

.0774

.0814

.0836

.0723

.0743

.0678

.0734

.0666

.0710

.0637

.0648

.0704

)

) )

) ) ) ) ) ) ) ) ) ) ) ) ) ) ) ) ) ) ) ) ) ) ) ) ) ) )

) )

optimal

)

1

)

, 49 , 23 , 1 , 30 , 11 , 79 , 26 , 46 , 28 , 60 , 34 , 52 , 34 , 73 , 46 , 67 , 34 , 67 , 46 , 73 , 34 , 52 , 34 , 60 , 28 , 46 , 26 , 79 , 11 , 30 , 1 , 23 , 49

Minimax

, n

and

( 45

( n

( 95 ( 52 ( 45 ( 68 ( 45 ( 80 ( 50 ( 91 ( 56 ( 100 ( 59 ( 104 ( 60 ( 111 ( 66 ( 112 ( 67 ( 112 ( 66 ( 111 ( 60 ( 104 ( 59 ( 100 ( 56 ( 91 ( 50 ( 80 ( 45 ( 68

( 52 ( 95

β−

minimax

1

.8021

.8033

.9261

.8022

.8545

.8020

.8026

.8021

.8071

.8025

.8033

.8014

.8023

.8013

.8001

.8033

.8066

.8033

.8001

.8013

.8023

.8014

.8033

.8025

.8071

.8021

.8026

.8020

.8545

.8022

.9261

.8033

.8021

Design

and

α

.0500

.0318

.0299

.0563

.0564

.0670

.0636

.0709

.0679

.0768

.0701

.0777

.0700

.0769

.0704

.0762

.0683

.0792

.0685

.0793

.0654

.0737

.0825

.0830

.0757

.0723

.0649

.0734

.0685

.0712

.0671

.0659

.0707

designs,

Single-Stage

n

95

54

50

68

50

81

50

91

57

100

59

106

61

111

66

112

67

112

66

111

61

106

59

100

57

91

50

81

50

68

50

54

95

) 8 ,.

θ

3.353

4.750

6.333

3.000

3.857

2.429

3.051

2.154

2.667

2.000

2.455

1.909

2.333

1.857

2.270

1.833

2.250

1.833

2.270

1.857

2.333

1.909

2.455

2.000

2.667

2.154

3.051

2.429

3.857

3.000

6.333

4.750

3.353

Single-stage

(. 1= )∗ x p .15 .2 .25 .25 .3 .3 .35 .35 .4 .4 .45 .45 .5 .5 .55 .55 .6 .6 .65 .65 .7 .7 .75 .75 .8 .8 .85 .85 .9 .9 .95 .95 .95

8.2 β− , 1 y

able ∗

p

.05

.1

.15

.2

.25

.3

.35

.4

.45

.5

.55

.6

.65

.7

.75

.8

.85

T (α

146

Randomized Phase II Cancer Clinical Trials

EN

83.69

47.03

31.90

58.94

37.97

70.07

43.24

79.21

47.79

85.93

51.60

90.87

54.02

94.64

54.81

98.06

54.90

97.99

54.67

94.44

53.72

90.52

51.13

85.41

47.07

78.38

42.27

68.92

36.40

57.21

28.68

43.35

79.89

Design

β− .8502 .8505 .8505 .8506 .8512 .8507 .8512 .8505 .8509 .8503 .8506 .8500 .8501 .8501 .8509 .8501 .8504 .8501 .8509 .8501 .8501 .8500 .8506 .8503 .8509 .8501 .8512 .8507 .8507 .8506 .8529 .8502 .8501

1

with

o-Stage

α

test

Tw

.0570

.0396

.0261

.0633

.0568

.0715

.0657

.0760

.0709

.0782

.0730

.0799

.0756

.0830

.0740

.0821

.0772

.0797

.0792

.0834

.0786

.0855

.0734

.0793

.0767

.0818

.0714

.0785

.0724

.0757

.0660

.0689

.0743

)

)

)

)

)

)

)

)

)

)

)

)

)

)

exact

)

) ) ) )

)

)

)

)

)

)

)

)

)

)

)

) ) ) )

1

, 36

, 30

, 35

, 39

, 41

, 44

, 42

, 42

, 44

, 41

, 39

, 32

, 30

, 25 , 10 , 17 , 32

Optimal

, n

, 21 , 13 , 25 , 17

, 19

, 20

, 22

, 23

, 24

, 23

, 24

, 23

, 22

, 20

, 19

, 13

( n

( 114 ( 61 ( 40 ( 82 ( 51 ( 100 ( 60 ( 114 ( 68 ( 124 ( 74 ( 132 ( 78 ( 137 ( 79 ( 145 ( 80 ( 145 ( 79 ( 137 ( 78 ( 132 ( 74 ( 124 ( 68 ( 116 ( 60 ( 100 ( 53 ( 82 ( 41 ( 62 ( 116

Fisher’s

for

EN

86.67

48.09

33.29

61.28

39.19

80.92

44.12

86.52

50.82

92.66

53.34

101.53

58.54

96.59

58.15

108.20

58.98

108.18

58.08

96.47

58.41

101.41

53.03

92.40

50.48

86.19

43.44

80.61

38.23

60.25

32.08

46.13

84.60

Design

designs

β−1 .8504 .8502 .8501 .8501 .8508 .8501 .8503 .8500 .8502 .8503 .8503 .8501 .8505 .8502 .8504 .8502 .8504 .8502 .8504 .8502 .8505 .8501 .8503 .8503 .8502 .8500 .8503 .8501 .8508 .8501 .8501 .8502 .8504

o-stage

o-Stage

tw

Tw

α

.0549

.0376

.0251

.0613

.0549

.0705

.0650

.0748

.0685

.0768

.0724

.0770

.0728

.0813

.0719

.0769

.0756

.0773

.0783

.0821

.0784

.0874

.0728

.0790

.0729

.0810

.0705

.0753

.0720

.0740

.0641

.0686

.0731

)

) ) ) ) ) ) ) ) ) ) ) ) ) ) ) ) ) ) ) ) ) ) ) ) ) ) ) ) ) ) ) ) )

optimal

1

, 53

, 62

, 64

, 78

, 60

, 80

, 80

, 60

, 78

, 64

, 62

, 53

Minimax

, n

, 28 , 23 , 37 , 23 , 65 , 25

, 34

, 31

, 41

, 39

, 41

, 39

, 41

, 31

, 34

, 25 , 65 , 23 , 37 , 23 , 28

and

( n

( 110 ( 60 ( 39 ( 79 ( 50 ( 94 ( 58 ( 107 ( 64 ( 117 ( 71 ( 122 ( 73 ( 128 ( 74 ( 133 ( 74 ( 133 ( 74 ( 128 ( 73 ( 122 ( 71 ( 117 ( 64 ( 107 ( 58 ( 94 ( 50 ( 79 ( 39 ( 60 ( 110

β−

minimax

1

.8508

.8547

.8574

.8507

.8545

.8534

.8551

.8520

.8524

.8526

.8531

.8518

.8537

.8527

.8559

.8530

.8546

.8529

.8559

.8527

.8537

.8518

.8531

.8526

.8524

.8520

.8551

.8534

.8545

.8507

.8574

.8547

.8508

Design

and

α

.0544

.0363

.0226

.0606

.0564

.0707

.0648

.0736

.0672

.0776

.0728

.0768

.0696

.0815

.0720

.0761

.0768

.0781

.0800

.0784

.0796

.0859

.0757

.0814

.0679

.0786

.0724

.0732

.0685

.0739

.0647

.0661

.0700

designs,

Single-Stage

n

110

62

40

79

50

95

58

107

64

118

71

122

73

132

74

133

74

133

74

132

73

122

71

118

64

107

58

95

50

79

40

62

110

) 85 ,. θ 3.353 4.750 6.333 3.000 3.857 2.429 3.051 2.154 2.667 2.000 2.455 1.909 2.333 1.857 2.270 1.833 2.250 1.833 2.270 1.857 2.333 1.909 2.455 2.000 2.667 2.154 3.051 2.429 3.857 3.000 6.333 4.750 3.353

Single-stage

(. 1= )∗ x p .15 .2 .25 .25 .3 .3 .35 .35 .4 .4 .45 .45 .5 .5 .55 .55 .6 .6 .65 .65 .7 .7 .75 .75 .8 .8 .85 .85 .9 .9 .95 .95 .95

8.3 β− , 1 y

able ∗

p

.05

.1

.15

.2

.25

.3

.35

.4

.45

.5

.55

.6

.65

.7

.75

.8

.85

T (α

Randomized Phase II Cancer Clinical Trials

147

EN

99.20

55.34

42.35

70.55

44.90

83.89

52.10

95.13

57.88

103.66

61.32

110.60

65.76

115.00

67.28

118.88

67.40

118.81

67.12

114.81

65.44

110.24

60.81

103.17

57.15

94.37

50.90

82.79

43.31

68.80

36.89

51.83

95.49

Design

β− .9002 .9001 .9279 .9002 .9002 .9003 .9002 .9001 .9009 .9001 .9001 .9000 .9001 .9002 .9003 .9001 .9002 .9001 .9003 .9002 .9001 .9000 .9001 .9001 .9009 .9001 .9002 .9003 .9002 .9002 .9061 .9002 .9002

1

with

o-Stage

Tw

α

test

.0611

.0450

.0373

.0665

.0587

.0745

.0682

.0779

.0724

.0794

.0752

.0820

.0788

.0838

.0771

.0827

.0761

.0806

.0781

.0847

.0765

.0863

.0792

.0795

.0803

.0826

.0751

.0805

.0703

.0763

.0702

.0712

.0755

)

) ) ) ) ) ) ) ) ) ) ) ) ) ) ) ) ) ) ) ) ) ) ) ) ) ) ) ) ) ) ) ) )

exact

1

, 7

, 44

Optimal

, 40

, 46

, 53

, 52

, 59

, 57

, 57

, 59

, 52

, 53

, 46

, 40

, n

, 46 , 24 , 14 , 32 , 20

, 21

, 26

, 27

, 29

, 29

, 31

, 29

, 29

, 27

, 26

, 21

, 20 , 32

, 18

( n

( 135 ( 73 ( 55 ( 98 ( 61 ( 118 ( 74 ( 135 ( 82 ( 146 ( 88 ( 160 ( 95 ( 163 ( 98 ( 172 ( 97 ( 172 ( 98 ( 163 ( 95 ( 160 ( 88 ( 146 ( 82 ( 135 ( 74 ( 118 ( 61 ( 98 ( 55 ( 76 ( 136

Fisher’s

for

EN

105.49

59.84

52.44

76.01

45.93

90.37

54.28

99.69

66.60

109.85

66.93

125.87

70.32

118.01

72.56

133.98

74.31

133.96

72.49

117.89

70.17

125.76

66.74

109.58

66.40

99.25

53.69

89.84

44.89

75.23

44.88

58.51

103.70

Design

β

designs

−1 .9000 .9002 .9114 .9001 .9013 .9001 .9002 .9000 .9002 .9002 .9000 .9000 .9002 .9000 .9001 .9001 .9000 .9001 .9001 .9001 .9002 .9001 .9000 .9002 .9002 .9000 .9002 .9001 .9013 .9001 .9114 .9002 .9000

o-stage

o-Stage

tw

Tw

α

.0595

.0412

.0335

.0649

.0569

.0726

.0656

.0762

.0692

.0782

.0720

.0793

.0776

.0818

.0743

.0786

.0739

.0790

.0762

.0834

.0756

.0883

.0719

.0784

.0807

.0820

.0721

.0798

.0687

.0750

.0709

.0700

.0740

)

) )

)

)

)

)

) ) ) ) ) ) ) ) )

) ) )

)

) ) )

) ) ) ) ) ) ) ) ) ) )

optimal

1

, 72

, 1

, 64

, 66

, 76

, 78

, 78

, 76

, 66

, 64

, 1

, 72

Minimax

, n

, 43

, 54 , 27

, 35

, 54

, 50 , 102 , 48

, 52 , 106 , 56 , 106 , 52

, 48 , 102 , 50

, 54

, 35

, 27 , 54

, 43

( 55

( 55

and

( n

( 130 ( 71

( 93 ( 59 ( 112 ( 69 ( 128 ( 77 ( 139 ( 81 ( 147 ( 89 ( 153 ( 90 ( 159 ( 90 ( 159 ( 90 ( 153 ( 89 ( 147 ( 81 ( 139 ( 77 ( 128 ( 69 ( 112 ( 59 ( 93

( 71 ( 130

β−

minimax

1

.9005

.9036

.9549

.9007

.9037

.9001

.9029

.9012

.9002

.9015

.9009

.9007

.9029

.9016

.9027

.9011

.9015

.9010

.9027

.9016

.9029

.9007

.9009

.9015

.9002

.9012

.9029

.9001

.9037

.9007

.9549

.9036

.9005

Design

and

α

.0596

.0412

.0352

.0650

.0525

.0705

.0643

.0754

.0689

.0768

.0709

.0789

.0769

.0835

.0736

.0783

.0744

.0794

.0772

.0798

.0771

.0888

.0697

.0803

.0809

.0827

.0686

.0788

.0687

.0748

.0656

.0707

.0742

designs,

Single-Stage

n

130

72

60

93

60

112

69

128

77

140

81

147

89

158

90

159

90

159

90

158

89

147

81

140

77

128

69

112

60

93

60

72

130

) 9 ,.

θ

3.353

4.750

6.333

3.000

3.857

2.429

3.051

2.154

2.667

2.000

2.455

1.909

2.333

1.857

2.270

1.833

2.250

1.833

2.270

1.857

2.333

1.909

2.455

2.000

2.667

2.154

3.051

2.429

3.857

3.000

6.333

4.750

3.353

Single-stage

(. 1= )∗ x p .15 .2 .25 .25 .3 .3 .35 .35 .4 .4 .45 .45 .5 .5 .55 .55 .6 .6 .65 .65 .7 .7 .75 .75 .8 .8 .85 .85 .9 .9 .95 .95 .95

8.4 β− , 1 y

able ∗

p

.05

.1

.15

.2

.25

.3

.35

.4

.45

.5

.55

.6

.65

.7

.75

.8

.85

T (α

148

Randomized Phase II Cancer Clinical Trials

EN

60.83

35.11

23.96

42.80

28.03

49.48

30.99

56.17

34.81

60.21

36.10

65.02

37.82

66.78

39.43

67.36

39.56

67.32

39.33

66.63

37.62

64.87

35.75

59.83

34.13

55.56

30.12

48.57

26.45

41.30

21.32

32.23

57.67

Design

β− .8008 .8033 .8014 .8016 .8024 .8009 .8016 .8003 .8019 .8006 .8003 .8004 .8014 .8002 .8012 .8000 .8006 .8000 .8012 .8002 .8014 .8010 .8003 .8006 .8011 .8006 .8024 .8009 .8004 .8016 .8022 .8007 .8011

1

with

o-Stage

test

Tw

α

.0836

.0620

.0448

.0925

.0800

.1060

.0925

.1133

.1061

.1155

.1053

.1210

.1113

.1186

.1168

.1205

.1147

.1234

.1148

.1235

.1126

.1203

.1221

.1193

.1145

.1213

.1060

.1139

.1075

.1110

.0949

.1041

.1098

exact

)

) ) ) ) ) ) ) ) ) ) ) ) ) ) ) ) ) ) ) ) ) ) ) ) ) ) ) )

)

) )

1

)

)

. 22

, 9

, 7

Optimal

, n

, 26 , 17 , 11 , 19 , 12

, 14 , 26 , 14 , 30 , 17 , 27 , 19 , 32 , 19 , 35 , 18 , 35 , 19 , 32 , 19 , 26 , 17 , 30 , 12 , 23 , 12 , 22

, 17

, 11 , 22

( n

( 81 ( 44 ( 29 ( 58 ( 37 ( 69 ( 42 ( 79 ( 49 ( 84 ( 50 ( 95 ( 52 ( 95 ( 55 ( 94 ( 56 ( 94 ( 55 ( 95 ( 52 ( 96 ( 50 ( 84 ( 50 ( 81 ( 43 ( 69 ( 38 ( 59 ( 30 ( 46 ( 83

Fisher’s

for

EN

63.00

35.11

23.96

43.46

28.41

52.42

32.01

59.74

36.19

61.35

38.25

75.76

38.88

76.73

39.62

74.05

39.95

74.03

39.53

76.69

38.77

75.70

38.09

61.08

35.87

59.46

31.48

51.98

27.53

42.52

21.76

32.81

61.38

designs

Design

β−1 .8001 .8033 .8014 .8003 .8009 .8004 .8010 .8001 .8007 .8005 .8005 .8000 .8007 .8000 .8016 .8004 .8017 .8004 .8016 .8000 .8007 .8000 .8005 .8005 .8007 .8001 .8010 .8004 .8009 .8003 .8014 .8033 .8001

o-stage

o-Stage

tw

Tw

α

.0823

.0620

.0448

.0896

.0783

.1036

.0919

.1097

.1016

.1147

.1007

.1115

.1100

.1153

.1169

.1216

.1150

.1252

.1151

.1260

.1147

.1234

.1240

.1134

.1163

.1214

.1004

.1083

.1068

.1099

.0919

.1036

.1071

)

) ) ) ) ) ) ) ) ) ) ) ) ) ) ) ) ) ) ) ) ) ) ) ) ) ) ) ) ) ) ) ) )

optimal

1

, 40 , 17 , 11 , 25 , 16 , 36 , 19 , 42 , 23 , 37 , 27 , 65 , 26 , 66 , 21 , 59 , 22 , 59 , 21 , 66 , 26 , 65 , 27 , 37 , 23 , 42 , 19 , 36 , 16 , 25 , 11 , 17 , 40

Minimax

, n

and

( n

( 78 ( 44 ( 29 ( 56 ( 36 ( 65 ( 41 ( 74 ( 46 ( 81 ( 47 ( 85 ( 49 ( 86 ( 54 ( 87 ( 54 ( 87 ( 54 ( 86 ( 49 ( 85 ( 47 ( 81 ( 46 ( 74 ( 41 ( 65 ( 36 ( 56 ( 29 ( 44 ( 78

β−

minimax

1

.8005

.8075

.8109

.8033

.8016

.8023

.8025

.8054

.8074

.8022

.8056

.8005

.8015

.8006

.8026

.8032

.8013

.8032

.8026

.8006

.8015

.8005

.8056

.8022

.8074

.8054

.8025

.8023

.8016

.8033

.8109

.8075

.8005

Design

and

α

.0827

.0631

.0450

.0884

.0747

.1036

.0879

.1076

.0953

.1149

.0986

.1112

.1121

.1155

.1009

.1228

.1015

.1265

.1043

.1263

.1033

.1237

.1114

.1173

.1208

.1150

.1020

.1088

.1023

.1098

.0929

.0948

.1065

designs,

Single-Stage

n

79

45

29

56

36

65

41

74

46

83

47

85

53

86

54

87

54

87

54

86

53

85

47

83

46

74

41

65

36

56

29

45

79

) 8 ,.

θ

3.353

4.750

6.333

3.000

3.857

2.429

3.051

2.154

2.667

2.000

2.455

1.909

2.333

1.857

2.270

1.833

2.250

1.833

2.270

1.857

2.333

1.909

2.455

2.000

2.667

2.154

3.051

2.429

3.857

3.000

6.333

4.750

3.353

Single-stage

(. 15= )∗ x p .15 .2 .25 .25 .3 .3 .35 .35 .4 .4 .45 .45 .5 .5 .55 .55 .6 .6 .65 .65 .7 .7 .75 .75 .8 .8 .85 .85 .9 .9 .95 .95 .95

8.5 β− , 1 y

able ∗

p

.05

.1

.15

.2

.25

.3

.35

.4

.45

.5

.55

.6

.65

.7

.75

.8

.85

T (α

Randomized Phase II Cancer Clinical Trials

149

EN

71.17

40.61

27.56

50.29

32.14

59.40

37.28

66.49

40.16

72.98

43.71

76.34

46.31

80.04

46.96

83.00

47.07

82.95

46.86

79.88

45.07

76.08

43.28

72.57

39.56

65.68

36.31

58.49

30.87

48.76

24.43

37.47

67.92

Design

β− .8502 .8505 .8506 .8501 .8502 .8506 .8527 .8500 .8506 .8503 .8506 .8503 .8510 .8503 .8504 .8500 .8502 .8500 .8504 .8503 .8510 .8503 .8506 .8503 .8506 .8500 .8519 .8503 .8514 .8500 .8505 .8518 .8503

1

with

o-Stage

test

Tw

α

.0881

.0678

.0516

.0963

.0847

.1091

.1004

.1147

.1062

.1203

.1129

.1209

.1138

.1252

.1112

.1205

.1138

.1196

.1156

.1240

.1151

.1234

.1114

.1277

.1147

.1178

.1155

.1201

.1050

.1150

.1016

.1073

.1140

exact

)

)

) ) ) ) ) ) ) ) ) ) ) ) ) ) ) ) ) ) ) ) ) ) ) ) ) ) ) ) ) ) )

1

, 37

, 39

, 39

, 45

, 45

, 39

, 39

, 37

, 14 , 22 , 7 , 15 , 27

Optimal

, n

, 35

, 11 , 24 , 16 , 29 , 17 , 32 , 18

, 19

, 22

, 24

, 23

, 24

, 22

, 19

, 18 , 32 , 15 , 26

( 35

( n

( 94 (52,18) ( 34 ( 68 ( 42 ( 82 ( 51 ( 93 ( 56 ( 102 ( 62 ( 107 ( 65 ( 114 ( 65 ( 115 ( 66 ( 115 ( 65 ( 114 ( 65 ( 107 ( 62 ( 102 ( 56 ( 93 ( 52 ( 84 ( 43 ( 69

( 53 ( 98

Fisher’s

for

EN

74.20

41.27

27.56

53.18

33.09

64.71

38.15

67.92

42.01

82.03

46.22

79.37

50.53

93.40

50.16

91.60

50.57

91.59

50.11

93.36

50.45

79.22

46.00

81.91

41.72

67.52

37.60

64.33

32.34

52.50

24.75

39.45

72.52

designs

Design

β−1 .8500 .8506 .8506 .8502 .8500 .8502 .8506 .8502 .8506 .8502 .8503 .8501 .8501 .8501 .8507 .8500 .8500 .8500 .8507 .8501 .8501 .8501 .8503 .8502 .8506 .8502 .8506 .8502 .8500 .8502 .8506 .8506 .8500

o-stage

o-Stage

tw

Tw

α

.0870

.0676

.0516

.0950

.0823

.1067

.0976

.1120

.0992

.1133

.1122

.1200

.1062

.1148

.1082

.1170

.1132

.1203

.1163

.1210

.1163

.1159

.1104

.1256

.1071

.1146

.1160

.1190

.1000

.1102

.0997

.1021

.1101

)

) ) ) ) ) ) ) ) ) ) ) ) ) ) ) ) ) ) ) ) ) ) ) ) ) ) ) ) ) ) ) ) )

optimal

1

, 48 , 24 , 11 , 37 , 21 , 48 , 23 , 43 , 29 , 68 , 30 , 55 , 39 , 79 , 37 , 74 , 38 , 74 , 37 , 79 , 39 , 55 , 30 , 68 , 29 , 43 , 23 , 48 , 21 , 37 , 11 , 24 , 48

Minimax

, n

and

( n

( 92 ( 51 ( 34 ( 65 ( 41 ( 78 ( 49 ( 88 ( 52 ( 94 ( 59 ( 100 ( 60 ( 106 ( 61 ( 107 ( 61 ( 107 ( 61 ( 106 ( 60 ( 100 ( 59 ( 94 ( 52 ( 88 ( 49 ( 78 ( 41 ( 65 ( 34 ( 51 ( 92

β−

minimax

1

.8502

.8526

.8581

.8529

.8515

.8521

.8541

.8518

.8506

.8511

.8535

.8504

.8524

.8508

.8551

.8520

.8538

.8520

.8551

.8508

.8524

.8504

.8535

.8511

.8506

.8518

.8541

.8521

.8515

.8529

.8581

.8526

.8502

Design

and

α

.0868

.0677

.0531

.0952

.0785

.1058

.0948

.1113

.0990

.1132

.1067

.1210

.1034

.1148

.1089

.1178

.1147

.1214

.1184

.1215

.1176

.1180

.1145

.1205

.0999

.1180

.1158

.1141

.0980

.1082

.1019

.0983

.1065

designs,

Single-Stage

n

92

51

35

65

41

78

49

88

52

94

59

104

60

106

61

107

61

107

61

106

60

104

59

94

52

88

49

78

41

65

35

51

92

) 85 ,. θ 3.353 4.750 6.333 3.000 3.857 2.429 3.051 2.154 2.667 2.000 2.455 1.909 2.333 1.857 2.270 1.833 2.250 1.833 2.270 1.857 2.333 1.909 2.455 2.000 2.667 2.154 3.051 2.429 3.857 3.000 6.333 4.750 3.353

Single-stage

(. 15= )∗ x p .15 .2 .25 .25 .3 .3 .35 .35 .4 .4 .45 .45 .5 .5 .55 .55 .6 .6 .65 .65 .7 .7 .75 .75 .8 .8 .85 .85 .9 .9 .95 .95 .95

8.6 β− , 1 y

able ∗

p

.05

.1

.15

.2

.25

.3

.35

.4

.45

.5

.55

.6

.65

.7

.75

.8

.85

T (α

150

Randomized Phase II Cancer Clinical Trials

EN

85.99

48.08

35.39

60.77

38.59

72.23

44.47

82.02

49.91

90.25

53.06

94.99

55.43

98.95

57.54

101.01

57.77

100.96

57.43

98.81

55.22

94.71

52.66

89.81

49.36

81.41

43.57

71.28

37.10

59.26

30.74

45.15

82.76

Design

β− .9005 .9009 .9174 .9004 .9001 .9004 .9000 .9000 .9001 .9000 .9005 .9003 .9005 .9000 .9006 .9001 .9001 .9001 .9006 .9000 .9005 .9003 .9005 .9000 .9001 .9000 .9000 .9004 .9001 .9004 .9004 .9010 .9002

1

with

o-Stage

Tw

α

test

.0936

.0743

.0623

.1026

.0887

.1129

.1026

.1187

.1112

.1234

.1131

.1221

.1160

.1277

.1217

.1275

.1204

.1275

.1211

.1258

.1185

.1325

.1255

.1243

.1176

.1247

.1136

.1182

.1104

.1149

.1068

.1080

.1151

)

) ) ) ) ) ) ) ) ) ) ) ) ) ) ) ) ) ) ) ) ) ) ) ) ) ) ) ) ) ) ) ) )

exact

1

, 8

, 40

Optimal

, 36

, 45

, 47

, 51

, 58

, 53

, 53

, 58

, 51

, 47

, 41

, 36

, n

, 42 , 23 , 13 , 29 , 17

, 21

, 26

, 26

, 31

, 31

, 29

, 31

, 31

, 26

, 26

, 21

, 17 , 29

, 19

( n

( 115 ( 62 ( 45 ( 83 ( 52 ( 100 ( 61 ( 112 ( 68 ( 126 ( 74 ( 132 ( 75 ( 134 ( 79 ( 142 ( 81 ( 142 ( 79 ( 134 ( 75 ( 132 ( 74 ( 126 ( 68 ( 115 ( 61 ( 100 ( 52 ( 83 ( 45 ( 64 ( 116

Fisher’s

for

EN

89.25

48.69

42.91

64.23

39.89

77.32

47.06

90.77

54.32

103.51

56.31

102.82

56.69

100.77

62.85

120.19

64.15

120.65

62.79

100.67

56.55

102.72

56.13

103.39

54.08

90.56

46.66

76.91

39.03

63.54

36.75

46.93

87.55

Design

β

designs

−1 .9002 .9001 .9019 .9000 .9007 .9001 .9002 .9001 .9000 .9000 .9004 .9002 .9003 .9001 .9001 .9000 .9000 .9000 .9001 .9001 .9003 .9002 .9004 .9000 .9000 .9001 .9002 .9001 .9007 .9000 .9019 .9001 .9002

o-stage

o-Stage

tw

Tw

α

.0919

.0735

.0627

.0988

.0855

.1082

.1000

.1143

.1094

.1212

.1079

.1179

.1152

.1279

.1151

.1171

.1093

.1198

.1103

.1261

.1186

.1315

.1268

.1278

.1204

.1156

.1048

.1150

.1111

.1135

.0977

.1058

.1121

)

) )

)

)

) ) ) ) ) ) ) ) ) ) ) ) )

)

) ) ) ) ) ) ) ) ) ) ) ) ) ) )

optimal

1

, 60

, 1

, 74

, 88

, 82

, 67

, 67

, 82

, 88

, 74

, 1

, 60

Minimax

, n

, 30

, 46 , 25 , 58 , 34

, 41

, 42

, 38

, 46 , 107 , 49 , 108 , 46

, 38

, 42

, 41

, 34 , 58 , 25 , 46

, 30

( 45

( 45

and

( n

( 110 ( 60

( 78 ( 50 ( 93 ( 57 ( 105 ( 65 ( 117 ( 68 ( 121 ( 72 ( 130 ( 77 ( 132 ( 77 ( 132 ( 77 ( 130 ( 72 ( 121 ( 68 ( 117 ( 65 ( 105 ( 57 ( 93 ( 50 ( 78

( 60 ( 110

β−

minimax

1

.9020

.9033

.9512

.9014

.9006

.9004

.9019

.9007

.9014

.9005

.9034

.9020

.9002

.9002

.9037

.9001

.9026

.9001

.9037

.9002

.9002

.9020

.9034

.9005

.9014

.9007

.9019

.9004

.9006

.9014

.9512

.9033

.9020

Design

and

α

.0915

.0737

.0670

.0946

.0843

.1067

.1001

.1142

.1096

.1214

.1047

.1179

.1171

.1227

.1109

.1169

.1095

.1199

.1122

.1202

.1103

.1191

.1120

.1283

.1222

.1144

.1040

.1158

.1124

.1139

.1036

.1055

.1126

designs,

Single-Stage

n

110

60

50

78

50

93

57

105

65

117

68

121

75

131

77

132

77

132

77

131

75

121

68

117

65

105

57

93

50

78

50

60

110

) 9 ,.

θ

3.353

4.750

6.333

3.000

3.857

2.429

3.051

2.154

2.667

2.000

2.455

1.909

2.333

1.857

2.270

1.833

2.250

1.833

2.270

1.857

2.333

1.909

2.455

2.000

2.667

2.154

3.051

2.429

3.857

3.000

6.333

4.750

3.353

Single-stage

(. 15= )∗ x p .15 .2 .25 .25 .3 .3 .35 .35 .4 .4 .45 .45 .5 .5 .55 .55 .6 .6 .65 .65 .7 .7 .75 .75 .8 .8 .85 .85 .9 .9 .95 .95 .95

8.7 β− , 1 y

able ∗

p

.05

.1

.15

.2

.25

.3

.35

.4

.45

.5

.55

.6

.65

.7

.75

.8

.85

T (α

Randomized Phase II Cancer Clinical Trials

151

EN

52.14

30.73

20.98

36.08

24.43

42.94

26.44

47.09

29.46

51.75

31.59

55.02

32.72

56.29

33.20

56.78

33.32

56.75

33.11

56.19

32.53

55.11

31.17

51.37

28.98

46.58

25.71

42.03

22.99

35.09

18.65

28.16

49.45

Design

β− .8004 .8007 .8005 .8002 .8024 .8015 .8020 .8002 .8001 .8003 .8001 .8003 .8003 .8010 .8003 .8010 .8007 .8010 .8003 .8010 .8003 .8022 .8001 .8003 .8001 .8002 .8003 .8015 .8008 .8009 .8007 .8017 .8010

1

with

o-Stage

test

Tw

α

.1152

.0813

.0481

.1222

.1066

.1445

.1221

.1507

.1408

.1582

.1477

.1570

.1445

.1602

.1491

.1656

.1528

.1685

.1549

.1686

.1542

.1651

.1505

.1601

.1430

.1599

.1458

.1590

.1428

.1458

.1267

.1419

.1483

exact

)

) ) ) ) ) ) ) ) ) ) ) ) ) ) ) ) ) ) ) ) ) ) ) ) ) ) ) )

)

)

1

)

) )

, 7

, 6 , 9

Optimal

, n

, 24 , 15 , 10 , 19 , 13 , 18 , 13 , 23 , 14 , 24 , 12 , 30 , 16 , 32 , 16 , 32 , 18 , 32 , 16 , 32 , 16 , 28 , 12 , 24 , 14 , 23 , 11 , 18

, 17

, 20

( n

( 68 ( 38 ( 25 ( 47 ( 31 ( 60 ( 35 ( 65 ( 40 ( 73 ( 45 ( 75 ( 45 ( 76 ( 46 ( 77 ( 45 ( 77 ( 46 ( 76 ( 45 ( 77 ( 45 ( 73 ( 40 ( 65 ( 36 ( 60 ( 33 ( 48 ( 26 ( 40 ( 70

Fisher’s

for

EN

53.73

30.73

20.98

36.08

25.71

47.88

26.46

47.66

33.40

54.95

37.78

62.04

35.25

62.10

34.50

60.81

34.90

60.80

34.46

62.07

35.19

62.00

37.74

57.84

33.23

47.31

25.94

47.68

25.27

35.09

19.04

28.60

52.42

designs

Design

β−1 .8005 .8007 .8005 .8002 .8005 .8003 .8022 .8011 .8005 .8001 .8000 .8001 .8002 .8001 .8004 .8005 .8007 .8005 .8004 .8001 .8002 .8001 .8000 .8001 .8005 .8011 .8022 .8003 .8005 .8002 .8005 .8007 .8005

o-stage

o-Stage

tw

Tw

α

.1121

.0813

.0481

.1222

.1022

.1349

.1209

.1491

.1342

.1467

.1292

.1517

.1389

.1625

.1479

.1692

.1545

.1727

.1572

.1737

.1581

.1711

.1559

.1638

.1472

.1531

.1425

.1518

.1427

.1427

.1249

.1406

.1410

)

) ) ) ) ) ) ) ) ) ) ) ) ) ) ) ) ) ) ) ) ) ) ) ) ) ) ) ) ) ) ) ) )

optimal

1

, 36 , 15 , 10 , 19 , 19 , 40 , 15 , 29 , 26 , 47 , 35 , 55 , 28 , 54 , 25 , 50 , 26 , 50 , 25 , 54 , 28 , 55 , 23 , 47 , 26 , 29 , 15 , 40 , 19 , 19 , 10 , 15 , 36

Minimax

, n

and

( n

( 65 ( 38 ( 25 ( 47 ( 30 ( 54 ( 34 ( 62 ( 39 ( 67 ( 40 ( 68 ( 41 ( 69 ( 42 ( 70 ( 42 ( 70 ( 42 ( 69 ( 41 ( 68 ( 41 ( 67 ( 39 ( 62 ( 34 ( 54 ( 30 ( 47 ( 25 ( 38 ( 65

β−

minimax

1

.8031

.8040

.8050

.8043

.8012

.8005

.8057

.8003

.8005

.8028

.8101

.8006

.8034

.8012

.8092

.8043

.8079

.8043

.8092

.8012

.8034

.8006

.8101

.8028

.8005

.8003

.8057

.8005

.8012

.8043

.8050

.8040

.8031

Design

and

α

.1078

.0799

.0509

.1200

.0991

.1343

.1220

.1512

.1264

.1424

.1295

.1518

.1392

.1631

.1515

.1713

.1581

.1751

.1618

.1746

.1601

.1716

.1589

.1660

.1491

.1522

.1311

.1466

.1386

.1446

.1305

.1392

.1411

designs,

Single-Stage

n

65

38

26

48

30

54

35

63

39

67

41

68

41

69

42

70

42

70

42

69

41

68

41

67

39

63

35

54

30

48

26

38

65

) 8 ,.

θ

3.353

4.750

6.333

3.000

3.857

2.429

3.051

2.154

2.667

2.000

2.455

1.909

2.333

1.857

2.270

1.833

2.250

1.833

2.270

1.857

2.333

1.909

2.455

2.000

2.667

2.154

3.051

2.429

3.857

3.000

6.333

4.750

3.353

Single-stage

(. 2= )∗ x p .15 .2 .25 .25 .3 .3 .35 .35 .4 .4 .45 .45 .5 .5 .55 .55 .6 .6 .65 .65 .7 .7 .75 .75 .8 .8 .85 .85 .9 .9 .95 .95 .95

8.8 β− , 1 y

able ∗

p

.05

.1

.15

.2

.25

.3

.35

.4

.45

.5

.55

.6

.65

.7

.75

.8

.85

T (α

152

Randomized Phase II Cancer Clinical Trials

EN

61.52

35.50

24.68

43.97

28.03

50.85

32.19

58.22

35.50

62.60

37.18

66.87

38.57

68.97

40.96

70.12

41.25

70.08

40.88

72.67

38.40

66.64

36.89

62.01

35.02

57.62

31.35

50.09

26.71

42.70

21.94

33.02

58.94

Design

β− .8501 .8504 .8519 .8503 .8502 .8508 .8511 .8507 .8505 .8515 .8508 .8503 .8500 .8501 .8506 .8516 .8502 .8516 .8506 .8502 .8500 .8503 .8508 .8502 .8505 .8501 .8505 .8508 .8502 .8503 .8519 .8520 .8506

1

with

o-Stage

test

Tw

α

.1214

.0924

.0621

.1321

.1132

.1453

.1345

.1575

.1443

.1567

.1453

.1670

.1547

.1660

.1599

.1686

.1563

.1713

.1559

.1604

.1559

.1664

.1659

.1692

.1576

.1627

.1473

.1591

.1461

.1538

.1386

.1451

.1516

exact

)

) ) ) ) ) ) ) ) ) ) ) ) ) ) ) ) ) ) ) ) ) ) ) ) ) ) ) ) ) )

) )

1

), 7

Optimal

, n

, 29 , 19 , 11 , 21 , 12 , 26 , 16 , 30 , 18 , 36 , 20 , 36 , 21 , 40 , 23 , 39 , 21 , 39 , 23 , 50 , 21 , 36 , 20 , 34 , 18 , 27 , 14 , 26 , 12 , 21

, 14 , 26

( n

( 81 ( 44 ( 30 ( 59 ( 37 ( 69 ( 43 ( 80 ( 48 ( 84 ( 50 ( 92 ( 52 ( 93 ( 55 ( 96 ( 57 ( 96 ( 55 ( 92 ( 52 ( 92 ( 50 ( 85 ( 48 ( 82 ( 44 ( 69 ( 37 ( 59 ( 31 ( 46 ( 83

Fisher’s

for

EN

62.00

35.50

24.68

47.58

28.76

52.01

32.60

63.64

37.22

65.29

39.81

78.21

40.70

76.97

41.47

80.61

41.85

80.60

41.41

76.92

40.60

78.15

39.70

65.14

36.99

63.45

32.05

51.56

28.13

47.08

22.36

33.53

60.17

designs

Design

β−1 .8503 .8504 .8519 .8501 .8521 .8506 .8508 .8502 .8501 .8500 .8501 .8501 .8510 .8502 .8503 .8501 .8501 .8501 .8503 .8502 .8510 .8501 .8501 .8500 .8501 .8502 .8508 .8506 .8521 .8501 .8519 .8504 .8503

o-stage

o-Stage

tw

Tw

α

.1197

.0924

.0621

.1301

.1097

.1411

.1344

.1497

.1349

.1530

.1398

.1561

.1568

.1537

.1589

.1595

.1569

.1632

.1564

.1627

.1548

.1603

.1616

.1621

.1615

.1679

.1439

.1503

.1362

.1545

.1373

.1429

.1496

)

) ) ) ) ) ) ) ) ) ) ) ) ) ) ) ) ) ) ) ) ) ) ) ) ) ) ) ) ) ) ) ) )

optimal

1

, 37 , 19 , 11 , 36 , 19 , 35 , 19 , 51 , 27 , 50 , 32 , 68 , 29 , 63 , 27 , 71 , 28 , 71 , 27 , 63 , 29 , 68 , 32 , 50 , 27 , 51 , 19 , 35 , 19 , 36 , 11 , 19 , 37

Minimax

, n

and

( n

( 78 ( 44 ( 30 ( 56 ( 35 ( 65 ( 42 ( 74 ( 45 ( 78 ( 46 ( 87 ( 50 ( 89 ( 53 ( 89 ( 53 ( 89 ( 53 ( 89 ( 50 ( 87 ( 46 ( 78 ( 45 ( 74 ( 42 ( 65 ( 35 ( 56 ( 30 ( 44 ( 78

β−

minimax

1

.8535

.8459

.8542

.8511

.8545

.8523

.8577

.8528

.8559

.8515

.8514

.8506

.8501

.8533

.8523

.8508

.8510

.8508

.8523

.8533

.8501

.8506

.8514

.8515

.8559

.8528

.8577

.8523

.8545

.8511

.8542

.8549

.8535

Design

and

α

.1148

.0897

.0618

.1292

.1046

.1411

.1294

.1469

.1298

.1575

.1402

.1531

.1468

.1541

.1392

.1600

.1405

.1637

.1437

.1649

.1426

.1610

.1437

.1485

.1664

.1672

.1544

.1480

.1286

.1536

.1408

.1290

.1506

designs,

Single-Stage

n

81

44

30

56

35

65

43

74

45

80

46

87

53

89

54

89

54

89

54

89

53

87

46

80

45

74

43

65

35

56

30

44

81

) 85 ,. θ 3.353 4.750 6.333 3.000 3.857 2.429 3.051 2.154 2.667 2.000 2.455 1.909 2.333 1.857 2.270 1.833 2.250 1.833 2.270 1.857 2.333 1.909 2.455 2.000 2.667 2.154 3.051 2.429 3.857 3.000 6.333 4.750 3.353

Single-stage

(. 2= )∗ x p .15 .2 .25 .25 .3 .3 .35 .35 .4 .4 .45 .45 .5 .5 .55 .55 .6 .6 .65 .65 .7 .7 .75 .75 .8 .8 .85 .85 .9 .9 .95 .95 .95

8.9 β− , 1 y

able ∗

p

.05

.1

.15

.2

.25

.3

.35

.4

.45

.5

.55

.6

.65

.7

.75

.8

.85

T (α

Randomized Phase II Cancer Clinical Trials

153

EN

76.02

42.05

35.39

53.71

34.27

64.10

39.69

71.53

43.08

79.41

47.04

83.91

49.92

85.87

51.04

86.88

51.41

86.85

50.96

85.76

49.72

83.69

46.70

79.01

42.59

71.03

38.86

63.29

32.95

52.54

30.66

39.58

73.17

Design

β− .9000 .9001 .9379 .9001 .9026 .9003 .9001 .9002 .9004 .9000 .9004 .9000 .9002 .9000 .9003 .9002 .9007 .9002 .9003 .9000 .9002 .9001 .9004 .9000 .9004 .9002 .9001 .9003 .9008 .9001 .9172 .9003 .9000

1

with

o-Stage

test

Tw

α

.1262

.1040

.0934

.1397

.1202

.1541

.1432

.1567

.1456

.1668

.1579

.1621

.1581

.1684

.1541

.1747

.1561

.1777

.1580

.1775

.1566

.1735

.1548

.1659

.1573

.1663

.1608

.1638

.1474

.1576

.1439

.1466

.1577

exact

)

) ) ) ) ) ) ) ) ) ) ) ) ) ) ) ) ) ) ) ) ) ) ) ) ) ) ) ) ) ) ) ) )

1

, 37

, 42

, 53

, 54

, 54

, 54

, 54

, 48

, 42

, 15 , 29 , 7 , 18 , 37

Optimal

, n

, 22 , 13 , 29 , 17 , 34 , 19 , 41 , 23

, 25

, 27

, 30

, 31

, 30

, 27

, 25

, 23 , 41 , 19 , 34

( 45

( n

( 101 ( 53 ( 45 ( 71 ( 45 ( 87 ( 54 ( 96 ( 58 ( 110 ( 64 ( 110 ( 68 ( 113 ( 68 ( 115 ( 68 ( 115 ( 68 ( 113 ( 68 ( 114 ( 64 ( 110 ( 58 ( 96 ( 54 ( 87 ( 46 ( 71

( 55 ( 101

Fisher’s

for

EN

79.15

42.47

42.91

56.73

34.27

70.70

41.45

74.60

44.79

91.11

51.15

92.22

54.72

87.17

54.79

87.39

56.12

87.36

54.76

87.10

54.66

92.16

51.00

91.04

44.55

74.34

41.08

70.43

33.08

56.19

36.75

40.80

77.69

designs

Design

β−1 .9001 .9005 .9252 .9000 .9026 .9001 .9007 .9002 .9002 .9000 .9003 .9001 .9002 .9001 .9002 .9002 .9001 .9002 .9002 .9001 .9002 .9001 .9003 .9000 .9002 .9002 .9007 .9001 .9026 .9000 .9252 .9005 .9001

o-stage

o-Stage

tw

Tw

α

.1223

.1026

.0918

.1379

.1202

.1506

.1359

.1530

.1406

.1546

.1525

.1600

.1443

.1692

.1510

.1754

.1578

.1786

.1606

.1791

.1605

.1785

.1550

.1725

.1432

.1551

.1597

.1649

.1444

.1492

.1422

.1406

.1527

optimal

)

) )

) ) ) ) ) ) ) ) ) ) ) ) ) ) ) ) ) ) ) ) ) ) ) ) ) ) ) ) ) )

1

)

, 55 , 26 , 1 , 43 , 17 , 58 , 30 , 56 , 33 , 82 , 39 , 81 , 46 , 63 , 45 , 60 , 48 , 60 , 45 , 63 , 46 , 81 , 39 , 82 , 33 , 56 , 30 , 58 , 17 , 43 , 1 , 26 , 55

and

Minimax

, n

( 45

( n

( 96 ( 52 ( 45 ( 67 ( 45 ( 81 ( 50 ( 90 ( 54 ( 99 ( 61 ( 102 ( 62 ( 108 ( 63 ( 111 ( 63 ( 111 ( 63 ( 108 ( 62 ( 102 ( 61 ( 99 ( 54 ( 90 ( 50 ( 81 ( 45 ( 67

( 52 ( 96

β

minimax

−1 .9006 .9037 .9698 .9004 .9299 .9012 .9045 .9014 .9022 .9002 .9032 .9008 .9013 .9007 .9023 .9008 .9011 .9008 .9023 .9007 .9013 .9008 .9032 .9002 .9022 .9014 .9045 .9012 .9299 .9004 .9698 .9037 .9006

Design

and

α

.1209

.0987

.0968

.1370

.1225

.1506

.1330

.1555

.1446

.1522

.1471

.1604

.1440

.1630

.1522

.1560

.1586

.1590

.1623

.1592

.1616

.1710

.1584

.1728

.1446

.1589

.1445

.1591

.1537

.1424

.1484

.1385

.1465

designs,

Single-Stage

n

96

52

50

67

50

81

50

93

56

99

61

102

62

113

63

114

63

114

63

113

62

102

61

99

56

93

50

81

50

67

50

52

96

) 9 ,.

θ

Single-stage

(. 2

3.353

4.750

6.333

3.000

3.857

2.429

3.051

2.154

2.667

2.000

2.455

1.909

2.333

1.857

2.270

1.833

2.250

1.833

2.270

1.857

2.333

1.909

2.455

2.000

2.667

2.154

3.051

2.429

3.857

3.000

6.333

4.750

3.353

= )∗

x p .15 .2 .25 .25 .3 .3 .35 .35 .4 .4 .45 .45 .5 .5 .55 .55 .6 .6 .65 .65 .7 .7 .75 .75 .8 .8 .85 .85 .9 .9 .95 .95 .95

8.10 β− , 1 y

able ∗

p

.05

.1

.15

.2

.25

.3

.35

.4

.45

.5

.55

.6

.65

.7

.75

.8

.85

T (α

154

Randomized Phase II Cancer Clinical Trials

8.2.1.1

Choice of a 1 and a

For now, we assume that n 1 and n 2 are given. We may consider different

options of choosing a 1. For example,

• We may wish to stop the trial early if the experimental arm is worse

than the control. In this case, we choose a 1 = 0. Note that this a 1 is

constant with respect to z 1.

• We may choose a 1 so that the conditional probability of early termi-

nation given z 1 is no smaller than a prespecified level ψ 0 (= 0 . 6 to 0 . 8 ) under H 0 : θ = 1, that is,

[ (a 1+ z 1 )/ 2]−1



PET0 (z 1 ) = P (X 1 − Y 1 < a| z 1 , H 0 ) =

f 1 (x 1| z 1 , θ = 1 ) ≥ ψ 0 ,

x 1= m 1−

where [ c] denotes the largest integer not exceeding c.

• We may choose a 1 so that the conditional probability of early termi-

nation given z 1 is no larger than a prespecified level ψ 1 (= 0 . 02 to 0 . 1 ) under Ha : θ = θa, that is,

[ (a 1+ z 1 )/ 2]−1



PET1 (z 1 ) = P (X 1 − Y 1 < a| z 1 , Ha) =

f 1 (x 1| z 1 , θa) ≤ ψ 1 .

x 1= m 1−

Most standard optimal two-stage phase II trials stop early when the observed

response probability from stage 1 is no larger than the specified response

probability under H 0; refer to Chapter 2 (Simon, 1989; Jung et al., 2004) for

single-arm trial cases and Tables 7.1 to 7.9 for randomized trial cases based

on binomial distributions. Based on this, we propose to use a 1 = 0 among the

above three options. This option simplifies the computations for study design

too.

With a 1 fixed at 0, we choose the second-stage rejection value a conditioning

on (z 1 , z 2 ). Given type I error rate α∗, a = a(z 1 , z 2 ) is chosen as the smallest integer satisfying

α(z 1 , z 2 ) ≡ P (X 1 − Y 1 ≥ a 1 , X − Y ≥ a| z 1 , z 2 , θ = 1 ) ≤ α∗ .

We calculate α(z 1 , z 2 ) by

P (X 1 ≥ (a 1 + z 1 )/ 2 , X 1 + X 2 ≥ (a + z 1 + z 2 )/ 2| z 1 , z 2 , θ = 1 ) m 1+

m 2+



=

I { x 1 ≥ (a 1 + z 1 )/ 2 , x 1 + x 2 ≥ (a + z 1 + z 2 )/ 2}

x 1= m 1− x 2= m 2−

× f 1 (x 1| z 1 , 1 ) f 2 (x 2| z 2 , 1 ), where I (· ) is the indicator function.

Randomized Phase II Cancer Clinical Trials

155

Given z 1 and z 2, the conditional power under Ha : θ = θa is obtained by 1 − β(z 1 , z 2 ) = P (X 1 − Y 1 ≥ a 1 , X − Y ≥ a| z 1 , z 2 , θa) m 1+

m 2+



=

I { x 1 ≥ (a 1 + z 1 )/ 2 , x 1 + x 2 ≥ (a + z 1 + z 2 )/ 2}

x 1= m 1− x 2= m 2−

× f 1 (x 1| z 1 , θa) f 2 (x 2| z 2 , θa).

Note that, as in the single-stage case, the calculation of type I error rate

α(z 1 , z 2 ) and rejection values (a 1 , a) does not require specification of the common response probability p x = p y under H 0, and that the conditional power

1 − β(z 1 , z 2 ) requires specification of the odds ratio θa under Ha, but not the response probabilities for the two arms, p x and p y.

8.2.1.2

Choice of n 1 and n 2

Now we discuss how to choose sample sizes n 1 and n 2 at the design stage based

on some optimality criteria.

Given (α∗ , β∗ ), we propose to choose n 1 and n 2 so that the marginal power is maintained above 1 − β∗ while controlling the conditional type I error rates

for any (z 1 , z 2 ) below α∗ as in the choice of (a 1 , a). For stage l(= 1 , 2 ), the marginal distribution of Zl = Xl + Yl has a probability mass function

m





l+



nl

nl

gl (zl) =

pxl

pzl− xl

x

x qnl − xl

x

z

y

qnl− zl+ xl

y

x

l

l − xl

l = ml−

for zl = 0 , . . . , 2 nl. Under H 0 : p x = p y = p 0, this is expressed as m





l+



nl

nl

g 0 l(zl) = pzl

.

0 q 2 nl − zl

0

x

z

x

l

l − xl

l = ml−

Furthermore, Z 1 and Z 2 are independent. Hence, we choose n 1 and n 2 so that the marginal power is no smaller than a specified level 1 − β∗, that is,

2 n 1

2 n 2



1 − β ≡

{1 − β(z 1 , z 2 )} g 1 (z 1 )g 2 (z 2 ) ≥ 1 − β∗ .

z 1=0 z 2=0

The marginal type I error rate for a chosen two-stage design is calculated by

2 n 1

2 n 2



α ≡

α(z 1 , z 2 )g 01 (z 1 )g 02 (z 2 ).

z 1=0 z 2=0

Since the conditional type I error rate is controlled below α∗ for any (z 1 , z 2 ), the marginal type I error rate does not exceed α∗.

156

Randomized Phase II Cancer Clinical Trials

Although we do not have to specify any response rates for testing, we need

to do so when choosing (n 1 , n 2 ) at the design stage. If the specified response rates are different from the true ones, then the marginal power may be different from the expected one for the chosen sample sizes. But even in this case,

the two-stage Fisher’s test is still valid in the sense that it always controls

both the conditional and marginal type I error rates below the specified level.



Let PET

2 n 1

0 ≡ E{PET0 ( Z 1 )| H 0} =

PET

z

0 (z 1 )g 01 (z 1 ) denote the marginal

1 =0

probability of early termination under H 0. Then, among those (n 1 , n 2 ) satisfying the (α∗ , 1 − β∗ )-condition, the Simon-type (1989) minimax and the optimal designs can be chosen as follows:

• Minimax design has the smallest maximal sample size n(= n 1 + n 2 ).

• Optimal design has the smallest marginal expected sample size EN under

H 0, where

EN = n 1 × PET0 + n × ( 1 − PET0 ).

Tables 8.2 to 8.10 report the sample sizes (n, n 1 ) of the minimax and optimal

two-stage designs for α∗ = 0 . 1, 0.15, or 0.2, 1 − β∗ = 0 . 8, 0.85, or 0.9, and various combinations of ( p x , p y ) under Ha. For comparison, we also list the sample size n of the single-stage design under each setting. Note that the

maximal sample size of the two-stage minimax is slightly smaller than or equal

to the sample size of the single-stage design. If the experimental therapy is

inefficacious, however, the expected sample sizes of two-stage minimax and

optimal designs are much smaller than the sample size of the single-stage

design.

One of the popular approaches for randomized phase II trials is to use the

asymptotic method. Given (α∗ , p y , n 1 , n 2 ), we find c satisfying α = P (X 1 − Y 1 ≥ 0 , X − Y



≥ c| p x = p y )

2 n ˆ pˆ

q

using the normal approximation to binomial distributions, where ˆ p = (X +

Y )/ 2 n and ˆ

q = 1 − ˆ p. For an approximate critical value c, the exact type I

error rate is calculated by using the true binomial distribution. For a specified

p x (= p y ), the exact power is calculated similarly. From Table 8.5, the minimax design under (α∗ , 1 − β∗ , p x , p y ) = ( 0 . 15 , 0 . 8 , 0 . 5 , 0 . 35 ) has (n, n 1 ) = ( 86 , 66 ), for which the asymptotic method has α = 0 . 157 and 1 − β = 0 . 840. Since the sample size is relatively large in this case, the asymptotic method controls the

power close to the nominal α∗ = 0 . 15.

Now, we consider the minimax design (n, n 1 ) = ( 29 , 11 ) under (α∗ , 1 − β∗ , p x , p y ) = ( 0 . 15 , 0 . 8 , 0 . 35 , 0 . 05 ). In this case, the asymptotic method has α =

0 . 244, which is far larger than the nominal α∗ = 0 . 15 because of the small

sample size.

Randomized Phase II Cancer Clinical Trials

157

8.2.2

Two-Stage Designs with Both Superiority and

Futility Interim Tests

So far, we have investigated two-stage designs with a futility stopping rule

only. One may also want to stop the trial early when the experimental arm is

significantly more efficacious than the control. In this section, we consider a

two-stage randomized phase II trial with an interim look for both futility and

superiority. A two-stage phase II trial with early stopping values (a 1 , b 1 ) and a rejection value a at the second stage that are chosen conditional on z 1 and

z 2 is conducted as follows:

Stage 1: Randomize n 1 patients to each arm; observe x 1 and y 1.

a. Given z 1 (= x 1 + y 1 ), find stopping value a 1 = a 1 (z 1 ) and b 1 =

b 1 (z 1 ).

b. If x 1 − y 1 ≤ a 1, then reject the experimental therapy and stop the

trial.

c. If x 1 − y 1 ≥ b 1, then accept the experimental therapy and stop the

trial.

d. If a 1 < x 1 − y 1 < b 1, then proceed to the second stage.

Stage 2: Randomize n 2 patients to each arm; observe x 2 and y 2 (z 2 = x 2 + y 2 ).

a. Given (z 1 , z 2 ), find a rejection value a = a(z 1 , z 2 ).

b. Accept the experimental arm if x − y > a, where x = x 1 + x 2 and y = y 1 + y 2.

At the design stage of a two-stage design, we have to determine (n 1 , n 2 ) and

(a 1 , b 1 , a) for all possible values of (z 1 , z 2 ).

8.2.2.1

Choice of a 1, b 1, and a

Suppose that (n 1 , n 2 ) are given. Then we have to choose the critical values

(a 1 , b 1 , a) conditioning on (z 1 , z 2 ). A complete search of optimal designs will go through all possible values of (a 1 , b 1 , a) for all (z 1 , z 2 ) values. This is practically impossible due to its heavy computation. In the two-stage designs based on

binomial test that were discussed in Chapter 7, the early stopping values

for futility and superiority were determined around the expected differences

under H 0 and under Ha, respectively. Based on this observation, we propose

to use a 1 = −1 as in the designs with futility test only (note that equality

sign is included in the lower stopping value here) and b 1 = [ n 1 ( p x − p y )] + 1

for ( p x , p y ) that are specified under Ha for power calculation. Here, [ c] is the largest integer not exceeding c. Once (a 1 , b 1 ) are chosen for stage 1, we choose a = a(z 1 , z 2 ) for given (z 1 , z 2 ) after stage 2 as the smallest integer satisfying α(z 1 , z 2 ) ≡ P (X 1 − Y 1 ≥ b 1| z 1 , θ = 1 )

+ P (a 1 < X 1 − Y 1 < b 1 , X − Y > a| z 1 , z 2 , θ = 1 ) ≤ α∗ , where α∗ denotes a prespecified type I error rate.

158

Randomized Phase II Cancer Clinical Trials

Given z 1 and z 2, the conditional power under Ha : θ = θa is obtained by 1− β(z 1 , z 2 ) = P (X 1− Y 1 ≥ b 1| z 1 , θa)+P (a 1 < X 1− Y 1 < b 1 , X− Y > a| z 1 , z 2 , θa).

Note that, as in the single-stage case, the calculation of the type I error rate

α(z 1 , z 2 ) and critical values (a 1 , b 1 , a) does not require specification of the common response probability p x = p y under H 0, and that the conditional

power 1 − β(z 1 , z 2 ) requires specification of the odds ratio θa under Ha, but not the response probabilities for the two arms, p x and p y.

8.2.2.2

Choice of n 1 and n 2

Now we discuss how to choose sample sizes n 1 and n 2 at the design stage based

on some optimality criteria.

Given (α∗ , 1 − β∗ ), we propose to choose n 1 and n 2 so that the marginal power is maintained above 1− β∗ while controlling the conditional type I error

rates for any (z 1 , z 2 ) below α∗ as in the choice of (a 1 , b 1 , a). We choose n 1 and n 2 so that the marginal power is no smaller than a specified level 1 − β∗,

that is,

2 n 1

2 n 2



1 − β ≡

{1 − β(z 1 , z 2 )} g 1 (z 1 )g 2 (z 2 ) ≥ 1 − β∗ .

z 1=0 z 2=0

The marginal type I error rate is calculated by

2 n 1

2 n 2



α ≡

α(z 1 , z 2 )g 01 (z 1 )g 02 (z 2 ).

z 1=0 z 2=0

Since the conditional type I error rate is controlled below α∗ for any (z 1 , z 2 ), the marginal type I error rate does not exceed α∗.

Given z 1, the probability of early termination is calculated as

PET h(z 1 ) = 1 − P (a 1 < x 1 − y 1 < b 1| Hh)

under Hh (h = 0 , a). Let





PET ≡ 1 E{PET0 (Z 1 )| H 0} + E{PET1 (Z 1 )| Ha}

2



2 n 1



2 n 1



= 1

PET0 (z 1 )g 01 (z 1 ) +

PET1 (z 1 )g 1 (z 1 )

2

z 1=0

z 1=0

denote the mean of the marginal probabilities of early termination under

H 0 and Ha. Then, among those (n 1 , n 2 ) satisfying the (α∗ , 1 − β∗ )-condition, the Simon-type (1989) minimax and the optimal designs can be chosen as

follows:

Randomized Phase II Cancer Clinical Trials

159

• Minimax design has the smallest maximal sample size n(= n 1 + n 2 ).

• Optimal design has the smallest marginal expected sample size EN under

H 0, where

EN = n 1 × PET + n × ( 1 − PET ).

Tables 8.11 to 8.19 report the sample sizes (n, n 1 ) of the minimax and optimal

two-stage designs for α∗ = 0 . 1, 0.15, or 0.2, 1 − β∗ = 0 . 8, 0.85, or 0.9, and various combinations of ( p x , p y ) under Ha.

8.3

Extensions

In this section, we investigate unbalanced two-stage designs with both futility

and superiority tests and conditional p-values for two-stage designs based on

Fisher’s exact test.

8.3.1

Unbalanced Two-Stage Randomized Trials

One may want to accrue more patients to one arm than the other for some

reasons, for example, to treat more patients by an experimental therapy than

a control. In this case, the test statistic based on the difference in number of

responders between two arms that has been considered so far is not appropri-

ate. Let ml and nl denote the sample sizes at stage l(= 1 , 2 ) of arms x and y, respectively (m = m 1 + m 2 , n = n 1 + n 2 ). Also, let Xl and Yl denote the number of responders among stage l patients of arms x and y, respectively

(X = X 1 + X 2 , Y = Y 1 + Y 2 ). If we want to assign γ times larger number of patients to arm x than to arm y, then we have ml = γ × nl and m = γ × n.

Note that a choice of γ = 1 corresponds to the balanced two-stage designs

considered in the previous section. When γ = 1, it does not make sense to

directly compare the numbers of responders between arms at each stage. For

the odds ratio, θ = ( p x q y )/(q x p y ), we want to design a study for H 0 : θ = 1, H 0 : θ = θa(> 1 ), where qk = 1 − pk.

With an interim look with both futility and superiority tests, we consider

following two-stage design.

• Stage 1: Accrue m 1 patients to arm x and n 1 patients to arm y, and

observe X 1 and Y 1. For ˆ p x , 1 = X 1 /m 1, ˆ p y , 1 = Y 1 /n 1, ˆ qk, 1 = 1 − ˆ pk, 1, and ˆ

θ 1 = (ˆ p x , 1ˆ q y , 1 )/(ˆ q x , 1ˆ p y , 1 ), (a) If ˆ

θ 1 ≤ 1, reject arm x and stop the trial.

(b) If ˆ

θ 1 ≥ θa, accept arm x and stop the trial.

(c) If 1 < ˆ θ 1 < θa, proceed to the second stage.

160

Randomized Phase II Cancer Clinical Trials

1

EN

76.97

42.76

28.98

54.49

34.18

64.38

39.71

72.97

44.06

80.05

47.67

84.76

49.49

88.38

50.00

87.47

49.74

87.47

50.00

88.25

49.49

84.76

47.67

80.05

44.18

72.97

39.71

64.38

34.57

54.49

28.98

42.76

76.97

Fisher’s

for

0

Design

EN

77.89

44.02

29.83

55.51

35.51

64.76

40.06

73.47

44.40

80.67

47.90

85.43

50.43

88.52

50.91

90.80

51.27

90.77

50.83

88.87

50.27

85.23

47.65

80.42

44.91

73.07

39.53

64.14

34.21

54.56

28.59

42.33

76.13

testsy

β−

eriorit

o-Stage

1

.8010

.8010

.8064

.8025

.8012

.8007

.8007

.8002

.8001

.8008

.8013

.8021

.8008

.8015

.8001

.8008

.8011

.8008

.8001

.8013

.8008

.8021

.8013

.8008

.8048

.8002

.8007

.8007

.8013

.8025

.8064

.8010

.8010

sup

Tw

α

and

.0528

.0345

.0213

.0618

.0528

.0734

.0654

.0773

.0733

.0801

.0750

.0835

.0793

.0834

.0810

.0881

.0851

.0911

.0868

.0855

.0867

.0853

.0809

.0855

.0860

.0862

.0821

.0863

.0795

.0837

.0759

.0672

.0789

y

Optimal

)

) ) ) ) ) ) ) ) ) ) ) ) ) ) ) ) ) ) ) ) ) ) ) ) ) ) ) ) ) ) ) ) )

futilit

1

, 54

, 54

, 60

, 58

, 58

, 61

, 54

, 54

, n

, 50 , 27 , 20 , 34 , 21 , 40 , 25 , 47 , 25

, 30

, 31

, 31

, 32

, 31

, 31

, 30

, 26 , 47 , 25 , 40 , 20 , 34 , 20 , 27 , 50

( n

( 97 ( 54 ( 35 ( 71 ( 45 ( 84 ( 51 ( 95 ( 59 ( 103 ( 62 ( 112 ( 66 ( 113 ( 67 ( 119 ( 67 ( 119 ( 67 ( 113 ( 66 ( 112 ( 62 ( 103 ( 60 ( 95 ( 51 ( 84 ( 45 ( 71 ( 35 ( 54 ( 97

terimin

1

oth

35.33

67.97

41.20

76.75

44.24

84.03

50.36

98.65

56.05

89.79

51.37

92.90

51.36

92.90

51.37

89.79

56.05

98.65

50.36

84.03

44.24

76.75

41.20

67.97

35.33

55.65

33.04

50.57

79.30

b

EN

79.30

50.57

30.29

55.65

with

0

Design

EN

80.28

50.78

30.73

56.90

35.72

68.40

41.45

76.91

46.33

84.27

50.48

99.38

56.34

90.05

51.50

93.20

51.46

93.18

51.43

89.98

56.31

99.35

50.35

84.12

46.08

76.68

41.08

68.09

35.10

56.31

33.12

50.65

79.17

designs

β−

o-Stage

1

.8000

.8007

.8015

.8005

.8014

.8000

.8012

.8003

.8007

.8005

.8046

.8000

.8001

.8022

.8016

.8001

.8002

.8001

.8016

.8023

.8001

.8000

.8046

.8005

.8007

.8003

.8012

.8000

.8014

.8005

.8001

.8007

.8000

o-stage

Tw

tw

)

α

8

.0503

.0315

.0219

.0593

.0509

.0683

.0623

.0737

.0708

.0773

.0693

.0772

.0695

.0804

.0774

.0805

.0789

.0838

.0815

.0846

.0724

.0737

.0739

.0802

.0827

.0805

.0761

.0797

.0774

.0813

.0633

.0658

.0792

,.

Minimax

optimal

(. 1

) ) ) ) ) ) ) ) ) ) ) ) ) ) ) ) ) ) ) ) ) ) ) ) ) ) ) ) ) ) ) ) )

=

n

, 61 , 49 , 25 , 42 , 25 , 54 , 30 , 60 , 34 , 67 , 40 , 93 , 52 , 67 , 35 , 74 , 35 , 74 , 35 , 67 , 52 , 93 , 40 , 67 , 34 , 60 , 30 , 54 , 25 , 42 , 32 , 49 , 61

and

)∗ β

( 94 ( 52 ( 34 ( 68 ( 43 ( 80 ( 50 ( 91 ( 56 ( 99 ( 59 ( 105 ( 60 ( 110 ( 65 ( 110 ( 65 ( 110 ( 65 ( 110 ( 60 ( 105 ( 59 ( 99 ( 56 ( 91 ( 50 ( 80 ( 43 ( 68 ( 34 ( 52 ( 94

− , 1∗ θ

Minimax

(α

3.353

4.750

6.333

3.000

3.857

2.429

3.051

2.154

2.667

2.000

2.455

1.909

2.333

1.857

2.270

1.833

2.250

1.833

2.270

1.857

2.333

1.909

2.455

2.000

2.667

2.154

3.051

2.429

3.857

3.000

6.333

4.750

3.353

with

x p .15 .2 .25 .25 .3 .3 .35 .35 .4 .4 .45 .45 .5 .5 .55 .55 .6 .6 .65 .65 .7 .7 .75 .75 .8 .8 .85 .85 .9 .9 .95 .95 .95

8.11 test

y

able

p

.05

.1

.15

.2

.25

.3

.35

.4

.45

.5

.55

.6

.65

.7

.75

.8

.85

T exact

Randomized Phase II Cancer Clinical Trials

161

1

EN

86.27

48.01

31.66

60.70

38.57

72.74

44.40

82.84

50.14

91.22

53.33

96.49

56.53

99.44

57.34

57.34

57.34

99.44

56.53

96.49

53.33

91.22

50.14

82.84

44.40

72.74

38.57

60.70

31.97

48.01

86.27

102.68

102.68

Fisher’s

for

0

88.33

49.70

33.36

63.80

40.34

75.11

46.60

85.33

51.28

92.10

55.42

99.29

57.50

59.61

59.54

59.50

57.33

99.02

55.10

91.74

50.85

84.78

45.93

74.30

39.14

62.60

31.45

47.44

85.99

Design

EN

101.24

103.60

103.54

101.11

testsy

β−

o-Stage

1

.8501

.8506

.8531

.8509

.8521

.8504

.8504

.8514

.8514

.8505

.8516

.8500

.8502

.8501

.8529

.8518

.8514

.8518

.8529

.8501

.8502

.8500

.8516

.8505

.8514

.8514

.8504

.8504

.8522

.8509

.8522

.8506

.8501

eriorit

Tw

sup

α

and

.0575

.0406

.0245

.0668

.0564

.0760

.0682

.0805

.0729

.0825

.0783

.0858

.0780

.0852

.0836

.0887

.0862

.0916

.0893

.0887

.0817

.0889

.0831

.0875

.0839

.0884

.0854

.0886

.0805

.0789

.0770

.0684

.0797

y

Optimal

)

) ) ) ) ) ) ) ) ) ) ) ) ) ) ) ) ) ) ) ) ) ) ) ) ) ) ) ) ) ) ) ) )

1

futilit

, n

, 51 , 27 , 21 , 36 , 21 , 42 , 27 , 49 , 31 , 54 , 32 , 56 , 36 , 62 , 32 , 54 , 32 , 54 , 32 , 62 , 36 , 56 , 32 , 54 , 31 , 49 , 27 , 42 , 21 , 36 , 20 , 27 , 51

( n

( 114 ( 63 ( 40 ( 84 ( 53 ( 101 ( 61 ( 115 ( 67 ( 124 ( 74 ( 136 ( 75 ( 135 ( 82 ( 146 ( 82 ( 146 ( 82 ( 135 ( 75 ( 136 ( 74 ( 124 ( 67 ( 115 ( 61 ( 101 ( 53 ( 84 ( 40 ( 63 ( 114

terimin

1

oth

EN

91.93

49.31

33.24

61.27

39.35

75.34

47.78

88.37

53.15

96.81

56.19

59.61

60.13

60.12

60.13

59.61

56.19

96.91

53.15

88.37

47.78

75.34

39.35

61.27

33.21

49.31

91.93

102.32

103.24

103.77

103.77

103.24

102.32

b

with

0

Design

EN

92.56

50.60

33.91

63.60

39.89

77.87

48.04

88.72

53.34

98.48

57.84

60.18

60.23

60.20

60.18

60.08

57.66

98.77

53.09

88.44

47.65

77.45

39.03

62.79

33.33

49.13

91.34

102.44

105.74

105.31

105.29

105.66

102.33

designs

β

o-Stage

−1 .8507 .8541 .8527 .8502 .8504 .8503 .8525 .8514 .8519 .8500 .8502 .8509 .8505 .8504 .8520 .8501 .8508 .8500 .8520 .8504 .8505 .8509 .8502 .8502 .8519 .8514 .8525 .8503 .8504 .8502 .8512 .8541 .8507

Tw

o-stage

tw

)

α

85

.0544

.0376

.0254

.0637

.0542

.0727

.0637

.0751

.0689

.0783

.0737

.0781

.0737

.0821

.0751

.0827

.0798

.0857

.0833

.0867

.0833

.0783

.0831

.0846

.0731

.0800

.0774

.0823

.0787

.0838

.0715

.0784

.0779

,.

Minimax

optimal

(. 1

) ) ) ) ) ) ) ) ) ) ) ) ) ) ) ) ) ) ) ) ) ) ) ) ) ) ) ) ) ) ) ) )

=

n

, 70 , 34 , 25 , 43 , 25 , 58 , 35 , 67 , 40 , 77 , 43 , 80 , 46 , 78 , 45 , 76 , 45 , 76 , 45 , 78 , 46 , 80 , 43 , 78 , 40 , 67 , 35 , 58 , 25 , 43 , 26 , 34 , 70

and

)∗ β

( 109 ( 61 ( 39 ( 79 ( 50 ( 94 ( 58 ( 107 ( 64 ( 117 ( 70 ( 122 ( 72 ( 130 ( 73 ( 131 ( 73 ( 131 ( 73 ( 130 ( 72 ( 122 ( 70 ( 117 ( 64 ( 107 ( 58 ( 94 ( 50 ( 79 ( 39 ( 61 ( 109

− , 1∗ θ

Minimax

(α

3.353

4.750

6.333

3.000

3.857

2.429

3.051

2.154

2.667

2.000

2.455

1.909

2.333

1.857

2.270

1.833

2.250

1.833

2.270

1.857

2.333

1.909

2.455

2.000

2.667

2.154

3.051

2.429

3.857

3.000

6.333

4.750

3.353

with

x p .15 .2 .25 .25 .3 .3 .35 .35 .4 .4 .45 .45 .5 .5 .55 .55 .6 .6 .65 .65 .7 .7 .75 .75 .8 .8 .85 .85 .9 .9 .95 .95 .95

8.12 test

y

able

p

.05

.1

.15

.2

.25

.3

.35

.4

.45

.5

.55

.6

.65

.7

.75

.8

.85

T exact

162

Randomized Phase II Cancer Clinical Trials

1

EN

98.87

54.77

34.94

69.98

44.08

83.57

51.51

95.18

56.34

61.95

64.32

68.28

68.74

68.28

64.32

61.95

56.34

95.61

51.92

83.57

44.08

69.98

35.24

55.13

98.87

104.82

111.07

117.37

118.38

118.38

117.37

111.07

104.82

Fisher’s

0

for

58.01

39.35

74.29

47.47

89.18

54.62

60.90

66.05

68.66

68.54

70.30

68.41

68.43

65.72

60.36

53.53

88.36

46.41

73.10

37.20

55.71

Design

EN

103.96

101.04

109.85

117.63

121.83

123.79

123.74

121.67

117.34

109.46

100.02

101.79

testsy

β−

o-Stage

1

.9000

.9012

.9037

.9005

.9029

.9009

.9003

.9007

.9005

.9000

.9018

.9002

.9016

.9004

.9002

.9003

.9007

.9003

.9002

.9004

.9016

.9003

.9018

.9000

.9005

.9005

.9004

.9009

.9029

.9005

.9042

.9011

.9000

eriorit

Tw

sup

α

.0610

.0432

.0311

.0676

.0589

.0770

.0683

.0811

.0764

.0834

.0787

.0865

.0815

.0865

.0822

.0872

.0808

.0879

.0877

.0870

.0827

.0875

.0875

.0869

.0876

.0881

.0832

.0881

.0841

.0861

.0741

.0811

.0842

andy

Optimal

)

) ) ) ) ) ) ) ) ) ) ) ) ) ) ) ) ) ) ) ) ) ) ) ) ) ) ) ) ) ) ) ) )

1

, 65 , 36 , 24 , 44 , 28 , 52 , 33 , 59 , 34 , 65 , 39 , 66 , 39 , 71 , 35 , 72 , 47 , 72 , 35 , 71 , 39 , 66 , 39 , 65 , 34 , 58 , 32 , 52 , 28 , 44 , 23 , 35 , 65

futilit

, n

( n

( 132 ( 72 ( 48 ( 97 ( 61 ( 119 ( 71 ( 136 ( 82 ( 148 ( 88 ( 162 ( 93 ( 166 ( 96 ( 169 ( 90 ( 169 ( 96 ( 166 ( 93 ( 162 ( 88 ( 148 ( 82 ( 136 ( 71 ( 119 ( 61 ( 97 ( 48 ( 72 ( 132

terimin

1

EN

57.84

39.29

75.17

45.88

91.03

53.13

62.18

69.27

67.42

69.31

68.74

69.31

67.42

69.27

62.18

53.13

91.03

45.88

75.17

39.25

57.84

oth

103.73

102.23

120.65

121.72

123.19

120.74

120.74

123.19

121.72

120.77

102.23

103.73

b

0

with

58.76

39.97

76.01

47.77

92.55

55.49

63.98

70.48

70.21

69.48

70.30

69.40

70.07

70.35

63.70

54.98

92.09

46.97

75.23

39.38

57.23

Design

EN

104.71

105.00

120.77

122.18

126.96

124.31

124.27

126.87

122.05

121.09

104.67

102.84

designs

β−

o-Stage

1

.9000

.9006

.9010

.9001

.9002

.9001

.9003

.9003

.9003

.9002

.9000

.9004

.9001

.9000

.9003

.9004

.9007

.9004

.9003

.9000

.9001

.9004

.9000

.9002

.9003

.9003

.9003

.9001

.9002

.9001

.9012

.9006

.9000

Tw

o-stage

tw

α

)

.0599

.0416

.0290

.0653

.0558

.0717

.0665

.0769

.0702

.0779

.0718

.0800

.0787

.0839

.0772

.0837

.0808

.0870

.0831

.0847

.0841

.0836

.0711

.0805

.0802

.0827

.0791

.0807

.0785

.0790

.0703

.0761

.0807

9 ,. Minimax

)

)

)

)

)

)

)

)

)

)

)

)

)

)

optimal

(. 1

) ) ) )

)

)

)

)

)

)

)

)

)

)

)

) ) ) )

=

n

, 70 , 40 , 30 , 54 , 32 , 69 , 38 , 78 , 48 , 100 , 58 , 94 , 49 , 93 , 45 , 85 , 47 , 85 , 45 , 93 , 49 , 94 , 58 , 101 , 48 , 78 , 38 , 69 , 32 , 54 , 31 , 40 , 70

and

)∗ β

( 130 ( 71 ( 46 ( 93 ( 59 ( 112 ( 69 ( 128 ( 77 ( 139 ( 81 ( 147 ( 88 ( 157 ( 90 ( 159 ( 90 ( 159 ( 90 ( 157 ( 88 ( 147 ( 81 ( 139 ( 77 ( 128 ( 69 ( 112 ( 59 ( 93 ( 46 ( 71 ( 130

− , 1∗ θ

Minimax

(α

3.353

4.750

6.333

3.000

3.857

2.429

3.051

2.154

2.667

2.000

2.455

1.909

2.333

1.857

2.270

1.833

2.250

1.833

2.270

1.857

2.333

1.909

2.455

2.000

2.667

2.154

3.051

2.429

3.857

3.000

6.333

4.750

3.353

with

x p .15 .2 .25 .25 .3 .3 .35 .35 .4 .4 .45 .45 .5 .5 .55 .55 .6 .6 .65 .65 .7 .7 .75 .75 .8 .8 .85 .85 .9 .9 .95 .95 .95

8.13 test

y

.1

.2

.3

.4

.5

.6

.7

.8

able

p

.05

.15

.25

.35

.45

.55

.65

.75

.85

T exact

Randomized Phase II Cancer Clinical Trials

163

1

61.77

34.57

23.60

43.52

27.69

52.05

32.61

57.91

35.00

64.04

38.25

68.04

39.71

68.82

40.73

69.31

41.08

69.31

40.73

68.82

39.71

68.04

38.25

63.86

35.00

57.91

32.61

52.05

27.69

43.52

23.41

35.17

61.77

Fisher’s

EN

for

0

64.04

36.88

24.57

46.22

29.03

52.74

32.96

60.03

36.00

64.26

38.97

68.95

40.84

72.20

40.93

72.68

43.38

72.65

40.83

72.10

40.64

68.75

38.77

64.43

35.62

59.61

32.45

52.24

28.11

45.52

23.56

34.47

62.61

tests

Design

EN

y

β−

eriorit

o-Stage

1

.8005

.8033

.8075

.8010

.8007

.8001

.8015

.8003

.8002

.8001

.8004

.8004

.8020

.8005

.8008

.8015

.8025

.8015

.8008

.8005

.8020

.8004

.8004

.8009

.8002

.8003

.8015

.8001

.8007

.8010

.8081

.8053

.8005

sup

Tw

and

α

y

.0855

.0645

.0473

.0957

.0848

.1086

.0958

.1199

.1101

.1218

.1109

.1274

.1226

.1298

.1260

.1336

.1227

.1375

.1345

.1380

.1330

.1296

.1202

.1297

.1229

.1327

.1224

.1265

.1257

.1272

.1152

.1141

.1236

Optimal

)

) ) ) ) ) ) ) ) ) ) ) ) ) ) ) ) ) ) ) ) ) ) ) ) ) ) ) ) ) ) ) ) )

futilit

1

, n

, 43 , 22 , 15 , 31 , 16 , 34 , 20 , 36 , 21 , 40 , 26 , 41 , 21 , 45 , 20 , 45 , 29 , 45 , 20 , 45 , 21 , 41 , 26 , 41 , 21 , 36 , 20 , 34 , 16 , 31 , 16 , 20 , 43

( n

( 78 ( 45 ( 29 ( 57 ( 37 ( 67 ( 42 ( 79 ( 47 ( 84 ( 49 ( 92 ( 56 ( 95 ( 57 ( 96 ( 55 ( 96 ( 57 ( 95 ( 56 ( 92 ( 49 ( 84 ( 47 ( 79 ( 42 ( 67 ( 37 ( 57 ( 29 ( 45 ( 78

terimin

1

othb

EN

61.77

36.92

23.60

48.42

29.32

56.81

34.05

61.30

36.18

65.57

39.39

70.03

42.14

73.92

42.61

73.91

42.61

73.91

42.61

74.10

42.14

70.03

39.39

65.57

36.18

61.30

34.05

56.81

29.32

46.63

23.41

36.92

61.77

with

0

Design

EN

64.04

37.72

24.57

48.62

29.72

57.04

34.27

62.21

37.22

67.37

39.51

70.70

43.09

73.99

43.16

73.96

43.13

73.95

43.12

74.40

42.99

70.61

39.38

67.21

36.99

62.01

33.94

56.81

29.10

48.27

23.56

36.65

62.61

designs

β

o-Stage

−1 .8005 .8048 .8075 .8000 .8047 .8017 .8022 .8003 .8007 .8000 .8001 .8004 .8007 .8034 .8013 .8010 .8000 .8010 .8013 .8037 .8007 .8004 .8001 .8000 .8007 .8003 .8022 .8017 .8047 .8003 .8081 .8048 .8005

o-stage

Tw

tw

) 8

α

,.

.0855

.0625

.0473

.0881

.0793

.1027

.0920

.1102

.1053

.1192

.1035

.1170

.1140

.1196

.1115

.1262

.1131

.1301

.1162

.1315

.1163

.1292

.1084

.1259

.1207

.1193

.1144

.1158

.1139

.1199

.1152

.1134

.1236

optimal

(. 15

Minimax

) ) ) ) ) ) ) ) ) ) ) ) ) ) ) ) ) ) ) ) ) ) ) ) ) ) ) ) ) ) ) ) )

=

n

, 43 , 27 , 15 , 40 , 20 , 47 , 25 , 49 , 27 , 51 , 30 , 55 , 32 , 60 , 31 , 60 , 31 , 60 , 31 , 61 , 32 , 55 , 30 , 51 , 27 , 49 , 25 , 47 , 20 , 40 , 16 , 27 , 43

and

)∗ β

( 78 ( 44 ( 29 ( 55 ( 36 ( 65 ( 41 ( 73 ( 45 ( 81 ( 47 ( 84 ( 52 ( 86 ( 53 ( 86 ( 53 ( 86 ( 53 ( 86 ( 52 ( 84 ( 47 ( 81 ( 45 ( 73 ( 41 ( 65 ( 36 ( 55 ( 29 ( 44 ( 78

− , 1∗ θ

Minimax

(α

3.353

4.750

6.333

3.000

3.857

2.429

3.051

2.154

2.667

2.000

2.455

1.909

2.333

1.857

2.270

1.833

2.250

1.833

2.270

1.857

2.333

1.909

2.455

2.000

2.667

2.154

3.051

2.429

3.857

3.000

6.333

4.750

3.353

with

x p .15 .2 .25 .25 .3 .3 .35 .35 .4 .4 .45 .45 .5 .5 .55 .55 .6 .6 .65 .65 .7 .7 .75 .75 .8 .8 .85 .85 .9 .9 .95 .95 .95

8.14 test

y

able

p

.05

.1

.15

.2

.25

.3

.35

.4

.45

.5

.55

.6

.65

.7

.75

.8

.85

T exact

164

Randomized Phase II Cancer Clinical Trials

1

EN

70.35

38.54

25.69

48.62

31.54

59.23

36.36

66.75

40.63

73.35

43.37

77.94

44.99

80.16

46.68

81.65

47.20

81.65

46.68

80.16

44.99

77.94

43.37

73.35

40.63

67.93

36.73

59.23

31.54

48.62

25.69

38.54

70.35

Fisher’s

for

0

Design

EN

73.66

42.29

27.51

53.03

34.27

62.43

38.37

70.84

42.73

76.94

46.37

82.28

47.53

83.48

47.75

83.63

48.25

83.59

47.66

83.36

47.36

82.10

46.13

76.60

42.41

69.28

37.36

61.77

33.08

52.07

25.88

40.21

71.58

testsy

β−

eriorit

o-Stage

1

.8502

.8515

.8512

.8500

.8525

.8505

.8507

.8502

.8504

.8501

.8508

.8500

.8520

.8510

.8512

.8504

.8524

.8503

.8512

.8510

.8520

.8501

.8508

.8501

.8504

.8507

.8507

.8505

.8525

.8500

.8512

.8515

.8502

sup

Tw

α

and

.0914

.0705

.0516

.1020

.0927

.1136

.1047

.1201

.1092

.1268

.1181

.1278

.1203

.1288

.1238

.1329

.1304

.1370

.1333

.1387

.1355

.1362

.1324

.1336

.1211

.1290

.1230

.1303

.1272

.1308

.1195

.1114

.1271

y

Optimal

)

) ) ) ) ) ) ) ) ) ) ) ) ) ) ) ) ) ) ) ) ) ) ) ) ) ) ) ) ) ) ) ) )

futilit

1

, 44

, 53

, 51

, 49

, 49

, 51

, 53

, 44

, n

, 43 , 23 , 16 , 32 , 17 , 37 , 22 , 46 , 28

, 29

, 28

, 26

, 26

, 26

, 28

, 29

, 28 , 42 , 21 , 37 , 17 , 32 , 16 , 23 , 43

( n

( 94 ( 53 ( 33 ( 68 ( 45 ( 82 ( 50 ( 91 ( 54 ( 104 ( 60 ( 107 ( 63 ( 111 ( 65 ( 113 ( 66 ( 113 ( 65 ( 111 ( 63 ( 107 ( 60 ( 104 ( 54 ( 92 ( 50 ( 82 ( 45 ( 68 ( 33 ( 53 ( 94

terimin

1

oth

34.18

60.70

37.77

72.24

44.37

78.45

45.20

83.25

46.32

84.33

48.65

84.70

48.86

84.70

48.65

84.33

46.32

83.25

45.20

78.45

44.47

72.24

37.77

60.70

34.18

50.94

25.69

41.00

73.52

b

EN

73.52

41.00

25.69

50.94

with

0

Design

EN

74.33

42.13

27.51

53.98

34.53

63.87

39.90

73.51

44.51

79.32

46.50

85.45

47.10

86.92

49.62

86.96

50.47

86.94

49.57

86.85

46.96

85.33

46.30

79.17

44.77

73.26

39.54

63.45

33.98

53.35

25.88

40.63

72.80

designs

β−

o-Stage

1

.8505

.8529

.8512

.8500

.8507

.8504

.8503

.8502

.8501

.8500

.8500

.8502

.8509

.8501

.8502

.8503

.8507

.8503

.8502

.8501

.8509

.8502

.8500

.8500

.8504

.8502

.8503

.8504

.8507

.8500

.8512

.8529

.8505

o-stage

Tw

tw

)

α

85 ,.

.0877

.0682

.0516

.0966

.0823

.1096

.0985

.1139

.1002

.1153

.1137

.1241

.1140

.1213

.1140

.1257

.1206

.1296

.1237

.1302

.1270

.1265

.1266

.1217

.1064

.1257

.1207

.1244

.1090

.1236

.1195

.1159

.1207

Minimax

optimal

(. 15

) ) ) ) ) ) ) ) ) ) ) ) ) ) ) ) ) ) ) ) ) ) ) ) ) ) ) ) ) ) ) ) )

=

n

, 50 , 27 , 16 , 39 , 25 , 46 , 29 , 56 , 35 , 62 , 32 , 65 , 31 , 66 , 37 , 65 , 39 , 65 , 37 , 66 , 31 , 65 , 32 , 62 , 36 , 56 , 29 , 46 , 25 , 39 , 16 , 27 , 50

and

)∗ β

( 91 ( 51 ( 33 ( 65 ( 41 ( 78 ( 48 ( 88 ( 52 ( 94 ( 58 ( 103 ( 60 ( 105 ( 60 ( 106 ( 60 ( 106 ( 60 ( 105 ( 60 ( 103 ( 58 ( 94 ( 52 ( 88 ( 48 ( 78 ( 41 ( 65 ( 33 ( 51 ( 91

− , 1∗ θ

Minimax

(α

3.353

4.750

6.333

3.000

3.857

2.429

3.051

2.154

2.667

2.000

2.455

1.909

2.333

1.857

2.270

1.833

2.250

1.833

2.270

1.857

2.333

1.909

2.455

2.000

2.667

2.154

3.051

2.429

3.857

3.000

6.333

4.750

3.353

with

x p .15 .2 .25 .25 .3 .3 .35 .35 .4 .4 .45 .45 .5 .50 .55 .55 .6 .6 .65 .65 .7 .7 .75 .75 .8 .8 .85 .85 .9 .9 .95 .95 .95

8.15 test

y

able

p

.05

.1

.15

.2

.25

.3

.35

.4

.45

.5

.55

.6

.65

.7

.75

.8

.85

T exact

Randomized Phase II Cancer Clinical Trials

165

1

EN

81.46

46.03

28.91

59.67

36.61

69.88

42.31

79.20

47.50

87.48

52.82

94.21

54.07

97.61

56.33

57.38

56.33

96.42

54.07

94.21

52.82

87.48

47.50

79.20

42.31

69.88

36.99

58.11

29.23

46.40

81.46

100.79

100.79

Fisher’s

for

0

89.04

49.01

33.52

62.64

39.79

75.04

47.24

85.74

51.62

92.89

54.86

98.53

57.76

58.50

58.58

58.40

57.57

98.29

54.55

92.49

51.13

85.13

46.40

74.36

38.40

62.61

31.26

46.70

86.20

Design

EN

102.18

105.62

105.58

102.37

testsy

β−

o-Stage

1

.9001

.9013

.9054

.9005

.9014

.9002

.9028

.9002

.9017

.9001

.9001

.9001

.9009

.9002

.9014

.9007

.9011

.9007

.9014

.9001

.9009

.9001

.9001

.9001

.9017

.9002

.9028

.9002

.9006

.9004

.9053

.9008

.9001

eriorit

Tw

sup

α

and

.0983

.0750

.0612

.1032

.0905

.1148

.1101

.1247

.1159

.1272

.1166

.1290

.1219

.1303

.1224

.1296

.1268

.1288

.1307

.1345

.1296

.1331

.1232

.1308

.1259

.1331

.1297

.1292

.1228

.1281

.1212

.1204

.1243

y

Optimal

)

) ) ) ) ) ) ) ) ) ) ) ) ) ) ) ) ) ) ) ) ) ) ) ) ) ) ) ) ) ) ) ) )

1

futilit

, n

, 46 , 29 , 19 , 36 , 23 , 46 , 24 , 46 , 29 , 52 , 32 , 58 , 34 , 58 , 32 , 66 , 31 , 66 , 32 , 60 , 34 , 58 , 32 , 52 , 29 , 46 , 24 , 46 , 22 , 40 , 18 , 28 , 46

( n

( 118 ( 61 ( 41 ( 82 ( 51 ( 98 ( 64 ( 118 ( 69 ( 127 ( 73 ( 133 ( 77 ( 140 ( 80 ( 140 ( 81 ( 140 ( 80 ( 139 ( 77 ( 133 ( 73 ( 127 ( 69 ( 118 ( 64 ( 98 ( 51 ( 81 ( 41 ( 61 ( 118

terimin

1

oth

EN

87.90

48.74

31.97

64.36

39.35

77.96

47.18

87.58

51.23

97.04

55.27

58.59

56.83

59.60

56.83

58.59

55.27

97.04

51.23

87.58

47.18

77.96

39.35

64.36

31.97

48.74

87.90

101.79

110.74

114.79

114.79

110.74

101.79

b

with

0

Design

EN

90.40

49.99

33.10

67.12

39.89

78.19

47.89

89.42

52.62

99.39

55.44

60.94

59.79

61.49

59.72

60.81

55.25

99.23

52.32

89.19

47.53

77.81

39.03

66.62

31.45

48.57

88.84

101.91

112.70

116.45

116.44

112.65

101.80

designs

β

o-Stage

−1 .9001 .9005 .9001 .9005 .9009 .9005 .9001 .9001 .9000 .9001 .9006 .9004 .9005 .9001 .9004 .9000 .9003 .9000 .9004 .9001 .9005 .9004 .9006 .9001 .9000 .9001 .9001 .9005 .9009 .9005 .9001 .9005 .9001

Tw

o-stage

tw

)

α

9 ,.

.0919

.0737

.0585

.0963

.0864

.1083

.1004

.1153

.1095

.1210

.1107

.1188

.1201

.1250

.1203

.1178

.1151

.1204

.1233

.1213

.1168

.1266

.1185

.1300

.1220

.1183

.1098

.1193

.1173

.1189

.1105

.1136

.1201

Minimax

optimal

(. 15

) ) ) ) ) ) ) ) ) ) ) ) ) ) ) ) ) ) ) ) ) ) ) ) ) ) ) ) ) ) ) ) )

=

n

, 63 , 34 , 20 , 53 , 25 , 60 , 36 , 71 , 37 , 79 , 40 , 80 , 44 , 92 , 39 , 99 , 43 , 99 , 39 , 92 , 44 , 80 , 40 , 79 , 37 , 71 , 36 , 60 , 25 , 53 , 20 , 34 , 63

and

)∗ β

( 110 ( 60 ( 40 ( 78 ( 50 ( 93 ( 57 ( 105 ( 65 ( 117 ( 68 ( 121 ( 75 ( 131 ( 77 ( 132 ( 77 ( 132 ( 77 ( 131 ( 75 ( 121 ( 68 ( 117 ( 65 ( 105 ( 57 ( 93 ( 50 ( 78 ( 40 ( 60 ( 110

− , 1∗ θ

Minimax

(α

3.353

4.750

6.333

3.000

3.857

2.429

3.051

2.154

2.667

2.000

2.455

1.909

2.333

1.857

2.270

1.833

2.250

1.833

2.270

1.857

2.333

1.909

2.455

2.000

2.667

2.154

3.051

2.429

3.857

3.000

6.333

4.750

3.353

with

x p .15 .2 .25 .25 .3 .3 .35 .35 .4 .4 .45 .45 .5 .5 .55 .55 .6 .6 .65 .65 .7 .7 .75 .75 .8 .8 .85 .85 .9 .9 .95 .95 .95

8.16 test

y

able

p

.05

.1

.15

.2

.25

.3

.35

.4

.45

.5

.55

.6

.65

.7

.75

.8

.85

T exact

166

Randomized Phase II Cancer Clinical Trials

1

50.75

28.50

19.48

35.68

23.79

43.09

26.43

47.37

28.53

53.44

31.17

55.53

32.91

58.12

34.14

58.60

34.14

58.60

34.14

57.64

32.91

55.53

31.17

53.44

28.53

47.37

26.43

43.09

23.51

35.68

19.78

28.80

51.57

Fisher’s

EN

for

0

54.34

32.43

21.93

38.34

24.69

44.10

27.39

50.15

31.20

54.01

32.25

56.11

33.08

61.01

36.32

61.50

36.29

61.47

36.27

61.23

32.94

55.94

32.08

53.77

30.88

49.80

26.90

43.62

24.03

37.59

19.97

30.12

51.95

tests

Design

EN

y

β−

eriorit

o-Stage

1

.8004

.8022

.8066

.8006

.8002

.8012

.8004

.8001

.8010

.8008

.8001

.8017

.8010

.8003

.8027

.8003

.8008

.8003

.8027

.8007

.8010

.8017

.8001

.8008

.8010

.8001

.8004

.8012

.8035

.8006

.8075

.8048

.8007

sup

Tw

and

α

y

.1201

.0884

.0522

.1326

.1097

.1470

.1331

.1618

.1540

.1625

.1457

.1669

.1577

.1725

.1624

.1721

.1616

.1746

.1626

.1767

.1670

.1749

.1656

.1758

.1772

.1741

.1613

.1657

.1696

.1717

.1612

.1501

.1661

Optimal

)

) ) ) ) ) ) ) ) ) ) ) ) ) ) ) ) ) ) ) ) ) ) ) ) ) ) ) ) ) ) ) ) )

futilit

1

, n

, 36 , 17 , 12 , 24 , 16 , 28 , 16 , 31 , 19 , 34 , 22 , 34 , 20 , 38 , 24 , 38 , 24 , 38 , 24 , 40 , 20 , 34 , 22 , 34 , 19 , 31 , 16 , 28 , 11 , 24 , 11 , 16 , 32

( n

( 66 ( 40 ( 26 ( 48 ( 30 ( 56 ( 35 ( 65 ( 40 ( 70 ( 40 ( 74 ( 43 ( 80 ( 46 ( 81 ( 46 ( 81 ( 46 ( 79 ( 43 ( 74 ( 40 ( 70 ( 40 ( 65 ( 35 ( 56 ( 33 ( 48 ( 26 ( 40 ( 67

terimin

1

othb

EN

55.36

30.31

21.14

37.90

23.79

45.40

28.05

49.25

30.26

54.41

31.17

58.47

34.10

61.94

36.04

62.47

36.28

62.47

36.04

61.94

34.10

58.47

31.17

54.41

30.26

49.25

28.05

45.40

23.79

37.90

21.13

30.31

55.36

with

0

Design

EN

57.36

31.14

21.84

39.00

24.69

46.61

28.63

50.53

31.60

55.21

32.25

58.89

35.13

62.10

36.09

62.63

36.52

62.62

36.07

62.07

35.07

58.82

32.08

55.06

31.40

50.28

28.33

46.36

24.07

38.53

21.23

29.84

56.61

designs

β

o-Stage

−1 .8001 .8028 .8069 .8000 .8002 .8003 .8012 .8001 .8009 .8000 .8001 .8001 .8000 .8019 .8009 .8018 .8002 .8018 .8009 .8019 .8000 .8001 .8001 .8000 .8009 .8001 .8012 .8003 .8002 .8000 .8058 .8028 .8001

o-stage

Tw

tw

)

α

8

.1107

.0804

.0485

.1230

.1097

.1400

.1243

.1554

.1400

.1539

.1457

.1563

.1453

.1644

.1510

.1727

.1579

.1753

.1617

.1763

.1678

.1663

.1656

.1719

.1634

.1658

.1483

.1581

.1559

.1575

.1415

.1531

.1554

,.

optimal

(. 2

Minimax

) ) ) ) ) ) ) ) ) ) ) ) ) ) ) ) ) ) ) ) ) ) ) ) ) ) ) ) ) ) ) ) )

=

n

, 46 , 20 , 15 , 29 , 16 , 37 , 21 , 36 , 23 , 42 , 22 , 48 , 29 , 54 , 30 , 54 , 31 , 54 , 30 , 54 , 29 , 48 , 22 , 42 , 23 , 36 , 21 , 37 , 16 , 29 , 16 , 20 , 46

and

)∗ β

( 65 ( 37 ( 25 ( 46 ( 30 ( 54 ( 34 ( 62 ( 38 ( 66 ( 40 ( 68 ( 40 ( 69 ( 41 ( 70 ( 41 ( 70 ( 41 ( 69 ( 40 ( 68 ( 40 ( 66 ( 38 ( 62 ( 34 ( 54 ( 30 ( 46 ( 25 ( 37 ( 65

− , 1∗ θ

Minimax

(α

3.353

4.750

6.333

3.000

3.857

2.429

3.051

2.154

2.667

2.000

2.455

1.909

2.333

1.857

2.270

1.833

2.250

1.833

2.270

1.857

2.333

1.909

2.455

2.000

2.667

2.154

3.051

2.429

3.857

3.000

6.333

4.750

3.353

with

x p .15 .2 .25 .25 .3 .3 .35 .35 .4 .4 .45 .45 .5 .5 .55 .55 .6 .6 .65 .65 .7 .7 .75 .75 .8 .8 .85 .85 .9 .9 .95 .95 .95

8.17 test

y

able

p

.05

.1

.15

.2

.25

.3

.35

.4

.45

.5

.55

.6

.65

.7

.75

.8

.85

T exact

Randomized Phase II Cancer Clinical Trials

167

1

57.94

33.35

21.52

41.52

27.13

49.99

30.55

56.59

34.26

61.74

37.04

65.46

38.79

69.34

40.21

69.95

40.74

69.95

40.21

69.06

38.79

65.46

37.04

61.74

34.26

56.59

30.55

49.99

27.13

41.52

21.76

34.56

57.94

Fisher’s

EN

for

0

63.83

36.45

25.75

45.51

28.41

52.90

33.44

60.15

35.81

66.05

39.47

68.90

40.66

69.52

41.31

72.07

41.81

72.04

41.21

69.83

40.47

68.75

39.21

65.75

35.47

59.79

32.80

52.24

27.53

44.39

23.62

33.89

61.87

tests

Design

EN

y

β−

eriorit

o-Stage

1

.8506

.8502

.8520

.8506

.8502

.8508

.8514

.8506

.8513

.8505

.8516

.8505

.8507

.8504

.8506

.8501

.8507

.8501

.8506

.8516

.8507

.8505

.8516

.8505

.8513

.8506

.8514

.8508

.8502

.8506

.8569

.8512

.8506

sup

Tw

and

α

y

.1231

.0925

.0666

.1418

.1179

.1543

.1427

.1611

.1462

.1701

.1601

.1663

.1624

.1706

.1645

.1711

.1706

.1750

.1736

.1794

.1738

.1754

.1710

.1786

.1607

.1730

.1736

.1735

.1588

.1752

.1453

.1576

.1725

Optimal

)

) ) ) ) ) ) ) ) ) ) ) ) ) ) ) ) ) ) ) ) ) ) ) ) ) ) ) ) ) ) ) ) )

futilit

1

, n

, 37 , 25 , 14 , 24 , 16 , 30 , 18 , 39 , 22 , 39 , 23 , 46 , 22 , 40 , 21 , 51 , 21 , 51 , 21 , 41 , 22 , 46 , 23 , 39 , 22 , 39 , 18 , 30 , 16 , 24 , 13 , 20 , 37

( n

( 81 ( 43 ( 31 ( 60 ( 36 ( 70 ( 44 ( 77 ( 46 ( 88 ( 52 ( 88 ( 55 ( 94 ( 57 ( 90 ( 58 ( 90 ( 57 ( 94 ( 55 ( 88 ( 52 ( 88 ( 46 ( 77 ( 44 ( 70 ( 36 ( 60 ( 31 ( 44 ( 81

terimin

1

othb

EN

61.83

33.35

23.60

43.05

28.74

53.85

32.39

58.62

36.21

66.94

38.83

68.49

39.67

69.54

40.62

73.16

40.61

73.16

40.62

72.91

39.67

68.49

38.83

66.94

36.16

58.62

32.39

53.85

28.74

43.05

23.41

33.35

61.83

with

0

Design

EN

65.49

36.45

24.57

45.26

29.11

54.07

33.32

60.17

36.41

67.51

38.95

70.55

41.81

72.01

42.45

75.12

42.83

75.11

42.39

75.02

41.70

70.43

38.82

67.39

37.73

59.89

32.85

53.71

28.53

44.54

23.56

35.27

64.29

designs

β

o-Stage

−1 .8503 .8502 .8518 .8502 .8527 .8511 .8510 .8501 .8506 .8502 .8502 .8501 .8504 .8508 .8511 .8504 .8513 .8504 .8511 .8500 .8504 .8501 .8502 .8502 .8500 .8501 .8510 .8511 .8527 .8502 .8527 .8502 .8503

o-stage

Tw

tw

)

α

85

.1197

.0925

.0600

.1333

.1104

.1434

.1355

.1546

.1406

.1559

.1422

.1653

.1592

.1658

.1611

.1654

.1611

.1694

.1617

.1698

.1602

.1716

.1573

.1540

.1613

.1673

.1633

.1571

.1442

.1641

.1497

.1603

.1626

,.

optimal

(. 2

Minimax

) ) ) ) ) ) ) ) ) ) ) ) ) ) ) ) ) ) ) ) ) ) ) ) ) ) ) ) ) ) ) ) )

=

n

, 47 , 25 , 15 , 30 , 20 , 40 , 21 , 43 , 25 , 55 , 30 , 51 , 29 , 52 , 28 , 59 , 29 , 59 , 28 , 60 , 29 , 51 , 30 , 55 , 30 , 43 , 21 , 40 , 20 , 30 , 16 , 25 , 47

and

)∗ β

( 78 ( 43 ( 29 ( 56 ( 35 ( 65 ( 42 ( 74 ( 45 ( 78 ( 46 ( 87 ( 52 ( 89 ( 54 ( 89 ( 54 ( 89 ( 54 ( 88 ( 52 ( 87 ( 46 ( 78 ( 44 ( 74 ( 42 ( 65 ( 35 ( 56 ( 29 ( 43 ( 78

− , 1∗ θ

Minimax

(α

3.353

4.750

6.333

3.000

3.857

2.429

3.051

2.154

2.667

2.000

2.455

1.909

2.333

1.857

2.270

1.833

2.250

1.833

2.270

1.857

2.333

1.909

2.455

2.000

2.667

2.154

3.051

2.429

3.857

3.000

6.333

4.750

3.353

with

x p .15 .2 .25 .25 .3 .3 .35 .35 .4 .4 .45 .45 .5 .5 .55 .55 .6 .6 .65 .65 .7 .7 .75 .75 .8 .8 .85 .85 .9 .9 .95 .95 .95

8.18 test

y

able

p

.05

.1

.15

.2

.25

.3

.35

.4

.45

.5

.55

.6

.65

.7

.75

.8

.85

T exact

168

Randomized Phase II Cancer Clinical Trials

1

EN

70.78

37.99

26.51

50.00

31.18

60.68

37.06

69.70

40.98

75.14

44.76

81.18

46.85

84.24

48.57

88.66

48.48

88.66

48.57

84.24

46.85

81.18

44.76

75.92

40.98

69.70

37.06

60.68

31.18

50.00

25.89

37.99

70.78

Fisher’s

for

0

Design

EN

77.18

42.82

29.07

54.78

35.47

65.48

39.90

73.73

45.17

80.52

48.05

83.94

51.13

88.78

50.64

89.90

51.03

89.87

50.57

88.65

50.95

83.78

47.78

80.28

44.66

73.29

39.28

64.81

34.40

53.74

27.44

40.98

75.30

testsy

β−

eriorit

o-Stage

1

.9005

.9004

.9030

.9005

.9017

.9011

.9011

.9000

.9006

.9000

.9007

.9002

.9015

.9003

.9005

.9002

.9008

.9002

.9005

.9003

.9015

.9002

.9007

.9003

.9006

.9000

.9011

.9011

.9017

.9005

.9024

.9004

.9005

sup

Tw

α

and

.1260

.1071

.0756

.1427

.1275

.1580

.1424

.1636

.1580

.1690

.1595

.1665

.1645

.1766

.1605

.1718

.1679

.1744

.1708

.1774

.1723

.1674

.1638

.1738

.1738

.1757

.1633

.1730

.1710

.1702

.1537

.1670

.1690

y

Optimal

)

) ) ) ) ) ) ) ) ) ) ) ) ) ) ) ) ) ) ) ) ) ) ) ) ) ) ) ) ) ) ) ) )

futilit

1

, 46

, 58

, 52

, 62

, 62

, 52

, 58

, 45

, n

, 48 , 25 , 17 , 32 , 19 , 39 , 23 , 45 , 24

, 29

, 30

, 33

, 34

, 33

, 30

, 29

, 24 , 45 , 23 , 39 , 19 , 32 , 12 , 25 , 48

( n

( 97 ( 53 ( 35 ( 71 ( 46 ( 86 ( 52 ( 97 ( 61 ( 109 ( 63 ( 106 ( 68 ( 120 ( 65 ( 114 ( 65 ( 114 ( 65 ( 120 ( 68 ( 106 ( 63 ( 110 ( 61 ( 97 ( 52 ( 86 ( 46 ( 71 ( 38 ( 53 ( 97

terimin

1

oth

35.33

65.66

38.70

73.74

43.71

90.41

49.19

89.93

52.47

87.59

52.77

88.66

55.09

88.66

52.77

87.59

52.47

89.93

49.19

88.83

43.71

73.74

38.70

65.66

35.33

55.41

26.84

41.59

75.32

b

EN

75.32

41.59

26.84

55.41

with

0

Design

EN

79.70

42.76

28.86

57.55

35.72

68.09

40.65

74.71

44.93

90.65

49.86

91.30

53.83

89.32

53.90

89.90

55.67

89.87

53.86

89.24

53.76

91.23

49.68

90.11

44.67

74.43

40.23

67.74

35.10

57.07

27.04

41.20

78.42

designs

β−

o-Stage

1

.9000

.9018

.9014

.9001

.9011

.9004

.9002

.9001

.9001

.9000

.9004

.9000

.9004

.9003

.9003

.9002

.9002

.9002

.9003

.9003

.9004

.9001

.9004

.9000

.9001

.9001

.9002

.9004

.9011

.9001

.9014

.9018

.9000

o-stage

Tw

tw

)

α

9

.1227

.1029

.0755

.1371

.1173

.1521

.1388

.1550

.1443

.1554

.1548

.1603

.1456

.1722

.1525

.1718

.1582

.1744

.1624

.1747

.1623

.1765

.1595

.1728

.1508

.1606

.1613

.1654

.1509

.1526

.1557

.1535

.1612

,.

Minimax

optimal

(. 2

) ) ) ) ) ) ) ) ) ) ) ) ) ) ) ) ) ) ) ) ) ) ) ) ) ) ) ) ) ) ) ) )

=

n

, 58 , 27 , 16 , 45 , 25 , 52 , 28 , 55 , 32 , 81 , 36 , 79 , 44 , 63 , 43 , 62 , 47 , 62 , 43 , 63 , 44 , 79 , 36 , 80 , 32 , 55 , 28 , 52 , 25 , 45 , 16 , 27 , 58

and

)∗ β

( 95 ( 52 ( 35 ( 67 ( 43 ( 81 ( 50 ( 91 ( 55 ( 99 ( 61 ( 102 ( 62 ( 112 ( 63 ( 114 ( 63 ( 114 ( 63 ( 112 ( 62 ( 102 ( 61 ( 99 ( 55 ( 91 ( 50 ( 81 ( 43 ( 67 ( 35 ( 52 ( 95

− , 1∗ θ

Minimax

(α

3.353

4.750

6.333

3.000

3.857

2.429

3.051

2.154

2.667

2.000

2.455

1.909

2.333

1.857

2.270

1.833

2.250

1.833

2.270

1.857

2.333

1.909

2.455

2.000

2.667

2.154

3.051

2.429

3.857

3.000

6.333

4.750

3.353

with

x p .15 .2 .25 .25 .3 .3 .35 .35 .4 .4 .45 .45 .5 .5 .55 .55 .6 .6 .65 .65 .7 .7 .75 .75 .8 .8 .85 .85 .9 .9 .95 .95 .95

8.19 test

y

able

p

.05

.1

.15

.2

.25

.3

.35

.4

.45

.5

.55

.6

.65

.7

.75

.8

.85

T exact

Randomized Phase II Cancer Clinical Trials

169

• Stage 2: Accrue an additional m 2 patients to arm x and n 2 patients to

arm y, and observe X 2 and Y 2. For ˆ p x = X/m, ˆ p y = Y/n, ˆ

qk = 1 − ˆ pk,

and ˆ

θ = (ˆ p xˆ q y )/(ˆ q xˆ p y ),

(a) Accept arm x for further investigation if ˆ

θ ≥ a.

(b) Otherwise, reject arm x.

Given Zl = zl, Xl has probability mass function





ml

nl

θxl

f

xl

zl − xl





l (xl | zl , θ ) = ml+

ml

nl

θi

i = ml−

i

zl − i

for ml− ≤ xl ≤ ml+, where ml− = max ( 0 , zl − nl) and ml+ = min (zl, ml).

Let ˆ

θ 1 = { x 1 (n 1 − y 1 )} /{ y 1 (m 1 − x 1 )} and ˆ θ = { x(n − y)} /{ y(m − x)} denote the estimates of θ after stage 1 and 2, respectively. Note that ˆ θ 1 = ˆ θ 1 (x 1 ) is a function of x 1 given z 1, and ˆ

θ = ˆ θ(x 1 , x 2 ) is a function of (x 1 , x 2 ) given (z 1 , z 2 ). Given the type I error rate α∗ and (m 1 , m 2 , z 1 , z 2 ), we find a satisfying α(z 1 , z 2 ) ≤ α∗, where

α(z 1 , z 2 ) = P{ˆ θ 1 (X 1 ) ≥ θa| z 1 , H 0} + P{1 < ˆ θ 1 (X 1 ) < θa, ˆ θ(X 1 , X 2 ) ≥ a| z 1 , z 2 , H 0}

m 1+



=

I {ˆ θ 1 (x 1 ) ≥ θa} f 1 (x 1| z 1 , 1 ) x 1= m 1−

m 1+

m 2+



+

I {1 < ˆ θ 1 (x 1 ) < θa, ˆ θ(x 1 , x 2 ) ≥ a} f 1 (x 1| z 1 , 1 ) f 2 (x 2| z 2 , 1 ).

x 1= m 1− x 2= m 2−

The conditional power of the two-stage design is calculated by

1 − β(z 1 , z 2 ) = P{ˆ θ 1 (X 1 ) ≥ θa| z 1 , Ha} + P{1 < ˆ θ 1 (X 1 )

< θa, ˆ θ(X 1 , X 2 ) ≥ a| z 1 , z 2 , Ha}

m 1+



m 1+

m 2+



=

I {ˆ θ 1 (x 1 ) ≥ θa} f 1 (x 1| z 1 , θa) +

I {1 < ˆ θ 1 (x 1 )

x 1= m 1−

x 1= m 1− x 2= m 2−

< θa, ˆ θ(x 1 , x 2 ) ≥ a} f 1 (x 1| z 1 , θa) f 2 (x 2| z 2 , θa).

Noting that Zl is sum of two independent binomial random variables, Xl and

Yl , its probability mass function is give as

m





l+



ml

nl

gl (zl) =

pxl

pzl− xl

x

x qml − xl

x

z

y

qnl− zl+ xl

y

x

l

l − xl

l = ml−

170

Randomized Phase II Cancer Clinical Trials

for zl = 0 , . . . , ml + nl. Under H 0 : θ = 1, gl(zl) is expressed as m





l+



ml

nl

g 0 l(zl) =

pzl

x

z

y qml + nl − zl

y

.

x

l

l − xl

l = ml−

Hence, the marginal type I error rate and power of above two-stage design are

calculated by

m 1+ n 1

m 2+ n 2



α = E{ α(Z 1 , Z 2 )} =

α(z 1 , z 2 )g 01 (z 1 )g 02 (z 2 )

z 1=0

z 2=0

and

m 1+ n 1

m 2+ n 2



1 − β = E{1 − β(Z 1 , Z 2 )} =

{1 − α(z 1 , z 2 )} g 1 (z 1 )g 2 (z 2 ),

z 1=0

z 2=0

respectively. Since α(z 1 , z 2 ) ≤ α∗ for all (z 1 , z 2 ), we have α ≤ α∗.

For a specified a type I error rate α∗ and a power 1 − β∗, we want to select

a two-stage design satisfying α ≤ α∗ and 1 − β ≤ 1 − β∗. When Hh ( h = 0 , a) is true, the probability of early termination and the expected sample size for

arm x are calculated as

PET h = 1 − P{1 < ˆ θ 1 (X 1 ) < θa| z 1 , Hh}

and

EN h = m 1 × PET h + m × ( 1 − PET h),

respectively. Let EN = ( EN0 + EN a)/ 2 denote the average sample size for

arm x. Among the two-stage designs satisfying the (α∗ , 1 − β∗ )-restriction, the optimal design is defined as the one with the smallest EN.

The minimax design is defined as the one with the smallest m (or m + n) among the two-stage designs satisfying the (α∗ , 1 − β∗ )-restriction.

8.3.2

Conditional P-Value

When a randomized phase II trial is completed, we usually report whether to

accept or reject the experimental therapy, but not how significant the evidence

supporting the decision was. Toward this effort, we propose to calculate a p-

value conditioning on the total number of responders from each stage. If the

study is stopped after stage 1, we calculate a p-value using the standard

Fisher’s exact test. If the study is continued to the second stage to observe

(n 1 , n 2 , z 1 , z 2 ) and (x 1 , x 2 ), then a conditional p-value given (n 1 , n 2 , z 1 , z 2 ) is

Randomized Phase II Cancer Clinical Trials

171

calculated by

p-value = P{ˆ θ 1 (X 1 ) ≥ θa| z 1 , H 0} + P{1 < ˆ θ 1 (X 1 ) < θa, ˆ θ(X 1 , X 2 )

≥ ˆ θ(x 1 , x 2 )| z 1 , z 2 , H 0}

m 1+



=

I {ˆ θ 1 (i 1 ) ≥ θa} f 1 (i 1| z 1 , 1 ) i 1= m 1−

m 1+

m 2+



+

I {1 < ˆ θ 1 (i 1 ) < θa, ˆ θ(i 1 , i 2 ) ≥ ˆ θ} f 1 (i 1| z 1 , 1 ) f 2 (i 2| z 2 , 1 ), i 1= m 1− i 2= m 2−

where ˆ

θ = { x(n − y)} /{ y(m − x)}.

This p-value calculation can be applied to the two-stage randomized

phase II trial with an interim futility test only or with both futility and supe-

riority tests. Often, the realized sample size may be different from the planned

one due to various reasons. In this case, a p-value method can be very useful.

8.4

Discussions

A two-sample exact binomial test involves a nuisance parameter p 0, the com-

mon response rate for two arms under H 0. In order to remove the nuisance

parameter in testing, we considered controlling the maximal type I error rate

over p 0 ∈ ( 0 , 1 ) in Chapter 7, while we consider the Fisher’s exact test by conditioning the null distribution of the test statistic on the sufficient statistic of

p 0 in this chapter.

We compare the performance of our Fisher’s test with that of binomial test

with the strict type I error control. Figure 8.1 displays the type I error rate

and power in the range of 0 < p y < 1 − for single-stage designs with n = 60

per arm, = p x − p y = 0 . 15 or 0.2 under H 1, and α = 0 . 1, 0.15, or 0.2 under H 0 : p x = p y. The solid lines are for Fisher’s test, and the dotted lines are for binomial; the lower two lines represent type I error rate, and the upper two

lines represent power. As is well known, Fisher’s test controls the type I error

rate conservatively over the range of p y. The conservativeness gets slightly

stronger with small p y values close to 0. Binomial test controls the type I

error rate accurately around p y = 0 . 5, but becomes more conservative for p y

values far from 0 . 5, especially with small p y values. For α = 0 . 1, Fisher’s test and binomial test have similar power around 0 . 2 ≤ p y ≤ 0 . 4 except that the

binomial test is slightly more powerful for p y ≈ 0 . 4. Otherwise, Fisher’s test

is more powerful. The difference in power between the two methods becomes

larger with = 0 . 15. We observe similar trends overall, but the difference in

172

Randomized Phase II Cancer Clinical Trials

∆ = 0.15, α = 0.1

∆ = 0.15, α = 0.15

∆ = 0.15, α = 0.2

1.0

1.0

1.0

0.8

0.8

0.8

0.6

0.6

0.6

α or 1 – β 0.4

α or 1 – β 0.4

α or 1 – β 0.4

0.2

0.2

0.2

0.0

0.0

0.0

0.0 0.2 0.4 0.6 0.8

0.0 0.2 0.4 0.6 0.8

0.0 0.2 0.4 0.6 0.8

Py

Py

Py

∆ = 0.2, α = 0.1

∆ = 0.2, α = 0.15

∆ = 0.2, α = 0.2

1.0

1.0

1.0

0.8

0.8

0.8

0.6

0.6

0.6

α or 1 – β 0.4

α or 1 – β 0.4

α or 1 – β 0.4

0.2

0.2

0.2

0.0

0.0

0.0

0.0 0.2 0.4 0.6 0.8

0.0 0.2 0.4 0.6 0.8

0.0 0.2 0.4 0.6 0.8

Py

Py

Py

Figure 8.1

Single-stage designs with n = 60 per arm: Type I error rate and

power for Fisher’s test (solid lines) and binomial test (dotted lines).

power becomes smaller with = 0 . 2, especially when combined with a large

α(= 0 . 2 ).

Figure 8.2 displays the type I error rate and power of two-stage designs

with a futility test for n 1 = n 2 = 30 per arm. We observe that compared to

binomial test, Fisher’s test controls the type I error more accurately in most

range of p y values. If α = 0 . 1, Fisher’s test is more powerful than the binomial test over the whole range of p y values. But with a larger α, such as 0.15 or 0.2,

the binomial test is slightly more powerful for p y ≈ 0 . 4. As in the single-stage

design case, the difference in power diminishes as and α increase. Roughly

speaking, Fisher exact test is recommended for single-stage trials over the

binomial test, while the former is recommended over the latter only when

the response rate of the control is lower than 30% or higher than 60%. But

more accurate recommendation between the two tests under a design set can

be made by comparing the sample sizes of the optimal designs for these tests.

Randomized Phase II Cancer Clinical Trials

173

∆ = 0.15, α = 0.1

∆ = 0.15, α = 0.15

∆ = 0.15, α = 0.2

1.0

1.0

1.0

0.8

0.8

0.8

0.6

0.6

0.6

α or 1 – β 0.4

α or 1 – β 0.4

α or 1 – β 0.4

0.2

0.2

0.2

0.0

0.0

0.0

0.0 0.2 0.4 0.6 0.8

0.0 0.2 0.4 0.6 0.8

0.0 0.2 0.4 0.6 0.8

Py

Py

Py

∆ = 0.2, α = 0.1

∆ = 0.2, α = 0.15

∆ = 0.2, α = 0.2

1.0

1.0

1.0

0.8

0.8

0.8

0.6

0.6

0.6

α or 1 – β 0.4

α or 1 – β 0.4

α or 1 – β 0.4

0.2

0.2

0.2

0.0

0.0

0.0

0.0 0.2 0.4 0.6 0.8

0.0 0.2 0.4 0.6 0.8

0.0 0.2 0.4 0.6 0.8

Py

Py

Py

Figure 8.2

Two-stage designs with n 1 = n 2 = 30 per arm: Type I error rate

and power for Fisher’s test (solid lines) and binomial test (dotted lines).

References

Fisher, R.A. (1935). The logic of inductive inference (with discussion). Journal

of Royal Statistical Society, 98, 39–82.

Jung, S.H., Lee, T.Y., Kim, K.M., and George, S. (2004). Admissible two-

stage designs for phase II cancer clinical trials. Statistics in Medicine,

23, 561–569.

Simon, R. (1989). Optimal two-stage designs for phase II clinical trials. Con-

trolled Clinical Trials, 10, 1–10.





Chapter 9

Randomized Phase II Trials with

Heterogeneous Patient Populations:

Stratified Fisher’s Exact Test

Suppose that we want to compare the response rates between an experimental

arm and a control arm. Often in a between-arm comparison, the characteristics

of study patients may be heterogeneous. In this case, the heterogeneity is

characterized by some known predictors, and a stratified method is applied to

the final analysis. When the distribution of the stratification factors is identical

between two arms, unstratified testing ignoring the population heterogeneity

controls the type I error rate but loses statistical efficiency. If the distribution

of the predictors is different between two arms, however, unstratified testing

does not maintain the type I error rate accurately, which can be more serious

than losing statistical efficiency. In order to balance the distribution of the

factors, we usually randomize the patients by stratifying for the important

predictors.

In this chapter, we consider randomized phase II clinical trials based on

stratified Fisher’s (1935) exact test for a binary endpoint. We investigate

single-stage and two-stage designs for each test statistic.

9.1

Single-Stage Stratified Fisher’s Exact Test

In this section, we consider single-stage randomized phase II trials. Suppose

that there are J strata with different response rates. Let N denote the total



sample size, and n

J

j the sample size in stratum j (

n

j =1

j = N ). Among n j

patients in stratum j (= 1 , . . . , J ), m 1 j are allocated to arm 1 (experimental) and m 2 j to arm 2 (control), that is, m 1 j + m 2 j = n j . For stratum j, arm k(= 1 , 2 ) has a response rate pkj . Let qkj = 1 − pkj and θ j = p 1 j q 2 j /(q 1 j p 2 j ) denote the odds ratio in stratum j . Suppose that we want to test

H 0 : θ 1 = · · · = θJ = 1

against

H 1 : θ j ≥ 1 for j = 1 , . . . , J and θ j > 1 for some j = 1 , . . . , J.

175

176

Randomized Phase II Cancer Clinical Trials

For stratum j (= 1 , . . . , J ), let x j and y j denote the numbers of responders for arms 1 and 2, respectively, and z j = x j + y j denote the total number

of responders from the two arms. The frequency data in stratum j can be

described as in Table 9.1.

Table 9.1

Frequency data of 2 × 2 table for stratum

j (= 1 , . . . , J )

Arm

Response

Experimental

Control

Total

Yes

x j

y j

z j

No

m 1 j − x j

m 2 j − y j

n j − z j

Total

m 1 j

m 2 j

n j

9.1.1

Statistical Testing



We reject H

J

0 in favor of H 1 if S =

x

j =1 1 j is large. Under H 0, conditioning

on the margin totals (z j , m 1 j , n j ), x j has the hypergeometric distribution m 1 j

m 2 j

x

z

f

j

j − x j

0 (x j | z j , m 1 j , n j ) =





m j+

m j

m j

i = m j−

i

z j − i

for m j− ≤ x j ≤ m j+, where m j− = max ( 0 , z j − m 2 j ) and m j+ = min (z j , m 1 j ).

Let z = (z 1 , . . . , zJ ), m = (m 11 , . . . , m 1 J ), and n = (n 1 , . . . , n J ). Given (z, m, n), the conditional p-value for an observed value of s =

J

x

j =1

j , pv =

pv (s| z, m, n), is obtained by

pv = P(S ≥ s| z, m, n)



m 1+



m J+



J



J



=

· · ·

I 

i



j ≥ s

f 0 (i j | z j , m 1 j , n j ).

i 1= m 1−

i J = m J−

j =1

j =1

Given the type I error rate α∗, we reject H 0 if pv < α∗.

Note that Mante–Haenszel (1959) test rejects H 0 in favor of H 1 for a large

value of S, and its p-value is calculated using the standardized test statistic

W = S − E

√

,

V





which is asymptotically N ( 0 , 1 ) under H

J

J

0, where E =

E

V

j =1

j , V =

j =1

j ,

E j = z j m 1 j /n j , and Vj = z j m 1 j m 2 j (n j − z j )/{ n 2 (n j

j − 1 )}. Westfall, Zaykin,

and Young (2002) propose a permutation procedure for a stratified Mantel–

Haenszel test, which permutes the two-sample binary data within each

Randomized Phase II Trials with Heterogeneous Patient Populations

177

stratum in the context of multiple testing. Their permutation maintains the

margin totals for 2×2 tables, { (z j , m 1 j , n j ), 1 ≤ j ≤ J }, and E j and Vj depend on the margin totals only, so that the permutation-based Mantel–Haenszel test

will be identical to our stratified Fisher’s exact test if they go through all the



possible

J

(m

j =1

j + − m j− + 1 ) permutations. In order to save computing time,

a permutation test often randomly selects partial permutations to approxi-

mate the exact p-value. In this case, the resulting p-value approximated from

partial permutations will be varying, depending on the selected seed number

for random number generation or the number of permutations, while the exact

method always provides a constant exact p-value for a given data set.

Example 9.1

Li et al. (1979) are interested in whether thymosin (experimental), compared

to placebo (control), has any effect in the treatment of bronchogenic carci-

noma patients receiving radiotherapy. Table 9.2 summarizes the data for three

strata. The one-sided p-value to test if the experimental arm has a higher

treatment effect is 0.1563 by the stratified Fisher’s exact test.

Table 9.2

Response to thymosin in bronchogenic carcinoma patients

(T = thymosin, P = placebo)

Stratum 1

Stratum 2

Stratum 3

T

P

Total

T

P

Total

T

P

Total

Success

10

12

22

9

11

20

8

7

15

Failure

1

1

2

0

1

1

0

3

3

Total

11

13

24

9

12

21

8

10

18

9.1.2

Power and Sample Size Calculation

Jung et al. (2007) propose a sample size calculation method for the Mantel–

Haenszel test. In this section, we derive a sample size formula for the stratified

Fisher’s exact test by specifying the values of the same input parameters as

those for Mantel–Haenszel test by Jung et al. (2007). The following are input

parameters to be specified for a sample size calculation.

Input Parameters

• Type I and II error rate and power: (α∗ , 1 − β∗ )

• Response rates for arm 2 (control): (p 21 , . . . , p 2 J )

• Odds ratios: (θ 1 , . . . , θJ ) under H 1, where θj > 0. Note that, given p 2 j and θ j , we have p 1 j = θ j p 2 j /(q 2 j + θ j p 2 j ) for stratum j (= 1 , . . . , J ).

178

Randomized Phase II Cancer Clinical Trials

• Prevalence for each stratum: (η 1 , . . . , ηJ ), where ηj = E(n j/N). Note that η

J

j > 0 and

η

j =1

j = 1.

• Allocation proportion for arm 1 (experimental) within each stratum,

γ = m 1 j/n j, with 0 < γ < 1.

In a randomized phase II trial with the total sample size N prespecified at

the design stage, { (x j , z j , n j ), 1 ≤ j ≤ J } are random variables with following marginal and conditional probability mass functions that are indexed by the

above input parameters. Note that given n j , m 1 j = γ n j and m 2 j = ( 1 − γ )n j are fixed at the design stage, although they may be considered to be random

at the data analysis.

Distribution Functions

• Conditional distribution of x j given (z j, n j):





m 1 j

m 2 j

θxj

x

z

j

f

j

j − x j

j (x j | z j , n j ) =





m j+

m 1 j

m 2 j

θi

i = m j−

i

z

j

j − i

for m j− ≤ x j ≤ m j+, where m j− = max ( 0 , z j − m 2 j ), m j+ = min (z j , m 1 j ), and j = 1 , . . . , J . Under H 0, this is simplified to f 0 (x j | z j , n j ) =

f 0 (x j | z j , m 1 j , n j ).

• Conditional distribution of z j given n j:

Given n j , x j ∼ B(m 1 j , p 1 j ) and y j ∼ B(m 2 j , p 2 j ) are independent, so that the conditional probability mass function of z j = x j + yj is expressed

as

m





j +

m 1 j

m

m 2 j

z

m

g

1 j − x

j − x

2 j − z j + x

j (z j | n j ) =

px q

p

q

x

1 j 1 j

z

2 j

2 j

x= m

j − x

j −

for z j = 0 , 1 , . . . , n j and j = 1 , . . . , J , where qkj = 1 − pkj and B(m, p) denote the binomial distribution with number of trials m and success

probability p. Under H 0, this is simplified to

m





j +



z

n

m 1 j

m 2 j

g

j

j − z j

0 j (z j | n j ) = p

q

.

2 j 2 j

x

z

x= m

j − x

j −



Note that 0 p 0 ( 1 − p) 0 = 1 for p ∈ ( 0 , 1 ).

0

• Conditional distribution of (n 1 , . . . , nJ ) given N is multinomial with probability mass function

J



lN (n 1 , . . . , n J ) =

N !



ηnj

J

j

n

j =1

j ! j=1



for 0 ≤ n

J

1 ≤ N , . . . , 0 ≤ n J ≤ N and

n

j =1

j = N .

Randomized Phase II Trials with Heterogeneous Patient Populations

179

We first derive the power function for a given sample size N using these

distribution functions. Let z = (z 1 , . . . , zJ ) and n = (n 1 , . . . , n J ). Given (z, n) and type I error rate α∗, the critical value aα∗ = aα∗ (z, n) is the smallest integer a satisfying





m 1+



m J+



J



J



P(S ≥ a| z, n, H





0 ) =

· · ·

I

i j ≥ a

f 0 (i j | z j , n j ) ≤ α∗ .

i 1= m 1−

i J = m J−

j =1

j =1

Note that s ≥ aα∗ (z, n) if and only if pv (s| z, m, n) ≤ α∗. We call α(z, n) =

P(S ≥ aα∗| z, n, H 0 ) the conditional type I error rate given (z, n). Similarly, the conditional power 1 − β(z, n) given (z, n) is obtained by





m 1+



m J+



J



J



P(S ≥ aα∗| z, n, H





1 ) =

· · ·

I

i j ≥ aα∗

f j (i j | z j , n j ).

i 1= m 1−

i J = m J−

j =1

j =1

For a chosen N , the marginal type I error rate and power are given as

αN ≡ E{ α(z, n)| H 0} = En[ Ez{ α(z, n)| n, H 0}| n]



m 1+



m J+



=

· · ·

α(z

n∈ D

1 , . . . , z J ; n 1 , . . . , n J )

N z 1= m 1−

z J = m J−





 J





×  g 0 j(zj| nj) lN(n 1 ,... ,nJ)

j =1

and

1 − βN ≡ E{1 − β(z, n)| H 1} = En[ Ez{ α(z, n)| n, H 1}| n]



m 1+



m J+



=

· · ·

{1 − β(z

n∈ D

1 , . . . , z J ; n 1 , . . . , n J )}

N z 1= m 1−

z J = m J−





 J





×  gj(zj| nj) lN(n 1 ,... ,nJ),

j =1

respectively, where DN = { (n 1 , . . . , n J ) : 0 ≤ n 1 ≤ N, . . . , 0 ≤ n J ≤ N, J n

j =1

j = N } and E z (· ) denotes the expected value with respect to a random vector z.

Since α(z, n) ≤ α∗ for all (z, n), we have αN ≤ α∗. Given power 1 − β∗, the required sample size is chosen by the smallest integer N satisfying 1 − βN ≥

1 − β∗. In other words, while the statistical testing controls the conditional

type I error α(z, n) below α∗, the sample size is determined to guarantee a specified level of marginal power. In summary, a sample size is calculated as

follows.

180

Randomized Phase II Cancer Clinical Trials

Sample Size Calculation

(A) Specify input parameters: J , (α∗ , 1 − β∗ ), ( p 21 , . . . , p 2 J ), (θ 1 , . . . , θJ ), (η 1 , . . . , ηJ ), γ .

(B) Starting from the sample size for Mantel–Haenszel test NM H , do the

following by increasing N by 1,



(B1) For j = 1 , . . . , J , z

J

j ∈ [0 , n j ], n j ∈ [0 , N ], and

n

j =1

j = N ,

(i) Find aα∗ = aα∗ (z, n).

(ii) Calculate 1 − β(z, n) = P(S ≥ aα∗| z, n, H 1 ).

(B2) Calculate 1 − βN = E{1 − β(z, n)| H 1}.

(C) Stop (B) if 1 − βN ≥ 1 − β∗. This N is the required sample size.

9.1.3

Numerical Studies

We want to compare the small sample performance of the stratified Fisher’s

test and Mantel–Haenszel tests using simulations. In order to consider unequal

allocations among strata, let y j = n j /N . We generate B = 10 , 000 simulation samples of size N = 25, 50, or 75 with J = 2 strata under η 1 = 0 . 25, 0.5, or 0.75; (γ 1 , γ 2 ) = ( 1 / 4 , 3 / 4 ), ( 1 / 2 , 1 / 2 ), or ( 3 / 4 , 1 / 4 ); p 21 = 0 . 1, p 22 = 0 . 3, or 0.7; (θ 1 , θ 2 ) = ( 1 , 1 ), ( 5 , 10 ), ( 7 . 5 , 7 . 5 ), or ( 10 , 5 ). The stratified Fisher’s test, standard (unstratified) Fisher’s test, and Mantel–Haenszel test are applied to

each simulation sample, and the empirical power for each test is calculated as

the proportion of simulation samples rejecting H 0 with one-sided α∗ = 0 . 05.

The exact type I error rate and power for the stratified Fisher’s test can

be calculated by using the methods in Section 9.1.2, but through simulations

we want to compare the performance of the these testing methods applied to

the same data sets. We consider large odds ratios to investigate the perfor-

mance of Fisher’s tests and the Mantel–Haenszel test with small sample sizes.

Table 9.3 summarizes the simulation results. With 10,000 simulations and

α∗ = 0 . 05, the 95% confidence limits for the empirical type I error rate are

0 . 05 ± 0 . 004. Because of the discreteness of the exact tests and the conser-

vative control of the conditional type I error at all possible outcomes, the

stratified Fisher’s test is always conservative as expected, especially with a

small sample size ( N = 25). The unstratified test has a similar type I error

rate to stratified Fisher’s test when allocation proportions are identical be-

tween two strata (i.e., γ 1 = γ 2). However, if more patients are allocated in

the stratum with higher response rates (that is, γ 1 = 1 / 4 and γ 2 = 3 / 4), then the unstratified Fisher’s test becomes anticonservative. On the other hand, if

more patients are allocated to the stratum with smaller response rates (that

is, γ 1 = 3 / 4 and γ 2 = 1 / 4), then the unstratified Fisher’s test becomes very conservative. In this sense, testing ignoring the strata can be biased unless

the allocation proportions are identical across strata. With N = 25 or 50, the

Randomized Phase II Trials with Heterogeneous Patient Populations

181

Mantel–Haenszel test is anticonservative with p 22 = 0 . 7 (that is, when two

strata have very different response rates) or with η 1 = 0 . 75 (that is, when

a small number of subjects are allocated to the stratum with large response

probabilities). The anticonservativeness diminishes as N increases but is still

of some issue with η 1 = 0 . 75 and N = 75.

When allocation proportions are equal across the strata, ignoring the strata

results in a slight loss of statistical power. The stratified Fisher’s test is less

powerful than the Mantel–Haenszel test, but the difference in power decreases

in N . For all three testing methods, the power increases when more patients

are allocated to the stratum with the larger odds ratio, e.g., θ 1 < θ 2 and

η 1 < 1 / 2.

Table 9.4 reports the sample sizes for the Mantel–Haenszel test and strati-

fied Fisher’s test. Also reported are sample sizes for the stratified Fisher’s test

by fixing (m, n) or only n at their expected values. The design parameters are set at one-sided α∗ = 0 . 05; 1 − β∗ = 0 . 9; J = 2 strata; γ = 0 . 25, 0.5, or 0.75; (η 1 , η 2 ) = ( 0 . 25 , 0 . 25 ), (0.25,0.75), (0.5,0.5), (0.75,0.25), or (0.75,0.75); (p 21 , p 22 ) = ( 0 . 1 , 0 . 3 ); (θ 1 , θ 2 ) = ( 5 , 10 ), ( 7 . 5 , 7 . 5 ), or ( 10 , 5 ). For the stratified Fisher’s test, fixing (m, n) at their expected values reduces N , while fixing only n requires almost the same N compared to the case with random

(m, n). The sample sizes are minimized with a balanced allocation, that is,

γ = 1 / 2. We also observe that the cases of (η 1 , η 2 ), ( 1 − η 1 , η 2 ), (η 1 , 1 − η 2 ), and ( 1 − η 1 , 1 − η 2 ) require similar sample sizes. That is, when the allocation between two arms is unbalanced, the required sample size does not much depend on whether the larger arm is control or experimental across the different

strata.

Under each setting, the sample size for the stratified Fisher’s test is

about 30% larger than that of the Mantel–Haenszel test. This difference

results from the conservative type I error and power control of the strati-

fied Fisher’s test. For example, from Table 9.3, with (γ, η 1 , η 2 , p 21 , p 22 ) =

( 0 . 5 , 0 . 25 , 0 . 75 , 0 . 1 , 0 . 3 ), the stratified Fisher’s test controls the type I error at 0.0230 with N = 75 and has a power of 0.9042 at (θ 1 , θ 2 ) = ( 5 , 10 ). Under this design setting, the stratified Fisher’s test requires a sample size of size of

N = 75 with (α∗ , 1− β∗ ) = ( 0 . 05 , 0 . 9 ) from Table 9.4. For the Mantel–Haenszel test, the required sample size with (α∗ , 1 − β∗ ) = ( 0 . 0230 , 0 . 9042 ) under the same design setting is N = 73, which is close to N = 75 required for the stratified Fisher’s test. In other words, the conservativeness of the Fisher test results

from the discreteness of the exact testing distributions. The Mantel–Haenszel

test approximates this exact distribution when the sample size is large. Crans

and Schuster (2008) propose to conduct Fisher’s test with a larger type I error

α∗ = α + ( > 0) so that the maximal marginal type I error rate within the whole range [0 , 1] of the response probability under H 0 becomes close to the

intended α level.

Suppose that we want to design a study similar to that of Li et al.

(1979). Since this is a balanced randomization study, we fix (n 1 , n 2 , n 3 ) at (N/ 3 , N/ 3 , N/ 3 ) and (m 1 , m 2 , m 3 ) at (N/ 6 , N/ 6 , N/ 6 ). We further assume that

182

Randomized Phase II Cancer Clinical Trials

with

5387

4642

6261

4854

5223

3024

5919

5563

6689

6036

5583

4286

6485

6364

7143

6863

5649

5202

7950

7115

8983

7657

7898

6180

/. /. /. /. /. /. /. /. /. /. /. /. /. /. /. /. /. /.

/. /. /. /. /. /.

5)

test

5989

6782

4855

2671

3220

0435

7073

8318

5131

3447

3266

0511

6830

7967

5570

4460

3443

1077

9156

9555

8353

5581

6166

0870

/. /. /. /. /. /. /. /. /. /. /. /. /. /. /. /. /. /.

/. /. /. /. /. /.

(10,

. 3470 . 2395 . 4668 . 2803 . 3354 . 1192 . 3862 . 3156 . 5055 . 3980 . 3467 . 2019 . 4382 . 4054 . 5553 . 5014 . 3479 . 2937

. 6851 . 5318 . 8343 . 6426 . 6789 . 4568

tel–Haenszel

6332

5011

7179

5202

6053

2934

6219

5371

6958

5603

5717

3673

5959

5620

6543

5950

5013

4100

8816

7431

9463

8058

8734

6427

/. /. /. /. /. /. /. /. /. /. /. /. /. /. /. /. /. /.

/. /. /. /. /. /.

7.5)

7230

7143

5762

2693

3229

0354

7852

8356

5253

2914

2698

0308

6876

7500

4814

3510

2468

0592

9713

9702

8958

5609

6340

0614

test/Man

/. /. /. /. /. /. /. /. /. /. /. /. /. /. /. /. /. /.

/. /. /. /. /. /.

(7.5,

. 4305 . 2556 . 5764 . 2909 . 4061 . 1073 . 4091 . 2847 . 5366 . 3441 . 3627 . 1547 . 3815 . 3325 . 4739 . 3981 . 2896 . 1980

. 7918 . 5702 . 9064 . 6856 . 7890 . 4653

Fisher’s

6809

5062

7595

5003

6448

2523

5898

4737

6653

4796

5389

2684

5041

4463

5478

4532

3921

2703

9073

7422

9657

7930

9048

6240

/. /. /. /. /. /. /. /. /. /. /. /. /. /. /. /. /. /.

/. /. /. /. /. /.

10)

7864

7160

5878

2398

2817

0211

7984

8140

4608

2177

1740

0146

6508

6819

3681

2274

1315

0258

9837

9696

9174

5045

5754

0335

(5,

/. /. /. /. /. /. /. /. /. /. /. /. /. /. /. /. /. /.

/. /. /. /. /. /.

. 4812 . 2464 . 6164 . 2608 . 4447 . 0847 . 3750 . 2285 . 4852 . 2564 . 3260 . 0951 . 2830 . 2238 . 3572 . 2514 . 1904 . 0999

. 8271 . 5607 . 9343 . 6610 . 8273 . 4361

test/unstratified

. 10 )

Fisher’s

=

, 1 ( 1

0370

0572

0522

0493

0599

0314

0476

0668

0455

0507

0542

0255

0564

0669

0425

0478

0321

0162

0419

0525

0540

0460

0546

0473

/. /. /. /. /. /. /. /. /. /. /. /. /. /. /. /. /. /.

/. /. /. /. /. /.

p 21

= ) 2 0354 1785 0176 0189 0055 0007 0560 2987 0120 0210 0032 0001 0380 2124 0106 0166 0009 0004 0808 3873 0272 0278 0051 0002

,θ

/. /. /. /. /. /. /. /. /. /. /. /. /. /. /. /. /. /.

/. /. /. /. /. /.

stratified

and

1 (θ

. 0094 . 0149 . 0179 . 0161 . 0171 . 0059 . 0101 . 0157 . 0118 . 0164 . 0130 . 0052 . 0096 . 0125 . 0104 . 0097 . 0033 . 0019

. 0188 . 0228 . 0287 . 0219 . 0248 . 0170

of

er

strata,

owp 2= p 22 .3 .7 .3 .7 .3 .7 .3 .7 .3 .7 .3 .7 .3 .7 .3 .7 .3 .7 .3 .7 .3 .7 .3 .7

J

. 05,0 )

)

)

)

)

)

)

)

)

)

)

)

)

Empirical

=

2

/ 4

/ 2

/ 4

/ 4

/ 2

/ 4

/ 4

/ 2

/ 4

/ 4

/ 2

/ 4

,η

, 3

, 1

, 1

, 3

, 1

, 1

, 3

, 1

, 1

, 3

, 1

, 1

∗ α η 1 25 / 4

/ 2

/ 4

/ 4

/ 2

/ 4

/ 4

/ 2

/ 4

50

/ 4

/ 2

/ 4

( 1

( 1

( 3

( 1

( 1

( 3

( 1

( 1

( 3

( 1

( 1

( 3

9.3

=

=

N

N

(a)

(b)

ableT one-sided γ(

.25

.5

.75

.25

Randomized Phase II Trials with Heterogeneous Patient Populations

183

with

8373

8047

9173

8656

8377

7388

8821

8708

9425

9325

8567

8282

9250

8366

9726

8998

9197

7999

9490

9145

9812

9611

9408

8891

9627

9576

9907

9873

9581

9475

/. /. /. /. /. /. /. /. /. /. /. /.

/. /. /. /. /. /. /. /. /. /. /. /. /. /. /. /. /. /.

5)

test

9670

9930

8560

6685

6580

0854

9579

9863

8935

7958

6874

2060

9887

9949

9538

7538

8162

1235

9976

9999

9661

8395

8300

1121

9967

9990

9786

9312

8699

3032

/. /. /. /. /. /. /. /. /. /. /. /.

/. /. /. /. /. /. /. /. /. /. /. /. /. /. /. /. /. /.

(10,

. 7416 . 6658 . 8610 . 7785 . 7333 . 6067 . 7877 . 7632 . 8978 . 8757 . 7597 . 7184

. 8760 . 7293 . 9561 . 8442 . 8701 . 7008 . 9059 . 8395 . 9686 . 9294 . 9025 . 8244 . 9277 . 9172 . 9830 . 9751 . 9260 . 9038

tel–Haenszel

8652

7734

9344

8400

8476

7021

8486

8036

9153

8764

8109

7415

9639

8714

9919

9236

9646

8230

9586

8946

9873

9496

9519

8618

9468

9209

9837

9631

9323

8996

/. /. /. /. /. /. /. /. /. /. /. /.

/. /. /. /. /. /. /. /. /. /. /. /. /. /. /. /. /. /.

7.5)

9848

9911

8670

5956

5538

0442

9580

9773

8385

6826

5407

1125

9980

9969

9806

7500

8248

0862

9995

9996

9694

7792

7408

0473

9964

9983

9591

8521

7363

1583

test/Man

/. /. /. /. /. /. /. /. /. /. /. /.

/. /. /. /. /. /. /. /. /. /. /. /. /. /. /. /. /. /.

(7.5,

. 7670 . 6113 . 8818 . 7359 . 7542 . 5495 . 7407 . 6632 . 8521 . 7891 . 7015 . 6104

. 9335 . 7694 . 9844 . 8730 . 9339 . 7305 . 9214 . 8066 . 9768 . 9096 . 9153 . 7788 . 9024 . 8531 . 9672 . 9352 . 8917 . 8299

Fisher’s

8457

7099

9174

7606

8281

5971

7492

6698

8277

7383

7119

5740

9779

8654

9961

9223

9761

8142

9472

8375

9818

9044

9407

7738

8838

8135

9491

8778

8670

7582

/. /. /. /. /. /. /. /. /. /. /. /.

/. /. /. /. /. /. /. /. /. /. /. /. /. /. /. /. /. /.

10)

9864

9872

8247

4701

3740

0163

9394

9534

7025

4931

3242

0343

9995

9975

9872

7010

7684

0394

9993

9999

9506

6587

5448

0130

9919

9953

8914

6657

4821

0400

/. /. /. /. /. /. /. /. /. /. /. /.

/. /. /. /. /. /. /. /. /. /. /. /. /. /. /. /. /. /.

ued)

(5,

tin

. 7341 . 5288 . 8547 . 6250 . 7192 . 4254 . 6018 . 4961 . 7304 . 6033 . 5771 . 4141

. 9552 . 7572 . 9917 . 8660 . 9545 . 7096 . 9042 . 7246 . 9660 . 8388 . 8984 . 6646 . 8057 . 6984 . 9092 . 8070 . 7965 . 6444

test/unstratified

(con . 10 )

Fisher’s

=

, 1 ( 1 0522 0586 0498 0527 0507 0413 0550 0624 0525 0521 0458 0321 0474 0554 0472 0519 0559 0467 0472 0547 0498 0544 0487 0477 0543 0567 0491 0527 0469 0413

/. /. /. /. /. /. /. /. /. /. /. /.

/. /. /. /. /. /. /. /. /. /. /. /. /. /. /. /. /. /.

p 21

= ) 2 1345 6002 0212 0289 0014 0000 1024 4640 0211 0250 0016 0000 1274 5583 0279 0316 0028 0001 1974 7866 0258 0307 0013 0000 1521 6531 0237 0317 0016 0000

,θ

/. /. /. /. /. /. /. /. /. /. /. /.

/. /. /. /. /. /. /. /. /. /. /. /. /. /. /. /. /. /.

stratified

and

1 (θ . 0192 . 0229 . 0208 . 0243 . 0199 . 0142 . 0181 . 0197 . 0208 . 0206 . 0142 . 0083

. 0250 . 0279 . 0262 . 0291 . 0249 . 0235 . 0230 . 0266 . 0245 . 0280 . 0234 . 0212 . 0238 . 0238 . 0236 . 0249 . 0193 . 0171

of

er

strata,

owp 2=

7

p 22

.3

.7

.3

.7

.3

.7

.3

.7

.3

.7

.3

.7

.3

.7

.3

.7

.3

.7

.3

.7

.3

.7

.3

.7

.3

.7

.3

.7

.3

J

. 05,0 ) )

)

)

)

)

)

)

)

)

)

)

)

)

)

)

Empirical

=

2

/ 4

/ 2

/ 4

/ 4

/ 2

/ 4

/ 4

/ 2

/ 4

/ 4

/ 2

/ 4

/ 4

/ 2

/ 4

,η

, 3

, 1

, 1

, 3

, 1

, 1

, 3

, 1

, 1

, 3

, 1

, 1

, 3

, 1

, 1 ..

∗ α η 1 / 4

/ 2

/ 4

/ 4

/ 2

/ 4

75

/ 4

/ 2

/ 4

/ 4

/ 2

/ 4

/ 4

/ 2

/ 4

( 1

( 1

( 3

( 1

( 1

( 3

( 1

( 1

( 3

( 1

( 1

( 3

( 1

( 1

( 3

9.3

=

N

(c)

ableT one-sided γ( .5

.75

.25

.5

.75

184

Randomized Phase II Cancer Clinical Trials

Table 9.4

Sample size for Mantel–Haenszel test/stratified Fisher’s test

with (m, n) fixed/stratified Fisher’s test with n fixed/stratified Fisher’s test

under J = 2 strata, ( p 21 , p 22 ) = ( 0 . 1 , 0 . 3 ), one-sided α∗ = 0 . 05, and 1 − β∗ = 0 . 9

(θ 1 , θ 2 )

γ

(η 1 , η 2 )

(5, 10)

(7.5, 7.5)

(10, 5)

0.25

(0.25, 0.25)

46/59/61/61

51/64/66/66

65/80/82/82

(0.25, 0.75)

45/53/60/61

50/62/66/66

65/79/82/82

(0.5, 0.5)

36/43/45/45

39/48/49/49

50/59/62/62

(0.75, 0.25)

46/59/61/61

51/64/66/67

65/80/83/83

(0.75, 0.75)

46/53/60/61

51/60/66/66

65/76/83/83

0.5

(0.25, 0.25)

58/72/75/76

55/72/72/71

58/72/75/75

(0.25, 0.75)

58/65/75/75

54/65/70/71

58/72/75/75

(0.5, 0.5)

45/53/56/54

43/50/53/53

45/54/56/56

(0.75, 0.25)

59/72/75/76

56/66/71/71

59/72/76/78

(0.75, 0.75)

59/69/75/76

55/63/71/71

59/68/76/76

0.75

(0.25, 0.25)

78/96/97/98

59/75/76/76

52/64/67/67

(0.25, 0.75)

77/89/97/97

59/69/76/76

52/64/67/67

(0.5, 0.5)

61/70/73/73

47/55/57/57

41/49/51/51

(0.75, 0.25)

80/96/98/99

61/75/77/77

53/65/69/69

(0.75, 0.75)

80/85/98/99

61/69/77/77

53/62/69/69

(p 21 , p 22 , p 23 ) = ( 0 . 9 , 0 . 75 , 0 . 6 ), and (θ 1 , θ 2 , θ 3 ) = ( 1 , 30 , 30 ). (The estimates from Table 9.2 are ˆ

θ 1 = 0 . 833 and ˆ θ 2 = ˆ θ 3 = ∞.) In order to control the

one-sided conditional type I error at α∗ = 0 . 1 and the marginal power at

1 − β∗ = 0 . 9, we need N = 83. Under the design, this sample size provides

marginal αN = 0 . 0625 and power 1 − βN = 0 . 9087.

9.1.4

Discussions

Numerous testing methods have been proposed to test on two binomial pro-

portions adjusting for the stratum effect based on different assumptions. For

example, the Cochran (1954) test assumes common odds ratios across strata,

and Gart (1985) assumes common relative risks. The Mantel–Haenszel test

makes no assumption about the parameters. These methods are based on

large sample theories, so that their testing results may be distorted with a

small sample size or sparse data.

In this chapter, we propose to use an exact test extending Fisher’s test

to the analysis of many 2 × 2 tables together with its sample size calcu-

lation method for designing and analyzing randomized phase II trials with

heterogeneous patient populations. This test does not make any assumptions

of large sample size or equal parameter values across strata, so that it does

not require checking any assumptions before testing. The power and sample

sizes are compared between the exact test and the Mantel–Haenszel test using

Randomized Phase II Trials with Heterogeneous Patient Populations

185

simulations and the proposed sample size formulas. While the type I error rate

for the Mantel–Haenszel test can be anticonservative with a small sample size

or sparse data, the exact test always controls the type I error rate below a

specified level. When the effect size is so large that the required sample size is

small (say, about N = 70 or smaller), the exact test needs about 20% to 30%

larger sample size than the Mantel–Haenszel test. However, because of the

small sample sizes, the increase in sample size in this case is not very large in

absolute number (say, 10 to 20), so that for robustness of the testing results,

we propose to use the exact test by slightly increasing the sample size rather

than obtaining a biased result with an asymptotic test.

If J ≥ 3, the sample size calculation for the stratified Fisher’s test requires

a long computing time. We found, in calculating the marginal type I error rate

and power, that fixing the sizes of strata (n 1 , . . . , n J ) at their expected num-

bers provides very accurate sample sizes for the stratified Fisher’s test even

when (n 1 , . . . , n J ) are random, while drastically saving the computing time.

9.2

Two-Stage Designs with an Interim Futility Test

In this section, we consider two-stage randomized phase II clinical trials, so

that we can stop the trial early when the experimental arm is shown to be

inefficacious compared to the control. At stage l(= 1 , 2 ), Nl patients are randomized between two arms stratified for J strata. Let N = N 1 + N 2 denote the maximal sample size, and, for stage l, nlj the sample size in stratum j



(

J

n

j =1

l j = Nl ). Among nl j patients in stratum j (= 1 , . . . , J ), m 1 l j are allocated to arm 1 (experimental) and m 2 lj to arm 2 (control). For stratum j

during stage l, let xlj and ylj denote the numbers of responders for arms 1

and 2, respectively, and zlj = xlj + ylj the total number of responders from

the two arms. The frequency data in stratum j at stage l can be described as

in Table 9.5.

Table 9.5

Frequencies (and response probabilities) of stratum

j (= 1 , . . . , J ) at stage l(= 1 , 2 )

Arm 1

Arm 2

Total

Response

Yes

xlj ( p 1 j )

ylj ( p 2 j )

zlj

No

m 1 lj − xlj ( q 1 j )

m 2 lj − ylj ( q 2 j )

nlj − zlj

Total

m 1 lj

m 2 lj

nlj

In a two-stage randomized phase II trial with stage l sample size Nl pre-

specified, { (xlj , zlj , nlj ), 1 ≤ j ≤ J } are random variables with the following marginal and conditional probability mass functions. Note that given nlj ,

186

Randomized Phase II Cancer Clinical Trials

m 1 lj = γ nlj , and m 2 lj = ( 1 − γ )nlj are fixed at the design stage, although they may be random at the data analysis.

Distribution Functions

• Conditional distribution of xlj given (zlj, nlj):





m 1 lj

m 2 lj

θxlj

x

z

j

f

l j

l j − xl j

j (xl j | zl j , nl j ) =





mlj+

m 1 lj

m 2 lj

θi

i = mlj−

i

z

j

l j − i

for mlj− ≤ xlj ≤ mlj+, where mlj− = max ( 0 , zlj − m 2 lj ), mlj+ =

min (zlj , m 1 lj ), and j = 1 , . . . , J . Under H 0, this is simplified to m 1 lj

m 2 lj

x

z

f

l j

l j − xl j

0 (xl j | zl j , nl j ) =



.

mlj+

m 1 lj

m 2 lj

i = mlj−

i

zlj − i

• Conditional distribution of zlj given nlj:

Given nlj , x 1 lj ∼ B(m 1 lj , p 1 j ) and ylj ∼ B(m 2 lj , p 2 j ) are independent, so that the conditional probability mass function of zlj = xlj + ylj is

expressed as

m





l j +



m 1 lj

m

m 2 lj

z

m

g

1 l j − x

l j − x

2 k j − zl j + x

j (zl j | m 1 l j , nl j ) =

px q

p

q

x

1 j 1 j

z

2 j

2 j

x= m

l j − x

l j −

for zlj = 0 , 1 , . . . , nlj and j = 1 , . . . , J . Under H 0, this is simplified to m





l j +



z

n

m 1 lj

m 2 lj

g

l j

l j − zl j

0 j (zl j | nl j ) = p

q

.

2 j

2 j

x

z

x= m

l j − x

l j −

• We assume that, within each stratum, patients are randomized to arm

1 with probability γ , that is, m 1 lj /nlj = γ .

• Let η

J

j denote the prevalence of stratum j (

η

j =1

j = 1 ). At stage l , the

conditional distribution of (nl 1 , . . . , nl J ) given the stage l sample size N

J

l =

n

j =1

l j is multinomial with probability mass function

J



h(nl 1 , . . . , nl J | Nl) =

Nl !



ηnlj

J

j

n

j =1

l j ! j=1



for 0 ≤ n

J

l 1 ≤ Nl , . . . , 0 ≤ nl J ≤ Nl and

n

j =1

l j = Nl .



Let S

J

l =

x

j =1 l j and S = S 1 + S 2. A two-stage randomized phase II trial with a futility rejection value a 1 and the second-stage rejection value a are chosen

conditional on { (zlj , nlj ), l = 1 , 2 , j = 1 , . . . , J } is conducted as follows.

Randomized Phase II Trials with Heterogeneous Patient Populations

187

Stage 1: Recruit N 1 patients, of which N 11 = γ N 1 are randomized to arm 1

and N 21 = ( 1− γ )N 1 are randomized to arm 2; observe { (x 1 j , z 1 j ), j =

1 , . . . , J } together with (n 1 j , j = 1 , . . . , J ).

a. Given { (z 1 j , n 1 j ), j = 1 , . . . , J }, find a stopping value a 1.

b. If S 1 ≥ a 1, proceed to stage 2.

c. Otherwise, reject the experimental therapy (arm 1) and stop the

trial.

Stage 2: Recruit N 2 patients, of which N 12 = γ N 2 patients are randomized to arm 1 and N 22 = ( 1 − γ )N 2 patients are randomized to arm 2;

observe { (x 2 j , z 2 j ), j = 1 , . . . , J } together with (n 2 j , j = 1 , . . . , J ).

a. Given { (zlj , nlj ), l = 1 , 2; j = 1 , . . . , J }, find a rejection value a.

b. Accept the experimental arm for further investigation if S ≥ a.

Given the type I error rate α∗, we have to determine critical values (a 1 , a)

conditioning on { (zlj , nlj ), l = 1 , 2 , j = 1 , . . . , J }.

9.2.1

How to Choose (a 1 , a)

In this section, we assume that (N 1 , N 2 ) are given. After stage 1, we determine a rejection value a 1 for S 1 conditioning on the observed values of { (z 1 j , n 1 j ), j =

1 , . . . , J }. We may consider following approaches:

(I) We may wish to stop the trial if the experimental arm has a smaller

number of responders than the expected number of responders under



H

J

0. In this case, we choose a 1 = [

z

j =1 1 j m 11 j /n 1 j ], where [ c] denotes

the largest integer not exceeding c.

(II) Based on type II error rate spending: For a chosen β 1 (< β∗ ), we choose

the smallest integer a 1 satisfying

P{ S 1 < a 1| (z 1 j , n 1 j , θ j ), j = 1 , . . . , J } ≤ β 1 , where the conditional probability in the left-hand side is calculated by





m 11+



m 1 J+



J



J



· · ·

I 

i



1 j < a 1

f j (i 1 j | z 1 j , n 1 j ).

i 11= m 11−

i 1 J = m 1 J−

j =1

j =1

(III) Probability of early termination (PET): One may want to choose a 1 so

that the conditional PET under H 0 is at least a prespecified level ψ by

choosing

P[ S 1 < a 1|{ (z 1 j , n 1 j ), j = 1 , . . . , J } , H 0] ≥ ψ, where the conditional probability in the left-hand side is calculated by

the largest integer a 1 satisfying





m 11+



m 1 J+



J



J



· · ·

I 

i



1 j < a 1

f 0 (i 1 j | z 1 j , n 1 j ).

i 11= m 11−

i 1 J = m 1 J−

j =1

j =1

188

Randomized Phase II Cancer Clinical Trials

Suppose that a 1 is chosen by one of these methods. Then, the rejection value

for stage 2, a, is chosen so that the conditional type I error rate is controlled

at or below a specified level α∗, that is, a is the smallest integer satisfying

α(z, n) ≤ α∗, where

α(z, n) = P(S 1 ≥ a 1 S ≥ a| z, n, H 0 )





m 11+



m 1 J+



m 21+



m 2 J+



J



2

J



=

· · ·

· · ·

I 

i



1 j ≥ a 1 ,

ilj ≥ a

i 11= m 11−

i 1 J = m 1 J− i 21= m 21−

i 2 J = m 2 J−

j =1

l=1 j=1

2

J



×

f 0 (ilj | zlj , nlj ).

l=1 j=1

For chosen (a 1 , a), the conditional power is calculated by

1 − β = P(S 1 ≥ a 1 S ≥ a| z, n, H 1 )





m 11+



m 1 J+



m 21+



m 2 J+



J



2

J



=

· · ·

· · ·

I 

i



1 j ≥ a 1 ,

ikj ≥ a

i 11= m 11−

i 1 J = m 1 J− i 21= m 21−

i 2 J = m 2 J−

j =1

k=1 j=1

2

J



×

f j (ilj | zlj , nlj ).

l=1 j=1

9.2.2

Two-Stage Designs for Stratified Fisher’s Exact Test

To design a randomized phase II trial based on the Fisher test, we need

to specify design parameters: (i) (α∗ , 1 − β∗ ); (ii) response rates under H 1,

{ (p 1 j, p 2 j), j = 1 , . . . , J}; (iii) allocation proportions, γ = Nk 1 /Nk; prevalence of each cluster, η j = nkj /Nk for j = 1 , . . . , J .

With values of these design parameters specified, we calculate sample size

(N 1 , N 2 ) as follows:

• Given N,

For N 1 = 1 , . . . , N − 1 and N 2 = N − N 1, calculate



1. For n

J

l j = 0 , . . . , Nl and

n

j =1

l j = Nl ,

(i) For zlj = 0 , 1 , . . . , nlj ,

– Find (a 1 , a) to control the conditional type I error rate

α(z, n) below α∗.

– For the chosen (a 1 , a), calculate the conditional power 1 − β

(z, n).

(ii) Calculate the conditional power

n 11



n 1 J

n 21



n 2 J



2

J



1− β(n) =

· · ·

· · ·

{1− β(z, n)}

g j (zlj | nlj ),

z 11=0

z 1 J =0 z 21=0

z 2 J =0

l=1 j=1

where m 1 lj is the round-off value of γ nlj .

Randomized Phase II Trials with Heterogeneous Patient Populations

189

2. Calculate the marginal power





2



1 − β =

{1 − β(n)}

h(nl 1 , . . . , nl J | Nl),

(n 11 ,... ,n 1 J )∈ C 1 (n 21 ,... ,n 2 J )∈ C 2

l=1

where Cl = { (nl 1 , . . . , nl J ) : 0 ≤ nl 1 ≤ Nl, . . . , 0 ≤ nl J ≤



N

J

l ,

n

j =1

l j = Nl } for l = 1 , 2.

3. If 1 − β ≥ 1 − β∗, save (N 1 , N ) as a candidate design, and repeat

the above procedure with N 1 = N 1 + 1

• Repeat the above procedure with N = N + 1.

For a design (N 1 , N 2 ) satisfying the (α∗ , 1 − β∗ )-condition, the conditional probability of early termination under H 0 is calculated as

PET0 (z 11 , . . . , z 1 J , n 11 , . . . , n 1 J ) = P(S 1 < a 1| z 11 , . . . , z 1 J , n 11 , . . . , n 1 J ).

Recall that a 1 may be a function of (z 11 , . . . , z 1 J , n 11 , . . . , n 1 J ). But to simplify the computing time, we propose to choose option (i), that is, a 1 =



[

J

z

j =1 1 j m 11 j /n 1 j ]. By taking the expectation of the conditional probability of early termination with respect to (z 11 , . . . , z 1 J , n 11 , . . . , n 1 J ), we obtain the marginal probability of early termination under H 0, PET0. Among those

(N 1 , N 2 ) satisfying the (α∗ , 1 − β∗ )-condition, the Simon-type (1989) minimax and the optimal designs can be chosen as follows:

Minimax design chooses (N 1 , N 2 ) with the smallest maximal sample size N (= N 1 + N 2 ).

Optimal design chooses (N 1 , N 2 ) with the smallest marginal expected

sample size EN under H 0, where

EN = N 1 × PET0 + N × ( 1 − PET0 ).

For a chosen two-stage design (N 1 , N 2 ), we can calculate the marginal type

I error rate α by taking expectation of the conditional type I error rate

α(z 11 , . . . , z 1 J , n 11 , . . . , n 1 J ) with respect to (z 11 , . . . , z 1 J , n 11 , . . . , n 1 J ).

9.2.3

Conditional P-Value

When a study is completed, one may want to calculate a p-value to see how

significant the outcome is. If the a trial is terminated after stage 1, then

we calculate a p-value using the Fisher exact test for a single-stage design.

Suppose that the study is completed after the second stage with observations

x together with marginal totals (z, m, n). For the observed test statistics s

J

l =

x

j =1 1 l j and s = s 1 + s 2, let a 1 denote the rejection value for stage 1

that is chosen by one of the rules proposed in Section 9.2.1 with s 1 ≥ a 1. Then,

190

Randomized Phase II Cancer Clinical Trials

the conditional p-value is calculated as

p-value = P(S 1 ≥ a 1 , S ≥ s| z, m, n, H 0 )





m 11+



m 1 J+



m 21+



m 2 J+



J



2

J



=

· · ·

· · ·

I 

i



1 j ≥ a 1 ,

ilj ≥ a

i 11= m 11−

i 1 J = m 1 J− i 21= m 21−

i 2 J = m 2 J−

j =1

l=1 j=1

2

J



×

f 0 (ilj | zlj , mlj , nlj )

l=1 j=1

for mlj− = max ( 0 , zlj − m 2 lj ) and mlj+ = min (zlj , m 1 lj ).

References

Cochran, W.C. (1954). Some methods of strengthening the common χ 2 tests.

Biometrics, 10, 417–451.

Crans, G.G. and Schuster, J.J. (2008). How conservative is Fisher’s exact

test? A quantitave evaluation of the two-sample comparative binomial

trial. Statistics in Medicine, 27, 3598–3611.

Fisher, R.A. (1935). The logic of inductive inference (with discussion). Journal

of Royal Statistical Society, 98, 39–82.

Gart, J.J. (1985). Approximate tests and interval estimation of the common

relative risk in the combination of 2 × 2 tables. Biometrika, 72, 673–677.

Jung, S.H., Chow, S.C., and Chi, E.M. (2007). A note on sample size calcu-

lation based on propensity analysis in nonrandomized trials. Journal of

Biopharmaceutical Statistics, 17, 35–41.

Li, S.H., Simon, R.M., and Gart, J.J. (1979). Small sample properties of the

Mantel–Haenszel test. Biometrika, 66, 181–183.

Mantel, N. and Haenszel, W. (1959). Statistical aspects of the analysis of data

from retrospective studies of disease. Journal of the National Cancer

Institute, 22, 719–748.

Simon, R. (1989). Optimal two-stage designs for phase II clinical trials. Con-

trolled Clinical Trials, 10, 1–10.

Westfall, P.H., Zaykin, D.V., and Young, S.S. (2002). Multiple tests for ge-

netic effects in association studies. Methods in Molecular Biology, vol.

184 Biostatistical Methods, pp. 143–168. Stephen Looney, Ed., Humana

Press, Toloway, NJ.





Chapter 10

Randomized Phase II Clinical Trials

Based on Survival Endpoints:

Two-Sample Log-Rank Test

While binary endpoints, such as overall response, are popularly used as the

primary outcome of phase II cancer clinical trials, we sometimes use time to

an event, such as time to progression or recurrence, as the primary outcome

as well. When the study endpoint is time to an event, the maximum likeli-

hood estimator (MLE) for exponential survival distributions may be used to

compare survival distributions among treatment arms. Sample size calculation

methods for test statistics based on the MLE of exponential distributions have

been proposed by Pasternack and Gilbert (1971), George and Desu (1973),

and Lachin (1981). Rubinstein et al. (1981) propose to use the sample size

formula derived for the MLE test for the log-rank test by showing that this

formula provides a reasonable power for the log-rank test through simulations.

Their simulations are limited to balanced designs only.

Because of their robustness, nonparametric rank tests are generally pre-

ferred to parametric MLE tests in survival analysis. The log-rank test (Peto

and Peto, 1972) has been widely used for testing the equality of two survival

distributions in the presence of censoring. The asymptotic normality of the

log-rank test can be found in Andersen et al. (1982) and Fleming and Harring-

ton (1991). Numerous methods have been proposed for sample size estimation,

including Lakatos (1977), Schoenfeld (1983), and Yateman and Skene (1992).

In this chapter, we discuss design of randomized phase II clinical trials with

a survival endpoint to be analyzed by the log-rank test.

10.1

Two-Sample Log-Rank Test

10.1.1

Test Statistic

In this chapter, we assume that arm 1 is a control arm and arm 2 is an ex-

perimental arm. Suppose that nk patients are randomized to arm k ( k = 1 , 2) and the survival times from the nk patients are independent and identically

191

192

Randomized Phase II Cancer Clinical Trials

distributed with cumulative hazard function k(t) and hazard function λk(t) =

∂k(t)/∂t. Under the proportional hazards assumption, = λ 1 (t)/λ 2 (t) denotes the hazard ratio. We want to test H 0 : = 1 against H 1 : > 1.

Let Tki denote the survival time for patient i in arm k (1 ≤ i ≤ nk; k = 1 , 2).

Then we usually observe (Xki , δki ), where Xki is the minimum of Tki and cen-

soring time Cki and δki is an event indicator taking 1 if the patient had an event

and 0 otherwise. Within each arm, the censoring times are independent of the





survival times. Let N

nk

nk

k (t ) =

δ

I (X

i =1 ki I ( Xki ≤ t ) and Yk (t ) =

i =1

ki ≥ t )

denote the death and the at-risk processes for arm k, respectively. Let

N (t) = N 1 (t) + N 2 (t) and Y (t) = Y 1 (t) + Y 2 (t). Then, the log-rank test statistic is given as

∞ Y 1 (t)Y 2 (t)

W = 1

√

{ d ˆ 1 (t) − d ˆ 2 (t)} ,

n 0

Y (t)



where ˆ



t

k (t ) =

Y

0

k (s)−1 d Nk (s) is the Nelson–Aalen (Nelson, 1969; Aalen,

1978) estimator of k(t). Under H 0, W/ˆ

σ is asymptotically standard normal

with

∞ Y

ˆ

σ 2 = 1

1 (t )Y 2 (t ) d N(t)

n 0

Y (t) 2

see, for example, Fleming and Harrington (1991). Hence, we reject H 0, in favor

of H 1, if W/ˆ

σ > z 1− α with one-sided type I error rate α.

10.1.2

Sample Size Calculation

Let pk = nk/n ( p 1 + p 2 = 1 ) denote the allocation proportion for arm k.

We assume that patients are accrued with a constant accrual rate, r , during

an accrual period and followed during an additional follow-up period b after

the last patient is entered. Let Sk(t) = exp{− k(t)} = P (Tki ≥ t) denote the survivor function for arm k, and G(t) = P (Cki ≥ t) denote the survivor function of the censoring distribution which is common between two arms.

The following results are based on Theorem 4.1. Note that Yk(t)/n uniformly

converges to pk G(t)Sk(t). Under H 1, ˆ

σ 2 converges to

∞

σ

G(t)S

2 =

1 (t ) 2 S 2 (t )

p 2 p

d

0

1

2

1 (t )

0

{ p 1 S 1 (t) + p 2 S 2 (t)}2

∞

+

G(t)S 1 (t)S 2 (t) 2

p 1 p 2

d

2

2 (t )

0

{ p 1 S 1 (t) + p 2 S 2 (t)}2

and the variance of W is given as

∞

σ

G(t)S

2 =

1 (t )S 2 (t ) 2

p

d

1

1 p 2

2

1 (t )

0

{ p 1 S 1 (t) + p 2 S 2 (t)}2

∞

+

G(t)S 1 (t) 2 S 2 (t)

p 2 p

d

1

2

2 (t ).

0

{ p 1 S 1 (t) + p 2 S 2 (t)}2

Randomized Phase II Clinical Trials Based on Survival Endpoints

193

√

Furthermore, under H 1, we can show that E (W ) =

nω, where

∞

ω =

G(t)S 1 (t)S 2 (t)

p 1 p 2

{ d 1 (t) − d 2 (t)} .

0

p 1 S 1 (t) + p 2 S 2 (t)

Hence, given n, the power is given as





W

1 − β = P

≥ z 1− α| H 1

ˆ

σ



√

√



σ

=

W −

nω

0

nω

P

≥

z

| H

σ

1− α −

1

1

σ 1

σ 1



√



σ

=

nω

¯



0 z

,

σ 1− α −

1

σ 1

where ¯

(· ) = 1 − (· ) and (· ) is the cumulative distribution function of the standard normal distribution. Given power 1 − β, the required sample size is

given as





σ

2

0 z 1− α + σ 1 z 1− β

n =

.

( 10 . 1 )

ω

Note that this formula is derived without a parametric assumption for survival

distributions or a nearby alternative assumption hypothesis.

By modifying George and Desu’s (1973) formula, Rubinstein et al. (1981)

propose to approximate the sample size for the log-rank test by that of the

exponential MLE test, that is,





log

2

1

= D−1 + D−1

( 10 . 2 )

z

1

2

1− α + z 1− β

under a balanced allocation ( p 1 = p 2 = 1 / 2 ), where 1 denotes the hazard ratio under H 1 and Dk denotes the number of events from arm k.

Using a nearby alternative hypothesis approximation (that is, 1 ≈ 1),

Schoenfeld (1983) derives the total number of events,

(z 1− α + z 1− β) 2

D =

( 10 . 3 )

p 1 p 2 ( log 1 ) 2

required for the log-rank test.

Noting that for 1 ≈ 1 or S 1 (t) ≈ S 2 (t), we have log 1 ≈ 1 − 1 and the probability of an event for arm k is

∞

dk = P (Tk ≤ C) ≈ −

G(t)d Sk(t),

0

we can show that our formula (10.1) can be approximated by the latter two

formulas (10.2) and (10.3) under the balanced allocation.

194

Randomized Phase II Cancer Clinical Trials

10.1.2.1

Under Exponential Survival and Uniform

Censoring Distributions

Suppose that patients are accrued at a constant rate during accrual period a

and all patients are followed for an additional follow-up period b after com-

pletion of accrual. Then, Cki ∼ U (b, a + b) with survivor function G(t) = 1 if t ≤ b; = 1 − (t − b)/a if b < t ≤ a + b; = 0 if t > a + b. Furthermore, suppose that the survival times have an exponential distribution with hazard rate λk

for arm k(= 1 , 2 ). Then, we have Sk(t) = exp (− λkt) and k(t) = λkt.

Under these distributional assumptions, we have





a+ b

a+ b

(

σ

e− ( 2 λ 1+ λ 2 )t

t − b)e− ( 2 λ 1+ λ 2 )t

2 = p 2 p

dt − 1

dt

0

1

2 λ 1

0

(p 1 e− λ 1 t + p 2 e− λ 2 t) 2

a b

(p 1 e− λ 1 t + p 2 e− λ 2 t) 2





a+ b

a+ b

(

+

e− (λ 1+2 λ 2 )t

t − b)e− (λ 1+2 λ 2 )t

p 1 p 2 λ

dt − 1

dt

2 2

0

(p 1 e− λ 1 t + p 2 e− λ 2 t) 2

a b

(p 1 e− λ 1 t + p 2 e− λ 2 t) 2

(10.4)





a+ b

a+ b

(

σ

e− (λ 1+2 λ 2 )t

t − b)e− (λ 1+2 λ 2 )t

2 = p

λ

dt − 1

dt

1

1 p 2

2 1

0

(p 1 e− λ 1 t + p 2 e− λ 2 t) 2

a b

(p 1 e− λ 1 t + p 2 e− λ 2 t) 2





a+ b

a+ b

(

+

e− ( 2 λ 1+ λ 2 )t

t − b)e− ( 2 λ 1+ λ 2 )t

p 2 p

dt − 1

dt

1

2 λ 2

0

(p 1 e− λ 1 t + p 2 e− λ 2 t) 2

a b

(p 1 e− λ 1 t + p 2 e− λ 2 t) 2

(10.5)

and





a+ b

a+ b (

ω =

e− (λ 1+ λ 2 )t

t − b)e− (λ 1+ λ 2 )t

p 1 p 2 (λ 1 − λ 2 )

dt − 1

dt .

0

p 1 e− λ 1 t + p 2 e− λ 2 t

a b

p 1 e− λ 1 t + p 2 e− λ 2 t

(10.6)

We calculate these integrals using a numerical method. By plugging these in

(10.1), we can calculate the sample size for given input values of (α, 1 − β,

λ 1 , λ 2 , a, b, p 1 ).

The required number of events at the analysis is calculated by D = n( p 1 d 1 +

p 2 d 2 ), where

∞

dk = −

G(t)d Sk(t) = 1 − e− bλk ( 1 − e− aλk ).

0

aλk

10.1.2.2

When Accrual Rate Is Specified Instead of

Accrual Period

Now, we consider a sample size calculation when the accrual rate r is given

instead of the accrual period a. Given (α, 1 − β, λ 1 , λ 2 , r, b, p 1 ), σ 2 = σ 2 (a), 1

1

σ 2 = σ 2 (a), and ω = ω(a) are functions of a from (10.4)–(10.6). Also, under 2

2

a constant accrual rate assumption, we have n = a × r approximately. So, by

Randomized Phase II Clinical Trials Based on Survival Endpoints

195

replacing n with a × r in (10.1), we obtain an equation on a,





σ

2

0 (a)z 1− α + σ 1 (a)z 1− β

a × r =

.

ω(a)

We solve this equation using a numerical method, such as the bisection

method. Let a∗ denote the solution to this equation. Then, the required sample

size is obtained as n = a∗ × r.

Example 10.1

Suppose that the control arm is known to have 20% of 1-year progression-free

survival (PFS). We want to show that the experimental arm is expected to

increase 1-year PFS to 40%. Assuming an exponential PFS model, the annual

hazard rates for the two arms are λ 1 = 1 . 609 and λ 2 = 0 . 916 with a hazard ratio of 1 = 1 . 756. Assuming a monthly accrual of 5 patients ( r = 60 per

year) and b = 1 year of additional follow-up period, the required sample size

for the log-rank test with 1-sided α = 10% and 90% of power with balanced

allocation ( p 1 = p 2 = 1 / 2) is given as n = 102 (51 per arm), requiring an accrual period of about 20 months ( a = 102 / 5). In the final analysis, we expect

D = 89 events (48 and 41 for arms 1 and 2, respectively) under H 1.

10.2

Two-Stage Log-Rank Test

Multistage clinical trial design for the two-sample log-rank has been widely

investigated, for example, Slud and Wei (1982) and Tsiatis (1982). For ran-

domized phase II trials, two-stage design will be most appropriate due to its

small size and relatively short study period compared to large-scale phase III

trials. With a survival endpoint, it is important to find a reasonable interim

analysis time point. If it is scheduled for an early stage of a study, we may not

have enough number of events for a reasonable probability to stop the study

early in case of futility or superiority of the experimental therapy. On the

other hand, if it is scheduled for a late stage of the study, we may have most

of the planned patient accrual already so that the interim analysis may not

be able to save resources even when the analysis result indicates to stop the

trial. This is likely to happen for a phase II trial with a fast patient accrual.

If this is the case, we may consider the single-stage design that was discussed

in the previous section.

10.2.1

Statistical Testing

We conduct an interim analysis at time τ that may be determined in terms

of the number of events or calendar time. We assume that τ is smaller than

196

Randomized Phase II Cancer Clinical Trials

the planned accrual period a, so that we can save the number of patients if

the experimental therapy does not show efficacy compared to the control.

For patient i (= 1 , . . . , nk) in arm k, let Tki denote the survival time with survivor distribution Sk(t) and cumulative hazard function k(t), and eki denote the entering time (0 ≤ eki ≤ a). Cki denotes the censoring time at the

final analysis with survivor function P (Cki ≥ t) = G(t) that is defined by the

accrual and missing trends and additional follow-up period. The censoring

time at the interim analysis is denoted as ˜

Cki = max{min (τ − eki , Cki ), 0}. For

a patient who is accrued during stage 1 (that is, eki < τ ), ˜

Cki has a survivor

function G 1 (t) = P{min (τ − eki , Cki ) ≥ t}. We observe ( ˜

Xki , ˜ δki ) at the in-

terim analysis and (Xki , δki ) at the final analysis, where ˜

Xki = min (Tki , ˜

Cki ),

˜

δki = I (Tki ≤ ˜ Cki), Xki = min (Tki, Cki), and δki = I (Tki ≤ Cki). We define at-risk processes ˜

Yki (t) = I ( ˜

Xki ≥ t) and Yki (t) = I (Xki ≥ t), and

event processes ˜

Nki (t) = ˜ δki I ( ˜

Xki ≤ t) and Nki (t) = δki I (Xki ≤ t). De-





fine ˜

Y

nk

˜

nk

k (t ) =

Y

Y

i =1

ki (t ), ˜

Y (t) = ˜

Y 1 (t) + ˜

Y 2 (t), Yk(t) =

i =1

ki (t ), Y (t ) =





Y

nk

˜

nk

1 (t ) + Y 2 (t ), ˜

Nk(t) =

N

N

i =1

ki (t ), ˜

N (t) = ˜

N 1 (t) + ˜

N 2 (t), Nk(t) =

i =1

ki (t ),

and N (t) = N 1 (t) + N 2 (t).



Let ˜

n =

n

I (e

i =1

ki ≤ T ) denote the number of patients who are entered

before the interim analysis (˜ n < n). Test statistics at the interim and final

analyses are calculated as

∞ ˜ Y 1 (t)˜ Y 2 (t)

W 1 = 1

√

{ d ˜ 1 (t) − d ˜ 2 (t)}

˜

n

˜

0

Y (t)

and

∞ Y 1 (t)Y 2 (t)

W = 1

√

{ d ˆ 1 (t) − d ˆ 2 (t)} ,

n 0

Y (t)





respectively. Here, ˜



t ˜

t

k (t ) =

Y

Y

0

k (s)−1 d ˜

Nk(s) and ˆ

k(t) = 0 k(s)−1 dNk(s) are

the Nelson–Aalen (Nelson, 1969; Aalen, 1978) estimate of k(t) from the data

at the interim analysis and the final analysis, respectively.

For large sample sizes at the interim and final analyses, the null distribution

of (W 1 , W ) is approximately bivariate normal with means 0, variances and

covariance that can be approximated by

∞ ˜ Y 1 (t)˜ Y 2 (t)

var (W 1 ) = ˆ

σ 2 = 1

d ˜

N (t),

1

˜

n

˜

0

Y (t) 2

∞ Y 1 (t)Y 2 (t)

var (W ) = ˆ

σ 2 = 1

d N (t),

n 0

Y (t) 2

and cov (W ) = ˆ

σ 2, respectively; see, for example, Tsiatis (1982).

1

For the patients who enter the study after τ (that is, eki > τ ), their survival

times are censored at time 0 at the interim analysis (that is, ˜

Xki = 0 and

˜

δki = 0), so that they make no contributions to W 1 and ˆ σ 2. A two-stage trial

1

using the log-rank test is conducted as follows. In this chapter, we consider

Randomized Phase II Clinical Trials Based on Survival Endpoints

197

two-stage designs with an interim analysis using the futility test only, but an

extension to those with both futility and superiority is straightforward:

• Design stage: Specify α and an interim analysis time and an early stop-

ping value c 1.

• Stage 1: If W 1 /ˆ σ 1 < c 1, then reject the experimental therapy (arm 2) and stop the trial. Otherwise, proceed to stage 2.

• Stage 2: If W/ˆ σ ≥ c, then accept the experimental therapy. Here, critical value c satisfies





α =

W 1

P

≥ c



1 , W ≥ c H 0

,

ˆ

σ 1

ˆ

σ

which can be approximated by





∞

α =

φ(

c 1 − ˆ

ρz

z) ¯



d z,

c

1 − ˆ

ρ 2

√

where ˆ

ρ = ˆ σ 1 /ˆ σ, and φ(· ) and ¯ (· ) are the probability density function and the survivor function of N ( 0 , 1 ) distribution, respectively.

Wieand, Schroeder, and O’Fallon (1994) propose a two-stage design with an

interim futility test when 50% of the events that are expected at the final

analysis are observed. They assume that the accrual period is long enough,

compared to the median survival time, so that the interim analysis can be

conducted during accrual period. They propose an early termination when

the estimated hazard rate for the experimental arm is larger than that of the

control arm. This is approximately equivalent to using c 1 = 0 in our two-stage

design. Readers may read Pampallona and Tsiatis (1994) and Lachin (2005)

about general group sequential futility testing methods.

10.2.2

Sample Size Calculation

Let pk = nk/n ( p 1 + p 2 = 1 ) denote the allocation proportion for arm k.

At first, we derive a power function given τ and c 1 together with accrual

period a, follow-up period b, k(t) for k = 1 , 2 under H 1, and (α, 1 − β).

An interim analysis time τ may be determined in terms of calendar time

or observed number of events, but at the design stage, we assume that it is

determined as a calendar time. If we want to specify it in terms of the number

of events, we can convert it to a calendar time based on the expected accrual

rate and specified survival distributions at the design stage. We choose a value

for c 1 depending on how aggressively we want to screen out an inefficacious

experimental therapy at the interim analysis.

The power function is given as





W 1

1 − β = P

≥ c 1 , W ≥ c| H 1 .

ˆ

σ 1

ˆ

σ

198

Randomized Phase II Cancer Clinical Trials

In order to derive a power function, we have to calculate c for a specified type

I error rate α, that is,





α =

W 1

P

≥ c 1 , W ≥ c| H 0 ,

ˆ

σ 1

ˆ

σ

although it may be recalculated at the final analysis using the collected sur-

vival data. Hence, for a power calculation, we need to derive the limits of

ˆ

σ 2 and ˆ σ 2 under both H

1

0 and H 1, and E (W 1 ), E (W ), var (W 1 ), and var (W ) under H 1. By the independent increment of the log-rank test statistic, the

√

correlation coefficient of W 1 and W is

var (W 1 )/ var (W ) under both H 0 and

H 1.

We derive the following asymptotic results using Theorem 4.1. Under H 0,

we have E (W 1 ) = E (W ) = 0. Furthermore, for large n, we can show that ˆ

σ 21

and ˆ

σ 2 converge

∞

v 1 = − p 1 p 2

G 1 (t)d S 2 (t)

0

and

∞

v = − p 1 p 2

G(t)d S 2 (t),

0

respectively, under H 0. Note also that var (W 1 ) = v 1 and var (W 1 ) = v under H 0.

Hence, by independent increment of the log-rank statistic, corr (W 1 , W ) is ρ 0 =

√ v 1 /v under H 0. We need this asymptotic result under H 0 to calculate c.

√

√

Under H 1, we have E (W 1 ) =

˜

nω 1 and E (W ) =

nω, where

∞

ω

G 1 (t)S 1 (t)S 2 (t)

1 = p 1 p 2

{ d 1 (t) − d 2 (t)}

0

p 1 S 1 (t) + p 2 S 2 (t)

and

∞

ω =

G(t)S 1 (t)S 2 (t)

p 1 p 2

{ d 1 (t) − d 2 (t)} .

0

p 1 S 1 (t) + p 2 S 2 (t)

Furthermore, ˆ

σ 2 and ˆ σ 2 converge to

1

∞

σ

G

2

=

1 (t )S 1 (t ) 2 S 2 (t )

p 2 p

d

01

1

2

1 (t )

0

{ p 1 S 1 (t) + p 2 S 2 (t)}2

∞

+

G 1 (t)S 1 (t)S 2 (t) 2

p 1 p 2

d

2

2 (t )

0

{ p 1 S 1 (t) + p 2 S 2 (t)}2

and

∞

σ

G(t)S

2 =

1 (t ) 2 S 2 (t )

p 2 p

d

0

1

2

1 (t )

0

{ p 1 S 1 (t) + p 2 S 2 (t)}2

∞

+

G(t)S 1 (t)S 2 (t) 2

p 1 p 2

d

2

2 (t ),

0

{ p 1 S 1 (t) + p 2 S 2 (t)}2

Randomized Phase II Clinical Trials Based on Survival Endpoints

199

respectively. The variances of W 1 and W are given as

∞

σ

G

2

=

1 (t )S 1 (t )S 2 (t ) 2

p

d

11

1 p 2

2

1 (t )

0

{ p 1 S 1 (t) + p 2 S 2 (t)}2

∞

+

G 1 (t)S 1 (t) 2 S 2 (t)

p 2 p

d

1

2

2 (t )

0

{ p 1 S 1 (t) + p 2 S 2 (t)}2

and

∞

σ

G(t)S

2 =

1 (t )S 2 (t ) 2

p

d

1

1 p 2

2

1 (t )

0

{ p 1 S 1 (t) + p 2 S 2 (t)}2

∞

+

G(t)S 1 (t) 2 S 2 (t)

p 2 p

d

1

2

2 (t ),

0

{ p 1 S 1 (t) + p 2 S 2 (t)}2

respectively, under H 1. By independent increment of the log-rank statistic,

corr (W 1 , W ) is given as ρ 1 = σ 11 /σ 1.

In summary, (W 1 /ˆ

σ 1 , W/ˆ σ) is asymptotically distributed as N( 0 , 0 ) under H 0 and N (µ, 1 ) under H 1, where

√





˜

nω

1 ρ

σ 2 /σ 2

ρ

µ =

1 /σ 11

√

,

0

,



11

01

1 σ 11 σ 1 /σ 01 σ 0

.

nω/σ

0 =

1 =

1

ρ 0 1

ρ 1 σ 11 σ 1 /σ 01 σ 0

σ 2 /σ 2 .

1

0

If (X, Y ) is a bivariate normal random vector with means µx and µy,

variances σ 2 and σ 2, and correlation coefficient ρ, then it is well known

x

y

that the conditional distribution of X given Y = y is normal with mean

µx + (ρσx/σy)(y − µy) and variance σ 2 ( 1− ρ 2 ). This result simplifies the calcu-x

lation of type I error rate and power below. For example, given design param-

eters (α, 1 − β, p 1 , r, b, 1 (t), 2 (t), τ, c 1 ), (X, Y ) = (W 1 /ˆ

σ 1 , W/ˆ σ) is asymp-

totically N ( 0 , 0 ) under H 0. So, in this case, Y ∼ N ( 0 , 1 ) and the conditional distribution of X given Y = y is N (ρ 0 y, 1 − ρ 2 ). Note that c satisfies 0

∞ ∞

∞ ∞



α = P (X ≥ c 1 , Y ≥ c) =

f (x, y)dxdy =

f (x| y)dx

f (y)dy,

c

c 1

c

c 1

where f (x, y), f (y), and f (x| y) denote the probability density functions of (X, Y ), Y , and X| Y = y, respectively. Here, f (y) = φ(y) and





∞

c 1 − ρ 0 y

f (x| y)dx = ¯



,

c

1 − ρ 20

so that we obtain c by solving the equation





∞

α =

φ(

c 1 − ρ 0 y

y) ¯



d y.

c

1 − ρ 20

200

Randomized Phase II Cancer Clinical Trials

If the interim analysis time and the stopping value are reasonably chosen, the

power of a two-stage design is not much lower than that of the corresponding

single-stage design. So, when searching for the required accrual period (or

sample size) of a two-stage design, we may start from that of the corresponding

single-stage design. Assuming an accrual pattern with a constant accrual rate,

the design procedure of a two-stage design can be summarized as follows:

• Given (α, 1 − β, p 1 , r, b, 1 (t), 2 (t)), calculate the sample size n and accrual period a 0 required for a single-stage design.

• Determine an interim analysis time τ during the accrual period a 0 of

the chosen single-stage design (that is, τ < a 0) and the stopping value

c 1 at the interim analysis.

• Then the accrual period required for a two-stage design is obtained

around a 0 as follows:

(A) At a = a 0 (note that ˜ n = rτ and n = ra 0),

– Obtain c by solving equation





∞

α =

φ(

c 1 − ρ 0 z

z) ¯



d z.

c

1 − ρ 20

– Given (˜ n, n, c 1 , c, α), calculate





∞

¯

c 1 − ρ 1 z

power =

φ(z) ¯

d z,

¯

c

1 − ρ 21

where



√



√

σ

ω ˜ n

σ

ω n

¯

01

1

0

c 1 =

c

and ¯

c =

c −

.

σ

1 −

11

σ 01

σ 1

σ 0

(B) If the power is smaller than 1 − β, increase a slightly, and repeat

(A) until the power is close enough to 1 − β. We may change the

interim analysis time τ at this step too.

At the design stage, we may want to calculate the stopping probabilities under

H 0 and under H 1

PET0 = P(W 1 /ˆ

σ 1 ≤ c 1| H 0 ) = (c 1 )

and

PET1 = P(W 1 /ˆ

σ 1 ≤ c 1| H 1 ) = (¯ c 1 ).

While PET0 should not be too small in order for an interim futility test to

be of worth, PET1 should not be too large to avoid early rejection of an

efficacious therapy with immature data.

Randomized Phase II Clinical Trials Based on Survival Endpoints

201

10.2.2.1

Under Uniform Accrual and Exponential

Survival Models

Suppose that the survival distributions are exponential with hazard rates λ 1

and λ 2 in arms 1 and 2, respectively. If patients are accrued at a constant rate

during period a and followed for an additional period of b, and the interim

analysis takes place before completion of accrual (that is, τ < a), then the

censoring distribution at the interim analysis is U ( 0 , τ ) and that after the

second stage is U (b, a + b) with survivor functions



 1

if t ≤ 0

G 1 (t) =  1 − t/τ if 0 < t ≤ τ

0

if t > τ

and



 1

if t ≤ b

G(t) =

,

 1 − (t − b)/a if b < t ≤ a + b

0

if t > a + b

respectively. Since τ < a, G 1 (t) is free of a. Note that we only assume administrative censoring. If loss to follow-up is expected, then we may incorporate

it in the calculation if its distribution is given, or we may increase the final

sample size by the expected proportion of loss to follow-up.

Under these distributional assumptions, σ 2, σ 2, and ω are the same as those 0

1

in (10.4), (10.5), and (10.6), respectively, and

v 1 = p 1 p 2{1 − 1

τλ ( 1 − e− λ 1 τ )} ,

1

v = p 1 p 2{1 − 1 e− bλ 1 ( 1 − e− λ 1 a)} , aλ 1

τ



(τ −

λ

τ

(τ −

σ

p

t)e− ( 2 λ 1+ λ 2 )t

t)e− (λ 1+2 λ 2 )t

2 = p 21 2 λ 1

2

dt + p 1 p 22

dt,

01

τ

0

(p 1 e− λ 1 t + p 2 e− λ 2 t) 2

τ

0

(p 1 e− λ 1 t + p 2 e− λ 2 t) 2





λ

τ

(τ −

τ

(τ −

σ

t)e− (λ 1+2 λ 2 )t

p

t)e− ( 2 λ 1+ λ 2 )t

2 = p 1 p 22 1

2 λ 2

dt + p 21

dt,

11

τ

0

(p 1 e− λ 1 t + p 2 e− λ 2 t) 2

τ

0

(p 1 e− λ 1 t + p 2 e− λ 2 t) 2

and

τ (τ −

ω

t)e− (λ 1+ λ 2 )t

1 = p 1 p 2 (λ 1 − λ 2 )

dt.

τ

0

p 1 e− λ 1 t + p 2 e− λ 2 t

We use a numerical method to calculate these integrals.

Example 10.2

From Example 10.1, a single-stage randomized phase II trial requires n = 102

under the design setting (α, 1 − β, λ 1 , λ 2 , r, b, p 1 ) = ( 0 . 1 , 0 . 9 , 1 . 609 , 0 . 916 , 60 , 1 , 1 / 2 ). Under the same design setting, a two-stage trial with an interim analysis at τ = 1 year with c 1 = −0 . 5 requires n = 106, which is only slightly larger than that for the single-stage design. At the interim and final analyses,

we expect 46 and 93 events, respectively, under H 1. The probabilities of early

202

Randomized Phase II Cancer Clinical Trials

termination are given as PET0 = 0 . 31 and PET1 = 0 . 03. From B = 10 , 000

simulations, this two-stage design with n = 106 has an empirical type I error

of 9.9% and power of 91%, which are very close to the nominal α = 10% and

1 − β = 90%, respectively.

10.3

Stratified Two-Sample Log-Rank Test

for Single-Stage Designs

Suppose that the patient population consists of J strata defined by some strat-

ification factors. In this case, the randomization of patients will be stratified by

the factors so that the two treatment arms have similar patient characteristics

in terms of the stratification factors, and the resulting data will be analyzed by

the stratified log-rank test. Lakatos (1988) proposed a sample size calculation

for the stratified log-rank test using a Markov process method. In this sec-

tion, we derive a sample size formula using the stochastic integral method for

a single-stage design. An extension to two-stage designs can be easily derived

as in the previous section for the unstratified two-sample log-rank test.

10.3.1

Test Statistic

Suppose that nkj patients are randomized to arm k ( k = 1 , 2) from stratum j (= 1 , . . . , J ) whose survival times have a cumulative hazard function kj (t)

and a hazard function λkj (t) = ∂kj (t)/∂t. We want to test

H 0 : 1 j (t) = 2 j (t) for all j = 1 , . . . , J

against

H 1 : 1 j (t) ≥ 2 j (t) for all j = 1 , . . . , J

and with inequality for some j = 1 , . . . , J.

Let Tkji and Ckji denote the survival and censoring times, respectively,

for patient i (= 1 , . . . , nkj ) from stratum j (= 1 , . . . , J ) assigned to arm k(= 1 , 2 ). For Xkji = min (Tkji , Ckji ) and δkji = I (Tkji ≤ Ckji ), let Nkj (t) =

n



k j

δ

nkj I (X

i =1 k ji I ( Xk ji ≤ t ) and Yk j (t ) =

i =1

k j i ≥ t ) denote the event and the at-

risk processes for arm k and stratum j , respectively. Let N j (t) = N 1 j (t)+ N 2 j (t) and Y j (t) = Y 1 j (t) + Y 2 j (t). Then, the stratified log-rank test statistic is given as

J

∞ Y 1 j(t)Y 2 j(t)

W = 1

√

{ d ˆ 1 j(t) − d ˆ 2 j(t)} ,

n

Y j (t)

j =1

0

Randomized Phase II Clinical Trials Based on Survival Endpoints

203





where

t

n =

2

J

n

Y

k=1

j =1

k j and ˆ

kj(t) = 0 kj(s)−1 dNkj(s) are the Nelson–

Aalen (Nelson, 1969; Aalen, 1978) estimator of kj . Under H 0, W/ˆ

σ is asymp-

totically standard normal with

J

∞ Y

ˆ

σ 2 = 1

1 j (t )Y 2 j (t ) d N j(t),

n

Y j (t) 2

j =1

0

see Schoenfeld and Tsiatis (1987). Hence, we reject H 0, in favor of H 1, if

W/ˆ

σ > z 1− α with one-sided type I error rate α.

10.3.2

Sample Size Calculation

Let n j = n 1 j + n 2 j denote the sample size of stratum j. Suppose that 100 pk% of the patients from each stratum are allocated to arm k(= 1 , 2 ), so that we have

pk = nkj /n j ( p 1+ p 2 = 1 ) for stratum j. Let γ j = n j /n denote the prevalence of stratum j (

J

γ

j =1

j = 1). We assume that patients are accrued with a constant

accrual rate, r , during an accrual period and followed during follow-up period b

after the last patient is entered. Let Skj (t) = exp{− kj (t)} denote the survivor

function of the survival distribution for arm k in stratum j , and G(t) =

P(Ckji ≥ t) denote the survivor function of the common censoring distribution.

We assume that the survival and the censoring times are independent for each

patient. We derive the following sample size formula using Theorem 4.1.

Under stratified randomization, Ykj (t)/n uniformly converges to pkγ j G(t)Skj (t).

Under H 1, ˆ

σ 2 converges to

J

∞

σ

G(t)S

2 =

1 j (t ) 2 S 2 j (t )

p

γ p

d

0

1 p 2

j

1

{

1 j (t )

p 1 S 1 j (t) + p 2 S 2 j (t)}2

j =1

0

∞



+

G(t)S 1 j (t)S 2 j (t) 2

p 2

d 2 j (t)

0

{ p 1 S 1 j(t) + p 2 S 2 j(t)}2

and the variance of W is given as

J

∞

σ

G(t)S

2 =

1 j (t )S 2 j (t ) 2

p

γ p

d

1

1 p 2

j

2

{

1 j (t )

p 1 S 1 j (t) + p 2 S 2 j (t)}2

j =1

0

∞



+

G(t)S 1 j (t) 2 S 2 j (t)

p 1

d 2 j (t) .

0

{ p 1 S 1 j(t) + p 2 S 2 j(t)}2

√

Furthermore, under H 1, the expected value of W is approximated by

nω,

where

J

∞

ω =

G(t)S 1 j (t)S 2 j (t)

p 1 p 2

γj

{ d 1 j(t) − d 2 j(t)} .

p 1 S 1 j (t) + p 2 S 2 j (t)

j =1

0

204

Randomized Phase II Cancer Clinical Trials

Hence, given n, the power is given as





W

1 − β = P

≥ z 1− α| H 1

ˆ

σ



√

√



σ

=

W −

nω

0

nω

P

≥

z

| H

σ

1− α −

1

1

σ 1

σ 1



√



σ

=

nω

¯



0 z

,

σ 1− α −

1

σ 1

where ¯

(· ) = 1 − (· ) and (· ) is the cumulative distribution function of the standard normal distribution. Hence, the required sample size for power 1 − β

is given as





σ

2

0 z 1− α + σ 1 z 1− β

n =

.

( 10 . 7 )

ω

If the patients are expected to be accrued with a constant rate r , we can

change the formula (10.7) into an equation on accrual period and solve it with

respect to the accrual period a as in the previous sections.





The expected number of events at the analysis is D = n

J

2

γ

j =1

k=1

j pk dk j ,

where

∞

dkj = P (Tkj ≤ Ckj ) = −

G(t)d Skj (t).

0

Example 10.3

Suppose that the patient population of a study consists of two strata (J = 2 )

with γ 1 = 40% of high-risk stratum ( j = 1 ) and γ 2 = 60% of low-risk stratum ( j = 2 ). The control arm (k = 1 ) is known to have S 11 ( 1 ) = 10% and S 12 ( 1 ) =

30% of 1-year PFS for strata 1 and 2, respectively. We would be interested

in the experimental arm (k = 2 ) if it has at least S 21 ( 1 ) = 20% and S 22 ( 1 ) =

50% of 1-year PFS for strata 1 and 2, respectively. Assuming exponential

PFS models, the annual hazard rates are given as λ 11 = 2 . 30, λ 12 = 1 . 20, λ 21 = 1 . 61, and λ 22 = 0 . 69, resulting in hazard ratios of 1 = λ 11 /λ 21 = 1 . 43

and 2 = λ 12 /λ 22 = 1 . 74 for strata 1 and 2, respectively. Assuming that this study is able to accrue 5 patients per month ( r = 60 per year) and patients

will be followed for an additional b = 1 year, the required sample size for the

stratified log-rank test with one-sided α = 10% and 1− β = 90% with balanced

allocation ( p 1 = p 2 = 1 / 2) is given as n = 144 (72 per arm), requiring an accrual period of about 29 months ( a = 144 / 5). In the final analysis, we expect

about D = 128 events under H 1. From B = 10 , 000 simulations, the stratified test with n = 144 has an empirical type I error of 10.1% and power of 90%,

which are close to the specified α = 10% and 1 − β = 90%, respectively.

Although the stratified log-rank test always controls the type I error rate, its

power depends on the prevalence of each stratum. For example, suppose that

the true prevalence in Example 10.3 is γ 1 = 60% for the high-risk stratum

Randomized Phase II Clinical Trials Based on Survival Endpoints

205

and γ 2 = 40% for the low-risk stratum, instead of (γ 1 , γ 2 ) = ( 40% , 60% ).

Assuming that all other design parameter values are unchanged, the required

sample size is n = 163, compared to n = 144 when (γ 1 , γ 2 ) = ( 40% , 60% ).

Hence, it is recommended to check the observed prevalence of each stratum

in the middle of the study, and recalculate the sample size if the observed

prevalence is very different from the specified one at the study design.

References

Aalen, O.O. (1978). Nonparametric inference for a family of counting pro-

cesses. Annals of Statistics, 6, 701–726.

Andersen, P.K., Borgan, O., Gill, R.D., and Kidding, N. (1982). Linear non-

parametric tests for comparison of counting processes with application

to censored survival data (with discussion). International Statistical Re-

view, 50, 219–258.

Fleming, T.R. and Harrington, D.P. (1991). Counting Processes and Survival

Analysis. Wiley, New York.

George, S.L. and Desu, M.M. (1973). Planning the size and duration of a trial

studying the time to some critical event. Journal of Chronic Disease, 27,

15–24.

Lachin, J.M. (1981). Introduction to sample size determination and power

analysis for clinical trials. Controlled Clinical Trials, 2, 93–113.

Lachin, J.M. (2005). A review of methods for futility stopping based on con-

ditional power. Statistics in Medicine, 24, 2747–2764.

Lakatos, E. (1977). Sample sizes based on the log-rank statistic in complex

clinical trials. Biometrics, 64, 156–160.

Lakatos, E. (1988). Sample sizes based on the log-rank statistic in complex

clinical trials. Biometrics, 44, 229–241.

Nelson, W. (1969). Hazard plotting for incomplete failure data. Journal of

Quality Technology, 1, 27–52.

Pampallona, S. and Tsiatis, A.A. (1994). Group sequential designs for one-

sided and two-sided hypothesis testing with provision for early stopping

in favor of the null hypothesis. Journal of Statistical Planning and In-

ference, 42, 19–35.

Pasternack, B.S. and Gilbert, H.S. (1971). Planning the duration of long-term

survival time studies designed for accrual by cohorts. Journal of Chronic

Disease, 24, 13–24.

206

Randomized Phase II Cancer Clinical Trials

Peto, R. and Peto, J. (1972). Asymptotically efficient rank invariant test pro-

cedures (with discussion). Journal of the Royal Statistical Society, Series

A, 135, 185–206.

Rubinstein, L., Gail, M., and Santner, T. (1981). Planning the duration of a

comparative clinical trial with loss to follow-up and a period of continued

observation. Journal of Chronic Disease, 27, 15–24.

Schoenfeld, D.A. (1983). Sample size formula for the proportional hazards

regression model. Biometrics, 39, 499–503.

Schoenfeld, D.A. and Tsiatis, A.A. (1987). A modified log rank test for highly

stratified data. Biometrika, 74, 167–175.

Slud, E.V. and Wei, L.J. (1982). Two-sample repeated significance tests based

on the modified Wilcoxon statistic. Journal of American Statistical So-

ciety, 77, 862–868.

Tsiatis, A.A. (1982). Repeated significance testing for a general class of statis-

tics used in censored survival analysis. Journal of American Statistical

Society, 77, 855–861.

Wieand, S., Schroeder, G., and O’Fallon, J.R. (1994). Stopping when the

experimental regimen does not appear to help. Statistics in Medicine,

13, 1453–1458.

Yateman, N.A. and Skene, A.M. (1992). Sample size for proportional haz-

ards survival studies with arbitrary patient entry and loss to follow-up

distributions. Statistics in Medicine, 11, 1103–1113.





Chapter 11

Some Flexible Phase II

Clinical Trial Designs

In this chapter, we discuss two statistical methods for design and analysis of

some flexible phase II clinical trial designs. These methods are presented in

terms of a survival endpoint. However, the concept of the first method, called

generalized log-rank test, can be extended to any type of endpoints.

11.1

Comparing Survival Distributions under

General Hypothesis Testing

We start this section with an example from a single-arm phase II trial that

motivated the statistical methods discussed below.

Example 11.1

Chemotherapy ABVD has been a standard regimen for patients with

nonbulky stage I and II Hodgkin’s lymphoma. In a previous study on 6 cycles

of ABVD, each patient had a fluorodeoxyglucose positron-emission tomogra-

phy (FDG-PET) imaging after 2 cycles of ABVD, for example, Hutchings et

al. (2006) and Gallamini et al. (2007). It was found that patients with a neg-

ative PET image (group 1) and those with a positive PET image (group 2)

had 3-year progression-free survival (PFS) of S 1 ( 3 ) = 0 . 86 and S 2 ( 3 ) = 0 . 52, respectively. Assuming an exponential PFS model, these correspond to annual

hazard rates of λ 1 = 0 . 05 and λ 2 = 0 . 22, respectively, and the hazard ratio λ 2 /λ 1 is estimated as 0 = 4 . 3. In a new phase II trial, patients with a negative PET image after 2 cycles of ABVD will be treated by an additional 2 cycles

of ABVD, whereas those with a positive PET image after 2 cycles of ABVD

will be treated by 2 cycles of a more aggressive chemotherapy called escalated

BEACOPP, followed by radiation therapy. By the PET-guided chemotherapy

strategy, it is believed that the 3-year PFS of the PET-positive patients can

be increased to lower the hazard ratio compared to that of the PET-negative

207

208

Randomized Phase II Cancer Clinical Trials

patients. Note that the group 1 patients will receive the same treatment as

that of the previous study providing the historical data. For the true hazard

ratio , we want to test H 0 : ≥ 0 against H 1 : < 0 in this study.

11.1.1

Generalized Log-Rank Test

The study of Example 11.1 is conceptually a single-arm trial since we do not

randomize the patients. We will apply the statistical method that will be

discussed in this section to this study. We will also demonstrate the method

with a randomized phase II clinical trial.

In this section, we present the statistical method in terms of a randomized

trial. Let nk denote the number of patients in arm k and Tki the survival time for patient i in arm k (1 ≤ i ≤ nk; k = 1 , 2). We observe (Xki , δki ), where Xki is the minimum of Tki and the censoring time Cki , and δki is an event indicator taking the value 1 if the patient experiences an event and 0 otherwise.

For arm k, Tk 1 , . . . , Tk,n are IID with hazard function λ

k

k (t ), cumulative haz-



ard function

t

k (t ) =

λ

0

k (s)ds, and survivor function Sk (t ) = exp (− k (t )).

Under the proportional hazards assumption, = λ 2 (t)/λ 1 (t) denotes the hazard ratio. From the Cox (1972) regression model using the treatment indicator

as the only covariate, the partial score function W () and the information

function ˆ

σ 2 () are given as

∞ Y 1 (t)Y 2 (t)

W () =

{ d ˆ 1 (t) − d ˆ 2 (t)} ,

0

Y 1 (t) + Y 2 (t)

and

∞

Y

ˆ

σ 2 () =

1 (t )Y 2 (t )

d N (t),

0

{ Y 1 (t) + Y 2 (t)}2



respectively, where ˆ



t

k (t ) =

Y −1 (t)d N

0

k

k (t ) is the Aalen–Nelson estimator



(Aalen, 1978; Nelson, 1969) for

nk

k (t ), Yk (t ) =

I (X

i =1

ki ≥ t ) and Nk (t ) =

nk δ

i =1 ki I ( Xki ≤ t ) are the at-risk process and the event process for group k, respectively, N (t) = N 1 (t) + N 2 (t), and I (· ) is the indicator function. Note that W ( 1 ) is the standard log-rank test statistic (Peto and Peto, 1972). We

call W () the generalized log-rank test.

As n → ∞, W ( 0 )/σ ( 0 ) converges to the standard normal distribution

under H 0 : = 0 see, for example, Fleming and Harrington (1991). Since

W ()/ˆ

σ () is monotone decreasing in , we reject H 0 in favor of H 1 : < 0

if W ( 0 )/ˆ

σ( 0 ) > z 1− α with one-sided type I error rate α.

The partial maximum likelihood estimate (pMLE)

is obtained by solv-

ing W () = 0. The pMLE is a consistent estimator of the true hazard ra-

tio . Furthermore, by the asymptotic linearity, the score-type test statis-

tic W ( 0 )/ˆ

σ( 0 ) is asymptotically equivalent to the Wald-type test statistic

ˆ

σ ( 0 )(

− 0 ), so that our sample size formula derived in the following section

is valid for both types of test statistics.

Some Flexible Phase II Clinical Trial Designs

209

11.1.2

Sample Size Calculation

We want to estimate the sample size n(= n 1 + n 2 ) under a specific alternative hypothesis that H 1 : = 1 (< 0 ) with a desired power. Jung et al. (2005) propose a sample size formula with 0 > 1 and 1 = 1 for noninferiority

trials. We want to extend their formula for general 0 and 1 with 1 < 0

in this section. Let pk = nk/n denote the allocation proportion for arm k.

The asymptotic results in this section are derived under H 1. For arm k,

let fk(t) = − ∂ Sk(t)/∂t denote the probability density function of the survival

distribution. Note that S 2 (t) = S 1 (t) 1 and f 2 (t) = 1 f 1 (t)S 1 (t) 1−1 under H 1.

For a censoring variable C, let G(t) = P(C ≥ t) denote the survivor function of the censoring distribution which is common to the two arms. By Jung et

al. (2005), ˆ

σ 2 () is asymptotically equivalent to nσ 2 (), where

∞

σ

G(t)S

2 () =

1 (t )S 2 (t ){ p 1 f 1 (t ) + p 2 f 2 (t )}

p 1 p 2

dt.

(11.1)

0

{ p 1 S 1 (t) + p 2 S 2 (t)}2

By the definition of W (), we have

W ( 0 ) − W ( 1 ) = n−1 / 2 ( 0 − 1 )

∞

×

Y 1 (t)Y 2 (t)

d N (t),

0

{ Y 1 (t) + 0 Y 2 (t)}{ Y 1 (t) + 1 Y 2 (t)}

which is asymptotically equivalent to nω, where

ω = ( 0 − 1 )p 1 p 2

∞

×

G(t)S 1 (t)S 2 (t){ p 1 f 1 (t) + p 2 f 2 (t)}

dt.

(11.2)

0

{ p 1 S 1 (t) + 0 p 2 S 2 (t)}{ p 1 S 1 (t) + 1 p 2 S 2 (t)}

Note that Sk(t) are the survivor functions of the survival distributions

under H 1.

Under H 1, the generalized log-rank statistic can be expressed as

W ( 0 )

ˆ

σ(

= W( 1 ) ×

1 ) + W( 0 ) − W( 1 ),

ˆ

σ ( 0 )

ˆ

σ( 1 )

ˆ

σ ( 0 )

ˆ

σ( 0 )

which, from (11.1) and (11.2), can be approximated by

√

W ( 1 )

σ

ω

× 1 +

n ,

σ 1

σ 0

σ 0

where σ 2 = σ 2 (

h

h ) for h = 0 , 1.

Suppose that we want to estimate the sample size for detecting H 1 : = 1

with a power of 1 − β by the generalized log-rank test with a one-sided α at

H 0 : = 0, that is,





√



W ( 0 )

W ( 1 )

σ 1

ω n

1 − β = P

> z 1− α| H 1 ≈ P

×

+

> z 1− α| H 1 .

ˆ

σ( 0 )

σ 1

σ 0

σ 0

210

Randomized Phase II Cancer Clinical Trials

Since W ( 1 )/σ 1 is approximately N ( 0 , 1 ) under H 1, we have



√

ω

σ

−

n

0

z 1− β = z 1− α −

.

σ 0

σ 1

Hence, the required sample size is obtained by

(σ 0 z 1− α + σ 1 z 1− β) 2

n =

.

(11.3)

ω 2

Note that ω, σ 2, and σ 2 are functions of the survival distributions S

0

1

1 (t ) and

S 2 (t) under H 1, and the common censoring distribution G(t). They are calculated using numerical integration methods.

The power of the generalized log-rank test roughly depends on the number

of events, rather than the number of patients, so that one may want to cal-

culate the expected number of events at the final data analysis. The number

of events D under H 1 is calculated as in the standard log-rank test, that is,

∞

D = n( p 1 d 1 + p 2 d 2 ), where dk = 1 +

S

0

k (t )d G(t ) and Sk (t ) are the sur-

vivor functions of survival distributions specified under H 1, see, for example,

Schoenfeld (1983). Note that if the survival distributions are shorter, then the

required sample size becomes smaller.

11.1.2.1

Under Uniform Accrual and Exponential

Survival Models

In this section, we will illustrate the application of the proposed methods

when designing a clinical trial for comparing survival distributions with right

censoring as follows.

(A) An exponential distribution can be uniquely specified by a single param-

eter, such as the hazard rate, the median or the survival probability at a

chosen time point. Furthermore, the family of exponential distributions

fits real survival data relatively well. So, we often specify the survival

distributions using exponential distributions with hazard rates λk, that

is, Sk(t) = exp (− λkt).

(B) When a trial is open, patients are usually uniformly recruited during

the accrual period a and additional follow-up period b. In this case, we

have



 1

if t ≤ b

G(t) =

.

 1 − (t − b)/a if b < t ≤ a + b

0

if t > a + b

Under these distributional models, we have

a+ b (

σ

p

2 =

1 λ 1 e− λ 1 t + p 2 λ 2 e− λ 2 t )e− (λ 1+ λ 2 )t p

dt

h

1 p 2 h

0

(p 1 e− λ 1 t + h p 2 e− λ 2 t) 2





a+ b (

− 1

t − b)( p 1 λ 1 e− λ 1 t + p 2 λ 2 e− λ 2 t )e− (λ 1+ λ 2 )t dt ( 11 . 4 )

a b

(p 1 e− λ 1 t + h p 2 e− λ 2 t) 2

Some Flexible Phase II Clinical Trial Designs

211

for h = 0 , 1, and

a+ b

(

ω = (

p 1 λ 1 e− λ 1 t + p 2 λ 2 e− λ 2 t )e− (λ 1+ λ 2 )t 0 − 1 ) p 1 p 2

dt

0

(p 1 e− λ 1 t + 0 p 2 e− λ 2 t)(p 1 e− λ 1 t + 1 p 2 e− λ 2 t) a+ b

(

− 1

t − b)( p 1 λ 1 e− λ 1 t + p 2 λ 2 e− λ 2 t )e− (λ 1+ λ 2 )t dt .

( 11 . 5 )

a b

(p 1 e− λ 1 t + 0 p 2 e− λ 2 t)(p 1 e− λ 1 t + 1 p 2 e− λ 2 t) We calculate (11.4) and (11.5) using a numerical integration method. By

plugging these in (11.3), we calculate a required sample size for given

(λ 1 , 0 , 1 , α, 1 − β, p 1 , a, b). Note that the hazard rate for the control arm, λ 1, will be identical under both H 0 and H 1, but that for the experimental arm will be λ 2 = λ 1 / 0 under H 0 and λ 2 = λ 1 / 1 under H 1.

These distributional assumptions can be easily extended to nonexponential

survival models and a nonuniform censoring (or accrual) distribution. Fur-

thermore, we assume that there is no loss to follow-up by (B), but it can be

easily extended to account for possible loss to follow-up by incorporating it

to the censoring distribution, see Jung, Kim, and Chow (2008).

11.1.2.2

When Accrual Rate Is Specified instead

of Accrual Period

Suppose that patients are expected to enter the study at a rate of r during the

accrual period based on the number of patients treated by the study member

sites recently. At the design stage of a new trial, we usually can estimate r

from the number of patients recruited to the study center recently, while the

accrual period a is unknown. In this case, (B) is replaced by

(B) Patients are accrued following a Poisson distribution with rate r , and

are followed for a period b after the completion of accrual.

With (λ 1 , 0 , 1 , α, 1 − β, p 1 , r, b) specified, from (11.4) and (11.5), ω = ω(a) and σh = σh(a) for h = 0 , 1 are functions of the unknown a. Hence, under (A) and (B), (11.3) is expressed as

{ σ 0 (a)z 1− α + σ 1 (a)z 1− β}2

n =

.

( 11 . 6 )

ω 2 (a)

On the other hand, under the Poisson accrual distribution (B), we have

n = a × r.

( 11 . 7 )

By equating the right-hand sides of (11.6) and (11.7), we obtain an equation

on a,

{ σ 0 (a)z 1− α + σ 1 (a)z 1− β}2

a × r =

.

( 11 . 8 )

ω 2 (a)

Equation (11.8) is solved using a numerical method, such as the bisection

method. Let a∗ denote the solution to Equation (11.8). Then, given an accrual

212

Randomized Phase II Cancer Clinical Trials

rate r instead of an accrual period a, we obtain the sample size by n = a∗ × r.

The procedure for a sample size calculation may be summarized as follows:

(I) Specify the input variables:

• Type I and II error rates, (α, β)

• Allocation proportions, (p 1 , p 2 )

• Hazard rate λ 1 for the control arm under exponential survival

model, and hazard ratios 0 and 1 under H 0 and H 1, respectively

• Accrual rate r and follow-up period b

(II) Solve

{ σ 0 (a)z 1− α + σ 1 (a)z 1− β}2

a × r =

ω 2 (a)

with respect to a using the bisection method.

(III) For the solution a = a∗ to the equation in (II), the required sample size

is given as n = a∗ × r.

11.1.3

Sample Size Calculation under a

General Accrual Pattern

In (B), we assume a constant accrual rate over the whole accrual period.

Usually in a multicenter trial, however, it takes a while (usually 1 to 2 years)

until the study is approved by the institutional review boards of the study

centers and the accrual rate is stabilized. Let u(t) for t ≥ 0 be the function

representing the pattern of patient accrual over a time period. For example,

if we expect that the accrual will be linearly increasing for the first a 0 years,

called the run-in time, and maintain a constant accrual rate of r per year after

that, then we have

rt for 0 ≤ t ≤ a

u(t) =

0 .

( 11 . 9 )

r

for t > a 0

This is similar to the piecewise linear accrual pattern considered by Yateman

and Skene (1992). Given an accrual period of a and an accrual function u(t),

(11.7) is extended to

a

n =

u(s)ds.

( 11 . 10 )

0

The accrual function u(t) is related to the censoring distribution function

G(t) as follows. Let E denote the entry time of a patient in the study. The

probability density function of E is expressed as



a

u(t)/

u(s)ds if 0 ≤ t ≤ a

0

.

0

otherwise

Since, for each patient, the censoring time C is related to the entry time E by

Some Flexible Phase II Clinical Trial Designs

213

C = a + b − E, the survivor function of C, G(t) = P(C ≥ t), is given as



 1

if t ≤ b





G(t) = P(E ≤ a + b − t) =

a+ b− t

a



u(s)ds/

u(s)ds

if b < t ≤ a + b .

0

0

0

if t > a + b( 11 . 11 )

By calculating σ 2 (a), σ 2 (a), and ω(a) using this G(t) and equating the right-0

1

hand sides of (11.3) and (11.10), we obtain an equation on a for a general

accrual pattern. Using the solution a∗ to this equation, we obtain the required



sample as

a∗

n =

u(s)ds.

0

Combining (11.10) and (11.11), we calculate the probability of observing

∞

an event from a patient in arm k by dk = 1 − n−1

S

0

k (t )u(a + b − t )dt .

For example, for the piecewise linear accrual pattern of (11.9), we have





a

r a 2 / 2

if 0 ≤ a ≤ a

u(s)ds =

0

r a 2 / 2 + r(a − a

0

0

0 )

if a > a 0

and







 ra 2 / 2 + r(a − a

0

0 )

if t < b

a+ b− t

 ra 2 / 2 + r(a + b − a

u(s)ds =

0

0 − t )

if b ≤ t < a + b − a 0

 r(a + b − t) 2 / 2

if a + b − a

0





0 ≤ t < a + b

0

if t ≥ a + b

that are used to calculate G(t) in (11.11).

The sample size calculation procedure for a general accrual pattern can be





summarized as follows. Since

a

a

n =

u(s)ds, the term

u(s)ds is canceled

0

0

out in the equation of (II) below.

(I) Specify the input variables:

• Type I and II error probabilities (α, β)

• Allocation proportions, p 1 , p 2

• Hazard rate λ 1 for the control arm under exponential survival

model, and hazard ratios 0 and 1 under H 0 and H 1, respectively

• Accrual pattern u(t), and follow-up period b

(II) Solve

{˜ σ 0 (a)z 1− α + ˜ σ 1 (a)z 1− β}2

1 =

˜

ω 2 (a)

with respect to a using the bisection method, where

a+ b ˜ G(t)e− λ 1 ( 1+ 1 )t(p

˜

σ 2 (

1 e− λ 1 t + 1 p 2 e− 1 λ 1 t )

a) =

dt,

0

0 λ 1 p 1 p 2

0

(p 1 e− λ 1 t + 0 p 2 e− 1 λ 1 t) 2

a+ b

˜

σ

G(t)e− λ 1 ( 1+ 1 )t

2 (a) =

dt,

1

1 λ 1 p 1 p 2

0

p 1 e− λ 1 t + 1 p 2 e− 1 λ 1 t

a+ b

˜

ω(

G(t)e− λ 1 ( 1+ 1 )t

a) = ( 0 − 1 )λ 1 p 1 p 2

dt,

0

p 1 e− λ 1 t + 0 p 2 e− 1 λ 1 t



and ˜

a+ b− t

G(t) =

u(s)ds.

0

214

Randomized Phase II Cancer Clinical Trials

(III) For the solution a = a∗ to the equation in (II), the required sample size



is obtained by

a∗

n =

u(t)dt.

0

This approach to the general accrual trend can be incorporated with any

sample size calculation methods for survival data analysis that are discussed in

the previous chapters. The following is an example from a randomized phase

II trial.

Example 11.2

(A Randomized Phase II Trial)

We consider the example of a randomized phase II trial for patients with lo-

cally advanced nasopharyngeal carcinoma. A high-dose (arm 1) chemotherapy

A concurrent with radiotherapy is a standard treatment for the patient pop-

ulation. However, the high-dose chemotherapy is not well tolerated by most

patients. So, we want to investigate a low-dose (arm 2) concurrent chemother-

apy A administered more frequently (weekly vs. every 3 weeks). In arm 2, 1 / 3

of the arm 1 dose is given weekly, so that the total doses are identical between

the two arms if the treatments are given for the whole cycles. It is known

that the high-dose chemotherapy has a 3-year progression-free survival (PFS)

of S 1 ( 3 ) = 0 . 75, corresponding to a hazard rate of λ 1 = 0 . 096 under an exponential PFS model. In the new randomized phase II trial, we will not be

interested in the low-dose chemotherapy if its 3-year PFS is S 2 ( 3 ) = 0 . 65 or lower, corresponding to 0 = 1 . 4974, and will be very much interested in it if

its 3-year PFS is S 2 ( 3 ) = 0 . 8 or higher, corresponding to 1 = 0 . 7757 under an exponential model. Because the weekly low-dose regimen is more tolerable

than the high-dose regimen, the patients in arm 2 have a higher chance of

receiving the scheduled whole cycles than those in arm 1. So, the cumulative

dose in arm 2 will be higher than that in arm 1, and the low-dose regimen

will possibly extend the PFS for arm 2 slightly beyond that of arm 1.

Assuming an equal allocation p 1 = p 2 = 0 . 5, an annual accrual rate of

r = 55 patients and b = 3 years of additional follow-up after completion of

accrual, we need n = 138 patients ( nk = 69 per arm) for 1 − β = 80% power

for detecting H 1 : 1 = 0 . 7757 by the generalized log-rank test with one-sided α = 10% for H 0 : 0 = 1 . 4974. We expect about 42 events (progressions or deaths) at the final data analysis.

In order to validate this sample size, 10,000 samples of size n = 138 are gen-

erated from the design setting of ( p 1 , λ 1 , 1 , r, b) = ( 0 . 5 , 0 . 096 , 0 . 7757 , 55 , 3 ), and the generalized log-rank test with one-sided α = 0 . 1 is applied to each

simulated sample. The empirical power is obtained as 0.7920, which is very

close to the nominal 1 − β = 0 . 8. We also conduct simulations to check the

small sample property of the generalized log-rank test by generating 10,000

samples of size n = 138 under H 0 : 0 = 1 . 4974. The empirical type I error rate is 0.0923, which is very close to the nominal α = 0 . 1.

Extending this example, suppose that the accrual is expected to linearly

increase for the first year (a 0 = 1 ) and maintain a constant accrual rate of

Some Flexible Phase II Clinical Trial Designs

215

r = 55 per year from the beginning of the second year. Then, we obtain

a∗ = 3 years and n = 136. With the slightly longer accrual period (3 years

138 / 55 = 2 . 5 years), this design setting requires a slightly smaller sample

size (136 vs. 138) than the setting with a constant accrual rate which was

considered above.

Example 11.1

(revisited):

Let’s consider the PET-guided Hodgkin’s lymphoma trial discussed earlier.

Under H 0, we specify 0 = 4 . 3. By the PET-guided chemotherapy strategy,

it is believed that the 3-year PFS of the PET-positive patients can be in-

creased to S 2 ( 3 ) = 0 . 74, from 0.52, with a corresponding annual hazard ratio of λ 2 = 0 . 10, resulting in a hazard ratio of 1 = 2 . 0. The previous study observed about p 2 = 20% of PET-positivity. Assuming an annual accrual rate

of r = 60 patients and b = 3 years of additional follow-up after completion

of accrual, we need n = 195 patients for 1 − β = 90% power for detecting

H 1 : 1 = 2 by the generalized log-rank test with one-sided α = 10% for

H 0 : 0 = 4 . 3. Under this specific alternative hypothesis, we expect about 47

events (progressions or deaths) at the data analysis. Since this is not a random-

ized trial, the resulting allocation proportions may be slightly different from

the specified ( p 1 , p 2 ) = ( 0 . 8 , 0 . 2 ). If the observed allocation proportions are close to 0.5, the planned sample size has enough power. However, if they are

farther from 0.5, we may have to check the statistical power of the study based

on the observed proportions, while other design parameters are fixed at the

values used when designing the study. In this power checking, we may use the

estimated censoring distribution ˆ

G(t) based on the accrual times of patients

too.

Simulation studies are conducted to evaluate the calculated sample size

under the above design settings of H 0 and H 1, respectively. Using 10,000 sim-

ulation samples of size n = 132 under each hypothesis, the empirical type I

error rate and power are observed as 0.0984 (to be compared to α = 0 . 1) and

0.8749 (to be compared to 1 − β = 0 . 9), respectively.

We may consider the PET-guided Hodgkin’s lymphoma trial as a single-arm

phase II trial using the hazard ratio between PET negative group treated with

4 cycles of ABVD and positive group treated with 2 cycles of escalated BEA-

COPP followed by radiation therapy after 2 cycles of ABVD as the primary

endpoint. This study uses the outcome (or the estimated hazard ratio) from

a previous study (which treated both PET positive and negative groups by

the standard 4 cycles of ABVD) as a historical control. A possible randomized

trial with the same study objective is to randomize patients between a control

arm treated by 4 cycles of ABVD, regardless of postcycle 2 PET result, and

an experimental arm with the PET-guided treatment. The standard log-rank

test that is discussed in Chapter 10 can be used to compare the PFS between

the two arms in this case.

216

Randomized Phase II Cancer Clinical Trials

Response

Arm 1: A

B1

No resp.

off study

R

Response

Arm 2: A

B2

No resp.

off study

Figure 11.1

A randomized phase II trial design for comparing maintenance

therapies.

11.2

Randomized Phase II Trials for Comparing

Maintenance Therapies

Suppose that we want to compare the survival distributions between two

maintenance therapies combined with a common induction therapy through

a randomized phase II clinical trial. In treatment arm 1, patients are treated

by an induction therapy A; if they respond, then they proceed to a standard

maintenance therapy B 1; otherwise, they are off the study therapy. In treat-

ment arm 2, patients are treated by the same induction therapy A; if they

respond, then they proceed to an experimental maintenance therapy B 2; oth-

erwise, they are off the study therapy. The procedure of the trial is described

in Figure 11.1. For an intent to treat analysis, all randomized patients are

included in the analysis as randomized whether they receive the preassigned

maintenance therapy or not.

11.2.1

Two-Sample Log-Rank Test

Suppose that ˜

nk patients are randomized to arm k(= 1 , 2 ), among which nk

patients respond to induction therapy A and proceed to maintenance therapy

Bk, and n 0 k patients do not respond to induction therapy A and are off the study therapy. Let n 0 = n 01 + n 02 denote the total number of nonresponders

to induction therapy A, and n = ˜ n 1 + ˜ n 2 = n 1 + n 2 + n 0 the total number of patients. Let T 0 ki denote the survival time with cumulative hazard function

0 (t) for patient i(= 1 , . . . , n 0 k) in arm k who does not respond to the induction therapy, and Tki denote the survival time with cumulative hazard function

k(t) for patient i(= 1 , . . . , nk) in arm k who responds to the induction therapy and receives maintenance therapy Bk. For censoring times C 0 ki and Cki , we observe from arm k { (X 0 ki , δ 0 ki ), i = 1 , . . . , n 0 k; (Xki , δki ), i = 1 , . . . , nki }, where X = min (T, C) and δ = I (T ≤ C). We want to test H 0 : 1 (t) = 2 (t) against H 1 : 1 (t) > 2 (t).

Let Yki (t) = I (Xki ≥ t), Y 0 ki (t) = I (X 0 ki ≥ t), Nki (t) = δki I (Xki ≤ t), and N

nk

0 ki (t ) = δ 0 ki I ( X 0 ki ≥ t ). Further, let Yk (t ) =

Y

i =1

ki (t ), Y 0 k (t ) =





n 0 k Y

nk

N

n 0 k N

i =1

0 ki (t ), Nk (t ) =

i =1

ki (t ), N 0 k (t ) =

i =1

0 ki (t ), Y 0 (t ) = Y 01 (t ) +

Y 02 (t), and N 0 (t) = N 02 (t) + N 02 (t). The log-rank test statistic based on intent

Some Flexible Phase II Clinical Trial Designs

217

to treat analysis is given as

∞

Y 2 (t) + Y 02 (t)

W = 1

√ [

{ d N 1 (t) + d N 01 (t)}

n

0

Y 1 (t) + Y 2 (t) + Y 0 (t)

∞

−

Y 1 (t) + Y 01 (t)

{ d N 2 (t) + d N 02 (t)}] .

0

Y 1 (t) + Y 2 (t) + Y 0 (t)

and its variance estimator under H 0 is

∞ { Y

ˆ

σ 2 = 1

1 (t ) + Y 01 (t )}{ Y 2 (t ) + Y 02 (t )} { d N 1 (t) + d N 2 (t) + d N 0 (t)} .

n 0

{ Y 1 (t) + Y 2 (t) + Y 0 (t)}2

Under H 0, W/ˆ

σ is asymptotically standard normal. Hence, we reject H 0, in

favor of H 1, if W/ˆ

σ > z 1− α with one-sided type I error probability α.

11.2.2

Sample Size Calculation

Let pk = ˜ nk/n denote the allocation proportion for arm k ( p 1 + p 2 = 1 ), and γ = (n 1+ n 2 )/n = 1− n 0 /n denote the response rate of maintenance therapy A.

Note that nk/n = γ pk and n 0 k/n = ¯

γ pk, where ¯ γ = 1 − γ denotes the

probability of nonresponse for A. We assume that patients are accrued with a

constant accrual rate, r , during the accrual period and followed during follow-

up period b after the last patient is entered. Let Sk(t) = exp{− k(t)} denote

the survivor function of the survival distribution for arm k for the patients

who respond to induction therapy A and proceed to maintenance therapy Bk,

S 0 (t) = exp{− 0 (t)} denote the survivor function for the patients who do not respond to A in either arm, and G(t) denote the survivor function of the

common censoring distribution. We derive a sample size formula of the two-

sample log-rank test for an intent-to-treat analysis in terms of the following

design parameters:

• Type I error probability α and power 1 − β

• Allocation proportions p 1 , p 2 (p 1 + p 2 = 1 )

• Response probability of induction therapy, γ

• S 0 (t) = survivor function of nonresponders to the induction therapy

Sk(t) = survivor function of arm k(= 1 , 2 ) for patients who respond to the induction therapy and receive maintenance therapy Bk

• Accrual rate r (or accrual period a) and additional follow-up period b

Treatment arm k has a mixture survival model with survivor function ˜

Sk(t) =

γ Sk(t)+¯ γ S 0 (t). Let fk(t) = − ∂ Sk(t)/∂t denote the probability density function for k = 0 , 1 , 2, and ˜ fk(t) = − ∂ ˜ Sk(t)/∂t = γ fk(t) + ¯

γ f 0 (t) denote the mixture

probability density function for arm k = 1 , 2. Then, the hazard function for

arm k is given as

γ f

˜

λ

k (t ) + ¯

γ f 0 (t)

k (t ) =

.

γ Sk(t) + ¯ γ S 0 (t)

218

Randomized Phase II Cancer Clinical Trials

From Section 10.1.2, the required sample size is given as





σ

2

0 z 1− α + σ 1 z 1− β

n =

,

ω

where

∞

∞

σ

G(t)˜ S

G(t)˜ S

2 =

1 (t ) 2 ˜

S 2 (t)˜ λ 1 (t)

1 (t )˜

S 2 (t) 2˜ λ 2 (t)

p 2 p

dt + p

dt

0

1

2

˜

˜

1 p 2

2

˜

˜

0

{ p 1 S 1 (t) + p 2 S 2 (t)}2

0

{ p 1 S 1 (t) + p 2 S 2 (t)}2

and

∞

∞

σ

G(t)˜ S

G(t)˜ S

2 =

1 (t )˜

S 2 (t) 2˜ λ 1 (t)

1 (t ) 2 ˜

S 2 (t)˜ λ 2 (t)

p

dt + p 2 p

dt.

1

1 p 2

2

˜

˜

1

2

˜

˜

0

{ p 1 S 1 (t) + p 2 S 2 (t)}2

0

{ p 1 S 1 (t) + p 2 S 2 (t)}2

√

Furthermore, under H 1, we can show that E (W ) =

nω, where

∞

ω =

G(t)˜ S 1 (t)˜ S 2 (t){˜ λ 1 (t) − ˜ λ 2 (t)}

p 1 p 2

dt.

˜

˜

0

p 1 S 1 (t) + p 2 S 2 (t)

The number of events D under H 1 is calculated by D = n(¯

γ d 0 + γ p 1 d 1 +



γ

∞

p 2 d 2 ), where dk = 1 +

S

0

k (t )d G(t ) for k = 0 , 1 , 2.

We can estimate the required sample size as in the previous section assuming

exponential survival models and the given accrual rate instead of the accrual

period.

Example 11.3

Suppose that patients who do not respond to a common induction therapy A

have 10% of 6-month progression-free survival (PFS). Patients who respond to

induction therapy A and receive a standard maintenance therapy B 1 are known

to have a 6-month PFS of 50%. We will be very interested in an experimental

maintenance therapy B 2, combined with induction therapy A, if patients who

respond to induction therapy A and receive B 2 have a 6-month PFS of 70%

or higher. Assuming an exponential PFS model, the annual hazard rates for

the patient groups are λ 0 = 4 . 605, λ 1 = 1 . 386, and λ 2 = 0 . 713. It is expected that this study is able to accrue 5 patients per month ( r = 60 per year), and

we plan to follow the patients for additional b = 1 year. Then, the required

sample size for the log-rank test with one-sided α = 10% and 90% of power

with balanced allocation ( p 1 = p 2 = 1 / 2) is given as n = 116 (˜ nk = 58 per arm), requiring an accrual period of about 24 months ( a = 116 / 5). At the final

analysis, we expect D = 105 events (55 and 47 for arms 1 and 2, respectively)

under H 1.

Some Flexible Phase II Clinical Trial Designs

219

References

Aalen, O.O. (1978). Nonparametric inference for a family of counting pro-

cesses. Annals of Statistics, 6, 701–726.

Cox, D.R. (1972). Regression models and life tables (with discussion). Journal

of Royal Statistical Society B, 34, 187–220.

Fleming, T.R. and Harrington, D.P. (1991). Counting Processes and Survival

Analysis. Wiley, New York.

Gallamini, A., Hutchings, M., Rigacci, L., Specht, L., Merli, F., Hansen, M.,

Patti, C., Loft, A., Di Raimondo, F., D’Amore, F., Biggi, A., Vitolo,

U., Stelitano, C., Sancetta, R., Trentin, L., Luminari, S., Iannitto, E.,

Viviani, S., Pierri, I., and Levis, A. (2007). Early interim 2-[18F]fluoro-

2-deoxy-D-glucose positron emission tomography is prognostically supe-

rior to international prognostic score in advanced-stage Hodgkin’s lym-

phoma: A report from a joint Italian-Danish study. Journal of Clinical

Oncology, 25 (24), 3746–3752.

Hutchings, M., Loft, A., Hansen, M., Pedersen, L.M., Buhl, T., Jurlander, J.,

Buus, S., Keiding, S., D’Amore, F., Boesen, A.M., Berthelsen, A.K., and

Specht, L. (2006). FDG-PET after two cycles of chemotherapy predicts

treatment failure and progression-free survival in Hodgkin lymphoma.

Blood, 107 (1), 52–59.

Jung, S.H., Kang, S.J., McCall, L., and Blumenstein, B. (2005). Sample size

computation for noninferiority log-rank test. Journal of Biopharmaceu-

tical Statistics, 15, 957–967.

Jung, S.H., Kim, C., and Chow, S.C. (2008). Sample size calculation for the

log-rank tests for multi-arm trials with a control. Journal of Korean

Statistical Society, 37, 11–22.

Nelson, W. (1969). Hazard plotting for incomplete failure data. Journal of

Quality Technology, 1, 27–52.

Peto, R. and Peto, J. (1972). Asymptotically efficient rank invariant test pro-

cedures (with discussion). Journal of the Royal Statistical Society, Series

A, 135, 185–206.

Schoenfeld, D.A. (1983). Sample size formula for the proportional hazards

regression model. Biometrics, 39, 499–503.

Yateman, N.A. and Skene, A.M. (1992). Sample size for proportional haz-

ards survival studies with arbitrary patient entry and loss to follow-up

distributions. Statistics in Medicine, 11, 1103–1113.





Randomized Phase II Cancer Clinical T

Biostatistics

In cancer research, a traditional phase II trial is designed as a single-

arm trial that compares the experimental therapy to a historical

control. This simple trial design has led to several adverse issues,

including increased false positivity of phase II trial results and

Randomized

negative phase III trials. To rectify these problems, oncologists

and biostatisticians have begun to use a randomized phase II trial

that compares an experimental therapy with a prospective control

Phase II Cancer

therapy.

Randomized Phase II Cancer Clinical Trials explains how to

Clinical Trials

properly select and accurately use diverse statistical methods for

designing and analyzing phase II trials. The author first reviews

the statistical methods for single-arm phase II trials since some

methodologies for randomized phase II trials stem from single-arm

phase II trials and many phase II cancer clinical trials still use single-

arm designs. The book then presents methods for randomized

phase II trials and describes statistical methods for both single-arm

and randomized phase II trials. Although the text focuses on phase

II cancer clinical trials, the statistical methods covered can also be

used (with minor modifications) in phase II trials for other diseases

and in phase III cancer clinical trials.

Suitable for cancer clinicians and biostatisticians, this book shows

rials

how randomized phase II trials with a prospective control resolve

the shortcomings of traditional single-arm phase II trials. It provides

readers with numerous statistical design and analysis methods for

randomized phase II trials in oncology.

Sin-Ho Jung

Jung

K13295

K13295_Cover.indd 1

3/25/13 10:44 AM





Document Outline


Contents

Preface

Chapter 1 Introduction

Chapter 2 Single-Arm Phase II Trial Designs

Chapter 3 Inference on the Binomial Probability in Single-Arm Multistage Clinical Trials

Chapter 4 Single-Arm Phase II Clinical Trials with Time-to-Event Endpoints

Chapter 5 Single-Arm Phase II Trials with Heterogeneous Patient Populations: Binary and Survival Outcomes

Chapter 6 Randomized Phase II Trials for Selection: No Prospective Control Arms

Chapter 7 Randomized Phase II Cancer Clinical Trials with a Prospective Control on Binary Endpoints (I): Two-Sample Binomial Test

Chapter 8 Randomized Phase II Cancer Clinical Trials with a Prospective Control on Binary Endpoints (II): Fisher’s Exact Test

Chapter 9 Randomized Phase II Trials with Heterogeneous Patient Populations: Stratified Fisher’s Exact Test

Chapter 10 Randomized Phase II Clinical Trials Based on Survival Endpoints: Two-Sample Log-Rank Test

Chapter 11 Some Flexible Phase II Clinical Trial Designs





